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Abstract
Novel Natural Products as Modifiers of Multidrug Resistance
Deoxyspergualin, an immunosuppressive antibiotic, is similar to cyclosporin A and FK506 
in some of its properties and mechanisms of action. We therefore decided to examine the 
effects of deoxyspergualin in multidrug resistant (MDR) cells. Deoxyspergualin did not 
alter the drug accumulation deficit observed in the MDR, P-glycoprotein-overcxprcssing 
cell lines EMT6/AR1.0 or H69/LX4. In addition it was not able to inhibit the ability of 
pH]azidopine to photolabel P-glycoprotein. It is unlikely, therefore, that deoxyspergualin 
is a substrate for P-glycoprotein. Our data suggests ^ a t  deoxyspergualin is not a good 
candidate for development as a resistance modifier. Its maintenance of activity in classical 
MDR cells and its potent in vivo antitumour activity, however, makes deoxyspergualin a 
promising agent for further investigation into its potential clinical use as an antitumour
agent
Several novel fungal products, supplied by Xenova Ltd, were tested for their ability to 
modify both P-glycoprotein- and MRP-mediated MDR. We demonstrated that, within this 
series, the most potent modifiers of MDR contained within their structure a 
tetrahydroisoquinoline group attached to a benzylidene ring in either the meta or para 
position together with the presence of a diketopiperazine ring. The ability of a molecule to 
be positively charged and lipophilic at physiological pH are also important determinarits of 
activity as a modifier of P-glycoprotein-mediated MDR. The active compounds inhibit the 
ability of [3H]azidopine to photolabel P-glycoprotein indicating that they may rev ise  
MDR by themselves binding to P-glycoprotein. Two compounds, XR9006 ^ d  XR905I 
are effective modifiers of P-glycoprotein-mediated MDR. XR9051 is currently 
undergoing in vivo studies at Xenova.
We discovered a novel fungal product modifier of MRP-mediated MDR, XR9173. This 
compound, synthesised by scientists at Xenova, is cationic at physiological pH and 
possesses a tetrahydroisoquinoline group. It is also, therefore, an effective modifier of P- 
glycoprotein-mediated MDR. Recent findings suggest that MRP is identical to the 
glutathione (GSH) conjugate transporter (Jedlitschky et oL, 1994). It is unlikely, however, 
Siat XR9I73 reverses MRP-mediated MDR by competing for the same efflux mechanism 
as GSH as it is not anionic at physiological pH. Our results provide evidence to support 
the theory that MRP may co-exist with another transporter which is able to transport 
cationic drugs across the cell membrane and that these transporters are ab le , in some way, 
to regulate each others' activity.
A potential regulatory mechanism for P-glycoprotein function is modification of 
phosphorylation. We initially intended to examine the effect of the Xenova compounds on 
P-clycoprotein phosphorylation. Scientists at Xenova demonstrated that the compounds in 
this series were not substrates for PKC. It is unlikely, therefore, that they would have any 
effect on the phosphorylation status of P-glycoprotein. We had already started to examme 
the effect of several inhibitors of PKC and the PKC activator TPA on the phosphorylaüon 
of P-glycoprotein and on drug transport. The results of these initial studies 
interesting and so we decided to continue with this study. We demonstrated that the PKC 
inhibitor calphostin C inhibits the phosphorylation of P-glycoprotein and increases dmg 
accumulation in MDR cells. This indicates that altering P-glycoprotein phosphorylation 
may indeed alter its function. Interestingly, non-light-activated calphostin C, which docs 
not inhibit PKC, also significantly increased drug accumulation in MDR cells. It appears 
that other actions of PKC inhibitors with respect to P-glycoprotein, i.e. their ability to bind 
directly to P-glycoprotein, must also be considered when attempting to correlate effects on 
P-glycoprotein phosphorylation with cflccis on drug transport.
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1.1 Introduction to cancer chemotherapy
1.1.1 The History of cancer chemotherapy
The earliest documents known to mention the occurrence and treatment of cancer are 
medical manuscripts of Chinese and Sumerian origin, from the third millennium BC. 
Physicians thought then that cancer was caused by the derangement of regulatory 
processes and tried to correct this with the use of acupuncture. Hippocrates (460-377 
BC.) is considered to be the founder of scientific medicine as practised in the West. 
His works contain numerous references to the causes and treatment of cancer. In his 
writings malignant tumours are referred to for the first time as carcinomas. He argued 
that, 'separation of the humours' (blood, phlegm and bile) through toxins arising in 
the body, particularly black bile' caused the disease. He recommended the 
detoxification of the body using agents such as arsenic, sulphur, laxatives and 
hellebore. Surgical intervention, he wrote, should be used as a last resort. Clams 
Galen (131-200 AD.), the founder of experimental physiology and pathology, wrote 
five hundred works, including various manuscripts on cancerology. He considered 
'black bile', atra bilis, of particular importance, regarding it as the cause of cancer. 
This dogma remained, undisputed, into the eighteenth century.
The Complete Housewife or Accomplished Gentlewoman's Companion', published 
in 1729, suggests the following cures for cancer:
1. An approved remedy for cancer o f the breast: Take the hard knobs or warts which 
grow on the legs o f  a Stone-Horse, dry them carefully and powder them; give from  
one scruple to half a dram, every morning and evening in a glass o f  sack. You must 
continue taking them for a month or six weeks, or longer i f  the cancer is far gone.
2. For a cancer in the mouth; take celandine, columbine, sage and fennel, o f each one 
handful, stamp and strain them and to the juices put a spoonful o f  honey\ half a 
spoonful o f burnt alum: mix and beat all these together and wrap in a little flax (about 
a stick) and rub the cancer with it: i f  it bleeds Tis the better.
3. To disperse tumours; take half a pound o f figs, two ounces o f White Lilly-root, 
two ounces o f bean flour or meal; boil these in water 'til it comes to a poultice; spread 
it thick on a cloth, apply it warm and swift as often as it goes dry.
(Infonnation taken from: Issels, J., Cancer a Second Opinion: Published 1975)
Fortunately, in the last 250 years cancer treatments have developed greatly from these 
early herbal remedies. However, the first documented demonstration that a chemical 
agent was capable of causing remission in a human malignancy was not until 1942, 
when a patient with lymphoma obtained a brief clinical remission after treatment with 
the alkylating agent nitrogen mustard (Gilman. 1963). Following this initial 
documentation, a large number of drugs have been developed and tested for their 
potential clinical activity. Table 1.1 shows the historical development of 
chemotherapy.
Table 1,1
The historical development of cancer chemotherapy
DATE A G EN T DISEASE TREATED ,,
1865 Potassium Arsenite Leukaemias, various malignancies
1893 Coley's Toxins Various malignancies
1941 Oestrogens
Androgens
Carcinoma of the prostrate/breast
1942 Nitrogen Mustard Lymphomas, solid tumours
1948-1950 Adrenocoiticoids 
Antifolates (Methotrexate)
Leukaemias, lymphomas, multiple 
myeloma
Acute leukaemia, choriocarcinoma
1950-1955 Busulfan 
6-mercaptopuiine 
Actinomycin D
Chlorambucil
Chronic granulocytic leukaemia 
Acute leukaemia
Wilms tumour, testicular tumour, 
choriocarcinoma 
CLL, non-Hodgin's lymphoma, 
Hodgkin's disease, ovarian cancer
1955-1960 5-Fluorouracil 
Cyclophosphamide 
Vinca alkaloids 
Mitomycin D
Carcinoma of the breast/GI tiact 
Lymphomas, solid tumours 
Lymphomas, acute leukaemias 
GI tumours
1960-1965 Hydroxyurea
Mithramycin
Nitrosoureas
Daunorubicin
Chronic granulocytic leukaemia 
Testicular cancer 
Lymphomas, brain tumours 
Acute leukaemia
1965-1970 L-Asparaginase 
Dacarbazine(DTIC) 
6-Thioguanine 
Cytosine Arabinoside
Acute leukaemia
Melanoma
Acute leukaemia
Acute myeloblastic leukaemia
1970-1975 Doxorubicin
Bleomycin
Various tumours 
Lymphomas, head/neck cancer
1975-1980 Antioestrogens
Cisplatin
Breast cancer
Testicular, lung and ovarian cancer
1980-1985 Etoposide(VP-16)
Mitoxantrone
Small cell lung cancer 
Breast cancer
1985-1990 Interferon
Carboplatin
Ifosfamide/mesna
Leukaemias 
As cisplatin 
As cyclophosphamide
1990-
present
Taxol
Fludarabine
Ovarian cancer 
Leukaemias
1 . 1 . 2  Classification and pharmacology of chemotherapeutic
agents
Anticancer agents may be classified into three main groups according to their 
biochemical activities or their origins (Table 1.2). These groups include the alkylating 
agents, antimetabolites and natural products that have anticancer activity. Inevitably, 
some drugs appear in more than one class.
Table 1.2
Major families of drugs used in cancer chemotherapy
A tK V L A T lN G
a c c e n t s
A N T IM E T  A B O T U 'E S
N A T U R A L  : 
P ttO O tiC T S
M I S C .
Nitrogen Mustards Metliotrexate
Doxorubicin Cisplatin
Chlorambucil Daunorubicin DTIC (Dacarbazine)
Melphalan
5-Ruorouiacil Actinomycin C Procarbazine
Cyclophosphamide Cytosine Arabinoside Bleomycin
Busulfan Vinblastine6-Thioguanine
Nitrosoureas: Vincristine
(e.g. BCNU, CCNU &
6-Mercaptopurine VP-16 (Etoposide)
Meüiyl-CCNU) Taxol®
Mitomycin C Mitomycin C
(i) A lkylating agents
Alkylating agents, although chemically diverse in structure, are all able to undergo 
transformation to produce electrophilic (electron deficient) reactive intermediates. 
These reactive groups are capable of forming covalent bonds on nucleophilic (excess 
electrons) moieties on biological molecules including amino, phosphate, sulphydryl 
and hydroxyl groups. The process of covalent binding to alkyl groups is referred to 
as alkylation. Alkylating agents may be mono- or bifunctional depending on the 
presence of either one or two reactive groups on the molecule. Nucleophilic chemical 
groups that are potential sites of alkylation occur on almost all biological molecules.
alkylation of bases in DNA appears to be the major cause of lethal toxicity (Figure 
l.l.b). Bifunctional alkylating agents (the most common form of alkylating agent 
used in the clinic) cause cross linking of DNA strands, whereas the toxicity of 
monofunctional alkylating agents may be related to single strand breaks in DNA or 
damaged bases. Figure 1.1.a shows the structure of some alkylating agents 
commonly used in the clinic and Figure l .l .b  shows the formation of a reactive 
intermediate followed by alkylation at the N-7 position of the DNA base, guanine by 
nitrogen mustard.
Figure 1.1
(a) Structure of alkylating agents commonly used in the clinic
H00C-(CH2)3
Chlorambucil
CH2CH2a
CHgCHgQ C
H
,^ch2CH2Ci
p —N
/ ^CHzCHgCI
Cyclophosphamide
(b) Alkylation at the N-7 position of guanine by nitrogen mustard
H3ON:
.CHzCHgCI
‘CH2CH2CI
Nitmgen Mustard -C l
CHg
+ /  \  Reactive intennediate 
H3C- N— QH2
CH2CH2CI
ÇH3
CICH2CH2— NCH2CH2
'n
NH2
H
N^^NH2
Guanine
Guanine, alkylated at N-7
(ii) A n tim etabo lites
Antimetabolites are drugs which have been synthesised to inhibit critical biochemical 
pathways, usually leading to inhibition of DNA and RNA synthesis, and tend to be 
cell cycle dependent For example, reduced folate is required for transfer of methyl 
groups in the biosynthesis of purines and in the conversion of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), a reaction 
which is catalysed by thymidilate synthetase. Reduced folate becomes oxidised in the 
latter reaction, and its regeneration is dependent on the enzyme dihydrofolate 
reductase (DHFR) for further reduction to the active form. Methotrexate is a 
competitive inhibitor of DHFR and thus prevents the formation of reduced folate. 
This inhibition may lead to a decrease in the availability of dTMP and/or purines 
leading to a cessation of DNA synthesis and ultimately cell death. Figure 1.2 shows 
the structure of folic acid, and its analogue methotrexate.
Figure 1.2
Structure of folic acid and methotrexate
C — N —  C —COOH
CHoCOOHFolic acid
H CH3
I
Methotrexate
I? V
C ^ N  — C —COOH
I
CH2
CH2COOH
(iii) Natural Products
Many natural product cytotoxic drugs have been derived from products of bacteria, 
fungi and plants. Table 1.3 illustrates some of these drugs, their source, use, 
mechanisms of action and loxicities.
Table 1.3
Natural product cytotoxic drugs
r>RUG:CJSE AND TOXICITY -  MECHÂNIXM O F  ACTION
D oxoru b icin  (S treptom yces)
USE: solid tumours 
D a u n o r u b ic in
USE: leukaemias 
TOXICITY : cardiotoxicity, 
myelosuppression, hair loss, nausea and 
vomiting, tissue necrosis at injection site and 
mucosistis
-intercalates between base pairs perpendicular 
to the long axis o f the double helix, leading 
to unwinding o f the DNA helix 
-causes single and double strand breaks in 
DNA (DNA Topoisomerase II strand cleavage) 
-in h ib its D N A  and R N A  syn th esis, 
preferential toxicity for cells in S phase 
-production o f  tlie superoxide radical (O2") 
leading to oxidative damage 
-binds to cell membranes
A ctinom ycin  D (S trep tom yces)
USE: childliood tumours
TOXICITY: M yelosuppression, GI toxicity
and hair loss
-binds to guanosine residues o f DNA, planar 
rings intercalate between adjacent base pairs of 
tlie D N A  helix. This causes inhibition o f the 
transcription of RNA
B leom ycin  (fungal)
Active component is bleomycin A2 
USE: (in combination) testicular cancer and 
lymphomas, minor use in cancers o f  head and 
neck
TOXICITY: interstitial fibrosis o f  lung, 
fever, chills, damage to skin
-formation o f bleomycin-ferrous iron complex 
follow ed by intercalation o f  tlie complex, 
helix unwinding, DNA strand breaks 
-formation o f superoxide/hydroxyl radicals 
catalysed by bleomycin-ferrous iron complex 
-preferential toxicity for cells in 0 2  phase
V inca A lkaloids(periw inkle plant) 
USE: (i) vinblastine(in  combination)- 
testicular cancer.
(ii) vincristine-childhood leukaemia.
(iii) both-lymphomas and solid tumours 
TOXICITY:vinblastine-myelosuppression, 
vincristine-neurotoxicity
-binds to tubulin, inhibit its polymeristaion 
and the formation o f microtubules
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Table 1.3
Natural product cytotoxic drugs (continued)
BK tJG:OSE AND TO X ICITY MECHANISM OF ACTION
P o d o p h y llo to x in  -V P -16 (Etoposide) 
(mandrake plant)
USE; small cell lung cancer and lymphomas 
TOXICITY : myelosuppression, hair loss
-DN A  Topoisomerase II strand cleavage 
-binds to tubulin, inhibit its polymerisation  
but does not e ffec t  the form ation o f  
microtubules
-inhibits nucleoside transport into cells and 
incorporation into RNA and D N A , causing 
single strand breaks
M aximum activity in late S and early G2 
p h a s e ___________________________________
TaxoI®(paclitaxel)-Pacific Yew tree 
(Taxus hrecifolia)
Taxotere® (docetaxel)-needles o f European 
Yew tree (Taxus baccata) 
USE:Experimental-Non small cell lung cancer 
TOXICITY; fluid retention ___________
-promotes assembly o f microtubules. Renders 
them resistant to depolymerisation
1.2 Factors affecting cell survival after drug
treatment
1.2.1 Introduction
Both tumours and normal tissue contain cells that are heterogeneous with respect to
proliferative state, intrinsic drug resistance, ability to repair drug-induced damage and 
cell cycle phase. Each of these factors may influence cell survival after treatment 
with specific cytotoxic drugs.. Additionally, limited diffusion of some drugs may 
lead to varying dosage to cells within the population. It is important to note that 
factors affecting survival of cells in tumours in the clinic are far more complicated 
than those illustrated in this section. The pharmacokinetics and pharmacodynamics of 
the drug in relation to the body as a whole must also be considered.
1 .2 .2  Cell proliferation rate
Cell proliferation rate is a major determinant of drug activity. This can be 
demonstrated in cells grown in culture. Cells in culture grow in a very characteristic 
fashion. Figure 1.3.a illustrates a typical sigmoid growth curve for cells growing in 
culture. During 'exponential phase' the cells are cycling rapidly. As cell numbers 
increase, cell crowding occurs, media nutrients are exhausted and proliferation rate 
slows due to an increase in cell cycling time and a decrease in growth fraction. Cell 
death rate increases to equal the rate of cell production and the cells eventually reach 
'plateau phase'. Figure 1.3.b shows the difference in the response of rapidly 
proliferating cells in exponential phase and slowly proliferating cells in plateau phase 
to exposure to doxorubicin. Exponential phase cells are more sensitive to most 
chemotherapeutic agents than plateau phase cells (Twentyman et a i,  1975). The 
spleen-colony assay has been used to compare the effects of drugs on cell survival in 
vivo (Bruce et a i, 1969; Van Putten et a i, 1972). Results from in vivo experiments 
are generally in agreement with those from experiments carried out on cells in culture. 
Cell proliferation rate therefore appears to influence the ability of cells to survive 
treatment with cytotoxic drugs.
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1 .2 .3  Cell cycle phase specificity
Almost all drugs show variations in lethal toxicity around the cell cycle (Mauro and 
Madoc Jones, 1970). For example, many antimetabolites exert lethal toxicity only for 
cells that are synthesising DNA (i.e. S-phase cells). In contrast, doxorubicin has 
maximum toxicity for S-phase cells, but also has some activity during other phases. 
The vinca alkaloids, vinblastine and vincristine, disrupt formation of the mitotic 
spindle. They also cause maximum toxicity in S-phase cells, when formation of the 
mitotic spindle is initiated. Alkylating agents generally have maximum lethal toxicity 
in two areas, at the G2/M and the Gi/S phase boundaries. In the clinic, specificity of 
many chemotherapeutic agents for certain phases of the cell cycle means that a partly 
synchronised cell population will remain. It seems, therefore, that scheduling 
anticancer drug regimens by giving subsequent treatment when a large number of 
survivors are again in the sensitive phase would maximise total cell kill. In vivo, cell 
cycling times are widespread throughout the cell population and synchrony is lost 
very rapidly making this type of dosing regimen unrealistic.
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Figure 1.3
(a) Typical growth curve for cells in culture
Plateau ^ a s e
3 1 0  - -
Lag phase
lential phase
0 8642
Days
(b) Survival curves for the treatment of exponential and plateau phase 
cells with an anthracycline (e.g. doxorubicin)
1.0
Plateau phase
0.1 -
0.01
0.001 Exponential (Aase
0.0001
4 5 6321
Drug dose 
(arfoitary units)
Figure 1.3. (a) A typical sigmoid growth curve for cells in culture. During exponential phase there 
is rapid cell cycling, but th ^e  is minimal cell proliferation during plateau phase, (b) Doxorubicin 
survival curves for exponential and plateau phase cells (Twentyman et ai,  1975) Adapted from 
Tannock and Mill, 1992.
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1.2 .4  Drug resistance
The differential sensitivity of chemotherapeutic agents is also dependent on the 
presence or development of drug resistance. Clinical drug resistance can be divided 
into two categories. Firstly, many tumour types that occur commonly in man (eg, 
colon cancer, lung cancer other than the small cell type) are unresponsive to 
chemotherapy from the initial diagnosis and are therefore said to demonstrate inherent 
resistance. Secondly, other tumour types such as small cell lung cancer, acute 
myeloid leukaemia and ovarian cancer frequently show a very good response to 
initial chemotherapy (complete response rate is typically 50%) but almost always the 
disease recurs within months and displays a progressive resistance to further drug 
treatment. Such tumours, therefore demonstrate acquired resistance. Clinical 
evidence of acquired drug resistance was observed as early as the 1940s. Good 
response rates were obtained in adult leukaemias and lymphomas, using nitrogen 
mustards or anti-folates as single agent therapies. These responses were, however, 
often short in duration and relapse was associated with acquired drug resistance to the 
original cytotoxic (Chabner et al„ 1990). Acquired resistance may result from the 
selection for and repopulation of the tumour by intrinsically drug resistant cells as a 
result of the failure of the first line treatment to eradicate this population. 
Alternatively, it may result from the induction, by the initial chemotherapeutic agent, 
of biochemical or genetic alterations which enhance cellular resistance levels to that 
agent and possible cross resistance to others. Tumours are populated by a 
heterogeneous mass of cells with differing biochemical, morphological and drug 
response characteristics. This heterogeneity within the tumour cell population may 
result from genetic lesions (point mutations or amplification) or changes in the 
regulation of genes encoding target proteins (Chabner et aL, 1990).
It is clear that development of drug resistance is not unique to cancer cells. A wide 
variety of organisms including bacteria, protozoa and insects are able to develop 
resistance to a number of toxic agents. Two common examples are the resistance
15
developed by the malaria parasite, Plasmodium falciparum^ to various antimalarials 
including chloroquine and proguanil and the bacterium, m ulti-resistant 
Staphylococcus aureus^ which is resistant to most antibiotics. Both these types of 
resistance create the threat of untreatable epidemics developing if not contained.
Identification of the mechanisms underlying the clinical phenomenon of drug 
resistance to chemotherapeutic agents has predominantly been based on laboratory 
studies comparing the characteristics of drug sensitive cells with either intrinsic or 
acquired drug resistant cell lines isolated from primary tumour samples or drug- 
resistant cell lines derived in the laboratory after chronic exposure to cytotoxic drugs. 
A spectrum of biochemical and genetic alterations can give rise to cytotoxic drug 
resistance. Firstly, decreased uptake or increased efflux of cytotoxic drug may result 
in a decreased concentration of drug at the target site. For example, the over 
expression of the membrane transport protein, P-glycoprotein (Endicott and Ling, 
1989, Gottesman and Pastan, 1993). Secondly, conformationally altered drug targets 
result in a decrease in drug action. Resistance to methotrexate is associated with 
alterations in levels of dihydrofolate reductase (DHFR), its target enzyme, either by 
the production of variant forms of the enzyme (Goldie et aL, 1980) or by the 
overexpression of DHFR by amplified genes (Schimke et al., 1984). The 
overexpression of topoisomerase I (topo I), the target enzyme for camptothecin 
(Kjeldsen et aL, 1988), or overexpression of topoisomerase H (topo H), the target 
enzyme for doxorubicin and etoposide (Beck, 1989), is another example of how a 
decrease in the expression or activity of the drug target protein itself may cause drug 
resistance. Alteration in the cellular metabolism of cytotoxic drugs by changes in the 
levels of metabolic enzymes has also been implicated as a mechanism for decreasing 
drug toxicity. For example, the tripeptide, glutathione (GSH) and its related enzymes 
are able to react with, and detoxify, many of the reactive alkylating agents used in the 
clinic (Arrick et aL, 1984; Russo et aL, 1986). Finally, a novel approach to 
understanding the mechanisms underlying drug resistance is one involving
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investigations into the modulation of cell death by the expression of certain genes. It 
is possible that some determinants of inherent drug sensitivity and resistance may be 
independent of those which involve the formation of the drug-target complex and its 
characteristic biochemical sequelae. A wide variety of antitumour drugs reportedly 
induce a conserved mode of active death, termed apoptosis, in susceptible cells. 
Expression of the gene bel -2, which inhibits apoptosis, may make cells resistant to 
drug-induced apoptosis by a novel mechanism affecting events downstream of the 
initiation of toxicity brought about by the drug (Fisher cr aü, 1993).
1.3 Mechanisms of drug resistance
1.3.1 Multidrug resistance (MDR)
As already discussed, to investigate the basis of drug resistance in the laboratory, 
drug resistant cell lines have been isolated by exposing various drug sensitive cancer 
cell lines to increasing doses of chemotherapeutic agents. If the selecting agent is one 
of a group of well defined natural products possessing a number of similar properties, 
including high molecular weight and lipophilicity, for example doxorubicin, the 
isolated resistant cells are frequently not only resistant to doxorubicin but may be 
cross resistant to other, structurally unrelated, natural product drugs with similar 
properties. This simultaneous resistance to many structurally unrelated drugs has been 
termed 'classical' multidrug resistance (MDR) or pleiotropic drug resistance. Over 25 
years ago Biedler and Riehm (1970) were first to describe the derivation of cells with 
a multidrug resistance phenotype. The group of drugs involved in the MDR 
phenotype includes doxorubicin, vincristine, vinblastine, actinomycin D, colchicine 
and etoposide but not agents such as cisplatin, cytosine arabinoside, 
cyclophosphamide and methotrexate, all agents synthesised in the laboratory. The 
usual pattern of cross resistance includes a large variety of cytotoxic agents that do not 
have a common structure or a common intracellular target. Although these diverse 
compounds share no structural similarity, one common feature is that in general, they 
are all amphiphathic (soluble in both water and lipid) with preferential solubility in
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lipid. In addition to the structural dissimilarity, the drugs in the MDR groups have 
different mechanisms of action; some affect microtubules, some inhibit DNA, RNA 
or protein synthesis. It is important to remember that MDR is a phenomenon 
occurring in cells derived in the laboratory. It provides a useful model for the 
elucidation of the mechanisms involved in drug resistance in the clinic. The following 
section describes the mechanisms of MDR in detail and examines their individual 
clinical relevance.
1.3 .2  Overexpression of a ITOkDa plasma membrane
glycoprotein (P-glycoprotein)
(i) In troduction
The first clue to the mechanism(s) underlying MDR came from drug transport studies 
which demonstrated that MDR cells accumulated less drug than drug sensitive cells 
(Dano, 1973; Ling etaL, 1974). Drug entry into the cell appeared to be normal, but 
the cells had developed the capacity to pump drugs back into the extracellular matrix. 
In 1976 Juliano and Ling linked this phenomenon with the expression of a cell 
surface glycoprotein of 170kDa, known as P-glycoprotein.
Table 1.4 lists classes of agents in cUnical or laboratory which are known to interact 
with P-glycoprotein. This list includes many hydrophobic natural compounds, semi­
synthetic analogues of natural products and synthetic organic compounds.
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Table 1.4
Classes of agent that interact with P-glycoprotein
ANTJCANCER OTHER CYTOTOXIC \  ' RESISTANCE ^
D R U G S AGENTS '  ^ ' MODIFIERS . ' '
Vinca alkaloids Antimicrotubule drugs Calcium channel blockers
(e.g. vinblastine) (e.g. colchicine) (e.g.verapamil)
Anthracyclines DNA intercalators Antiarrhythmics
(e.g. doxorubicin) (e.g. ethidium bromide) (e.g. quinidine)
E pipodophyllotox- Toxic peptides Im m unosuppressants
ins (e.g. etoposide) (e.g. valinomycin) (e.g.cyclosporine A, FK506)
A ntibiotics Steroid hormones
(e.g. actinomycin D) (e.g. progesterone)
Others A ntipsychotics
(e.g.taxol, mitomycin (e.g. phenothiazines)
C) Detergents (e.g. Tween-80)
M odified steroids A ntihistam ines
(e.g. tamoxifen) (e.g. terfenadine)
(ii) Molecular genetics and nomenclature o f P-glycoprotein
Genetic analysis has demonstrated that P-glycoprotein is produced by a small family 
of homologous genes, known as mdr or multidrug resistant genes, which have been 
cloned and sequenced from human, hamster and murine cells (Endicott and Ling,
1989).
A novel technique, known as in-gel renaturation, which allowed direct cloning of 
amplified segments of genomic DNA from gels, was used to isolate amplified 
genomic sequences in MDR hamster cells (Roninson, 1983). This technique was 
employed after cytogenetic analyses of these highly selected MDR cells indicated the 
presence of homogeneously staining regions (HSRs) and double minute
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chromosomes (Biedler et aL, 1970; Fojo et a i, 1985). An amplitied genomic 
fragment that detected mRNAs in drug resistant cells was then used to identify and 
isolate human genomic fragments from multidrug resistant KB cells, which also 
contained amplified genes (Roninson et aL, 1986) and was used as a probe to detect 
cross-hybridising cDNAs in the mouse (Gros et aL, 1986a). More traditional 
methods based on the overexpression of mdr mRNAs and their product, P- 
glycoprotein have also been used to clone mdr cDNAs. The laboratories of Borst and 
Melera used differential cDNA libraries to isolate cDNAs corresponding to mRNAs 
overexpressed in highly multidmg resistant Chinese hamster cells (Van der Bliek et 
aL, 1986; Scotto et aL, 1986), while Ling’s group used a monoclonal antibody to P- 
glycoprotein (Kartner et al, 1985) to clone a fragment of a cDNA that encoded a 
hamster P-glycoprotein (Gerlach et aL, 1986).
P-glycoprotein is encoded by the mdr gene family. Three classes of mdr gene have 
been identified in mammalian cells. Table 1.5 shows the classification of human, 
mouse and hamster mdr genes and their alternative designations (in brackets).
Table 1.5
Classification o f mammalian MDR  isoforms
Pgp Class Human - M ouse Hamster
Involved ; 
lu  MDR
I ^MDR 1 ^mdrlai mdrS) ^pgpl yes
II ^mdrlb(mdrl) yes
III bMDR3(MDR2) ^mdr2 no
References:
H:hen et aL, 1986 ; ^Van der Bliek et a i ,  1987; ^Hsu et a l ,  1989; ^Gros et a i ,  1988; 
^Ng et a i ,  1989
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In order to prove that the cloned mdr genes were responsible for MDR, several 
genetic approaches were adopted. Firstly, linkage between mdr sequences and drug 
resistance was demonstrated using gene transfer experiments using high molecular 
weight DNA (Gros et al., 1986b). After the isolation of full length, functional 
cDNAs, DNA-mediated transfer (Ueda et aL, 1987) or retroviral gene transfer (Guild 
et aL, 1988) showed that the cDNA were able to confer the full phenotype of 
multidrug resistant cells on drug-sensitive cells. Attempts to show that the human 
MDR3 and the closely related mouse mdr2 can confer multidrug resistance have been 
negative. Both are present in the liver in the canalicular membranes of hepatocytes. It 
is thought that they may have a role in phospholipid transport through the canalicular 
membrane into bile (Smit et al., 1994).
(Hi) Structure o f  P-glycoprotein
The availability of full-length mdr cDNAs was quickly followed by their sequencing 
and the analysis of these sequences. The human MDR genes are adjacent to each 
other on the long arm of chromosome 7 near 7q21.1 (Reviewed by Trent et aL,
1991). P-glycoprotein (c.l280 amino acids in length) is a highly conserved, 
tandemly-duplicated, molecule joined by a 'linker' sequence of approximately 60 
amino acids. Each half of the molecule consists of six transmembrane regions and 
two putative nucleotide-binding regions. As much as 40kDa of the molecular weight 
of P-glycoprotein is due to post-translational N-linked glycosylation. Inhibition of 
this glycosylation does not appear to affect the MDR phenotype (Beck et aL, 1982). 
The sequence of mdr cDNAs indicates significant sequence homology with many 
other energy dependent transport proteins (Gros et a l, 1986c). The main regions of 
sequence homology include the A and B binding folds of the Walker motifs for 
nucleotide binding and areas immediately between and around these two folds. This 
suggests that ATPase activity specific to a superfamily of transporters may be 
encoded in this region. This family is now known as the ATP-binding cassette 
(ABC) family, of which there are at least 40 members. Examples of proteins within
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this family include a pump that mediates chloroquine resistant in the malaria parasite, 
Plasmodium falciparum (Wilson et aL, 1989), a transporter for the ’a' peptide mating 
factor of yeast called STE6 (McGrath et aL, 1989) and the cystic fibrosis transport 
regulator (CFTR), the product of the cystic fibrosis gene (Riordan et aL, 1990).
(fv) Post-translational m odification o f  P-glycoprotein 
Many groups have been able to show that P-glycoprotein overexpressed in multidrug 
resistant cells undergoes covalent modification by phosphorylation (Chambers et aL, 
1990a & b; Bates et aL, 1992). Ma et al. (1991) demonstrated that P-glycoprotein 
molecules are subject to rapid cycles of phosphorylation/dephosphorylation. The 
universal occurrence and dynamic nature of this covalent modification may suggest an 
important role for phosphorylation in the mechanism of action of P-glycoprotein. This 
role is discussed at length in Chapter 7 of this thesis.
(v) Analysis o f  po in t mutations in P-glycoprotein 
The study of mutations occurring in the amino acid sequence of P-glycoprotein has 
led to speculation about its specific function. There are several examples of point 
mutations in P-glycoprotein that are known to alter the substrate specificity of the 
protein. Figure 1.4 is a schematic diagram of the 1280 amino acid structure of P- 
glycoprotein and indicates the positions of these mutations. The changes in 
specificity that occur due to these mutations fall into two classes: (a) Mutations that 
alter the pattern of resistance of the cell, so that resistance to some drugs is increased, 
and resistance to others is decreased and; (b) mutations that preserve, or slightly 
increase resistance to a certain class of drug, and decrease resistance to all others. 
Table 1.6 lists some recently described P-glycoprotein. point mutations and reveals the 
alteration in drug specificity caused by the mutation.
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Figure 1.4
A schematic diagram  of the s tru c tu re  of P-glycoprotein
membrane.
iooo
2oo 225
ATP 5 IT t
The position of several point mutations in the primary structure of P-glycoprotein is superimposed 
on the secondary structure of the multidrug transporter. Adapted from Gottesman et al., 1993.
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Table 1.6
Summary of P-glycoprotein point mutations
SU B ST ITU T IO N  
AND SITE ORIGIN
PBENOTYFE
h2Val to Gly @ 185 colchicine selected 
MDR cell line, 
KB-Cl
increased resistance to colchicine 
and etoposide, decreased 
resistance to vinca alkaloids, 
small decrease in resistance to 
anthracyclines and taxol
3Gly to Ala @ 338 
Ala to Pro @ 339
Chinese hamster 
cells, resistant to 
actinomycin D
increased resistance to 
actinomycin D, decreased 
resistance to other drugs
4,5gGr to Phe @941* mouse gene 
mdrl (mdr lb)
decreases the transport of 
colchicine and doxorubicin
6Gly to Ala @431 orl073* 
Lys to Arg @ 432 or 1074* 
(ATP binding sites)
mouse gene 
mdrl (mdr lb)
complete loss of function of the 
transporter, continued binding 
of azido-ATP
* represents genetically engineered mutations
References: ^Choi e ta l 1991; '^Kioka et aL, 1989; ^Devine et al., 1992; ^Hsu et al., 1990; ^Gros 
et at., 1991; ^Azzario et aL, 1989
The majority of these mutations occur in or around the transmembrane domains of P- 
glycoprotein. This may indicate that these regions are important in substrate
specificity.
(vi) Identification o f expression o f  P-glycoprotein
The expression of P-glycoprotein protein and mRNA in normal tissues and tumours 
has been determined in a number of ways. M D Rl mRNA can be detected by 
Northern blot or slot blot analysis, by RNAse protection, by in situ hybridisation and 
autoradiography or by a variety of quantitative polymerase chain reaction (PCR)- 
based assays. Some laboratories have used functional assays based on the ability of 
P-glycoprotein overexpressing MDR cells to extrude fluorescent dyes, such as 
rhodamine. If the reduced dye accumulation in MDR cells can tlien be reversed with a 
modifier such as verapamil or cyclosporin A, agents known to inhibit the function ol
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P-glycoprotein, then preliminary, but not definite evidence for the expression of P- 
glycoprolein can be obtained. Overexpression of P-glycoprotein protein has been 
measured using antibodies. Table 1.7 shows some of these antibodies and groups 
them according to their recognition site.
Table 1.7
Antibodies which detect P-glycoprotein
ANTIBODY SITE r e f e r e n c e
C219 internal Kartner er a/., 1985
C494 internal Kartner er fl/., 1985
JSB-1 internal Scheper et ai, 1988 •
MRK-16 external Hamada gf o/., 1986
MRK-17 external Hamada gr oA, 1986
265/F4 external Lathan et ai, 1985
HYB-612 external Meyers et a l . 1988
MAb57 external Cenciarelli et al, 1991
17F9 external Aiha.ra.etal, 1991
4E3.16 external Arceci et ai, 1992
UIC-2 external Mechetner er fll, 1992
The monoclonal antibody C219 is perhaps the most extensively characterised. It binds 
to its epitope near the ATP-binding site of P-glycoprotein (Georges et a l, 1990). 
C219 is not entirely specific for the MDRl product, it also recognises other proteins 
such as the MDR2 product and certain forms of myosin. The antibody is, however, 
useful for immunoprécipitations and Western blotting analysis for semi-quantitative 
determination of P-glycoprotein levels in tissues (Bell et a l, 1985), and for 
immunohistochemical detection of P-glycoprotein (Chan eta l, 1990). In contrast, the 
monoclonal antibody, MRK-16 has an external recognition site and is quite specific 
for human P-glycoprotein (Hamada et a l, 1986) and is very useful for FACS
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analysis or magnetic sorting of P-glycoprotein-bearing cells (Choi et al., 1991). It 
cannot be used for quantitative immunoprécipitation or Western blots.
(vii) Expression o f  P-glycoprotein in normal tissues 
The first studies on the expression of P-glycoprotein in normal tissues were 
examinations of M DRl gene expression, determined by levels of M DRl RNA (Fojo 
etal., 1987). This was soon followed by immunohistochemical studies using the 
MRK-16 antibody (Thiebaut et aL, 1987). These studies demonstrated there to be 
very high levels of P-glycoprotein in the adult adrenal gland, the brush border of the 
renal proximal tubule epithelium, the lumenal surface of biliary hepatocytes, small and 
large intestinal mucosal cells and pancreatic ductules. Since these first studies, P- 
glycoprotein expression has been observed in many other tissues, including the brain 
and testis (Thiebaut et al., 1989), the secretory glands of the pregnant epithelium 
(Bradley et aL, 1990), in placenta, in peripheral lymphocytes (Chaudhary et al.,
1992) and in CD34 bone marrow stem cells (Chaudhary et aL, 1991). Speculation 
concerning the normal physiological function of P-glycoprotein has been made based 
on the known cellular localisation. As P-glycoprotein is expressed in transporting 
epithelia in kidney, liver, pancreas and intestine and capillary endothelia in the brain 
and testis its role may involve transepithelial or transendothelial transport of 
xenobiotics or prevent their absorption. The brain and the testes are known to be 
pharmacological sanctuaries for metastatic cancer. The presence of P-glycoprotein in 
the capillaries of these organs may have some significance in terms of protecting these 
cells from chemotherapeutic damage by transporting cytotoxic drugs out of the cell. 
P-glycoprotein may serve a blood-tissue barrier function, keeping toxic metabolites 
and xenobiotics out of these tissues. In the liver P-glycoprotein is found on the biliary 
surface of hepatocytes, while in the intestinal mucosa and the proximal renal tubule P- 
glycoprotein is localised to the apical surface of lining epithelial cells, adjacent to the 
lumen (Thiebaut et aL, 1987). The localised distribution of P-glycoprotein in these 
organs is also suggestive of a membrane transport function. High-level expression in
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the adrenal gland suggests a role in steroid secretion or the protection of the 
membranes of steroid-secreting cells. The observation that progesterone is an 
inhibitor of P-glycoprotein (Yang et a i, 1989) supports this idea.
(viii) Expression o f  P-glycoprotein in human cancers
Intrinsic expression of. the MDRl gene is found in cancers derived from tissues that 
normally express the MDRl gene such as, kidney, liver, colon, pancreas and adrenal 
gland (Fojo et aL, 1987). Other untreated cancers such as acute and chronic 
leukaemia of children and adults, non-Hodgkin's lymphoma, chronic myelogenous 
leukaemia in blast crisis, non small cell lung cancer with neuro-endocrine properties, 
neuroblastoma, sarcoma and astrocytoma express high levels of M DRl RNA but 
originate from tissues that do not express M D Rl RNA at easily detectable levels 
(Gottesman etal., 1993). This observation has led to the suggestion that the process 
of malignant transformation may activate expression of the M DRl gene. This is 
supported by two studies. One study demonstrated that ras and mutant p53, two 
genes commonly associated with tumour progression, were able to stimulate the 
M DRl promoter (Chin et aL, 1992). Another study reported increased MDRl gene 
expression at invading margins of locally aggressive and metastatic cancers 
(Weinstein etal., 1991). M DRl gene expression is often observed in tumours that 
have relapsed during the course of, or after, chemotherapy. Examples of these 
include lymphoma, leukaemia, neuroblastoma, cancers of the breast and ovary, and 
multiple myeloma (Dalton et aL, 1989). This may indicate that either there was a small 
pre-cursor population of MDRl expressing cells that survived the initial treatment and 
then regrew to produce a drug resistant relapsed tumour or that the chemotherapy 
itself induced MDRl gene expression.
(ix) Mechanisms o f  P-glycoprotein-mediated multidrug resistance
A  interesting question with respect to MDR is how a single transporter can transport 
such a broad range of structurally heterogeneous substrates. It is difficult to imagine
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an enzyme-like binding site with the affinity for diverse substrates such as 
anthracyclines, alkaloids, actinoniycin D, cyclic and linear peptides as well as an 
assortment of other hydrophobic and amphiphathic compounds.
Before the demonstration of the ATP-dependent efflux pump activity of P- 
glycoprotein (Willingham et a i, 1986), drug resistance was attributed to a reduction 
in the permeability of the plasma membrane to certain drugs (Ling et al., 1974). 
When the efflux pump activity of P-glycoprotein was identified, this was thought to 
be the sole mechanism by which decreased intracellular drug accumulation was 
achieved. It has more recently been demonstrated that the multidrug resistance 
transporter is able to reduce influx of drug into the cytosol as well as increase efflux. 
Taking this fact into consideration the most popular current model for the mechanism 
of action of P-glycoprotein is one based on the removal of drug directly from the 
plasma membrane. This model, adapted from Gottesman et aL, 1993, is shown in 
figure 1.5. This type of model has been named the "hydrophobic vacuum cleaner" 
and has two major features:
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Figure 1.5
p-g |ycoprotein-"The hydrophobic vacuum cleaner" model
9
(
6
A possible mechanism of action for P-glycoproiein emphasising 2 features: (1) drugs may be detected 
in and ejected horn the plasma membrane; and (2) the transporter has a  3D structure involving one or 
more p l70  subunits, which bring both halves together to form a  single transporter channel. Adapted 
from Gottesman et al., 1993.
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Firstly , drugs can be detected and expelled as they en ter the plasm a 
m em brane.
The series of structurally diverse compounds belonging to the MDR phenotype are 
amphiphathic compounds that are preferentially soluble in lipid (hydrophobic). In 
this model, the primary determinant of specificity would be the ability of the substrate 
to intercalate into the lipid bilayer (i.e. hydrophobicity). Interactions with the 
substrate binding site would be of secondary importance, although they would still 
play a role in determining specificity. Hydrophilic drugs would not intercalate in the 
lipid bilayer in an appropriate fashion and would therefore not be substrates for the 
MDR transporter. This may provide an explanation for the unusual transport kinetics 
associated with P-glycoprotein-mediated transport If the substrate is extracted from 
the lipid bilayer, the actual concentration of drug that comes into direct contact with 
the protein is unknown and will be different from the concentration of the drug added 
to the cellular matrix (Higgins et aL, 1992a & b). There are two sets of data in 
support of the idea that drugs are transported directly from the plasma membrane. 
Firstly, Kessel et aL, demonstrated that rhodamine 123, a highly fluorescent 
mitochondrial laser dye which is an excellent P-glycoprotein substrate (Neyfakh et 
aL, 1988), has a different fluorescence excitation spectra in drug sensitive and 
resistant cells. In sensitive cells the excitation spectrum of riiodamine 123 resembles 
its spectrum in octanol, suggesting that the dye lies within a highly hydrophobic 
environment such as the plasma membrane. In contrast in resistant cells, the 
spectrum looks more like that of rhodamine in aqueous environment, suggesting that 
the drug has been removed from the plasma membrane (Kessel et aL, 1989). 
Localisation of rhodamine 123 in sensitive and MDR cells using confocal microscopy 
has confirmed this result (Weaver et aL, 1991). Secondly, Raviv et aL, in 1990 
showed that by measuring the transfer of energy from doxorubicin to iodinated 
naphthalene azide, a highly hydrophobic label of membrane constituents including 
transmembrane proteins, the presence of doxorubicin within the membranes of drug 
sensitive cells could be demonstrated. In drug resistant cells, however, doxorubicin
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was only found in the plasma membrane associated with P-glycoprotein. This result 
indicates that the MDR transporter has removed doxorubicin from the plasma 
membrane (Raviv etoL, 1990)
Sencondly, transport occurs through a single channel of the 
transporter.
The main evidence for the second feature of this model for the mechanism of the 
MDR transporter, a single transport channel, comes from binding and photoaffinity 
labelling data (Bruggeman et aL, 1992). Bruggeman was able to demonstrate that 
inhibition of azidopine labelling by vinblastine reduces labelling equivalently in both 
the amino- and the carboxy-terminal halves of P-glycoprotein, suggesting that these 
two binding sites are equivalent with respect to their ability to bind two different 
drugs. These data support a model for P-glycoprotein in which both halves of the 
transporter come together to form a single transport channel. Although it has also 
been shown recently that the precise binding sites of verapamil, a modifier of MDR, 
and vinblastine are not identical this does not necessarily provide negative evidence 
for the theory of single channel transport The transport channel for drugs, identified 
by the photoaffinity labels of Bruggeman, and the initial drug binding sites, which 
probably define how drugs enter the transporter may well be different (Gottesman et 
aL, 1993).
It is well documented that the process of drug transport by P-glycoprotein is active 
and ATP-dependent (Horio et aL, 1988). We know very little, however, concerning 
the way in which the energy of ATP is harnessed by the transporter. It has been 
demonstrated that both ATP sites are required for ATP-dependent drug transport to 
occur efficiently (Azzaria et aL, 1989) and that drugs are themselves capable of 
stimulating ATPase activity (Sarkardi et aL, 1992; Ambudkar et aL, 1992). In order 
to explain how the energy of ATP is transduced to result in the transport of drugs 
from the plasma membrane to the extra cellular matrix, Higgins et aL, introduced the
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idea üiat P-glycoprotein acts as a "llippase". In this model the drug is flipped from 
the inner leaflet of the lipid bilayer to either the outer leaflet of the lipid bilayer or the 
extra cellular medium (Higgins et aL, 1992b). Little is known about mechanisms of 
phospholipid flippases, therefore further experimentation is required before this idea 
can be supported or refuted.
An alternative model for the mechanism of MDR proposes that the characteristic 
reduced intracellular accumulation of drug in MDR cells is a result of perturbations in 
a variety of complex drug/cell interactions that are essentially precipitated by 
alterations in the character and magnitude of the plasma membrane electrode potential. 
Consistent with this model are many intracellular pH and plasma membrane electrical 
potential perturbations in MDR cells (Thiebaut et al., 1990; Roepe et al., 1993; Luz et 
aL, 1994; Wei et aL, 1994). Irregularities in chloride conductance, also in turn 
influence electrochemical potential (Gill et aL, 1992). This model essentially suggests 
that P-glycoprotein may act as an intracellular pH regulator, possibly acting to 
sequester drug molecules into specific subcellular compartments to mediate efflux or 
to affect pH-dependent binding of drugs to cellular targets (Roepe et aL, 1992 & 
1993). An elegant study carried out by Ruetz and Gros (1994) contradicts the 
evidence in support of this type of model. In this study the group examined drug 
uptake into inside-out plasma membrane or secretory vesicles made from S. cerevisiae 
harbouring overexpressed murine mdr3 protein. They found that, in mdr3- 
expressing secretory vesicles, vinblastine accumulation was not affected by the 
presence or absence of the membrane potential. In addition, they demonstrated that 
mdr3 caused an enhanced accumulation of the lipophilic cation and P-glycoprotein 
substrate tetraphenylphosphonium in secretory vesicles, despite the presence of a 
strong transmembrane proton gradient. The group conclude that P-glycoprotein 
mediated drug transport is not only independent of a proton gradient but is also not 
coupled to proton movement across the membrane of the secretory vesicle (Ruetz et 
a i, 1994a&b).
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A further speculative model was proposed by Gill and co-workers in 1992. This 
model suggests that P-glycoprotein is bi-functional, serving not only as a active drug 
transporter but also as a chloride channel activated by cell swelling. This suggestion 
was based on a number of observations. Firstly, hypotonicity-induced chloride 
conductances correlated with P-glycoprotein expression. Secondly, inhibitors of drug 
transport, including verapamil, inhibited hypotonicity-induced chloride conductances. 
Finally, site-directed mutations in the nucleotide-binding folds of P-glycoprotein, 
which prevent ATP hydrolysis but preserve ATP binding, eliminate drug transport 
dependent on ATP hydrolysis but did not effect chloride channel function dependent 
on ATP binding. Cystic fibrosis transmembrane regulator (CFTR), the protein 
product of the cystic fibrosis gene and another member of the ABC superfamily of 
transporters, is a cyclic AMP-dependent chloride channel. The fact that 
bifunctionality could, therefore, be a characteristic of CFTR and other ABC 
transporters makes this model even more intriguing. In contrast the findings of 
another group, Dong et a l, (1994), completely contradict those of Gill et aL They 
conclude that despite large differences in P-glycoprotein expression levels they found 
no differences in hypotonicity-induced chloride currents among three drug sensitive 
cell lines and their MDR sublines. They were also unable to demonstrate evidence of 
chloride current blockade by the resistance modifier, verapamil. Three other groups 
also provided contradictory evidence. Wang et aL (1994) found no difference in 
hypotonicity-induced chloride currents between the drug sensitive T-lymphoblastic 
cell line, CCRF-CEM and its classical MDR subline CEM/VLB100. Altenberg er aL 
(1994a&b) and Weaver et al. (1993) demonstrated that P-glycoprotein mediated active 
transport and electrodiffusive chloride transport are dissociated.
(x) Reversal o f  P-glycoprotein mediated multidrug resistance 
A number of approaches have been used to circumvent the problem of multidrug 
resistance in laboratory models. One such approach has been the use of additional
33
chemical compounds, resistance modifiers which, when co-administered with a 
cytotoxic drug lead to a partial or complete restoration of sensitivity in resistant cells. 
Tsuruo e ta l,  in 1981 provided the first evidence of a compound capable of restoring 
sensitivity to resistant cells. The group demonstrated that verapamil, a calcium 
channel blocker, was able to sensitise vincristine-resistant cells to vincristine and 
vinblastine. This was observed in vitro and in mice bearing Ehrlich ascites tumours 
resistant to vincristine. During the early 1980s verapamil was studied with great 
interest. It was originally thought that the increase in efflux of cytotoxic drugs 
observed in MDR cells may be linked to calcium transport and so calcium channel 
blockers should therefore restore sensitivity to these cells. Verapamil has, however, 
been shown to be an active modifier of MDR even in MDR cells which lack calcium 
channels. It has now been shown that verapamil is able to bind directly to P- 
glycoprotein (Safa et aL, 1988) and its mode of resistance modification is thought to 
be via competitive inhibition of P-glycoprotein (Zamora et aL, 1988; Tsuruo et aL, 
1981). The calcium channel blocking activity of verapamil is now considered to be 
unrelated to its resistance modifying action. It has been shown, however, to enhance 
ATP consumption (Broxterman e ta l ,  1988), to restore cytoplasmic pH (Vayuvegula 
et aL, 1988), to correct decreased membrane potential and to increase intranuclear 
concentrations of doxorubicin and. daunorubicin in MDR cells (Schuurhuis et aL,
1989). This may indicate that the mechanisms underlying the way in which verapamil 
reverses MDR are rather more complexed than simple competitive inhibition of P- 
glycoprotein.
During the 1980s, after the discovery of verapamil as a resistance modifier, other 
compounds including other calcium channel blockers and calmodulin inhibitors were 
demonstrated to have resistance modifying properties. Analysis of common physical- 
chemical properties shared by compounds that modulate MDR revealed that many of 
these agents had two planar aromatic domains and a basic nitrogen (Pearce et al.,
1990). Structural similarities may play a role in the ability of some compounds to
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modulate multidrug resistance but it appears that lipid solubility, physiological pH, 
cationic charge and molar refractivity are more important physiological properties of 
modulators (Zamora et al., 1988). The immunosuppressive agent, cyclosporin A, 
was initially identified as an effective resistance modifier due to its interaction with 
calmodulin. Slater et al. (1986a & b) were the first group to show the activity of 
cyclosporin A as a resistance modifiers. Cyclosporin A has a particularly high 
binding affinity to P-glycoprotein. Like verapamil, it may also inhibit P-glycoprotein 
competitively. Twentyman e ta l  (1987a & 1988) examined the relationship between 
immunosuppression and resistance modification for a number of cyclosporin A 
analogues. They found that chemically-modified cyclosporins could be non- 
immunosuppressive whilst being highly effective resistance modifiers (Twentyman et 
at., 1988). There are now several examples of 'second generation' chemosensitisers 
with high molar potency for reversing MDR. Studies carried out at Sandoz led to the 
identification of one such compound, PSC-833, a novel cyclosporin analogue, which 
is a lead compound for clinical trial as a resistance modifier (Gaveriaux et at., 1991). 
A novel approach to circumvention of MDR has been to combine modifiers. The 
rationale behind this strategy is to increase the therapeutic index of chemosensitisation 
by combining agents that produce a positive interaction in reversing MDR but differ in 
dose limiting toxicities. In vitro, various combinations of resistance modifiers have 
demonstrated a synergistic interaction. For example, verapamil in combination with 
either quinidine (Lehnert er a/L, 1991) or cyclosporin A (Huer fl/L, 1990). In addition 
to the use of drugs to circumvent the phenomenon of MDR other agents such as 
antibodies (Hamada etal., 1986; Merchetner e ta l,  1992), immunotoxins (Fitzgerald 
et at., 1987), antisense oligonucleotides (Thierry er aL, 1993) and liposome 
encapsulated drugs (Mickisch er aL, 1992) have all been shown to be valid 
approaches to the elimination of MDR in vitro. Further investigations and in vivo 
studies are required before their clinical potential can be evaluated. Modifiers of P- 
glycoprotein mediated MDR are characterised and discussed in more detail in Chapter 
4.
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(xi) Clinical trials
On the basis of experimental evidence of the importance of the concept of MDR 
reversal in overcoming chemotherapeutic refractiveness, several agents with the 
capability to reverse multidrug resistance have entered clinical trial over the last few 
years. For example verapamil (IV and oral), D-verapamil, cyclosporin A, quinidine 
sulphate, trifluoperazine and tamoxifen. Table 1.8 summarises the outcome of some 
of the earlier trials.
Table 1.8
Examples of the outcome of early clinical trials involving resistance 
m odifiers
THERAPY ; M ALIGNANCY ; & PATIENT NO*;
REM ISSIONS
COMPLETE
(PARTIAL)
REFERENCE
Verapamil
(Doxorubicin)
Ovarian (8) 0(0) Ozols et ai, 
1987
Verapamil
(VAD*)
Myeloma (22) 0(5) Salmon et al, 
1991
Verapamil
(VAD+cyclophos.)
non-Hodgkins
lymphoma(14)
4(7) Miller et al, 
1991
D-verapamil
(Doxorubicin)
Colorectal 05) 0(1) Chabner et al, 
1990
T rifluoperazine
(Doxorubicin)
Various (36) 1(6) Miller et al, 
1988
Cyclosporin A 
(Vinblastine)
Renal (15) 0(0) Rodenburg 
é ta l, 1991
*VAD-vincristine, doxorubicin, dexamethasone
Verapamil was the first and most extensively studied of the MDR modulators. 
Cardiotoxicity proved to be the dose-limiting toxicity at concentrations of l-2|iM, 
whereas in most MDR models, concentrations of 6-lOpM are required to inhibit fully 
P-glycoprotein. The D- and L- isomers of verapamil are equally effective as P- 
glycoprotein inhibitors (Damiani et aL, 1993). The D-isomer, however, has 
considerably less cardiovascular effects. The use ol D-vcrapamil has permilied
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modest increases in achievable serum levels (about 2piM), although cardiovascular 
effects remain dose-limiting. The main metabolite, norverapamil, is also an effective 
modulator of MDR. The combined serum effects of D-verapamil and its norverapamil 
metabolite may reach levels sufficient to reverse MDR. Tolcher et al. (1994) found 
that D-verapamil administration resulted in a 2-fold increase in the area under the 
curve (AUC) of paclitaxel (i.e. cytotoxicity of paclitaxel) without any effect on 
paclitaxel-induced toxicity. Dexniguldipine, a new calcium channel blocker 
analogue, is currently being evaluated in phase I trials. In vitro, dexniguldipine 
effectively reverses MDR at concentrations of l-2pM. Steady state serum levels of 
0.5mM have been achieved, with bradycardia as the dose limiting toxicity (Scheulen et 
aL, 1994). To date, no significant alterations in the pharmacokinetics of cytotoxic 
drugs involved in the MDR phenotype have been reported with dexniguldipine in 
vivo.
There have been numerous clinical trials using cyclosporin A as a modulator of MDR. 
These trials were preceded by two case reports showing evidence for the activity of 
cyclosporin A in combination with cytotoxic drugs in vivo. Firstly, in 1985, Kloke. 
and Osieka documented a case in which a patient with etoposide-refractory T-cell 
acute lymphocytic leukaemia (ALL) was given cyclosporin A in combination with 
etoposide, with the aim of selectively suppressing T-cell growth with the cyclosporin 
A. The combination resulted in a rapid decrease in circulating leukaemic cells and 
prolonged myelosuppression (Kloke et al., 1985). Secondly, Sonneveld described 
the use of cyclosporin A and daunorubicin in the treatment of a patient witli acute 
myelocytic leukaemia (AML). Circulating AML cells were found to be MDRl 
positive. Treatment of the patient with daunorubicin and cyclosporin A resulted in the 
elimination of the MDRl positive cells (Sonneveld et al., 1992). Unlike trials with 
verapamil, most of the cyclosporin A studies have documented marked effect on the 
pharmacokinetics of cytotoxic drugs and significant enhancement in chemotherapy- 
related toxicities (Linn er rï/., 1994; Bartlett er fl/., 1994; Fisher e r /?/., 1994a). The
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cyclosporin analogue, PSC 833, has emerged as a non-nephrotoxic, non 
immunosuppressive agent that is 5- to 10-fold more potent than cyclosporin A as a 
modifier of MDR. Phase I studies have indicated that serum concentrations of 0.5 to 
IpiM can be aehicvcd witli intravenous (Boote et al., 1994) and oral (Fisher et al., 
1994b) formulations. Dose-limiting toxicity is neurologic, with reversible ataxia 
predominating (Fisher et al. 1994b). Marked pharmacokinetic effects have been 
observed even at lower doses of PSC 833. Like cyclosporin A, increased 
myelosuppression requires an approximate 2-fold reduction in the administered dose 
of cytotoxic drug when given in combination with PSC 833. The prolonged half-life 
of MDR-related cytotoxic drugs when administered in combination with PSC 833 or 
cyclosporin A is likely to be due to impaired elimination via a direct inhibition of P- 
glycoprotein in the liver and to a lesser extent in the kidney.
It is clear that the best responses in the early verapamil and cyclosporin A trials (Table 
1.8) were achieved in the treatment of malignant lymphomas, leukaemias and multiple 
myeloma (Raderer et a l, 1993). There are several reasons why these initial clinical 
trials have indicated a predominantly negative outcome. Firstly, many of the 
modulators used in these clinical trials could not be administered at an optimal 
concentration due to inherent toxicity. For example, verapamil causes cardiac toxicity. 
Secondly, many of the clinical trials have been performed in an uncontrolled fashion 
involving only a small number of patients, sometimes with differing tumour types. 
These patients often have very advanced tumours making the chance of a response 
even smaller. In addition, most trials with agents that modify MDR have included 
patients with unknown P-glycoprotein expression and several phase 11 studies have 
been performed in tumours in which it is unlikely that the M DRl gene product is a 
major cause of drug resistance, such as, small cell lung cancer or ovarian cancer 
(Raderer et a i, 1993). Establishing the P-glycoprotein status of the tumour is 
especially important in order to correlate modifier activity with a direct effect on P- 
glycoprotein function. Another reason for the disappointing therapeutic outcome may
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be that the expression of P-glycoprotein may be heterogeneous within a given 
population of tumour cells (Rothenberg et a i, 1989) or mutant forms of P- 
glycoprotein may exist that may not be affected by agents that modulate the M DRl 
gene product (Hefzog et ùL, 1992). Finally, other mechanisms of resistance may co­
exist with the occurrence of P-glycoprotein in MDR cells. They may also exist in 
cells lacking P-glycoprotein causing resistance independently. These include changes 
in the levels of activity of the important nuclear target enzyme topoisomerase II (Beck, 
1989) and increased levels of intracellular GSH and glutathione-S-transferase, both of 
which act to increase detoxification of agents such as anthracyclines (Cowan et al., 
1986).
Phase I trails of currently available MDR modulators have yielded important 
pharmacological principles relating to the normal function of anticancer drugs 
involved in the MDR phenotype. Although these modulators lack the potency to 
reverse completely MDR at clinically achievable concentrations, encouraging clinical 
results have been obtained in the haematological malignancies.
1 .3 .3  Overexpression of the multidrug resistance associated
protein (MRP)
( i)  In troduction
Resistant tumour cells have been described that appear to express a 'classical' MDR 
phenotype (decreased cellular accumulation of drugs, altered cellular drug 
distribution, broad cross-resistance pattern) but do not overexpress the MDRl gene 
product P-glycoprotein.
(ii) The discovery o f  M RP
In 1988, Melvin Center was the first person to show that a surface membrane protein 
distinct from P-glycoprotein contributed to reduced cellular accumulation in
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HL60/ADR leukaemia cells (McGrath et a i, 1988). It was not until 1992 that this 
membrane protein was shown to be identical to the multidrug resistance associated 
protein (MRP) gene product The MRP gene which encodes for a 190kDa protein, 
was first cloned in tlie multidrug resistant H69/AR, small cell lung cancer cell line by 
Susan Cole and co-workers (Cole et al., 1992a). The MRP protein has recently 
been the subject of intense research interest due to the discovery that MRP is identical 
to the GSH conjugate transporter present in hepatocytes, macrophages and other 
normal cell types (Jedlitschky et at., 1994).
Isolation and sequencing of the MRP gene was carried out using cloned cDNAs 
which corresponded to mRNA highly expressed in the small cell lung cancer (SCLC) 
MDR cell line, H69/AR (Cole et al., 1992a). The primary sequence and predicted size 
(1531 amino acids) of the MRP gene, located on chromosome 16 (16pI3.i), 
indicated that it is a member of the ATP-binding cassette (ABC) transporter 
superfamily (Hughes et al., 1994). MRP possesses several hallmarks of ABC 
proteins - it is a bipartite molecule comprising 8 hydrophobic transmembrane regions 
in its N-terminal half and 4 in its C-terminal half, with both portions of the molecule 
containing nucleotide binding folds at their C-terminal ends (Figure 1.6). Despite 
overall structural similarities, comparison with other family members shows only 
distant amino acid identity with known ABC proteins (P-glycoprotein, 14% & CFTR, 
17%; Grant et al., 1994), identifying most closely with the leishmania P- 
glycoprotein-related molecule with most identity lying in the nucleotide binding 
regions. These findings make MRP an obvious candidate for the putative drug 
transporter in non-P-glycoprotein multidrug resistance cells. In order to confirm that 
MRP is directly responsible for the multidrug resistance (decreased drug 
accumulation) observed in these non-P-glycoprotein cell lines, transfection studies 
were carried out The stable transfection of both Hela cells (Grant et al., 1994) and 
the non-small cell lung cancer (NSCLC) SW-1573 cells (Zaman et al., 1994) 
demonstrated that MRP increases the resistance to natural product cytotoxic drugs
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such as doxorubicin, vincrislinc, vinblastine, etoposide and to a lesser extent taxol 
(Cole et a l,  1994). However, the issue is confused by the fact that the H69/AR cell 
line, is one of the few cell lines without an accumulation deticit (Cole et a l, 1992a & 
b). This indicates that at least in this system MRP does not contribute to MDR as a 
membrane drug efflux pump similar to P-glycoprotein. In addition, some MRP 
expressing MDR cell lines also demonstrate altered topoisomerase II activity . These 
data indicate that multiple resistance mechanisms may operate in MDR cells that 
express MRP or other transport proteins. Table 1.9 summarises data on a number of 
the well chaiacterised MRP-overexpressing cell lines.
Table 1.9
MRP overexpressing human MDR tumour cells lines
CELL LINE 
(TY PE)
SELEC Tlk(5
DRUG
DECREASED
DRUG
ACCUM ÜL
REFERENCE
COR-L23/K
(N SC L C )
doxorubicin yes Barrand et al., 
1994
MOR/Ü.4K  
(adenocar. lung)
doxorubicin y es Barrand et al., 
1994
SW -1573/1K 12U
(N SC L C )*
doxorubicin y es Baas et al., 1990
M CF7/VP  
(breast cancer)
V P-16 yes
Schneider et al., 
1995a
GLC4/ADK
(SC L C )*
doxorubicin y es M eijer et al., 1991
H 69/A R
(SC L C )*
doxorubicin no Cole et al., 1992
HL60/ADK
(leukaem ia)
doxorubicin yes
Krishnamachary 
et a l ,  1993
H L60/AK
(leukaem ia)
doxorubicin yes Lutzky et al., 1989
U -937-A 1U
(leukaem ia)
doxorubicin yes Slapak et al., 1994
*(N)SCLC-(Non) Small Cell Lung Cancer
41
Figure 1.6
The structure  of M RP
NH
COOH
Figure 1.6 demonstrates the predicted structure of MRP. Analysis of the deduced amino add  
sequence of MRP predicts that the NH2-proximaI half o f the molecule may contain 8 or more 
transmembrane segments followed by a  nucleotide binding domain R4BD1).
The COOH-pioximal half o f the molecule may contain only 4 transmembrane segments followed by
a second nucleotide binding domain (NBD2).
A and B, motifs arc characteristic of nucleotide-binding domains o f ABC transport proteins.
#, potential N-glycosylation sites that arc predicted to be on the outside o f the membrane. 
(Adapted from Almquist et ai, 1995)
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(Hi) Expression o f  M RP in normal human tissues 
Using RNase protection analysis, expression of MRP mRNA was found to be 
widespread in all normal tissues analysed, including kidney, stomach, lung, intestine, 
thyroid, bladder, testis, adrenal gland, pancreas, placenta, liver, ovary and muscle 
(Zaman et at., 1993). Localisation of MRP on a cellular level was examined by 
Thomas et a l  (1994). The group localised MRP on histological tissue sections using 
in situ hybridisation and demonstrated the high expression of MRP in normal 
bronchial epithelial cells. Initial data obtained using recently available monoclonal 
antibodies (Flens et a i, 1994; Hipfner et al., 1994) confirms the results of Thomas et 
a l MRP expression was also observed in the adrenal cortex and the epithelial cells of 
the GI tract.
(iv) M echanism(s) o f  M RP-mediated MDR
Like P-glycoprotein, MRP is capable of actively transporting cytotoxic drugs out of 
cells against a concentration gradient (Versantvoort et aL, 1992). Furthermore, 
transfection of MRP into drug sensitive tumours cells demonstrated that MRP caused 
the efflux of drugs such as daunorubicin against a concentration gradient in 
transfected cells (Zaman et al„ 1994). Conversely the H69/AR cell line in which 
MRP was originally cloned (Cole et aL, 1992a & b) does not show a decreased drug 
accumulation. Susan Cole explains this phenomenon by hypothesising that MRP, 
apart from being a plasma membrane transporter, may be capable of pumping drugs 
into cytoplasmic vesicles in preparation for removal by exocytosis (Cole et a i, 1992a 
& b). MRP is localised on the plasma membrane of tumour cells (including the MRP- 
overexpressing, laboratory derived, multidrug resistant cells). In highly MRP 
overexpressing cells a golgi-like localisation is also observed. This difference in 
MRP localisation may be important in terms of MRP mechanism. The observation of 
MRP expression on a golgi-like structure may explain why no intracellular 
accumulation deficit is observed in Susan Cole's H69/AR cells. Versantvoort et al. 
(1994) demonstrated that daunoi-ubicin transport in MRP overexpressing cells was
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saturable, dependent on ATP concentration in the millimolar range and could be 
competitively inhibited by the tyrosine kinase inhibitor, genistein. It is fairly clear that 
MRP induces ATP-dependent removal of drug from tumour cells. As in the case of 
P-glycoprotein, the mechanism for this active transport has not been precisely 
defined.
It has recently been demonstrated that MRP is identical to the GSH conjugate 
transporter present in hepatocytes, macrophages and other normal cell types 
(Jedlitschky e ta l ,  1994). Thomas etal. (1994) demonstrated high level expression 
of MRP mRNA in normal human bronchial epithelium and at the advancing edge of a 
variety of lung tumour types. Interestingly the leukotriene LTC4, the GSH conjugate 
of leukotriene LTA4, is transported in an ATP-dependent manner into membrane 
vesicles prepared from the MRP-overexpressing multidrug resistant cell line 
HL60/ADR (Leier et aL, 1994a & b). The LTC4 transport into these vesicles was 
competitively inhibited by the leukotriene LTD4 receptor antagonist MK571, an 
anionic quinoline derivative (Jedlitschky et al., 1994; Leier et al., 1994a&b). Photo 
affinity labelling using pH]LTC4 identified a distinct overexpression of a 190kDa 
protein species in membranes prepared from the HL60/ADR cells. This labelling was 
efficiently competed by MK571 (Jedlitschky et al., 1994; Leier et al., 1994a&b). 
These results together with the observed overexpression of MRP mRNA in human 
bronchial epithelium may indicate a normal physiological role for MRP as a 
transporter of GSH conjugates, specifically GSH conjugated leukotrienes in the lung. 
The relationship between GSH biochemistry and the activity of MRP has been further 
investigated by Versantvoort et af.( 1995a) Depletion of cellular glutathione by DL- 
buthionine S,R-sulphoxamine (BSO) in cells which overexpress MRP, resulted in a 
decrease of daunorubicin and rhodamine 123 efflux. Restoration of cellular GSH 
levels by the addition of GSH ester to the medium restored the efflux activity. The 
mechanism of action of MRP and its link with cellular GSH metabolism is currently 
the subject of intense research interest and is discussed further in Chapter 6 .
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(iv ) Clinical relevance of M RP
It is difficult to speculate about the clinical relevance of MRP due to the lack of 
detailed data on the expression of MRP in human primary tumour samples. Evidence 
is emerging that MRP mRNA may be expressed in acute myeloid leukaemia (AML) 
and multiple myeloma, although only at the baseline levels observed in normal 
lymphocytes. The results showed as much as a 10-fold variation between individual 
AMLs. These studies have also demonstrated that their is no relationship between the 
expression of P-glycoprotein and MRP (Burger et al., 1994; Hart et aL, 1994; 
Schneider e ta l,  1995). This compounds the problem of reversal of MDR as both P- 
glycoprqtein and MRP levels would need to be determined before treatment could be 
considered. Agents that inhibit MRP-mediated drug transport are still in the 
developmental stage. Possible ways of modifying MRP -mediated MDR are 
discussed in detail in Chapters 5 and 6. More recently, MRP overexpression has 
been observed in chronic lymphocytic leukaemia (CLL) (Burger et aL, 1995; Hart et 
aL, 1995) and prolymphocytic leukaemia (PLL) ((Burger et aL, 1995).
(y) O ther membrane transport proteins associated with MDR  
There are several reports of other non-P-glycoprotein cell lines that express drug 
transporter proteins other than P-glycoprotein or MRP. The majority of these novel 
transporters have not yet been identified nor have the cell lines been fully 
characterised. One protein that has been identified, is the I lOkDa product of the LRP 
gene. Overexpression of this llOkDa protein has been measured in many drug 
resistant cell lines and is often co-expressed with the MRP protein (Schepler et aL, 
1993). The protein is recognised by the monoclonal antibody LRP56, which was 
raised against the non-P-glycoprotein MDR cell line, SW-1573/1R50. The drug 
sensitive cells showed the same staining pattern with LRP56, localised in a punctate 
cytoplasmic fashion, but the intensity of the staining was less. LRP protein 
(originally named Lung Resistance-related Protein) overexpression has been found to
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predict a poor response to chemotherapy in acute myeloid leukaemia (List et aL,
1993) and ovarian carcinoma (Izequierdo etal., 1994). Scheffer et al. (1995) cloned 
the LRP gene and localised it to chromosome 16, close to the MRP  gene. The 
deduced amino acid sequence shows a 87.7% identity with the 104kDa rat major vault 
protein. Vaults are multi-subunit structures that may be involved in nucleo- 
cytoplasmic transport (Scheffer et at., 1995). The frequent up regulation of the LRP 
gene in MDR tumour cells together with its value in predicting in vitro and clinical 
response to chemotherapy support the view that LRP and/or vaults can, when co­
expressed with members of the transmembrane transporter family, contribute to 
cytostatic drug resistance.
1 .3 .4  Drug resistance m ediated by drug m etabolising and
detoxifying enzymes 
The tripeptide, glutathione (GSH) is the principal cellular non-protein thiol and is able 
to react with, and detoxify, many of the reactive alkylating agents used in 
chemotherapy (Arrick et aL, 1984; Russo et aL, 1987). This interaction is catalysed 
by a family of enzymes known as glutathione-S-transferases (GST). In addition, the. 
enzyme involved in the oxidation of GSH to the disulphide GSSG, glutathione 
peroxidase (GPX), can detoxify free radicals including those produced in DNA by a 
number of cytotoxic drugs (including alkylating agents and doxorubicin) and also 
reduce toxic peroxides (Arrick et aL, 1984; Russo et aL, 1987).
Modification of GSH metabolism has been proposed as a mechanism leading to 
resistance to a range of anticancer drugs, and under some conditions, radiation 
(Moscow et aL, 1988). Stepwise selection of sublines of cells for increasing 
resistance to cisplatin or to alkylating agents such as melphalan has resulted in cells 
with increased levels of GSH. For example, the melphalan resistant tumour cell line 
L1210, shows increased GSH compared to the parent line (Suzukaka et aL, 1986). It 
is important to note that this type of resistance cannot be referred to as 'classical
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MDR' since the cell lines are only cross resistant to a limited group of compounds 
such as alkylating agents and platinum analogues. Resistance in these sublines can 
be reversed as a result of inhibition of GSH by buthionine sulphoximine (BSO), an 
inhibitor of GSH synthesis or by depletion of cellular levels of GSH by agents which 
directly inactivate it, such as diethylmaleate (Russo et aL, 1987). Some cell lines 
selected for resistance to alkylating agents or to doxorubicin have increased activity of 
one or more GST isoenzymes (Kramer et aL, 1988). Many researchers believe that in 
order for a gene product to be causatively linked to drug resistance, transfection 
studies must be performed. This area has provided substantial controversy in the 
GST field. A number of transfection studies have been carried out and some 
disparity is apparent The lack of drug resistance in MCF7, breast carcinoma cells 
transfected with GSTt:, a  or p isoenzymes (Morrow et aL, 1993) led many to 
conclude that the link between enhanced GST and drug resistance is tenuous. In 
other GST transfection studies only low levels of resistance (1.5- to 3-fold) were 
observed in the transfected cell lines (Tew et aL, 1993). The significance of low level 
resistance has been the subject of much debate. It is worth noting, in this case, that 
when MDRl recipient transfected cells are tested, they usually only display 5- to 20- 
fold resistance compared to the original selected MDRI overexpressing cell line which 
frequently show resistance levels of 1,(XX)- to 10,000- fold compared to the sensitive 
line. For alkylating agent-resistant cell lines, the degree of selected resistance rarely 
exceed 20-fold; therefore it could be argued that the 1.5- to 3-fold resistance reported 
in the GST transfectants is relatively consistent There have been several reports 
which have largely alleviated tlie uncertainty of the earlier data. Firstly, yeast cells, 
Saccharomyces cerevisiae, transfected with mammalian GST isoenzymes (Black et 
aL, 1990) were significantly resistant to chlorambucil and doxorubicin (maximum 
resistance 8- and 16-fold respectively). Secondly, in mammalian cells, Schecter etal. 
(1993) recently transfected the rat Yc gene (a  family) into rat mammary tumour cells 
and showed high levels of induced resistance, in the range of 6- to 30-fold, to a 
number of nitrogen mustards. Finally two studies have demonstrated the transfection
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of Chinese hamster ovary cells with GSTtc (Miyazaki et aL, 1990) and GSTcc (Giaccia 
etaL, 1991). GSTjt increased resistance to cisplatin and carboplatin by 2- and 3- 
fold, while GSTa increased protection against bleomycin. It would seem reasonable 
to suggest that the positive transfection studies should satisfy the question as to 
whether or not GSTs have a direct role in some types of tumours. However, it is 
important not to disregard the negative data. There are several possible explanations 
for this negative data: (a) intrinsic G.SH/GST levels; (b) feedback control 
mechanisms; effective compartmentalisation of GSH/GST; (c) presence of a GSH- 
conjugate membrane efflux pump and (d) GSTs themselves may not be sufficient to 
cause resistance. In order for resistance to be observed, transfected cells may require 
the existence of putative cellular complimentary factors (Tew, 1994).
Increased activity of another GSH-dependent enzyme, selenium-dependent GSH 
peroxidase (GSPX) may augment resistance to some drugs of the classical MDR 
phenotype. This enzyme catalyses the elimination of some hydroperoxide toxic 
intermediates formed during oxidation-reduction cycling of some drugs such as the 
anthracyclines and mitomycin C. Overexpression of GSPX or processes which 
increase its substrate, reduced GSH, are potential mechanisms of antineoplastic 
resistance (Gessner et a l ,  1990; Dusre et a l,  1990). Additionally, resistance to 
doxorubicin has been associated with down-regulation of NADPH reductases 
(enzymes implicated in the formation of toxic free radical intermediates of doxorubicin 
metabolism) as well as modest increases in the expression of the detoxifying 
enzymes, GSPX and catalase (Singh et al., 1990). Finally, overexpression of 
glucuronyl transferase has been associated with daunorubicin resistance (Gessner et 
aL, 1990). The relevance of this observation is suggested by the ability of the 
enzyme to catalyse the glucuronidation and excretion of a toxic drug metabolite, 
daunorubinol.
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There are two further mechanisms leading to resistance to alkylating agents. Firstly, 
increased levels of metallothioneins, proteins rich in sulphydryl-containing cysteine 
residues, are associated with resistance to cisplatin and alkylating agents. The 
mechanism is presumed to be interaction with toxic electrophilic drugs or their 
metabolites. Cells transfected with the human metallothionein gene (Kelley et aL, 
1988) conferred resistance to both cisplatin and alkylating agents, suggesting a causal 
link between the metallothionein gene and drug resistance. However, studies of 
cisplatin resistant human ovarian cancer cells failed to demonstrate any link between 
drug resistance and metallothionein levels (Schilder et aL, 1990). The role of 
sulphydryl compounds in clinical drug resistance remains unclear. Secondly, 
increased expression of enzymes that increase the capacity of damaged cells to repair 
DNA, such as O^-alkylguanine DNA alkyltransfefase, an enzyme that removes 
adducts from the position of the base guanine, is associated with resistance to 
alkylating agents (Masuda et aL, 1990).
It seems unlikely that one single mechanism is responsible for the phenomenon of 
clinical drug resistance. It is more likely that a combination of several mechanisms 
including the overexpression of P-glycoprotein (or other membrane transport 
proteins), GSH-based detoxifying enzymes, altered topoisomerase II and DNA repair 
mechanism may result in resistance in the clinic.
1 .3 .5  Drug resistance associated with changes in
topoisomerase II
( i)  In troduction
Cellular control of DNA topology is achieved by the activities of the DNA 
topoisomerases. These enzymes modify the topological state of DNA by inducing 
cither transient single strand (topoisomerase type I) or double strand (topoisomerase 
type II) breaks in DNA. The human type II enzyme is found in two forms encoded 
by single copy genes yeilding homodimeric proteins of 17()kDa (topoisomerase Ila)
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and 180kDa (topoisomerase 11(3) (Negri etal., 1992). The more abundant isoform, 
topoisomerase Ila, is located at nuclear matrix-associated regions, a strategic location 
at the base of chromatin loop domains which infers both structural and functional 
roles (Wood et al., 1990). Topoisomerase lib is found predominantly in the 
nucleolus (Zini et al., 1992) and binds to GC-rich sequences present in gene 
promotor regions, suggesting participation in gene expression (Ura et al., 1991).
(H) Topoisomerase I  and drug resistance
The majority of the cell lines selected for resistance to topoisomerase I (topo I)-active 
agents exhibit decreased topo I activity (Nitiss et a l, 1988; Bjornsti et a i, 1989; Eng 
et a l,  1990; Sugimoto et a l, 1990). Selection of P388 leukaemia cells by in vivo 
treatment of tumour-bearing mice with camptothecin resulted in a cell line (P388/PC) 
that exhibited modest (8-fold) resistance to camptothecin (Eng et a l, 1990). Other 
cell lines selected for resistance to camptothecin-11 were also found to exhibit 
decreases in topo I content (Table 1.10). Selection of the P388 leukaemia cells in 
camptothecin-11 produced a resistant variant P388/CPT (Sugimoto et al., 1990). 
This cell line was 45-fold resistant to camptothecin-11 yet the enzyme content was 
reduced by only 3-fold (Table 1.10). This indicates that other factors may also 
contribute to the cellular sensitivity to camptothecin-11 as well as reduced topo I 
levels.
In two different cell lines a second major form of resistance to camptothecin has been 
observed. In these cell lines the topo I is mutated and the enzyme has altered catalytic 
properties. Higher levels of resistance were observed in these cell lines than in the 
resistant cells that have a quantitative decrease in topo I activity (Table 1.10).
(Hi) Topoisomerase II  and drug resistance
The term 'atypical' MDR is often used to describe a pattern of MDR associated with 
resistance to several antineoplastic drugs including anthracyclines, 
epipodophyllotoxins, amsacrinc (mAMSA), and mitoxantrone (Danks e ta l ,  1987).
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In contrast to classical P-glycoprotein-mediated MDR, this phenotype usually retains 
sensitivity to the vinca alkaloids. The drugs associated with this resistance pattern 
interact with topoisomerase II and DNA in a process that leads to DNA strand breaks 
and cytotoxicity. This 'atypical' MDR (at-MDR) has been associated with decreased 
activity of type II topoisomerases (topo II) (Morrow et aL, 1990) and/or with the 
presence of variant iforms of the enzyme whose activity does not facilitate drug- 
induced DNA damage (Zwelling et a i,  1989). Generally, drug accumulation is 
unaltered in topoisomerase-related MDR. However, a non-P-glycoprotein expressing 
MDR lung line has been described which showed both decreased topo II activity and 
reduced doxorubicin accumulation (de Jong et al., 1990). Thus, multiple 
mechanisms of resistance may co-exist in this phenotype. Various alterations in topo 
II have been found in tumour cells that express the atypical-MDR (at-MDR) 
phenotype. These alterations are summarised in Table 1.11. In some at-MDR cell 
lines, resistance is related primarily to quantitative changes in topo II activity and/or 
protein content In other cells that express the at-MDR phenotype, qualitative rather 
than quantitative alterations in target enzyme are present In addition to these 
quantitative and qualitative changes, it is possible that alterations in cellular processes 
that follow the formation of the topo E DNA complexes also contribute to at-MDR.
Another form of at-MDR is associated with a specific depletion of the nuclear matrix 
enzyme (Fernandes et aL, 1990). Two studies have indicated that VM-26 and m- 
AMSA react preferentially with the nuclear matrix DNA topo II in the parental line, 
CCRF-CEM leukaemia cells and induce a dissociation of newly replicated DNA from 
nuclear matrices of these cells (Fernandes et aL, 1988 & 1990). In contrast to the 
results obtained with the drug-sensitive CCRF-CEM cells, neither VM-26 nor m- 
AMS A affects the association of newly replicated DNA with nuclear matrices of the 
at-MDR CEM/VM-1 cells (Fernandes et al., 1988). The decreased interaction of VM- 
26 and m-AMSA with nuclear matrix topo II of CEM/VM-1 cells is related to a 
selective depletion of the matrix enzyme (Fernandes et al, 1990).
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Table 1.10
R esistance  associa ted  w ith  changes in topo isom erase  I
CELL LINE TOPO I ALTERATION
FOLD
RESISTANCE REFERENCE
P338/PC Decreased topo I (2 to 4-fold) 8 (CPT) Eng etal., 1990
HT-29/CPT Decreased topo I (8-fold) 4 (CPT-11)
Sugimoto etal., 
1990
St-4/CPT Decreased topo I (4-fold) 9 (CPT-11)
Sugimoto eta l, 
1990
P388/CPT Decreased topo I (3-fold) 45 (CPT-11)
Sugimoto etal., 
1990
CPT-K5 Mutated topo I >125 (CPT) Tam ura j/., 1990
CHO/CptR-B Mutated topo I >250 (CPT) Gupta, e ta l, 1988
CPT-Camptothecin
T ab le  1.11
R esistance asso c ia ted  w ith  changes in  topo isom erase  I I
CELL LINE ' /-T O P O iL  , ALTERATION'' : REFERENCE
P388/AMSA (in vivo) Decreased topo II activity Tan etal., 1989
KB/VP-1;
KB/VP-2 Decreased topo II content Takano eta l;  1991
P388/ADR/3;
P388/ADR/7
Decreased topo II mRNA 
and activity Deffie gr a/., 1989
HL-60/MX/2
Decreased topo II activity; 
depletion of nuclear matrix 
topo II
Harkcr et al, 1989
HL-60/AMSA
Point mutation on topo II 
gene; altered topo II 
catalytic activity
Hinds e ta l, 1991
CEM/VM-1
Point mutation in topo II 
gene; altered topo II 
catMytic activity; depletion 
of nuclear matrix topo II
Bugg eta l, 1991
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In summary, cellular resistance is thought to be the principle cause of treatment 
failure in patients undergoing therapy with anticancer agents, including topoisomerase 
Il-directed agents. Preclinical studies with experimental anti-topoisomerase I agents 
suggest that the emergence of resistance will likewise limit the clinical usefulness of 
these drugs in many instances.
1 .3 .6  Regulators of programmed cell death (apoptosis) as
mechanisms of drug resistance
( i)  In troduction
Almost all chemotherapeutic agents ultimately affect endogenous physiological 
pathways for cell death to kill cancer cells. Tumour cells may become relatively more 
resistant either by the loss of genes required for cell death or by the over activation of 
genes that block it.
(it) Definition o f  cell death
Cell death can be broadly defined into two mechanisms. Firstly, necrotic or 
pathologic cell death and secondly, apoptotic or physiologic cell death. Table 1.12 
summarises the characteristics of these two types of cell death.
Knowledge about the genes involved in programmed cell death and the alterations that 
can occur in at least some of them in cancer has begun to lead to new strategies for the 
development of therapeutic agents that unlike conventional pharmaceuticals would 
target cell death rather than cell division.
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T able 1.12
C h a ra c te r is tic s  o f the  m echan ism s o f cell death
MECHANISMS OF CELL DEATH CHARACTERISTICS
NECROSIS
(pathologic cell death)
-cellular ATP supplies are deleted owing to 
inability to accomplish oxidative phosphorylation 
-loss o f osm otic equilibrium, cell swelling and 
rupture
-spill o f cellular contents to extra cellular milieu, 
leads to inflammatory cell response, fibrosis and 
scaring
APOPTOSIS
(physiologic or programmed 
cell deatli)
-ce ll is an active participant in a process that 
requires energy, often depends on new RNA and 
protein synthesis
-typically involves morphological changes: cell 
shrinkage, plasma membrane blebbing, nuclear 
fragm entation and chromatin condensation  
(pyknosis).
-apoptotic cells are rapidly cleared through 
phagocytosis by viable cells
(Hi) Genes involved in cell death
A  variety of experimental observations have pointed to bcl-2 as a critical regulator of 
the cell death process. The bcl-2 (B-cell lymphoma-2) gene was first associated with 
the development of human neoplasia due to its frequent involvement in non- 
Hodgkin's lymphomas (Tsujimoto et al., 1986). Though bcl-2 plays a major role in 
the pathogenesis of B-cell lymphomas, where it contributes to neoplastic cell 
expansion by delaying or preventing programmed cell death, perhaps more important 
are the potential effects of overexpression of the gene on responses to therapy. Bcl-2 
protein has been shown, experimentally, to render cells more resistant to killing by 
dexam ethasone, cyclophospham ide, doxorubicin, daunom ycin, 5- 
fluorodeoxyuridine, 2-chlorodeoxyadenosine, fludarabine, taxol, etoposide (VP-16), 
camptothecin, nitrogen mustards, mitoxantrone, cisplatin, vincristine and some 
retinoids. The observation that Bcl-2 provides protection against such a wide variety 
of drugs with diverse mechanisms of action suggests that they all utilise the same final 
common pathway for ultimately inducing cell death and that Bcl-2 is a regulator of 
this pathway.
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It appears that resistance to drugs mediated by the over production of Bcl-2 is 
distinctly different from all other mechanisms of drug resistance. For example Bcl-2 
does not prevent entry of drugs into the cell or increase drug efflux out of the cell in 
contrast to P-glycoprotein, the product of the MDRl gene. Also it does not alter the 
extent to which drugs induce damage to DNA or the rate at which cells repair 
damaged DNA. In addition, Bcl-2 has no effect on nucleotide pools or rates of cell 
cycling. Although Bcl-2 has been reported to produce elevations in intracellular GSH 
levels in one cell line (Kane et a l, 1993), this has not been observed in several other 
tumour and leukaemia cell lines, indicating that there is no consistent link between 
Bcl-2 overexpression and increased detoxification of drug by GSH conjugation. It 
appears that in Bcl-2 overexpressing cells, drugs still enter the cell and induce 
damage, but this damage is somehow ineffectively translated into signals for cell 
death. In summary, Bcl-2 can convert anticancer drugs from cytotoxic to cytostatic.
(iv) Regulation o f  bcl-2
One mechanism that may play a role in bcl-2 gene dysregulation is the loss of function 
of the tumour suppressor p53. The p53 gene encodes a DNA-binding protein that 
functions at least in part as a transcription factor to induce cell cycle arrest and 
apoptosis, particularly in response to DNA damage induced by chemotherapeutic 
drugs and radiation (Volelstein et a l,  1992). The expression of the gene (wafl/cdi- 
1) is induced by p53. This gene interferes with the function of cyclins required for Gi 
to S phase transition (Marx 1993). In relation to apoptosis, it has recently been 
observed that gene transfer-mediated elevations in p53 activity can lead to rapid down 
regulation of bcl-2 gene expression (Miyashita et a l, 1994). In addition, in p53 
knock-out mice, Bcl-2 protein levels were discovered to be elevated in some tissues 
such as the spleen , prostate and thymus. It appears that loss of p53 can lead to 
increases in Bcl-2 protein levels in some tissues.
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It has recently been demonstrated that, in addition to transcriptional regulation of the 
bcl-2 gene by p53, it can also be regulated at the protein level by an opposing protein, 
Bax. This protein shares 21% amino acid identity with the Bcl-2 protein and binds to 
Bcl-2 preventing it from blocking cell death (Oltvai et a i, 1993). Loss of the bax 
gene is, therefore, equivalent to overproduction of Bcl-2. The p53 tumour 
suppressor can also regulate the expression of box in some tissues (Miyashita et al., 
1994). Elevation in p53 activity leads to an up regulation in bax gene expression. 
This strengthens the connection between p53 loss in human cancers and mechanisms 
for dysregulation of both bcl-2 gene and protein function.
Although the mechanisms underlying Bcl-2 protein function and regulation of bel -2 
gene expression are not clearly defined, several novel treatments for cancers in which 
bel -2 is overexpressed have been suggested. Firstly, scientists are searching by 
rational design and random drug screening for small molecules that could disrupt the 
Bcl-2/Bax interactions, thus abrogating Bcl-2 protein function. A second approach is 
the sequence-specific down regulation of bel -2 expression. This has already been 
reported in vitro in lymphoma cell lines and acute myeloid leukaemia cells using 
antisense oligonucleotides (Campos etaL, 1994). The results from these experiments 
indicated that a decrease in Bcl-2 protein levels markedly enhanced sensitivity to 
chemotherapeutic drugs. Alternatively, certain lymphokines and retinoids, known to 
regulate the expression of the bel -2 gene could be used to lower the levels of bcl-2 
expression thus rendering bel -2 overexpressing malignant cells more sensitive to the 
induction of apoptosis by chemotherapeutic agents and radiation. It is clear that 
knowledge at the molecular level of the mechanisms underlying the function of Bcl-2 
and related proteins will inevitably lead to the development of novel treatments for 
cancer which modulate the apoptosis pathway.
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2.1 Cell lines and culture conditions
A range of cultured cell lines of both human and mouse origin were used in the 
various studies described in this thesis. The mouse mammary carcinoma cell line 
EMT6/Ca /VJAC (henceforth referred to as EMT6/P) (Rockwell et al., 1972) 
originated in a mouse alveolar tumour nodule and was successively transplanted 
between animal and in vitro culture before growth in continuous culture. The drug 
resistant variant of this cell line. EMT6/AR1.0 was derived by continuous step-wise 
in vitro incubation with increasing concentrations of doxorubicin (Twentyman et 
al., 1989). These cells were finally maintained in a concentration of 1.0 |ig/ml 
doxorubicin. EMT6 grow as attached monolayers in Eagle's minimum essential 
medium (MEM) with Earle's salts supplemented with glutamine (0.5mmol/l), 
penicillin (lOOU/ml). streptomycin (lOOlig/ml) and 20% new-born calf serum 
(Sigma). They were disaggregated by rinsing the monolayers twice with a solution 
of trypsin (0.1%) (Life Technologies) in phosphate-buffered saline (PBS) followed 
by a 15 min incubation period. The cells were then resuspended in medium with 
mechanical disaggregation. The cell suspension was then counted manually using a 
haemocytometer counting chamber and then diluted appropriately for use in 
experiments.
NCI-H69 (henceforth referred to as H69/P) cells, originally supplied by Dr D 
Carney and Dr A Gazdar of the NCI/Navy Medical Oncology Branch, were derived 
from a patient who had received combination chemotherapy including doxorubicin. 
The drug resistant variant H69/LX4 was derived by continuous step-wise in vitro 
incubation with increasing concentrations of doxorubicin (Twentyman etal., 1986b, 
Reeve et al., 1989). The cells were finally maintained in a concentration of 0.4p.g/ml 
doxorubicin. This line grows as floating aggregates of cells in RPMI 1640 medium 
supplemented with glutamine (0.5mmol/l), penicillin (lOOU/ml), streptomycin 
(lOOp-g/ml) and 10% fetal calf serum (Sigma). The cells were reduced to a 
suspension containing small groups of cells mechanically by pipetting. In order to
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count the cells accurately a small aliquot of cells was further disaggregated into a 
single cell suspension by passing the cells through a 21G needle and syringe. The 
cell suspension was then counted manually using a haemocytometer counting 
chamber and then diluted appropriately for use in experiments.
The T-lymphoblastoid cell line CCRF-CEM (henceforth referred to as CEM) (Foley 
etal., 1965) and its vinblastine resistant subline CEM/VLB (Beck etal., 1979) were 
originally obtained from Dr Rosanne Padua, University of Wales. The drug 
resistant variant CEM/VLB was derived by step wise in vitro incubation with 
increasing concentrations of vinblastine. These cells grow in suspension in RPMI 
1640 medium supplemented with glutamine (0.5mmol/l), penicillin (lOOU/ml), 
streptomycin (lOO^ig/ml) and 10% fetal calf serum (Sigma). The drug resistant 
CEM/VLB cell line is stable in culture without the addition of vinblastine. The cell 
suspension was counted manually using a haemocytometer counting chamber and 
then diluted appropriately for use in experiments.
COR-L23 (henceforth referred to as L23/P) the human large cell lung cancer cell 
line was derived by Ballie-Johnson et al. (1985). Twentyman et al. (1986a)'derived 
a drug resistant variant C0R-L23/R (henceforth referred to as L23/R) by step-wise 
incubation with increasing concentrations of doxorubicin. The cells are maintained 
in 0.2}ig/ml doxorubicin. The L23/P and R cell lines were maintained as monolayer 
cultures in RPMI 1640 medium supplemented with glutamine (0.5mmol/l), 
penicillin (lOOU/ml), streptomycin (lOO^ig/ml) and 10% fetal calf serum (Sigma). 
The cells were harvested by subjecting the monolayers to two rinses with a solution 
of PBS containing trypsin (2%) and versene (0.02%) followed by an incubation 
period of 15 min at 37“C. The cells were then resuspended in medium and 
disaggregated by pipetting. The cell suspension was counted and diluted for 
experimental use as previously described.
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The adenocarcinoma line, MOR (henceforth referred to as MOR/P) was originally 
supplied by Dr M Ellison, Ludwig institute, Sutton. Like L23/R the resistant 
variants of MOR/P, MOR/0.2R and MOR/0.4R were derived by step-wise 
incubation with increasing concentrations of doxorubicin (Twentyman et al., 
1986a). The resistant cell lines were maintained in 0.2iig/ml and 0.4p.g/ml 
doxorubicin respectively. These cells were maintained and prepared for 
experimental use under the same conditions as the L23/P and R cell lines 
(Twentyman et at., 1986a).
All cells were maintained as stock cultures in plastic tissue culture flasks, incubated 
at 37 C in an atmosphere of 8% CO2 and 92% air. Drug was removed from the 
resistant variants 48h prior to their experimental use. The cells were harvested in the 
exponential phase of growth. All cell lines are routinely screened for mycoplasma 
and remained negative throughout this study.
2.2 Drugs and chemicals
All Xenova compounds were dissolved in dimethylsulphoxide (DMSO) at a 
concentration o f 5mM and stored in aliquots at -20"C. Deoxyspergualin was 
kindly provided by the Drug Development Branch of the National Cancer Institute, 
Bethesda, MD, USA. It was dissolved in sterile water at a concentration of 50mM 
and aliquots were stored at -20 C. Spermine and spermidine were obtained from 
Sigma and dissolved in sterile water at a concentration of 2M and 1.4M respectively 
and stored at -20 C. Cyclosporin A (Sandoz, Basel) was dissolved in absolute 
ethanol at 4.2mM and stored at 4 C. Cyclosporin A was routinely diluted in 
medium immediately before each experiment. Doxorubicin (Farmitalia) and 
colchicine (Sigma) were dissolved at concentrations of 0.86mM and 5mM
o
respectively in distilled H2O and aliquots were stored at -20 C. Taxol (Sigma) was 
dissolved in ethanol at a concentration of 5.8mM and stored at -20”C. Dilutions of 
these drugs in either PBS or culture medium was carried out immediately before
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use. Calphostin C (Sigma) and staurosporine (Sigma) were dissolved in DMSO at 
concentrations of 0.25mM and 0.2mM respectively and stored at 4"C in the dark. 
H7 (Sigma) and TPA (Sigma) were dissolved in distilled H2O at concentrations of 
14.4mM and lOmM respectively and stored at 4“C in the dark, Calcein AM 
(Molecular Probes inc) was stored at -20’C. Probenecid (Sigma) was dissolved in 
DMSO at a concentration of 0.5M immediately before use.
The following tritium-labelled drugs, daunorubicin (New England Nuclear, 
2.6Ci/mmol), colchicine (New England Nuclear, 60Ci/mmol) and . azidopine 
(Amersham, 49Ci/mmol)) were stored at -70"C. p2p]orthophosphate (lOmCi/mg 
carrier free) and p2p]ATP (>5000Ci/ml) were both obtained from Amersham and 
stored at 4’C in the dark.
Appropriate solvent controls were used in all experiments. Solvent concentrations 
did not exceed 0.1%.
23  Cytotoxicity and sensitisation assays using the
tétrazolium (MTT) reduction assay
2.3.1 Background
Assays which quantitate numbers of viable cells present following therapeutic 
procedures have many applications in cancer research. Traditionally these assays 
involved counting total viable cells (using haemocytometer chambers or electronic 
particle counters) Or colony counting (clonogenic assay). Other techniques used to 
assess chemosensitivity include radionucleotide incorporation assays and neutral red 
and trypan blue dye staining techniques. The need to process large numbers of 
samples led to attempts to introduce assays capable of automation. Mosmann et al. 
(1983) described a rapid colorimetric assay based on the ability of viable cells to 
convert a soluble tétrazolium salt, 3-4,5 dimethylthiazol-2,5 diphenyl tétrazolium 
bromide (MTT), into an insoluble formazan precipitate (Slater et al., 1963). The
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purple-coloured formazan crystals may be dissolved in a variety of organic solvents 
and the optical density of the resulting solution measured on a multiwell 
spectrophotometer. The number of viable cells is proportional to the concentration 
of the MTT reaction product Mosmann examined the definition of non-viable cells 
and concluded that only those cells with intact and functioning mitochondria could 
reduce MTT. The MTT dye reduction assay has several important advantages over 
other measures of cell viability. The assay is sensitive, reproducible over time and 
simple to carry ou t It is adaptable to several different cell types either monolayer or 
suspension, cell-cell interactions are, therefore, preserved. Multiple concentrations 
of compound can be evaluated either alone or in combination with other agents. 
The effect of a compound on a number of different cell lines may also be directly 
compared. There are dso  several important limitations that should be borne in mind 
when using this technique. Individual cell numbers are not quantifiable and this 
may cause problems in interpretation of results. It is important to remember that the 
MTT assay is not equivalent to a clonogenic assay for a number of reasons. Whilst 
determining the proportion of cells with intact reproductive integrity, the MTT assay 
takes no account of reduced growth rate induced by a drug. It is, therefore, difficult 
to distinguish between cytostatic (agents producing drug induced cell cycle delay) 
and cytotoxic (agents causing reproductive cell death) effects from results obtained 
in the MTT assay. The solvent used to solubilise the formazan product is also 
crucial. Light scatter interference due to protein precipitation when solubilising in 
acid-alcohol has been reported (Ruben et al., 1987). This is not a significant 
problem when solubilising in DMSO ^Twentyman et al., 1987b).
2.3.2 Method
Cytotoxicity of agents used in this study were determined using the tétrazolium 
(MTT) reduction colorimetric assay (Mosmann et al., 1983), as adapted for use in 
this laboratory (Twentyman er a/., 1987b). Single cell suspensions were prepared
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from exponentially growing cultures and inoculated into wells on 96 well tissue 
culture plates in a volume of 200jll/well at the following concentrations (Table 2.1):
T able 2.1
Cell p lating  nu m b er and  assay du ra tion
Cell line Plating number Assay Duration
EMT6/P 3x103 3 days
EMT6/AR1.0 6x103 3 days
H69/P 3x104 6 days
H69/LX4 5x104 6 days
CEM 2x104 4 days
CEM/VLB 4x104 4 days
L23/P 2x103 6 days
L23/R 4x103 6 days
MOR/P 2x104 6 days
MOR/0.4R 2.5x104 6 days
Cytotoxic agents were added 1 h later in a volume of 20pl. After an the appropriate 
incubation period (times were chosen such that untreated cells of each of the cell 
lines increased by 10-20 fold in number during the incubation period) 20|il of a 
5mg/ml solution of MTT (Sigma) in PBS were added to each well. The plates were 
re-incubated for 5 h. At the end of this period the medium was aspirated from each 
well, 200pl of dimethylsulphoxide was added and the plates were shaken on a plate 
shaker for 10 min. The optical densities of the wells were read on a Titretek 
Multiskan MCC/340 plate reader at a wavelength of 540nm and at a reference 
wavelength of 690nm. For resistance modification assays the above protocol was 
followed with the additional step of adding the modulating agent 1 h after the cells 
had been plated and 1 h before the addition of the dmg. In all experiments each drug
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dose was studied in 4 replicate wells and variation in final absorbance between 
replicate wells was generally less than 10%.
2.4 Clonogenic assay
2.4.1 Background
This is an alternative method for measuring the effect of drugs or radiation on cell 
survival. It measures the colony-forming ability of the cells (i.e. the ability of a 
single surviving cell to divide and produce a colony of at least 50 'daughter' cells).
2.4.2 Method
Clonogenic survival assays were carried out on EMT6/P and EMT6/AR1.0 cells. 
Cells in drug-containing medium at concentrations of 50 and 200 cells/ml for 
EMT6/P and EMT6/AR1.0 cells respectively were plated onto 9cm Petri dishes 
(Nunc). They were incubated at 37 C in a humidified atmosphere of 8% CO2 and 
92% air for 9 days. At the end of this incubation period the medium was removed, 
the plates rinsed in saline, and then fixed and stained simultaneously in a solution of 
5% crystal violet (Gurr) in 95% alcohol. Colonies were visualised with the aid of an 
Olympus stereo zoom microscope and those with greater than 50 cells were counted. 
The experiments were carried out in triplicate. After counting, the mean number of 
colonies per plate for each group was calculated.
Results were calculated as:
(i) Plating efficiency, given by the number of colonies on control plates calculated 
as a percentage of cells originally plated and
(ii) Surviving Fraction, given by the ratio of number of colonies on treated plates to 
number of colonies on control plates.
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2.5 Drug accumulation and efflux studies
2.5.1 Measuring drug accumulation using tritium-labelled drugs
(i) Tiitium^labelled drug accumulation studies in cells growing in monolayers 
The ability of adherent, monolayer cells to accumulate pHJdaunorubicin was 
determined as described previously (Wright et al., 1993). Briefly, 48 hours before 
the experiments, cells were inoculated into 6-well plates at 2x1 (M/well for EMT6/P 
and 4xl0^/well for EMT6/AR1.0 in a volume of 2ml. To commence experiments, 
medium was aspirated from the wells and replaced with medium containing 
[3H]daunorubicin (9.1 p.Ci/ml) together with unlabelled drug to give a final 
concentration of l|iM  and, where appropriate, resistance modifier (test compound) 
at varying concentration. As a positive control the accumulation study was also 
carried out in the presence of IpiM cyclosporin A. The plates were then incubated 
for a period of 1 h. At the end of this time, the wells were rinsed three times with ice 
cold PBS. One ml of distilled water was then added to each well and the plates were 
left for 1 h at room temperature in order to allow cell lysis to occur. At the end of 
this time the contents of each well were pipetted several times and 500p.l was 
removed and placed in scintillant (Quicksafe, Zinsser Analytic). Radioactivity was 
measured the following day on a Beckman LS 5000CE liquid scintillation counter.
(ii) Tritium-labelled drug accumulation studies in cells growing in suspension 
Cells inoculated at a concentration of 2xl0^/ml into 2ml Eppendorf tubes in a 
volume of 0.5ml were incubated at 37*C. After 30 min resistance modifier (test 
compound) at varying concentrations or cyclosporin A (ZpM) were added to the 
appropriate tubes in a volume of 10^ 11. The samples were then incubated for a 
further 30 min before the addition of tritium-labelled cytotoxic drug to a final 
concentration of O.liiCi/ml. The cells were then left to accumulate drug at 37“C for 
1 h (daunorubicin) and 2 h (colchicine). After this time period the cells were rinsed 
three times with ice cold PBS and finally lysed in 500p.l 0.1% SDS. The 
radioactivity was measured as described for EMT6.
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(Hi) Tritium-labelled drug efflux studies in cells growing in suspension 
Cells inoculated at a concentration of 2xlO^/ml into Falcon tubes in a volume of 
5ml were incubated at 37*0 for 30 min. The cells were loaded with tritium-labelled 
drug (O.lfxCi/ml) in tlie presence of either cyclosporin A (5|iM) or test compound 
for 30 min. Cells were then rinsed in ice cold PBS. One group of cells was 
resuspended in medium containing resistance modifier and the other group in 
medium without modifier. At each time point, beginning at 0 min, 0.5ml of cell 
suspension was removed from the Falcon tube and placed in a 2ml Eppendorf tube. 
Between time points the cells in the Falcon tubes were incubated at 37“C. The cells 
were pelleted by centrifugation and the medium was removed and placed in 
scintillation vials containing 5ml scintillant (Quicksafe, Zinsser Analytic). 
Radioactivity was measured as described previously.
2.5.2 Measuring drug accumulation and efflux using flow cytometry
(i) Drug accumulation
Cells inoculated at a concentration of 2xlO^/ml into Falcon tubes in a volume of 
5ml were incubated at 37‘C for 30 min. After 30 min resistance modifier (test 
compound) at varying concentrations or cyclosporin A (2iiM) were added to the 
appropriate tubes. The samples were then incubated for a further 30 min before the 
addition of fluorescent drug or dye. At each time point, beginning at 0 min, 0.5ml of 
cell suspension was removed from the Falcon tube and placed in a 2ml Eppendorf 
tube. The cells were pelleted by centrifugation and, following aspiration of the 
medium, cells were resuspended in 0.5ml ice cold PBS. Between time points the 
cells in the Falcon tubes were incubated at 37"C.
(ii) Drug efflux
Cells inoculated at a concentration of 2xl0^/ml into Falcon tubes in a volume of 
5ml were incubated at 37”C for 30 min. The cells were loaded with fluorescent drug 
or dye in the presence of either cyclosporin A (5piM) or test compound for 30 min.
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Cells were then rinsed in ice cold PBS. One group of cells was resuspended in 
medium containing resistance modifier and the other group in medium without 
modifier. Cells were collected for sampling as in the accumulation assay.
2.6. Photoaffinity labelling of P-glycoprotein in membranes
prepared from multidrug resistant cell lines
2.6.1 Isolation of plasma membranes vesicles
Membranes vesicles were prepared from the drug sensitive CEM and H69/P cells 
and their P-glycoprotein-overexpressing variants CEM/VLB and H69/LX4 as 
previously described (Barrand et al., 1992). Exponentially grown cultures were 
washed twice in PBS containing the protease inhibitors, aprotinin (2p.g/ml), 
leupeptin (5p.g/ml) and pepstatin (O.OSp-g/ml). Cells growing in monolayers were 
harvested using a cell scraper. The cells were then pelleted at 450g for 5 min at 
20”C. Following this the cells were lysed in ImM Tris pH 7.4 containing protease 
inhibitors. The nuclei and unbroken cells were removed from the homogenate by 
centrifugation at 450g for 10 min at 4°C and the cell membranes were then separated 
from the resultant supernatant by centrifugation at 60000g for 1 h at 4 C.
2.6.2 Determination of protein content
The biconchininic acid (BCA) protein assay utilises the biuret reaction involving 
copper reacting with peptide links in proteins to yield a purple reaction product. 
Protein standard solutions were made up using saline solutions of bovine serum 
albumin (BSA) encompassing a range 40-1200pg/ml. The assay was carried out in 
a 96 well plate. Standards were prepared in triplicate in volumes of lO i^l. PBS, 
lOp.1, was used as a blank. Test protein samples (plus dilutions) were placed in the 
wells in triplicate also in a volume of lOp.1. A volume of 200p.l working reagent 
was then added to the standards, samples and blank according to the method 
suggested by the manufacturers. The assay was then incubated at 37“C for 30 min 
followed by 15 min at room temperature on a plate shaker. Spcctrophotometric
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quantitation of protein was then carried out at a wavelength of 540nm and at a 
reference wavelength of 690nm. Standard curves and sample protein content were 
determined using Deltasoft software package.
2.6.3 Photoaffinity Labelling
Membrane protein (50p.g) in a volume of lOOjil (ImM Tris HCl, pH 7.4) was 
incubated in 96 well plates (Falcon) for 1 h in the dark at room temperature with 
0.03p.MpH]azidopine (Amersham, specific activity 49 Ci/mmol) in the absence or 
presence of 5^iM cyclosporin A or varying concentrations of resistance modifier 
(test compound). After incubation, samples were irradiated by placing the plates 
approximately 10cm away from an ultraviolet lamp (wavelength 360nm) for 30 min 
on ice. For control purposes one protein sample was exposed to pHjazidopine but 
not to UV light The labelled membranes were then run for 45 min at 200V on a 
7.5% SDS polyacrylamide gel. The gel was then fixed for 30 min in a solution of 
isopropanol: distilled water: acetic acid (25:65:10) and enhanced in 'Amplify' 
(Amersham) for a further 30 min. The enhanced gel was then dried under vacuum 
for 2 h and prepared for autoradiography. The fluorograms were exposed for 7 days.
2.6.4 Gel electrophoresis
For photoaffinity labelling, the labelled proteins were run on a 'Biorad' mini gel 
apparatus. Gels were prepared using 10ml volumes of a mixture comprising the 
volumes of the stock solutions shown below in table 2.2:
69
Table 2.2
Stock solutions for SDS polyacrylam ide gels (mini gel)
G E L ST A C K
Distilled H2 O 4.9ml Distilled H2 O 6.0ml
1.5M Tris-HCl, pH 8.8 2.5ml 0.5M Tris-HCl, pH 6.8 2.5ml
20% SDS 50[il 20% SDS 50[il
30% Acrylamide 2.5ml 30% Acrylamide 1.3ml
*10% Ammonium persulphate 50|il *10% Ammonium persulphate 50jil
*TEMED 5^1 *TEMED lOpl
*Adci immediately before pouring
TEMED is N,N,N',N'-tetrametliyIeÜiylenediamine, used at 0.5% v/v.
The prepared solutions were poured between two secured glass plates and allowed 
to set. The glass plates containing the gel were secured in the mini gel apparatus 
which was then filled with electrode buffer. 5|il of sample buffer was added to 20}il 
of each sample before loading on to the gel. Tble 2.3 shows the recipes for the 
sample and electrode buffers.
Table 2.3
Recipe fo r sam ple b u ffer and  electrode buffer
SAMPLE BtlPFEE ' ELECTRODE BÏIFEER
0.75M TRIS-HCl, pH 6.5 1ml Tris base 9g(15gd)
Glycerol 2ml Glycine 43.2g (72gd)
20% SDS 1ml SDS 3g (5g/l)
Mercaptoethanol 1ml Distilled H2 O to 600ml
Bromophenol blue a few grains
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2.7 Phosphorylation o f P-glycoprotein
2.7.1 Phosphorylation  of P-glycoprotein in m em branes
In order to determine the effect of inhibitors and activators of protein kinase on the 
phosphorylation status of P-glycoprotein we adapted the method of Staats et al. 
(1990). Membranes, prepared from H69/P and H69/LX4 cells using the method 
outlined in section 2.5.1, were incubated in a 25pl reaction mixture as in table 2.4.
Table 2.4
Reaction m ixture for phosphorylation of P-glycoprotein in m em branes
Reaction Mixtnre Stock Concentration ; Yoltmie <jil)
25pg protein
0.02M Tris HCl pH 7.4 l.OM 0.5
5mM MgCl2 O.IM 1.25
3mM 2-mercaptoethanol O.IM 0.75
8iiM ATP 0.9mM 2.2
3\iCi p2?]ATP lOgCi/iil 0.3
H20/Modifier to 25til
Incubations were carried out for 5 min on ice. The reaction was stopped by the 
addition of lOmM EDTA. After the addition of 5pl sample buffer the samples were 
electrophoresed on a 7.5% polyacrylamide gel. After electrophoresis the gel was 
dried on a vacuum drier for 1-2 h. Radiolabelled proteins contained in the dried gel 
were detected after autoradiography.
2.7.2 Gel electrophoresis
We used a large gel electrophoresis apparatus for running these samples due to the 
larger volumes. Gels were prepared using a mixture comprising the volumes of the 
stock solutions shown in table 2.5.
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Table 2.5
Solutions for SDS polyacrylamide gels (large gel)
G E L S T A C K
Distilled H2 O 11.5ml 
1.5M Tris-HCl, pH 8.8 10.0ml 
20% SDS 200gl 
30% Acrylamide 10.0ml 
*10% Ammonium persulphate 80p.l 
*TEMED 50|il
Distilled H2 O 9.2ml 
0.75M Tris-HCl, pH 6.5 3.5ml 
20% SDS lOOgl 
30% Acrylamide 3.0ml 
*10% Ammonium persulphate 80|il 
*TEMED 30p.l
*AdcI immediately before pouring
TEMED is N,N,N',N'-tetrametliylethylenediamine, used at 0.5% v/v.
As with the mini gel apparatus, the prepared solutions were poured between two 
secured glass plates and allowed to set. The glass plates containing the gel were 
secured in the gel apparatus which was then filled with electrode buffer (Table 2.6). 
5[l\ of sample buffer (see below) was added to 20p.l of each sample before loading 
on to the gel.
Table 2.6
Recipes for sample buffer and electrode buffer
Sample buffer Electrode buffer (WK)
Glycerol 2ml 
2-mercaptoethanol 1ml 
20% Sodium dodecyl sulphate(SDS) 1ml 
0.75M Tris HCl pH 6.5 1ml 
Bromophenol blue a few grains
Glycine 145g 
Tris base 30g 
Sodium dodecyl sulphate(SDS) lOg 
To IL with distilled H2 O 
Dilute 100ml with 900ml distilled 
H2 O before use to give IX
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2.7.3 Phosphorylation and immunoprécipitation of P-glycoprotein in
intact cells
In order to study the relationship between the effect of various protein kinase 
inhibitors on the transport of cytotoxic drugs in MDR cells and on P-glycoprotein 
phosphorylation, we examined P-glycoprotein phosphorylation in intact cells.
(i) Labelling
2x10^ cells/ml were incubated in phosphate-free culture medium (Sigma, MEM 
phosphate free) containing 2% fetal calf serum for 4 h at 37"C. After this time the 
cells were pelleted and resuspended in fresh phosphate-free medium. The cells were 
then placed in 2ml aliquots in 5ml Falcon tubes before the addition of the 
appropriate modifier in a volume of lOpJ. The cells where then re incubated at 37"C 
for a further 30 min before the addition of 200gCi/ml p^P] orthophosphate. After 
addition of the label the cells were incubated for 2 h at 37"C.
(ii) Lysate preparation
The cells were pelleted by centrifugation at 450g, 4*C for 5 min and then washed 
with ice cold PBS(+PI) before resuspension in 2ml ice cold PBSTDS(+PI)*(see 
table 2.7 for recipe). The Falcon tubes were then left on ice for 10 min. After this 
time the cells were disrupted using a 5ml syringe and 21G needle. After initial 
centrifugation at 450g at 4’C for 15 min, the supernatant was transferred to 5ml 
Beckman tubes and centrifuged on an ultracentrifuge (Sorvall OTD 65B) at 
120000g for 20 min.
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Table 2.7
Recipe for PBSTDS (lysis buffer)
^PBSTDS (lysis buffer): Quantity
lOx PBS (Phosphate buffered saline) lOml
100% Triton X-100 1ml
Sodium deoxycholate 0.5g
Sodium dodecyl sulphate (SDS) O.lg
Distilled H2 O to 100ml
*A11 solutions contain pro tease and phosphatase inhibitors (PI): 
To lOOmI:
Protease înbibitorsî
200|il aprotinin (1 mg/ml) 
20|il pepstatin (0.4mg/ml) 
500|il leupeptin (1 mg/ml)
Phosphatase inhibitory 1ml Sodium fluoride (M)
(Hi) Immunoprécipitation
After preparation of the cell lysate, Iftg of C219 monoclonal antibody (stock 
concentration lOOgg/ml) was added to 1ml supernatant in a 2ml Eppendorf tube. 
The tubes were placed inside a perspex box and incubated overnight at 4°C on a 
rocking platform. In the morning 50fil of protein A sepharose (50% v/v. Sigma) 
was added to each of the tubes which were then re-incubated at 4°C for a further 4 h. 
After this time the samples were centrifuged in a micro centrifuge at 450g, 4°C and 
then washed four times in ice cold PBSTDS (PI), repeating the centrifugation step 
between each wash. The final pellet was resuspended in 50|il sample buffer (see 
below), vortexed and left on ice for 30 min. The samples were then electrophoresed 
on a 7.5% polyacrylamide gel (see section 2.6.3 for recipes). After electrophoresis
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the gel was dried on a vacuum drier for 1-2 h. Radioactively labelled proteins 
contained in the dried gel were detected by autoradiography.
Table 2.8
Recipe for sample buffer
Sample Buffer
Glycerol 2ml
2-mercaptoethanol 1ml
20% Sodium dodecyl sulphate(SDS) 1ml 
0.75M Tris HCl pH 6.5 1ml
Bromophenol blue________ a few grains
2.8 C onfocal m ic ro sco p y
2.8.1 The principles of confocal imaging
The essential feature of a confocal microscope is that the illumination and detection 
are confined to the same spot in the specimen at any one time. If the spot is so small 
that its limits are set by diffraction, the resolution in a confocal microscope is greater 
than in a conventional one. The key feature of confocal imaging is that only objects 
or sections of objects that are in focus are detected. Out of focus regions appear 
black and therefore do not contribute to the image. A confocal microscope does not 
produce a complete optical image of the specimen. To build up an image it is 
necessary to scan the point probe over the field of view. This is done, in the case of 
the MRC 600 model, by scanning the beam over a fixed specimen (beam scanning). 
The image is generated electronically from a serial signal derived from the
photomultiplier output. The MRC 600 confocal microscope used in the laboratories
in Cambridge is of the epi-illumination design. In this design the same lens 
functions as both condenser and objective. This eliminates the need for exact 
matching and co-orientation of two lenses. Light from an aperture is refected into
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the rear of the objective lens and is focused on the specimen. Light returning from 
the specimen, as a result of either reflection or fluorescence, passes back through 
the lens and is focused on a second aperture, which allows a portion of the beam to 
pass to a detector such as a photomultiplier. The MRC 600, manufactured by 
Biorad, was developed from the MRC 500 confocal microscope originally 
developed in the Medical -Research Council laboratories in Cambridge.
2.8.2 M ethod
(i) For cells growing in suspension:
CEM and CEM/VLB cells were suspended at a concentration of 2x10^ cells per ml 
in a 5ml Falcon tube and incubated at 37"C. Test XR compound was added to the 
cell suspension at a concentration of 5p.M. After 30 min lOpM doxorubicin was 
added to the cells which were then incubated at 37"C for a further 2 h. The Falcon 
tubes were then centrifuged at 450g for 5 min at 4 C. The medium was then 
carefully aspirated and the cells were resuspended in 100|il of ice cold PBS. 
Approximately 20pl of this cell suspension was then placed onto a cover slip using a 
Gilson pipette. The cover slip was then inverted with the cell layer face down onto 
a clean glass microscope slide and sealed around the edges with clear nail varnish to 
prevent drying out of the preparation.
(ii) For cells growing as attached monolayers:
L23/P and L23/R cells were seeded in a volume of 2ml and at a concentration of 
5xl(y^/ml into 6 well plates containing a sterile coverslip in each well. After 48h test 
XR compound was added to each well to a concentration of 5pM. After 30 min 
lOpM doxorubicin was added to the well to produce a concentration of IOp.M. The 
plates were then incubated at 37*C for a further 2h. After this time the cover slips 
were removed from the wells and carefully rinsed twice in PBS by gripping the 
cover slip on the edge with a pair of tweezers and dipping it into two beakers of ice 
cold PBS. The excess PBS was then allowed to drain offbelrire the cover slip was
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inverted with the cell layer face down onto a clean glass microscope slide and sealed 
around the edges with clear nail varnish.
2.9 Glutathione (GSH) Assays
2.9.1 Intracellular GSH levels
Cells at a concentration of 2-4xl0^/ml were suspended in medium and placed in 2ml 
Eppendorf tubes (1ml per tube). Test drugs or solvent were then added to the cells 
and the tubes were incubated at 37’C for 1 h. After this time the cells were pelleted 
in a microfuge and rinsed twice in ice cold PBS. The pellet was the resuspended in 
200pl of solution A (EDTA lOOpl : distilled H2O 80^1 :TCA 20fil). The tubes 
were then vortexed and left on ice for 15 min. before being vortexed again. Finally, 
the tubes were centrifuged at maximum speed in a microfuge for 5 min. The 
supernatant is used for GSH determination. GSH levels were determined using a 
colorimetric assay, carried out in a 96 well plate (see table 2.9 for format). Sample 
GSH levels are determined from a standard curve. The colorimetric assay used here 
is based on the reduction of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTOT) by SH 
groups to form 2-nitrobenzoic-5-mercaptobenzoic acid. The nitromercaptobenzoic 
acid anion has an intense yellow colour and can be used to measure SH groups and, 
therefore, GSH.
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Table 2.9
Form at for GSH determination colorimetric assay
1
Standard*
2 3 4
5
5
A
6
M
7
P
8
L
9
E
10
S
11 12
Blank
A 0(67) blank
B 10 (57) blank
C 20 (47) blank
D 30 (37) blank
E 40 (27) blank
F 50 (17) blank
G 67(0) . blank
H - blank
* Values are volume of GSH standard in pi. Parentheses indicate volume of EDTA in pi
Each well contained: 133pl Tris buffer (pH8.9), 67pl of either sample (in sample 
columns 2-11), GSH standard/EDTA mix (in standard column 1) or EDTA (in blank 
column 12), 3.3lU DTNB.
After the addition of all the reagents, the plate was placed on a plate shaker for 15 
min. The optical densities of the wells were then read on a Titertek Multiskan 
MCC/340 plate reader at a wavelength of 412nm.
2.9.2 Cellular GSH release
Cells were suspended in 1ml of medium at a concentration of 5-lOxlOVml in Falcon 
tubes. Test drugs or solvent were then added to the cells and the tubes were 
incubated at 37’C for 1 h. After this time the cells were pelleted and rinsed twice in 
ice cold PBS. The pellet was then resuspended in lOOpl Kreb s buffer (+l|xl 
acivicin 20mM- a y-glutamyl transpeptidase (GGT) inhibitor) in 2ml Eppendorf 
tubes (each sample group was evaluated in duplicate). The cells were then 
incubated for a further I h at 37"C. After this time the cells were again pelleted and
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the supernatant was used for GSH measurement. To allow GSH release over 1 h to 
be calculated the experiment was carried out in duplicate. On addition of the Kreb's 
buffer, one of the duplicate sets of Eppendorf (i.e 2 out of 4) tubes were spun 
immediately to pellet the cells and remove the supernatant. GSH release prior to the 
1 h incubation was also, therefore, determined. The colorimetric assay was carried 
out in a 96 well plate, as in table 2.9. The standard column was, however, different 
(Table 2.10).
Table 2.10
GSH standards for GSH release assay
5(M)}iM GSH stock 
{volume }ll) Volume EDTA (pi)
GSH(nM )
0 60 0
10 50 5
20 40 10
30 30 15
40 20 20
50 10 25
60 0 30
GSH release was calculated as nmoles GSH per 10  ^cells per h by the following 
equations:
(1) Absorbance (sample) / Absorbance (InM  GSH- from standard curve)
(gives nmoles GSH in 60|il sample)
(2) ( l ) x  0.1 (m l) /0.06 (ml)
(gives nmoles GSH in whole sample)
(3) (2) xlO^ / total number of cells
(gives nmoles GSH/10^ cells/h)
79
C h a p t e r  3
The effect of deoxyspergualin on multidrug resistant 
cells
Contents
3.1 Introduction
3.2 Materials and Methods
3.2.1 Cell lines
3.2.2 Drug sensitivity testing
3.2.3 Drug accumulation studies
3.2.4 Photoaffinity labelling
3.3 Results
3.3.1 Toxicity of polyamines and deoxyspergualin
3.3.2 Effect of continuous exposure of deoxyspergualin oh the colony 
forming potential of EMT6/P and EMT6/AR1.0
3.3.3 Effect o f deoxyspergualin on the accumulation of pH]daunorubicin 
in EMT6/AR1.0 and H69/LX4 cells
3.3.4 Effect of deoxyspergualin on the sensitivity of EMT6/AR1.0 and 
H69/LX4 cells to doxorubicin.
3.3.5 Inhibition of pH] Azidopine covalent binding to P-glycoprotein in 
membranes prepared from H69/LX4 cells.
3.4 Discussion
80
3.1 Introduction
Deoxyspergualin (Figure 3.1) is a synthetic derivative of the anti-tumour antibiotic 
spergualin produced by a strain of Bacillus laterosporus (Takeuchi et a i ,  1981; 
Umezawa etaL,. 1981). Spergualin has good anti-tumour activity against murine 
neoplasms, including the lymphatic leukaemias L1210 and P388, mastocytoma 
P815, thymoma EL-4, sarcoma 180, and the myeloid leukaemia 1498 (Takeuchi et 
a l, 1981). Deoxyspergualin, currently in the National Cancer Institute (NCI) 
decision network, is more potent in vivo than spergualin and its direct synthesis is 
simpler therefore it was selected as a candidate for further development In addition 
to its anti tumour activity, deoxyspergualin has also been shown to possess 
immunosuppressive activity in both in vitro and in vivo systems (Nemoto et a i,. 
1987; Shiro et a i, 1992). The mechanism of immunosuppression of the drug is at 
present unclear, however, deoxyspergualin has been shown to increase interleukin 2 
production in mixed lymphocyte culture, to enhance natural killer cell activity in 
spleen cells of tumour bearing mice, and to activate T-lymphocytes (Ishizuka et al, 
1986).
Figure 3.1
The structure of deoxyspergualin .
0  
II
NH2-(CH2)3— NH— (CH2)4— NH— Ç
C H -O H
1
NH
I
NH2— C— NH— (CH2)6“” C 3HC1
NH O
Cyclosporin A and FK506 are also natural products possessing potent 
immunosuppressive properties (Shiro et a l, 1992). Deoxyspergualin has been 
shown to bind to the human constitutive heat shock protein Hsp70 (Nadler et al,
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1992). Cyclophilin, the cyclosporin A binding protein, FK506 binding protein, and 
the heat shock proteins are all involved in the regulation of protein folding. This and 
the ability of all three agents to inhibit the function of T-cell lymphocytes may 
suggest a common mechanism of action for these immunosuppressants.
Cells treated in vitro with one of a well defined group of, mainly natural product, 
cytotoxic agents acquire resistance to that agent and become simultaneously 
resistant to many other drugs that are structurally and functionally unrelated to the 
selecting drug (Biedler et al., 1970; Endicott et a l, 1989). Drugs involved include 
doxorubicin, vincristine, etoposide and taxol. These cells are said to possess a 
multidrug resistant phenotype and frequently overexpress a 170-kDa membrane 
glycoprotein (P-glycoprotein) which is believed to act as a drug efflux pump 
(Endicott et a l,  1989). This type of resistance is often referred to as 'classical 
MDR'.
Both FK506 and cyclosporin A have been shown to act as effective modifiers of 
classical MDR in that they can selectively restore sensitivity to the cells with 
acquired resistance (Jachez et a l, 1993; Twentyman et a l, 1987a). Deoxyspergualin 
is similar to cyclosporin A and FK506 in its properties and mechanism of action and 
multidrug resistant cells are cross resistant to cyclosporin A. We decided therefore 
to address the questions, does deoxyspergualin act as a modifier of P-glycoprotein- 
mediated MDR and are multidrug resistant cells cross resistant to deoxyspergualin?
The structure of the polyamine spermidine is present within the larger structure of 
deoxyspergualin, which can therefore be considered to be a spermidine analogue. 
Bovine serum copper amine oxidase catalyses thé oxidative deamination of 
spermidine to produce an aminoaldehyde, ammonia and hydrogen peroxide. It is 
thought that these aminoaldehydes are responsible for the toxicity of polyamines in 
vitro in the presence of bovine serum (Kunimoto et a l, 1985; Parchment et a l.
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1990) whereas other mechanisms may predominate in this cytotoxicity under 
conditions where other serum types, low in copper amine oxidase content, are used. 
For this reason all experiments involving the incubation of cells in medium were 
performed in duplicate using both bovine serum and horse serum, which is low in 
copper amine oxidase content (Kuramochi et a i, 1987).
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3.2 Materials and methods
3.2.1 Cell lines
We used the mouse mammary carcinoma cell line EMT6 /P and the human small 
cell lung cancer cell line H69/P together with their P-glycoprotein overexpressing 
sublines EMT6/AR1.0 and H69/LX4. For cell culture conditions see Section 2.1. 
All experiments involving the incubation of cells in medium were performed in 
duplicate using both bovine serum and horse serum.
3.2.2 Drug sensitivity testing
The cytotoxicty of deoxyspergualin and the polyamines, spermidine and spermine 
were determined using the tétrazolium (MTT) reduction colorimetric assay. 
Clonogenic survival assays were also carried out on EMT6/P and EMT6/AR1.0 
cells exposed to increasing concentrations of deoxyspergualin. The details of both 
these assays are described in Sections 2.3 and 2.4.
3.2.3 Drug accumulation studies
The effect of deoxyspergualin on the ability of EMT6/P and EMT6/AR1.0 cells 
and H69/P and H69/LX4 cells to accumulate pH]daunorubicin was determined as 
described in Section 2.5.2.i and 2.5.2.Ü respectively.
3.2.4 Photoaffinity labelling
Membranes were prepared from H69/P and H69/LX4 cells as described in Section 
2.6.1. Membrane protein (SOfig) in a volume of lOOpl (ImM Tris HCl pH 7.4) was 
incubated for 1 h in the dark at room temperature with 0.03pM pH ]azidopine 
(Amersham, specific activity 49 Ci/mmol) in the absence or presence of 5p.M 
cyclosporin A or increasing concentrations of deoxyspergualin (l-100|iM ). The 
details of this assay are described in Sections 2.6.
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3.3 Results
3.3.1 Toxicity of poly amines and deoxyspergualin
Both parent and resistant cell lines were more sensitive to the polyamines 
spermidine and spermine in the presence of bovine serum compared to horse serum. 
Typical datasets are shown in Figures 3.2. & 3.3. In the presence of bovine serum, 
EMT6/P, EMT6/AR1.0, H69/P and H69/LX4 cells are respectively 32, 32, 372 and 
483 fold more sensitive to spermidine than in the presence of horse serum. 
Corresponding figures for spermine are 175, 133, 321 and 444 fold respectively 
(Table 3.1). Interestingly in the human cell lines, H69/P and H69/LX4 the ratios of 
IC5 0 S in bovine serum compared to horse serum for spermine and spermidine are 
respectively 2-3 and 10-15 fold greater than in the mouse cell line EMT6/P and 
EMT6/ÀR1.0. This may be due to the differing levels of copper amine oxidase 
present in the two types of bovine serum (new-born calf serum in EMT6 and foetal 
calf serum in H69) used to culture the different cell lines.
Deoxyspergualin is an analogue of spermidine. However, its relative toxic effects in 
the different serum types do not reflect those of the polyamines in the different 
serum types. When fractional absorbance is plotted against increasing drug 
concentration (Figure 3.4), experiments carried out in the presence of bovine serum 
result in much steeper curves than those o b t^ e d  in the presence of horse serum. 
The surviving fraction in horse serum supplemented medium typically falls from 
80% to 2 0 % between 1 and 100  pM deoxyspergualin. In the bovine serum 
supplemented medium a similar fall in the curves is produced by only a 2-5 fold 
dose increase. Similar results were obtained in a number of independent 
experiments.
EMT6/AR1.0 and H69/LX4 show modest cross resistance to deoxyspergualin, 
spermidine and spermine in both bovine serum and horse serum although this is 
only significant (p<0.05. Student's t test) in EMT6/AR1.0 for deoxyspergualin in 
bovine serum and horse serum and for spermidine in horse serum alone (Table 3.2).
85
Figure 3.2
The toxicity of spermidine in (a) EM T6 /P  and EMT6/AR1.0 and (b) H69/P and 
H69/LX4 in the presence of horse serum  and bovine serum.
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serum. Figures represent typical data sets. Similar results were obtained in a number of independent 
epcperiments. Fractional absortemce is defined by mean optical density of treated group divided by
th a t  o f  th e  c o n tr o l  g ro u p
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Figure 3.3
The toxicity of spermine in (a) EM T6/P and EMT6/AR1.0 and (b) H69/P and 
H69/LX4 in the presence of horse serum  and bovine serum.
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Figure 3.4
The toxicity of deoxyspergualin
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Figure represent typical data sets. Similar results were obtained in a number o f independent 
experiments. Fractional absorbance is defined by mean optical density of treated group divided by
that of the control group
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Table 3.1
R atio  o f IC so^ bovine serum  com pared to horse serum
E M T 6 / P E M T 6 /A R L Ô B m /F H 6 9 /L X 4
200 133 320 443S perm ine 150 133 (68) (33)n=2 n=2 n=4 n=4
31b 31 372 483Sperm id ine (7) (10) (39) (17)
n=3 n=3 n=3 n=3'
^IC50=concentration o f  drug required to reduce fractional absorbance to 50% of control value 
^Values shown are means (standard error) from n independent experiments.
Where n=2, individual values are shown
Table 3.2
Resistance factors® fo r sperm ine, sperm idine and deoxyspergualiin
Sperm ine Sperm idine D eoxyspergualin
R A TIO BS m BS
■
BS BS "  m -- ' :
EM TO A R l.O
E M T 6/P
1.7b
(0.2)
n=4
2.2
(1.2)
n=4
2.3
(1.5)
n=4
1.5K
(0.5)
n=4
1.9<=
(0.7)
n=6
2.4«:
(0.4)
n=6
H69/LX4
H 69/P
1.3
(0.6)
n=6
1.7
(1.2)
n=6
1.2
(0.9)
n=4
1.4
(0.5)
n=4
1.2
(0.2)
n=6
1.8
(0.5)
n=6
^Resistance factor is defined by the IC50 o f drug in resistant line 
divided by the IC50 o f drug in the sensitive line 
^Values are means (standard error) from n independent experiments 
=p<0.05, value is significantly different from that o f the control (Student's t test)
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3.3.2 Effect of continuous exposure of deoxyspergualin on the colony
forming potential of EMT6/P and EMT6/AR1.0 
To investigate further the differing response of EMT6/P and EMT6/AR1.0 to 
deoxyspergualin in the different serum types we employed the clonogenic assay to 
examine the effect of deoxyspergualin (continuous exposure) on the number and 
size of colonies formed. The results obtained in the presence of bovine serum were 
similar to those produced in the MTT assay. The surviving fraction of colonies fell 
from 80% to 20 % between 2 and 20liM deoxyspergualin (Figure 3.5). However, in 
the presence of horse serum the curve dropped more steeply than the curve 
produced in the MTT assay. This is likely to be due to the fact that in horse serum, 
as deoxyspergualin concentration increased, colonies reduced in size (i.e. number of 
cells per colony) rather than number. Only those colonies with 50 or more cells are 
included in the count. At higher doses of deoxyspergualin (>0.1 p.M), there were 
many colonies containing fewer than 50 cells which were therefore not included in 
the count This accounts for the steeper curve obtained in this assay compared to the 
MTT assay which is contributed to by all viable cells without an arbitary cut-off 
poin t These data indicate that deoxyspergualin is cytostatic to EMT6/P and 
EMT6/AR1.0 in the presence of horse serum and cytotoxic in the presence of new­
born calf serum.
3.33 Effect of deoxyspergualin on the accumulation of
pH]daunorubicin in EMT6/AR1.0 and H69/LX4 cells
There was no difference in the accumulation of pH]daunorubicin between 
experiments carried out using medium supplemented with either 10% bovine serum 
or 10% horse serum in either the parent or resistant cell line. Figures 3.6.a & b 
show that deoxyspergualin, at concentrations of up to 200pM did not reverse the 
accumulation deficit in EMT6/AR1.0 or H69/LX4 cells. In comparison, cyclosporin 
A (IjiM) had an accumulation ratio of 17.6 in EMT6/AR1.0 (where accumulation 
ratio is defined by drug uptake in the presence of modifier divided by drug uptake
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in the absence of modifier) and restored [^Hjdaunorubicin accumulation to levels 
comparable to the parent line. The differential in accumulation between parent and 
resistant cells is much lower in the human cell line than the mouse cell line. 
Cyclosporin A (i.OpM) did not reverse the accumulation deficit in LX4 cells to the 
same extent as in EMT6/AR1.0 cells. However, cyclosporin A (5.0^iM) restored 
pH]daunorubicin accumulation to levels higher than those of the parent line.
Figure 3.5
Effect of deoxyspergualin on the colony forming ability of EMT6/P and 
EMT6/AR1.0 in the presence of either horse serum or bovine serum
1.2
1.0 -
0.8 -
ec 0 .6 -
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0.0 ■™r
1 10.1.01.001.0001
Deoxyspergualin pM
horse seniin EMT6/P (o), EMT6/AR1.0 (□)) or bovine serum (EMT6/P (• ) , EMT6/AR1.0 (■) 
Figure represent typical daia sets. Similar results were obtained in 2 independent experiments.
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Figure 3.6
(a) The effect of cyclosporin A (CsA) and deoxyspergualin (DSG) on the 
accumulation of pH jdaunorubicin (DNR) in EMT6/P (P) and EMT6/AR1.0 
(R) cells.
.'ÎÎK 5Î555
p R
0.1 1.0 10 20 40 100 200
CsA DSG (mM )----------->
(pM) ^
Parental cell Une < ■  ) .  Resistant ceU line ( □  ), Resistant cell line + cyclosponn A (B  ), 
Resistant cell line + deoxyspergualin ( Q  ). Figures represent typical data sets. Similar results were 
obtained in a number of indqiendent experiments.
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Figure 3.6
(b) The effect of cyclosporin A (CsA) and deoxyspergualin (DSG) on the 
accumulation of [^Hjdaunorubicin (DNR) in H69/P (P) and H69/LX4 (R) cells.
1.0 5.0 10 20 40 100 200 
CsA
P R
(pM)
DSG(pM)-
Parental cell line ( B  ) ,  Resistant cell line ( □  ), Resistant cell line + cyclosporin A (B  ), 
Resistant cell line + deoxyspergualin ( B  ). Figures represent typical data sets. Similar results were 
obtained in a number o f indqiendent experiments.
94
3.3.4. Effect of deoxyspergualin on the sensitivity of EMT6/AR1.0 and
H69/LX4 cells to doxorubicin.
There was no significant difference between the IC5 0 S of EMT6/AR1.0 in the 
presence or absence of deoxyspergualin in either serum type. However, 
deoxyspergualin (4|iM) caused a modest but significant decrease in IC5 0  for 
doxorubicin in H69/LX4 in the presence of horse serum (p<0.05, Student t test). In 
the presence of bovine serum there was no effect (Table 3.3).
Table 3.3
Effect of deoxyspergualin on the of doxorubicin in EMT6/AR1.0 and
H69/LX4
EMT6/AR1.0 (IC50
|liM )
H69/LX4 (IC50 IdM)
BS '  E S"" BS ES
Control 7.9b 4.0 1.1 1.3
(Z6) (2.4) (&5) (Ü5)
Deoxyspergualin 8.0 7.5 1.5 1.8
(2pM) (Z6) (3J) (&8) (0.4)
Deoxyspergualin 6.2 7.8 1.7 1.6c
(4pM) (1.0) (4.5) (&9) (&5)
^IC50=dose o f drug required to reduce fractional absorbance to 50% o f control value 
•’Values are means (standard error) from at least 3 independent experiments 
(’p<0.05, value is significantly different from that o f tlie control (Student's t test)
3.3.5 Inhibition of pH]Azidopine covalent binding to P-glycoprotein
in membranes prepared from H69/LX4 cells.
The potential of deoxyspergualin to inhibit the covalent binding of pH]azidopine to 
P-glycoprotein was studied using the photoaffinity labelling technique. Figure 3.7 
shows that the covalent binding of pH]azidopine is only seen after exposure to UV
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irradiation. With UV exposure there is a clear band at a molecular weight of 
170kDa in H69/LX4 but not in H69/P indicating the presence of pH]azidopine 
binding to P-glycoprotein. Covalent binding of pHJazidopine to P-glycoprotein 
only occurs in the resistant cell line after UV irradiation. Deoxyspergualin at 
concentrations of between 2 and 40 |iM does not inhibit the covalent binding of 
[^HJazidopine to P-glycoprotein. In contrast, however, clear inhibition was 
produced by cyclosporin A (IfiM).
Figure 3.7
Effect of deoxyspergualin (DSG) on the covalent photo incorporation of 
pHJazidopine to P-glycoprotein.
- P170
Lane number 1 2 3 4  5 6 7 8 9
Lane 1: H69/P membranes, Lanes 2-9: H69/LX4 membranes . (Lane 2: no U V  exposure, Lane 3: 
no modifier. Lane 4: + CsA 5|iM , Lane 5, 6, 7, 8 and 9: + DSG 2, 4, 10, 20 mid 40|iM
respectively.)
Figure represent typical data sets. Similar results were obtained in 3 independent experiments.
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3.4 Discussion
Copper amine oxidase contained in serum is thought to be responsible for the 
cytotoxicity of polyamines and deoxyspergualin in vitro (Shiro etaL,. 1992). Our 
studies support the theory that aminoaldehydes and hydrogen peroxide produced by 
the oxidative deamination of polyamines by copper amine oxidases are responsible 
for the cytotoxicity of these agents in vitro in the presence of bovine serum. 
However our results using horse serum which is low in copper amine oxidase 
content indicate that this may not be the only mechanism of toxicity. Spergualin has 
potent anti-tumour activity in mouse neoplasms (Tnkeuchi et at., 1981). Mouse 
serum is poor in copper amine oxidase (Shiro et al., 1992), therefore the antitumour 
effect of deoxyspergualin is unlikely to be due to its oxidation in murine blood. 
Hence the mechanism of cytotoxicity in this system may be other than via oxidative 
deamination by copper amine oxidase. The antitumour activity of spergualin was 
markedly reduced in immuno-deficient mice (Masaaki et al., 1986). It may 
therefore be possible that in vivo in the presence of serum types which are low in 
copper amine oxidase, e.g. mouse and human serum, the anti-tumour activity of 
deoxyspergualin may be due to activation of the immune system.
Kuramochi et al. (1987) also showed that the antiproliferative action of 
deoxyspergualin is different to that induced by copper amine oxidase. This group 
demonstrated that aminoguanidine, a potent inhibitor of copper amine oxidase 
activity did not decrease the growth inhibitory activity of deoxyspergualin in the 
presence of human serum, which is low in copper amine oxidase activity. They also 
showed that the survival curves produced by exposure of cells to deoxyspergualin in 
the presence of human ^rum  were shallow and therefore concluded that this may be 
due to the mechanism of action of deoxyspergualin in the presence of human serum 
being cytostatic rather than cytocidal. Our survival curves produced by plotting 
surviving fraction, detei*mined by measuring fractional absorbance in the MTT 
assay, against logio (concentration of drug) are also shallow in the presence of
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horse serum. Our results therefore support those of Kuramochi et a i  and it appears 
that in the absence of copper amine oxidase the mechanism of action of 
deoxyspergualin may indeed be cytostatic.
Nishikawa et al., (1991) showed that deoxyspergualin arrested cells in Gq/Gi phase 
and reduced the cycling cell population. The conversion of Go to G i phase and 
progression to S phase are two critical steps for cell proliferation. Our results show 
that in the absence of copper amine oxidase present in bovine serum, 
deoxyspergualin appears to exert a cytostatic effect on the cell population reflecting 
the drugs effect on cell cycle.
Cyclosporin A and FK506 are natural products possessing potent 
immunosuppressive properties and also the ability selectively to restore sensitivity 
to cells with acquired MDR. By studying the uptake of radio-labelled daunorubicin 
we were able to show that deoxyspergualin, unlike cyclosporin A and FK506, did 
not alter the drug accumulation deficit present in the cell line EMT6/AR1.0 and 
H69/LX4.
The use of the photo-active, tritium-labelled, arylazide, azidopine has enabled us to 
demonstrate that resistance modifiers such as cyclosporin A are able to inhibit the 
covalent binding of pHjazidopine to P-glycoprotein. The results obtained from our 
photoaffinity labelling experiments here show that deoxyspergualin does not inhibit 
the covalent binding of azidopine to P-glycoprotein suggesting that it is not a 
substrate for the protein. This is supported by the fact that deoxyspergualin does not 
reverse the accumulation deficit in EMT6/AR1.0 or H69/LX4 and that it is not 
capable of restoring the sensitivity of the drug resistant cell lines EMT6/AR1.0 or 
H69/LX4 to doxorubicin to the levels of the parent cells indicating deoxyspergualin 
does not modify classical MDR.
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The P-glycoprotein overexpressing human, MDR variant, H69/LX4 shows no cross 
resistance resistance to deoxyspergualin. The mouse EMT6/AR1.0 cells however, 
show modest but significant cross resistance to the drug. Deoxyspergualin is not a 
substrate for human P-glycoprotein, as wc demonstrated using photoaffinity 
labelling, and therefore is not removed from the human cells by the active transport 
drug efflux pump. It is possible that deoxyspergualin has a low but significant 
affinity for mouse P-glycoprotein, however the cross resistance observed in the 
mouse line may be due to an alternative mechanism other than incresed efflux by P- 
glycoprotein.
Cyclosporin A binds to a cytosolic protein, cyclophilin. FK506 also binds to an 
intracellular binding protein. Both these proteins have been shown to possess 
peptidyl-propyl cis-trans isomerase activity. If Cyclosporin A and FK506 exert 
there resistance modifying activity, at least in part, by the inhibition of peptidyl- 
propyl cis-trans isomerase activity then this may account for the lack of activity of 
deoxyspergualin which does not inhibit this enzyme (Nadler et al., 1992).
Our data suggests that deoxyspergualin, unlike Cyclosporin A and FK506, is not a 
good candidate for development as a resistance modifier. However, its maintenance 
of activity in classical multidrug resistant cells and its potent in vivo anti-tumour 
activity makes deoxyspergualin a promising agent for further investigations into its 
potential clinical use as an anti-tumour agent.
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4.1 Introduction
4 .1 .1  Xenova Ltd: M icrobial screen
(i) Background
Xenova Group pic is a biopharmaceudcal company specialising in the discovery and 
development of new small molecule drugs derived originally from naturally occurring 
micro-organisms, such as fungi and bacteria, and from plants. The Company's 
broad-based, proprietary platform technologies enable it rapidly to screen and evaluate 
large numbers of chemical compounds produced by these organisms. Candidate 
compounds, or leads, are then identified for development as new drugs for the 
treatment of a wide range of diseases, such as cancer, cardiovascular conditions, 
central nervous system disorders as well as serious chronic conditions, such as 
immune inflammatory disorders.
(ii) M icrobial Resources
Of the top-selling drugs world-wide in 1993,24 were small molecules and, of these, 
7 were derived originally from naturally occurring micro-organisms (microbes). Most 
microbial chemicals have inherent biological activity, making microbes a rich and 
inexhaustible source of drug leads for new therapeutic applications. Fungi alone have 
already proved to be a source of many valuable drugs, including beta lactam 
antibiotics for infectious diseases and cyclosporin for organ transplantation. Xenova 
has isolated approximately 25800 micro-organisms to date, and has access to over 
6800 species of plants. The company's resources in fungi, bacteria and lichens, as 
well as higher plants, provide a vast and largely untapped supply of structurally 
diverse chemical compounds potentially capable of arresting a wide variety of disease 
processes.
(Hi) Extraction and evaluation o f  compounds
Exotic fungi and plants are collected by ecologists and brought back to Xenova from 
places such as Ecquador, Brazil and Thailand. The fungi are then fermented on a
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small scale in various media which are deficient in some way. For example one 
medium is phosphorus deficient, another nitrogen deficient and so on. The idea being 
that the different stress conditions will lead to the production of different secondaiy 
metabolites. These cultures are then ultra filtered through lOkDa cut off membranes 
which allow the passage of liquid (broth) but leave behind the biomass, i.e. cells.. 
Hydrophilic compounds will be present in the aqueous extract The biomass is then 
extracted using 100% methanol (MeOH). This lyses the cells and allows the release 
of hydrophobic compounds which are also collected. The samples are dispensed into 
microtitre plates and stored at -20“C. The Biochemistry Department then uses these 
plates in screening assays. They use high-throughput technologies such as the 
TopCount' liquid scintillation counter used in the multidrug resistance screen for 
examining drug accumulation. Any sample which appears active will be retested and 
if it is consistently active it will be refermented before fractionation, using HPLC 
based assays, of the extract (broth or MeOH) by the Natural Product Chemistry 
Department Ideally interaction between scientists in both the Biochemistry and the 
Natural Product Chemistry Departments by assay-guided fractionation leads to the 
identification of the active compound. This 'active' is then passed to the molecular 
pharmacologists who evaluate the compound in mechanism-based secondary assays. 
It is at this stage that I receive compound for evaluation in our laboratory in 
Cambridge. If the conipound continues to show promising activity in these cell-based 
secondary assays it may become the subject of a medicinal chemistry programme to 
identify more potent‘actives’vith increased solubility and an improved toxicity profile. 
If the cumpuund cannot be syntlietically synthesised easily it may have to be isolated 
from large fermentations of the original organism (lOOO's of litres) before semi­
synthetic modification. Very promising compounds (lead compounds'), are then 
evaluated by the Pharmacology Department in in vivo models. This lengthy 
extraction and evaluation procedure will hopefully result in the identification of 
compounds suitable for progression into preclinical research and development 
followed by phase I clinical trials.
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4 .1 .2  Classification of modifiers of P-glycoprotein-mediated
multidrug resistance
( i)  In troduction
The following section focuses on com pounds that hâve been identified âS 
chemosensiti^rs and have potential clinical use based on their availability, prior 
clinical use and toxicological profile
(ii) Calcium channel blockers
Tsuruo's group was the first to show the ability of verapamil to reverse resistance in 
murine MDR cells (Tsuruo et al., 1981). Subsequently many investigators have 
demonstrated the chemosensitising activity of verapamil in various rodent and human 
MDR cell lines (Ford and Hait, 1990). A number of groups have shown that 
photoactivated verapamil analogues bind irreversibly to P-glycoprotein and that 
verapamil inhibits the binding of many chemotherapeutic drugs as well as other 
chemosensitisers to P-glycoprotein (Cornwell et a l,  1987; Safa et a l, 1988), 
suggesting that the mechanism of action of verapamil is through blocking the binding 
of drugs to P-glycoprotein. In terms of clinical potential for MDR modulation, 
verapamil is limited by its cardiovascular effects in humans at plasma concentrations 
in the 2 to 6 pM range needed for antagonism of MDR in vitro (Candell et aL, 1979). 
In a screen of 14 structural analogues of verapamil, the compound R o ll-2933 was 
found to be 10-fold more potent than verapamil for sensitising MDR murine leukaema 
cells to doxorubicin (Kessel et al., 1985). This agent is also less toxic in vivo to 
mice than verapamil. In addition the plasma levels of Rol 1-2933 achieved in vivo 
(less than 2pM) were effective in vitro, this agent is a promising candidate for clinical 
trials in humans. It was originally thought that the activity of these compound in 
MDR cells may be related to the calcium channel blocking activity of the drugs. 
Nifedipine, however, is known to be a potent calcium channel blocker but is a poor 
antagonist of MDR (Ramu et a i, 1984). Conversely, the dihydropyridine analogue, 
PAK-200 possesses very low calcium channel activity, yet it fully reversed resistance
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to vincristine at a dose of 5pM in a human MDR cell line (Niwa et a i, 1992). This 
indicates that there is a lack of correlation between calcium channel antagonism and 
anti-MDR activity. The use of less cardiotoxic enantiomers of verapamil (D- 
vcraparail) and its analogues may also provide a means for achieving clinically 
effective MDR reversal in the clinic.
(Hi) Calmodulin antagonists
The second class of MDR modifiers to be identified were drugs known to inhibit 
calmodulin-mediated processes. The phenothiazine calmodulin antagonist, 
trifluoperazine, caused a 10-fold increase in doxorubicin sensitivity in 40-fold 
resistant murine cells and a 5-fold increase in doxorubicin accumulation, but did not 
significantly alter drug cytotoxicity or accumulation in sensitive cell lines (Tsuruo et 
a i,  1982). The examination of structure-activity relationships for a series of 22 
phenothiazine derivatives led to the identification of the thioxanthene class of 
calmodulin antagonist MDR modifier (Ford et a l, 1989). The lead compound, trans- 
flupenthixol, reversed MDR in a number of human and murine MDR cell lines and in 
sensitive cells transfected with the M DRl gene, increased doxorubicin accumulation 
to a greater extent than either its stereoisomer cw-flupenthixol or verapamil, and 
inhibited photoactive azidopine binding to P-glycoprotein (Ford ef o l, 1990). Trans- 
flupenthixol has virtually no effect as a dopamine antagonist and as a result lacks in 
vivo toxicity due to extrapyramidal side effects (Johnstone et aL, 1978). This drug 
may, therefore, be uniquely suited for in vivo use as a MDR modifier.
(iv) Steroids and hormonal analogues
The expression of high levels of P-glycoprotein in the human adrenal cortex and 
placenta (Arceci et a l, 1988) suggests a possible role for the pump in the 
physiological transport of steriod hormones. Several groups have, therefore, studied 
whether steriods are natural substrates for P-glycoprotein or are chemosensitisers in 
combination with cytotoxic drugs. Progesterone increased the accumulation and
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enhanced the cytotoxicity of vinblastine in murine MDR macrophages that 
overexpress the mdrlb gene (Yang et aL, 1989 & 1990). It also inhibited the binding 
of vincristine and vinblastine to membranes prepared from MDR cells (Naito et a i, 
1989). Interestingly, unlike most Other resistance modifiers, progesterone does not 
appear to be a substrate for P-glycoprotein (Ueda et oL, 1992). This indicates that the 
ability of a compound to act as a chemosensitiser and inhibit transport of other drugs 
by P-glycoprotein is not necessarily related to its own ability to function as a 
substrate. Megesterol acetate (Megace), an orally active congener of progesterone, 
functions as an MDR modifier. Paradoxically, Megace increased the binding of a 
photoactive calcium channel blocker to P-glycoprotein by up to 2-fold but inhibited 
labelled Vinca alkaloid binding to P-glycoprotein by 50% (Fleming et al., 1992). 
These data strongly suggest that separate drug binding sites exist on P-glycoprotein 
for certain chemosensitising compounds and drug substrates.
Several groups have demonstrated that synthetic steroid analogues, such as tamoxifen 
and the related antiocstrogcn torcmifcnc are active chemosensitisers at concentrations 
of 2 to lOpM in a number of P-glycoprotein overexpressing MDR cell lines (Foster et 
al., 1988; Degregorio et al., 1989). In the clinic, high serum levels of these 
antioestrogens can be achieved due to their lack of side effects (at least during short 
term use). This suggests that they may be well tolerated, effective chemosensitisers 
when used in combination with cytotoxic agents for the treatment of clinical drug 
resistance.
(v) C yclosporins
Cyclosporin A, a hydrophobic cyclic peptide of 11 amino acids that is widely used in 
human organ transplantation, has been shown by several groups to reverse resistance 
in MDR (Slater et al., 1986a & b; Twentyman et a i, 1987a; Hait et al., 1989). It has 
been reported that cyclosporin A itself is accumulated less in P-glycoprotein 
overexpressing cells (Goldberg et a l, 1988). Cyclosporin A enhanced vincristine
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toxicity in both sensitive and vincristine-resistant Chinese hamster MDR cells, but by 
a 10-fold greater factor in the MDR cells. It completely reversed the 22-fold 
decreased level of vinblastine accumulation displayed by the MDR cells, but it also 
caused a 2-fold increase in vinblastine accumulation in the sensitive cells (Tamai et 
al., 1991). These data suggest that cyclosporin A may serve as a P-glycoprotein 
substrate and antagonise MDR at least in part via competitive inhibition of P- 
glycoprotein-mediated outward transport of cytotoxic drugs. They also imply, 
however, that cyclosporin A may modulate cytotoxicity via mechanisms other than 
competitive inhibition. Because of the profound immunosuppressive effects of 
cyclosporin A, there has been great interest in exploring the resistance modifying 
ability of other less immunosuppressive and nephrotoxic cyclosporin analogues. 
Researchers at Sandoz discovered that the cyclosporin D analogue, PSC 833, was 10- 
fold more potent than cyclosporin A. PSC 833 (IfiM) has been shown to cause 
nearly complete reversion of drug resistance to taxol in rodent cells, and it was 30- 
fold more potent than verapamil (Gaveriaux et ai, 1991).
In summary, the newly developed nonimmunosuppressive cyclosporin analogues, 
particularly PSC 833, appear to be good candidates for drug resistance modifying 
agents in the clinic owing to their increased potency and decreased toxicity.
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(vi) M iscellaneous compounds
Numerous compounds have been identified in the search for agents which circumvent 
MDR that do not belong to any of the previously discussed classes. Most of these 
agents are lipophilic in nature and they share a broad structural similarity that includes 
a heterocyclic ring separated at a distance from a cationic, amino group. Examples of 
this diverse group of resistance modifiers include: antiarrhythmics such as 
amiodarone (Chauffert et al., 1986) and quinidine (Tsuruo et a l, 1984); antimalarials 
such as chloroquine and quinacrine (Zamora et al., 1988); the indole alkaloid, 
reserpine (Beck et fl/., 1988); the antihistamine, terfenadine (Hait et a/., 1993); and 
antibiotics such as erythromycin (Hofsi et aL, 1989), cefoperazone (Gosland et ai, 
1989) and tetracycline (Kavallaris et aL, 1993).
There are two relatively new resistance modifiers that are of particular interest. 
Firstly, the acridone carboxamide derivative, GF120918, possesses remarkable 
potency for reversing MDR in several human and rodent MDR cell lines. GF120918 
is active at concentrations as low as 0.02ilM displaying similar activity to 5pM 
verapamil (Hyafil et a l, 1993). Secondly, a novel class of compounds active against 
MDR has been identified by screening natural products extracted from strains of 
cyanobacteria (blue-green algae). One of the isolates, tolyporphin, functions as a 
potent resistance modifier (Prinsep et aL, 1992). This agent sensitised MDR cells to 
daunomycin, vinblastine, VP-16 and taxol at doses of 0.1 pM. It also inhibited 
binding of labelled vinblastine and azidopine to P-glycoprotein.
4 .1 .3  Identification of natural product diketopiperazines as
modifiers of multidrug resistance
During the course of screening the Xenova microbial collection for novel modifiers of 
multidrug resistance scientists identified derivatives of a natural product 
diketopiperazine which displayed promising activity as a resistance modifier (Figure 
4.1). Previously, a group in Japan isolated a substance from the organism.
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Streptoverticillium aspergilloides which they discovered was a complex of two 
components, designated piperafizine A and B, structurally classified as the 
diketopiperazine family. Furthermore they demonstrated that compound A markedly 
enhanced the cytotoxicity of vincristine in Moser cells, a human colon carcinoma cell 
line with intrinsically high levels of P-glycoprotein, and moderately in the vincristine 
resistant P388 cell line. Piperafizine B showed a slight increase in the toxicity of 
vincristine only in the vincristine resistant P388 cells (Kamei et a i ,  1990). In 
leukaemia-bearing mice, piperafizine A significantly increased life span when used in 
combination with vincristine. We now have a large number of these diketopiperazine 
derivatives synthesised at Xenova. After primary screening at Xenova the most 
promising compounds were tested in our laboratory with the objective of elucidating 
their mechanism of action as well as forming a more detailed profile of their activity in 
combination with a variety of cytotoxic drugs and in a number of cell lines. The 
structures of the XR compounds studied in this Chapter are shown in figure 4.1.
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Figure 4.1
Structure of diketopiperazine analogues used in this study 
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Figure 4.1 (continued)
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4 .1 .3  A im s
(i) Tô establish the activity of a group of novel fungal product diketopiperazines 
as modifiers of P-glycoprotein mediated multidrug resistance.
(ii) To compare their activity in a number of different multidrug resistant cell lines 
and in combination with a variety of different drugs and to build a structure activity 
relationship.
(iii) To elucidate their mechanism of action.
I l l
4 .2  Materials and Methods
4 .2 .1  Cell Lines
We used the human T-lymphoblastoid leukaemia cell line CEM and the human small 
cell lung cancer cell line H69/P together with their P-glycoprotein overexpressing 
sublines CEM/VLB and H69/LX4. For cell culture conditions see Section 2.1.
4 .2 .2  Drug Sensitivity Testing.
The cytotoxicity of the Xenova compounds were determined using the tétrazolium 
(MTT) reduction colorimetric assay. This method is described in detail in Section 2.3.
4 .2 .3  Drug Accumulation Studies
The effect of the Xenova compounds on the ability of CEM and CEM/VLB cells to 
accumulate pH]daunorubicin and pHJcolchicine was determined as described in 
Section 2.5.2.Ü.
4 .2 .4  Photoaffinity Labelling
The effect of the Xenova compounds on the ability of pHjazidopine to photolabel P- 
glycoprotein in membrane protein prepared from drug sensitive CEM and P- 
glycoprotein overexpressing CEM/VLB cells was determined as described in Section 
2 .6 .2 .
4 .2 .5  Confocal microscopy
The effect of the Xenova compounds (5pM) on the distribution of lOpM doxorubicin 
in CEM and CEM/VLB cells was determined as described in Section 2.8.2.Ü.
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4.3 Results
4 .3 .1  Toxicity of XR com pounds in cell lines CEM , H69/P and
L23/P together with their respective MDR cell line 
varian ts CEM/VLB, H69/LX4 and L23/R 
Table 4.1 shows the toxicity of all 10 XR compounds in the parental CEM and H69/P 
cell lines together with their P-glycoprotein-overexpressing resistant variants 
CEM/VLB and H69/LX4 and in the parental cell line L23/P together with its MRP- 
overexpressing variant L23/R. The highest concentration of XR compound used in 
the studies presented in this chapter was 20pM. We received, the stock solutions 
dissolved in DMSO at a concentration of 5mM. We applied an upper concentration 
limit of 20pM as many of the compounds came out of solution when dissolved in 
medium at concentrations higher than 20{iM. We also wished to avoid having high 
concentrations of solvent in our experiments. The IC50S for compounds that are not 
toxic at concentration of 20pM are, therefore, not precisely defined. Table 4.1 
demonstrates that, where IC5 0 S are precisely defined in the parental and resistant cell 
lines, it is possible to calculate the resistance factor (resistance factor is defined by the 
IC5 0  of the drug in the resistant line divided by the IC5 0  of the drug in the sensitive 
line). The resistance factors, indicate that the resistant cell lines are modestly cross 
resistant to the XR compounds. XR9112 was the most toxic compound in all the cell 
lines. The general toxicity profile for the compounds was similar in all 6 cell lines. 
There were, however, some exceptions: for example, CEM, CEM/VLB, L23/P and 
L23/R are more sensitive to XR1824 than H69/P and H69/LX4.
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Table 4.1
Toxicity of XR compounds in sensitive and drug resistant cell lines
(a) CEM and CEM/VLB
IC50(fiM)
X R  C O M P O U N D C E M C E M /V L B
R e s is ta n c e
f a c t o r
X R 1500 >20* >20* N/D
X R 9006
11.0
13.3
>20
14.0 N/D
X R 9112
1.5
017)
n=3
2.9
(0.2)
n=3
1.9
X R 1824
5.7
(3.0)
n=3
8.0
(2.9)
n=3
1.4
X R 1829 >20*
>20
>20
11.2
N/D
X R 9051 >20* >20* N/D
X R 9089 >20* >20* N/D
X R 1818
7.3
(1.9)
n=3
10.0
(2.0)
n=3
1.4
X R 1779
10.8
(0.2)
n=3
12.7
(2.4)
n=3
1.2
X R 9019
9.1
14.0
16.3
>20 N/D
Values represent the mean (standard error) from n independent experiments. Where n<3, individual 
values are shown. *20)iM was tlie highest concentration studied, the IC50 value was >20 in at least 
3 independent experiments. IC50 represents the concentration of drug required to reduce fractional 
absorbance to 50% of control values in the tétrazolium reduction (MTT) assay.
N/D-not determined. Resistance factor is defined by tlie IC 50 of the drug in tlie resistant line divided
by the IC 5 0  o f  tlic drug in the sen sitive  line.
(b) H69/P and H69/LX4
I C sO d iM )
XR COMPOUND H69/P H69/LX4 Resistance
factor
X R 1500 >20* >20* N/D
X R 9006
>20
14.0
1 1 .5
>20* N/D
X R 9112
2 .5
(0.7)
n=3
3.5
( 1 .5 )
n=3
1 .4
X R 1824
12.1
(3.2)
n=3
14.8
(2.3)
n=3
1.2
X R 1829 >20* >20* N/D
X R 9051 >20* >20* N/D
X R 9089 >20* >20* N/D
X R 1818
9.7
(0.7)
n=3
14.5
(2.4)
n=3
1.5
X R 1779
7.6
(1.9)
n=3
9.4
(1.0)
n=3
1.2
X R 9019
14.5
(1.9)
n=3
>20* >1.4
Values represent the mean (standard error) from n independent experiments. Where n<3, individual 
values are shown. *20pM  was the highest concentration studied, the IC50 value was >20 in at least 
3 independent experiments. IC50 represents the concentration o f drug required to reduce fractional 
absorbance to 50% of control values in the tétrazolium reduction (MTT) assay.
N/D-not determined. Resistance factor is defined by the IC50 o f the drug in tlie resistant line divided
by tlie IC50 o f tlie drug in tlie sensitive line.
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(c) L23/P and L23/R
IC 50(^ M )
X R  C O M P O U N D L23/P U23/R
fa c to r
X R 1500 >20* >20* N/D
X R 9006 >20* >20* N/D
X R 9112
3.0
(L2)
n=3
3.5
019)
n=3
1.2
X R 1824
4.1
(&4)
n=3
4.6
018)
n=3
1.1
X R 1829 >20* >20* N/D
X R 9051 >20* >20* N/D
X R 9089 > 20* >20* N/D
X R 1818
4 .6
(1.6)
n = 3
5 .5
(1 .4 )
n= 3
1.2
X R 1779
12.7
(2.0)
n = 3
14 .3
(2.9)
n = 3
1.1
X R 9019
10.9
(Z7)
n = 3
14.2
11.3  
> 2 0
N/D
Values represent the mean (standard error) from n independent experiments. Where n<3, individual 
values are shown. *20|iM  was the highest concentration studied, the IC50 value was >20 in at least 
3 independent experiments. IC50 represents the concentration o f drug required to reduce fractional 
absorbance to 50% of control values in the tétrazolium reduction (MTT) assay.
N/D-not detennined. Resistance factor is defined by tlie IC50 of the drug in tlie resistant line divided
by the IC50 o f the drug in tlie sensitive line.
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4 .3 .2  Sensitisation of CEM , CEM/VLB, H69/P and H69/LX4
ceils to doxorubicin, colchicine and taxol by the XR 
com pounds
We examined the effect of 1 and 5|iM of each of the XR compounds on tlie sensitivity 
of the parental cell lines CEM and H69/P and their respective P-glycoprotein- 
overexpressing sublines CEM/VLB and H69/LX4. In the case of XR9112, due to its 
toxic effects, we used concentrations of 0.2 and lp,M. Sensitisation ratios are shown 
in table 4.2 (a-e) for the compounds at 1 and 5pM (0.2 and l|iM  for XR9112) in 
combination with colchicine, doxorubicin and taxol (taxol is only shown in CEM and 
CEM/VLB cells). Sensitisation ratio is defined by the ratio of IC5 0  in the 
presence/absence of modifier. The effect of the compounds is clearly dose and drug 
specific. At the higher dose of 5pM, XR9006 is the most effective modifier of 
colchicine resistance while XR9051 appears to be the most effective modifier of 
doxorubicin resistance in both CEM/VLB and H69/LX4 cells. The compounds had 
no effect on the sensitivity of the drug sensitive cell lines to either doxorubicin or 
colchicine (data not shown). At the lower concentration of IjiM, XR9006 was 
consistently the most effective modifier of both doxorubicin and colchicine resistance. 
At IpM, XR9112 was also an effective modifier of both doxorubicin and colchicine 
resistance. Its toxic effects limited experimentation at higher doses and indicate that it 
would not be a potentially good candidate for further investigations. XR1779 and 
XR1818 had only modest resistance modifying activity. They are also more toxic than 
the more effective modifiers XR9051 and XR9(X)6. XR1500 was one of the initial 
compounds to be discovered to have potential as a resistance modifier. Its effects are, 
however, modest in comparison to the newly synthesised analogues XR9051, 
XR9006 and XR9112. Initial studies with XR9019 show that it appears to be an 
effective modifier. Problems with its synthesis at Xenova have made further studies 
impossible. Interestingly, in combination with taxol, a different compound has the 
greatest resistance modifying activity. At a concentration of 5|iM XR9089, a 
compound which possessed only modest resistance modifying activity in combination
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with doxorubicin and colchicine, is the most effective of all the compounds in 
combination with taxol. This provides additional evidence that the effect of the XR 
compounds is dependent on the cytotoxic drug which it is used in combination with. 
Figures 4.2 (a-e) show graphical representations of the effect of the 2 best XR 
modifiers, XR9051 and XR9(X)6 on the sensitisation of CEM/VLB to doxorubicin, 
colchicine and taxol.
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Table 4.2
(a) Sensitisation of CEM /VLB cells to doxorubicin by XR Compounds
XR CP1> SensitisatiDn Ratio^ 
#  l |iM  XR CPD
Rafiu^ 
X R,CPD ■
1.41 1.75**
X R 1500 (0.20) (0.03)
n=3 n=3
6.64 21.35*
X R 9006 (Z80) CL87)
n=3 n=3
5.46 20.44**
2X R 9112 (L69) (L56)
n=3 n=3
1.40 5.22*
X R 1824 (0J8) (0.91)
n=3 n=3
2.04* 3.93*
X R 1829 (0.16) (0.54)
n=3 n=3
2.99 26.67*
X R 9051 (1.12) (4.41)
n=3 n=3
1.67 1.25
X R 9089 (0.67)
n=3
1.40
1.00 3.12
X R 1818 2.25
1.25 1.79
X R 1779 2.25 4.25
X R 9019
2.00 10.00
tRatio o f IC50 in presence/absence o f modifier. IC50 represents the dose o f drug required to reduce 
fractional absorbance to 50% o f  control values in the tétrazolium reduction (MTT) assay. 
*p<0.05 (significantly different from 1.0). **p<0.01 (highly significanUy different from 1.0) 
(Student's t test). Values are means o f n independent experiments.
Where n<3, individual values are shown. Parentheses show standard error.
^Due to toxicity of XR9112, doses o f 0.2 and O.lpM were used instead o f 1 and 5pM
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Table 4,2
(b) Sensitisation of H69/LX4 cells to doxorubicin by XR Compounds
XR CPD Sensitisation Rafio^ 
#  i m  XR CPD
Sensitisation - Ratio^ 
' XR CPD'
1.00 :L83*
X R 1500 (0.00) (0.67)
n=3 n=3
14.5 45.00*
X R 9006 (5.56) (10.41)
n=3 n=3
7.08* 2&00*
2X R 9112 (L39) (3.88)
n=3 n=3
1.33 7.42*
X R 1824 (0.33) (L29)
n=3 n=3
1.83 :L63
X R 1829 (Œ35) (&57)
n=3 n=3
3.30 57.50**
X R 9051 (1.90) (3.01)
n=3 n=3
1.67 2.27*
X R 9089 (0.42) (0.39)
n=3 n=3
0.93 1.10
X R 1818 (0.07) (0.10)
n=3 n=3
1.17 2.17
X R 1779 (0.19) (0.49)
n=3 n=3
5.0 11.53*
X R 9019 2.5 (1.75)
n=3
1 Ratio o f IC50 in presence/absence o f modifier. IC50 represents the dose o f drug required to reduce 
fractional absorbance to 50% o f control values in tlie tétrazolium reduction (MTT) assay. 
*p<0.05 (significantly different from 1.0). **p<0.01 (highly significantly different from 1.0) 
(Student's t test). Values are means o f n independent experiments.
Where n<3, individual values are shown. Parentheses show standard error.
^Due to toxicity o f X R 9112, doses o f 0.2 and O.ljiM were used instead o f  1 and 5pM
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Table 4.2
(c) Sensitisation of CEM/VLB cells to colchicine by XR Compounds
XR CVÙ .Sensitisation R a tW Sensitisation RatioX
® I mM  XR CPD ' #  XR CPD
0.62* 1.42
X R 1500 (0.08) (0.21)
n=4 n=4
7.57* 18.38**
X R 9006 (L27) (0.99)
n=3 n=4
/L28* 14.11**
2X R 9112 (L29) (2.01)
n=4 n=4
3.46 10.26*
X R 1824 (L24) (3.08)
n=4 n=3
L32 2L84
X R 1829 (0.24) (L45)
n=4 n=3
. 1.37 17.75**
X R 9051 (0.19) (2.88)
n=3 n=4
1.69 4.17
X R 9089 (0.13) (0.44)
n=4 n=3
0.72* 2.06
X R 1818 (0.10) (1.01)
n=4 n=3
0.77** 1.52
X R 1779 (0.03) (0.25)
n=4 n=4
4.00 10.00
X R 9019 1.17
iRatio o f IC50 in presence/absence o f modifier. IC50 represents the dose of drug required to reduce 
fractional absorbance to 50% o f control values in the tétrazolium reduction (MTT) assay. 
*p<0.05 (significandy different from 1.0). **p<0.01 (highly significantly different from 1.0) 
(Student's t test). Values are means o f n independent experiments.
Where n<3, individual values are shown. Parentlieses show standard error.
20u e to toxicity of X R 9112, doses o f 0.2 and O.lpM were used instead o f 1 and 5pM
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Table 4.2
(d) Sensitisation of H69/LX4 cells to colchicine by XR compounds
XR CPD Senslttsati<»i Rafiol 
' @ i m  XR CPD
Sensitisation Ratîo^ 
#  S u M X R C P D
0.75* 3.25
XR1500 (0.061) (0.97)
n=4 n=4
84#* 58J^*
XR9006 (2.04) (14.12)
n=4 n=4
3.10* 30.94*
2XR9112 (0.63) (10.20)
n=4 n=4
2.70 18.75*
X R1824 (0.80) (5J3)
n=4 n=3
1.20 2.50
X R1829 (0.20) (0J4)
n=4 n=4
:L35 42.50*
XR9051 (0.71) (6.00)
n=3 n=4
X R9089 1.89 15.00
(0.30)
n=3
6.00
0.94 1.78*
X R1818 (0.06) (0.33)
n=4 n=4
1.06 3.25*
X R1779 (0.20) (0.50)
n=4 n=3
3.42 27.50*
X R9019 (1.02) (6.61)
n=3 n=3
^Ratio o f IC50 in presence/absence o f  modifier. IC50 represents the dose of drug required to reduce 
fractional absorbance to 50% o f  control values in the tétrazolium reduction (MTT) assay. 
*p<0.05 (significantly different from 1.0). **p<0.01 (highly significantly different from 1.0) 
(Student's t test). Values are means o f n independent experiments.
Where n<3, individual values are shown. Parentlieses show standard error.
^Due to toxicity of X R 9112, doses of 0.2 and O.ljiM were used instead o f 1 and 5iiM
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Table 4.2
(e) Sensitisation of CEM/VLB cells to taxol by XR compounds
XR CPD
@ l\xU XR  CPD
Sensitisation 
#  5M M X RCPD
1.60 6.00*
X R1500 (0.30) (0.60)
n-3 n=3
12.77* 21.70**
X R9006 (L52) (L73)
n=3 n=3
11.10* 17.80**
2XR9112 (2.65) (L57)
n=3 n=3
2.00 8.00
X R 1824 3.50 9.10
2.00 5.00
X R 1829 1.20 4.70
2L20 22.30**
X R9051 (1.14) (1.30)
n=3 n=3
9.17* 26.58*
X R 9089 (2.14) (5^8)
n=3 n=3
4.17* 8.05
X R 1818 (0.43)
n=3
8.58
1.87 8.30
X R 1779 (0.19)
n=3
10.00
^Ratio o f  IC50 in presence/absence o f  modifier. IC50 represents the dose o f drug required to reduce 
fractional absorbance to 50% o f control values in the tétrazolium reduction (MTT) assay. 
*p<0.10 (significantly different from 1.0). **p<0.01 (highly significantly different from 1.0) 
(Student's t test). Values are means o f  n independent experiments.
Where n<3, individual values are shown. Parentheses show standard error.
^Due to toxicity of X R 9112, doses o f 0.2 and 0.1 pM were used instead o f 1 and 5pM
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Figure 4.2
Effect of (a) XR9006 and (b) XR9051 on the sensitivity of CEMTVLB 
cells to doxorubicin 
(a)
(b)
1.0
a  0.8-
0.4-
«  0.2- 
fa '
0.0
.01
doxorubicin ' (jiM)
.0001
iI
i
.0001 .001 .01 .1 
doxorubicin (fxM)
CEM (control) 
CEM/VLB (control) 
CEM/VLB (XR IjlM) 
-A—  CEM/VLB (XR 5\iM)
Figures rq)resent typical data sets. Similar results were obtained iq at least 3 independent
experiments. Mean (standard error) for sensitisation ratios are shôwn in table 4.2.
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'T
Figure 4.3
Effect of (a) XR9006 and (b) XR9051on the sensitivity of CEMA^LB 
cells to colchicine
(a)
1.0
S 0.8 -
S 0.6 -
S  0 .4 -
t  0.2 -
0.0
.01
colchicine (fiM)
.001.0001
(b)
8
1.0 -r 
0.8 -
SJ3
O 0.6 -
1
1 (14-
tS .
2 0.2 -b
0.0-
.0001 .001 .01
colchicine ftiM)
CEM (control) 
CEM/VLB (control) 
CEMAO.B (XR l^iM) 
CEMA^LB (XRS^iM)
Figures represent typical data sets. Similar results were obtained hi at least 3 independent
experiments. Mean (standard eiror) for scnsiUsaüon ratios are shown in table 4.2.
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Figure 4.4
Effect of (a) XR9006 and (b) XR90S1 on the sensitivity of CEM/VLB
cells to taxol
(a)
(b)
1.0
w
C 0-8- a
IS 0.6-
rt
1 0 .4 -0
12 0.2 -
b
0.0
100101.1.01.0001 .001
taxol (jiM)
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0.4 -
g 0.2-
0.0
10010.1.01.0001 .001
taxol (pM)
CEM (control) 
CEM/VLB (control) 
CEM/VLB (XR l^lM) 
-A—  CEM/VLB (XR 5^M)
Figures represent typical data sets. Similar results were obtained in at least 3 independent
experiments. Mean (standard error) for sensitisation ratios are shown in table 4.2.
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4 .3 .3 . Effect of XR compounds on the accumulation of 
[^H]daunorubicin and [^Hjcolchicine in CEM and 
CEM/VLB cells
The results of drug accumulation studies confirm those of the sensitisation 
experiments. The effects of the XR compounds on accumulation of tritiated drug 
appears to be dependent on the drug used. XR9006 at concentrations of 1 and lOpM 
has the greatest effect on the accumulation of pH]colchicine. In contrast XR9051 
has the greatest effect on the accumulation of pH]daunorubicin. At lower 
concentrations of 0.1 and IjiM, however, XR9006 and XR9112 have a greater effect 
than XR9051 on the accumulation of pHJdaunorubicin. It should be noted that the 
IC50 of XR9112 is 2.9pM in CEM/VLB cells (4 day exposure) and therefore the 
effects seen here on the accumulation of pHJdaunorubicin and pHJcolchicine may be 
due to toxic effects of the drug such as alterations in membrane permeability
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T a b le  4 .3
(a) Effect of XR compounds on the accumulation of pHJcolchicine in 
CEM/VLB cells.
ACCUMULATION RATIQi
XR CPD XR 0,% M XR I # M , XR m O ftM
1.22* 1.08 1.33
X R 1500 (0.05) (0.09) (0.27)
n=4 n=3 n=3
1.46** 2.51* 4.94*
X R 9006 (0.05) (0.46) (0.66)
n=4 n=3 n=3
1X%* 3.98* 4.51**
X R 9112 (0.20) (0.92) (0.24)
n=4 n=3 n=3
1.29 1.00 3 ^ 4
X R1824 (0.24) (0.12) (0.88)
n=3 n=3 n=3
1.07 0.94 L68
X R 1829 (0.14) (0.30) 0133)
n=3 n=3 n=3
1.11 Œ89 448*
X R9051 (0.15) (0.11) (1.20)
n=3 n=3 n=3
1.11 1.37 1.65*
X R 9089 (0.12) (0.26) (0.15)
n=3 n=3 n=3
1.37 0.71 1.85*
X R 1818 (0.31) (0.13) (0.09)
n=3 n=3 n=3
1.32 0.92 1.55
X R 1779 (0.28) (0.10) (0.20)
n=3 n=3 n=3
*p<0.05 (significantly different from 1.0) **pc0.01 (highly significantly different from 1.0)
(Student's t test).Values are means o f n independent experiments. Parentlieses show standard error.
1 . . . . pH JCO L accum ulation + XR
^Accumulation ra t io ^ -i— ----------  ------------------------
p H ]C O L  accum ulation - XR
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T a b le  4 .3
(b) Effect of XR compounds on the accumulation of [^HJdaunorubicin 
in CEM/VLB cells
ACCUMULATION RATIQi
XR CPD XR O JmM I X R m m X R  m O flM
1.02 (183 31W*
X R 1500 (0.08) (0.10) 0142)
n=3 n=3 n=3
:L38 10.84* 1L89*
X R 9006 (0.45) (2.00) (2.21)
n=4 n=4 n=4
5.70* 11.52* 12.04*
X R 9112 (1.14) (2.48) (2.47)
n=4 n=4 n=3
1.10 2.65 8.88*
X R 1824 (0.03) (0.77) (2.00)
n=3 n=4 n=4
1.11 1.52 5J8*
X R 1829 (0.06) (0.09) (1.25)
n=3 n=3 n=4
1.87 7.57 12.17**
X R9051 (0.48) (2.66) (1.12)
n=5 n=5 n=4
1.02 1.54 3.25*
X R 9089 (0.04) (0.23) (0.26)
n=3 n=3 n=3
0.68* 0.66* 1.80*
X R 1818 (0.08) (0.10) (0.06)
n=3 n=3 n=3
0.77* 0.75* Z78*
X R 1779 (0.03) (0.06) (0.21)
n=3 n=3 n=3
1.08 5.00** 11.12**
X R 9019 0136) (0.06) 0166)
n=3 n=3 n=3
+p<0.05 (significandy different from 1.0) **p<0.01 (highly significandy different from 1.0)
(Student's t test).Values are means o f n independent experiments. Parentheses show standard error.
. . . . . .  p H lD N R  accumulation + XR
Accumulation ralio=-
[^H ]DNR accum ulation - XR
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4 .3 .4  Effect of XR compounds on the photoaffinity labelling of
P-glycoprotein in membranes
We examined the effect of the XR compounds on the ability of pHJazidopine to 
photoaffinity label P-glycoprotein in membranes prepared from CEM and CEM/VLB 
cells. We found that all the compounds inhibited pHJazidopine labelling of P- 
glycoprotein (at least partially) at 5 and lOjiM. The more active compounds XR9051 
and XR9006 appear also to inhibit partially pHJazidopine binding at the lower dose 
of 2|iM. Figure 4.5 shows the effect of XR9051, XR9006, XR9089, XR9112 and 
XR1818 on the ability of pHJazidopine to photoaffinity label P-glycoprotein. 
XR1818 is not an active modifier but is still able to inhibit pHJazidopine labelling of 
P-glycoprotein at higher concentrations of 5 and lOjiM. In contrast XR9051, 
XR9006, XR9089 and XR9112 are all active modifiers at lower concentrations 
(IjiM) but they do not appear to inhibit pHJazidopine labelling of P-glycoprotein at 
this dose.
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Figure 4.5
Effect of XR9006, XR9051, XR9089, XR1500 and XR1818 on the 
ability of [3H]azidopine to photo-label P-glycoprotein
(a) XR9006
Lane number:
m P-glycoprotein
3 4 6 7 8 9
(b) XR9051
Lane number:
U
; »
P-glycoprotein
1 2 3 8 9
(c) XR1500
Lane number: 1 2  3 4
P-glycoprotein
6 7 8 9
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(d) XR9089
Lane number:
U* J  A— P-glycoprotein
3 4 5 6 7 8 9
(e) XR1818
P-glycoprotein
Lane number: 1 2 3 4  5 6 7 8 9
L egen d :
Lane 1; CEM (parent).
Lane 2; CEM/VLB (resistant) no UV  light.
Lane 3; CEM/VLB no modifier.
Lane 4; CEM/VLB + cyclosporin A 5|iM ,
Lane 5-9; CEM/VLB XR compound 0.5, 1.0, 2.0, 5.0 and lO.OpM respectively
(Note for X R1818, lanes 5-9;CEM/VLB-i-XR compound 10.0, 5.0, 2.0, 1.0 and 0.5fiM  respectively)
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4 .3 .5  A lterations in doxorubicin distribution in sensitive and
m ultidrug resistant cells brought about by XR compounds 
The photographs shown in figures 4.6 and 4.7 demonstrate the effect of XR 
compounds XR9051, XR9006, XR1500 and XR1818 on the distribution of 
doxorubicin in the drug sensitive CEM and the P-glycoprotein-overexpressing drug 
resistant CEM/VLB cells. Figures 4.6.a and 4.7.a show doxorubicin distribution in 
the parent and drug resistant cells respectively. In the drug sensitive CEM cells 
(Figure 4.6.a), doxorubicin appears to be mainly localised in the nucleus and the 
nuclear-cytoplasmic boundary. In contrast in the drug resistant CEM/VLB cells 
(Figure 4.7.a), doxorubicin fluorescence is reduced and there is no specific area of 
drug localisation within the cell. Figure 4.6.b-e show that the 4 XR compounds used 
here do not alter the doxorubicin distribution in the CEM cells. In the drug resistant 
cell line, however, all 4 of tlie XR compounds restore (at least partially) the pattern of 
doxorubicin distribution to that observed in the drug sensitive cell line (Figure 4.7.b- 
e). This effect is clearly dependent on the XR compound used. The more potent 
resistance modifiers XR9051 and XR9006 restore intracellular fluorescence in the 
drug resistant CEM/VLB cell line to the levels observed in the parental cell line 
(Figure 4.7.b & c). The same pattern of distibution is also seen, that is doxorubicin 
appears to be mainly localised in the nucleus and the nuclear-cytoplasmic boundary. 
XRI500 and XRI818 are less potent modifiers of P-glycoprotein-mediated MDR 
than XR9051 and XR9006. They appear to only partially restore intracellular 
fluorescence in the drug resistant CEM/VLB cell line (Figure 4.7.d-e). The following 
confocal settings were used to obtain the data presented in this chapter: 60X objective; 
Confocal aperture 5/15; Gain 900; Zoom 1.0; Neutral density 2, Kalman 10.
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Figure 4.6.a
Subcellular distribution of doxorubicin in the drug sensitive cell line 
CEM
mm
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Figure 4.6.b-e
The effect of XR9051(b), XR9006(c),  XR1500(d) and XR1818(e) on 
the subcellular distribution of doxorubicin in the drug sensitive cell 
line CEM 
(b) XR9051
■
1
(c) XR9006
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(d) X R1500
(e) XR1818
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Figure 4.7.a
Subcellular distribution of  doxorubicin in the drug resistant cell line 
CEM/VLB
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Figure 4.7.b-e
The effect of XR9051(b), XR9006(c), XR1500(d) and XR1818(e) on 
the subcellular distribution of doxorubicin in the drug resistant cell 
line CEM/VLB 
(b) XR9051
(c) XR9006
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(d) X R 1500
(e) XR1818
#
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4 .4  D is c u s s io n
4 . 4 . 1  General discussion
Since the original discovery of Tsuruo ét a l  (1981) that verapamil, a calcium channel 
blocker, was able to reverse MDR in vitro, a large number of compounds have been 
tested on MDR cell lines. It can be estimated that about 1% of organic chemicals 
might have this property (Robert et ai, 1994). Among the drug families sharing this 
property of reversing MDR in vitro are other calcium channel blockers (nicardipine, 
diltiazem), calmodulin inhibitors (trifluoperazine), cyclosporins, quinolines (quinine, 
quinidine) and numerous others (Section 4.1.3). These compounds share a high 
lipophilicity (generally due to the presence of several aromatic rings) and a positive 
charge at neutral pH (Zamora etoL, 1988). The development of several photoaffinity 
analogues of modulators or of anticancer drugs, undertaken in particular by Safa 
(1992), has proven that a number of modulators interact with P-glycoprotein by 
inhibiting its photoaffinity labelling. In our study we examined the effect of the XR 
compounds on the ability of pHJazidopine to photoaffinity label P-glycoprotein. We 
found that all the compounds inhibited [PHJazidopine labelling of P-glycoprotein (at 
least partially) at 5 and lOftM. The more active compounds XR9051 and XR9006 
appear also to inhibit partially pHJazidopine binding at the lower concentration of 
2|iM. Interestingly, although these modifiers are active at concentration below 2pM, 
they do not appear to have any effect on the ability of pHJazidopine to photoaffinity 
label P-glycoprotein at these low concentrations. This may be interpreted in a number 
of ways. Firstly, it is possible that the modifiers reverse drug resistance via a 
mechanism other than competitive inhibition of P-glycoprotein. They may for 
example, exert their action on the regulation of P-glycoprotein activity by 
phosphorylation: the fact that several modifiers are known inhibitors of protein kinase 
C was recognised long ago (Hamada et al, 1987; Chambers et al, 1990a & b). This 
seems unlikely as scientists at Xenova have found that the XR compounds do 
not affect PKC activity (see Chapter 7). Alternatively the compounds may be 
involved in drug redislrihulion wilhin the cell. Secondly, the extent to which a
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compound inhibits the photoalTinity labelling of P-glycoprotein by pHjazidopine may 
not necessarily be directly related to the reversing properties ot the compound. It is 
likely that there is more than one drug binding site on P-glycoprotein and therefore the 
ability of a compound to inhibit the binding of one photoaffinity ligand does not mean 
that it will inhibit the binding of other photoaffinity ligands or drugs to the same 
extent. None of the binding sites on P-glycoprotein for anticancer drugs or 
modulators have been identified to date, although some domains of the protein 
(transmembrane domains 6 and 12) seem to be especially involved in drug binding 
(Greenberger et al, 1993). There is even some experimental evidence against the 
direct interaction of some modifiers with P-glycoprotein (Jaffrezou e ta l,  1991).
Some of the modifiers inhibited pH]azidopine photolabelling although they are not 
active as modifiers of MDR. This may be due to the fact that they are highly 
lipophilic and alter the integrity of the membrane thus preventing photolabelling.
We have studied the effect of the XR compounds on the intracellular distribution of 
doxorubicin by exploiting the natural fluorescence of the anthracyclines to visualise 
the drug using a laser scanning confocal microscope. Our results presented here 
indicate that there is a reduced intracellular accumulation of doxorubicin in the drug 
resistant CEMA^LB cells and that the XR compounds restore intracellular drug 
accumulation rather than altering intracellular drug distribution. This supports the 
theory that dmg resistance in this cell line is associated with a decrease in intracellular 
cytotoxic drug accumulation and that the XR compounds inhibit the mechanism, 
probably P-glycoprotein, which causes this decreased drug accumulation.
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4 .4 .2  S tructure-activ ity  relationships
Compounds XR9006, XR9051, XR9019 and XR9112 all contain a 
tetrahydroisoquinoline (Figure 4.8) within their structures. This makes the molecules 
protonated at physiological pH (pH 7-9). Molecules that have been shown previously 
to be effective modifiers tend to be cationic (positively charged) lipophilic molecules 
(see structure of verapamil. Figure 4.9). This may explain why these compounds are 
the most effective modifiers of resistance in these cell lines. In contrast XR1500 
contains no charge at physiological pH. Although the molecule is lipophilic it is not 
cationic. This explains the difference in the activity of this compound and the 
tetrahydroisoquinoline substituted molecules. All the molecules with the exception of 
XR9089 contain a diketopiperazine (Figure 4.8) within their stmctures. Compounds 
containing this stmcture have previously been shown to be active resistance modifiers 
(Kamei et al, 1990).
F igure 4.8
The structu re  of tetrahydroisoquinoline and diketopiperazine groups
te trahydro isoqu ino line  diketopiperazine
■OCHj U ,R
A JV L
R ' V
O
Figure 4.9
The structure  of verapamil
verapam il
CH3O CN CII3
Ç— (CII2) 
CH(CIl3)2
CH3O — ^  —C  l 1 )3 N  ( € 113)2
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Interestingly, the only difference between XR9051 and XR9(K)6 is that the side chain 
containing tlie tetrahydroisoquinoline group is in the meta position on the benzylidene 
ring in XR9051 and in the para position in XR9006. This difference in positioning of 
the tetrahydroisoquinoline group will serve to alter the conformation of the molecule. 
This may explain why two seemingly similar structures may have different activities. 
The two compounds may bind to slightly different sites on P-glycoprotein. If we 
assume that cytotoxics drugs bind to more than one binding site on P-glycoprotein 
and that resistance modifiers work (at least in part) by binding competitively to these 
binding sites we may hypothesise that the differential activity of the XR compounds 
may be dependent on where they bind to P-glycoprotein. For example XR9051 is a 
better modifier of doxorubicin resistance than colchicine resistance whereas XR9006 
is a better modifier of colchicine resistance than doxorubicin. This may indicate that 
XR9051 binds to P-glycoprotein at or in very close proximity to the doxorubicin 
binding site and XR9006 binds to P-glycoprotein at or near the colchicine binding 
site. Figure 4.10 is a simplified diagram to illustrate this point. The circle represent 
drug binding sites and the squares XR compound binding sites. The XR9051 
binding site overlaps with the doxorubicin site to a greater extent than the colchicine 
site. In contrast, the XR9006 binding site overlaps with the colchicine site to a 
greater extent than the doxorubicin site. The detailed structure of P-glycoprotein is 
not shown.
Safa et al. (1985) suggested that theoretically a competitive antagonist should not 
affect the dissociation rate constant of another dmg. As such an antagonist can only 
bind when the bound drug has dissociated from the receptor site. Ferry et al. (1992) 
found that several 1,4-dihydropyridine analogues and other modifiers of P- 
glycoprotein-mediated MDR, including verapamil, increased the dissociation constant 
of pH]vinblastine indicating that they must be acting at a site distinct from the 
vinblastine-selective site. The group introduced the theory that drug binding domains 
on P-glycoprotein may be topographically distinct and allosterically coupled. If this
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theory is correct it is possible that the XR9051 and XR90()6 bind to separate 
(possibly overlapping) drug binding sites which are allosterically coupled so that drug 
binding to one site causes a conformational change to the other site resulting in an 
alteration of the drug specificity of that site.
F igure 4.10
A hypothetical representation of the interaction between the XR 
compounds XR9051 and XR9006 and the drugs doxorubicin and 
co lch ic ine .
P-GLYCOPROTEIN
R9051
XR900I
D O X -d oxoru b icin ; C O L -co lch ic in e
4 .4 .3  S tructure-toxicity  relationships
It is very difficult to measure the intrinsic toxicity of a drug without looking in more 
detail at the metabolism and kinetics of the agent. There are, however, several 
features of the 10 compounds studied here which may explain their toxicity profile. 
As mentioned above, the only difference between XR9051 and XR9006 is the 
position of the side chain containing the tetrahydroisoquinoline group. In XR9006 
the group is in the para position on the benzylidene ring whereas in XR9051 it is in 
the meta position. XR9006 is more toxic than XR9051 and this may be due to the 
fact tliat the para positioning of tlie tetrahydroisoquinoline group means that it is more 
likely to be exposed and therefore may be more prone to amide hydrolysis by 
proteases. The substituted analine (NH2 group attached to an aromatic ring) that
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results from such hydrolysis is known to have toxic properties. The most toxic 
molecule XR9112 has an ethyl group attached to the niü-ogen in the 5 position of the 
diketopiperazine ring. XR9112 is identical to XR9006 apart from the fact that 
XR9006 has a methyl group attached to the nitrogen in the 5 position of the 
diketopiperazine ring. The addition of alkyl groups to the molecule increases the 
lipophilicity. XR9112 is likely to be more lipophilic than XR9006 and therefore more 
membrane permeable. It may reach higher concentrations within the cell. This 
explains why XR9112 is more potent at lower doses and also why it is toxic at higher 
doses. The lipophilicity of the molecule may indicate that at high doses the molecule 
accumulates to a large degree in the cell membrane. This may affect the integrity (i.e. 
fluidity and rigidity) of the membrane. Compounds XR1779 and XR1818 are very 
lipophilic and have no positive charge at physiological pH. The toxicity of these 
compounds may also be due to the fact that they are likely to accumulate to a large 
degree in the cell membrane thus disrupting its integrity. The addition of alkyl groups 
increases the occurrence of steric interactions within the molecule and therefore causes 
changes in molecular conformation. These conformational changes may have 
important implications in terms of toxicity and activity. A molecule may be a 
substrate for more than one receptor. À very slight change in molecular conformation 
may cause a molecule to change its affinity for each receptor. It is possible that the 
addition of an alkyl group (as in the case of XR9112) may cause a conformational 
change thereby causing the molecule to have a greater affinity for a receptor which 
triggers a toxic response.
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4 .4 .4  Summary
It appears that within this series of compounds the presence of a diketopiperazine with 
a substituted tetrahydroisoquinoline group produces the most active compounds. 
XR9051 and XR9006 are the most active compounds. XR9051 is the best modifier 
of doxorubicin resistance and XR9006 is the best modifier of colchicine resistance. 
These data also confirm that molecules able to undergo protonation at physiological 
pH to form cationic species are the most effective modifiers of MDR. Lipophilicity is 
also important although extreme lipophilicity may also be the cause of toxicity due to 
alterations in membrane integrity. It also appears that the addition of alkyl groups 
also increases toxicity presumably by increasing lipophilicity.
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Chapter 5
The discovery of XR9173 
a modifier of multidrug resistance-associated protein 
(MRP)-mediated multidrug resistance
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5.1 Introduction
5.1.1 The multidrug resistance associated protein (MRP)
The multidrug resistance associated protein (MRP) is the product of an ATP- 
binding cassette transporter gene overexpressed in some tumour cells resistant to 
antineoplastic agents. Section 1.3.3.iv describes some of the proposed mechanisms 
of action of MRP. It is clear that MRP induces ATP-dependent removal of drug 
from tumour cells. The mechanisms for this active transport have not been clearly 
defined. These mechanisms are discussed further in Chapter 6 .
5.1.2 Revei^al of MRP-mediated MDR
P-glycoprotein mediated MDR can be reversed m vitro by resistance modifying 
agents such as cyclosporin A, verapamil and PSC-833. These agents are all 
currently undergoing clinical trials in an attempt to overcome clinical drug 
resistance. These modifiers have not, so far, been shown to reverse MRP-mediated 
MDR to the same extent as P-glycoprotein-mediated MDR (Zaman et a l,  1994; 
Leier et a i ,  1994a and b). Two important exceptions are the MRP-overexpressing 
HL60/ADR cell line where verapamil and PSC-833 are good inhibitors of drug 
transport (Feller et a l ,  1995) and the MRP-overexpressing POGB/DX cell line 
where verapamil was able to reverse drug resistance and to increase drug 
accumulation (Binashi et al., 1995).
Most of the well-characterised MRP overexpressing cell lines have been selected 
for resistance to doxorubicin (Lutzky et a l ,  1989; Cole et a l ,  I992a & b; 
Krishnamachary et al,. 1993; Barrand et al., 1994). Selection in doxorubicin has 
been shown to produce cells displaying a variety of resistance mechanisms. As well 
as overexpression of the membrane transport proteins, P-glycoprotein and MRP, 
other mechanisms such as a reduced topoisomersae II activity (Fernandes et a l,  
1994) and detoxification of doxorubicin and doxorubicin-induced free-radicals by 
GSH (Tew, 1994) have been demonstrated in cells selected in doxorubicin. Lutzky
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et al. (1989) found that depletion of cellular GSH by treating cells with the 
inhibitor of GSH synthesis, DL-buthionine S,R-sulfoximine (BSO), increased 
cellular daunorubicin accumulation and retention. More recently Versantvoort et al. 
(1995a) demonstrated that drug transport in MRP-overexpressing but not P- 
glycoprotein-overexpressing MDR cells can be regulated by cellular GSH levels. 
They found that BSO inhibited drug efflux from MRP. but not P-glycoprotein- 
mediated MDR cells and that this effect could be reversed by the restoration of 
intracellular GSH levels by treating the cells with GSH-ethylester which enters the 
cells and is then converted to GSH. This study also showed that BSO increases the 
toxicity of daunorubicin, vincristine and rhodamihe 123 in a number of MRP- 
overexpressing tumour cell lines. Other modulators of MRP have been reported. 
Firstly, the isoflavonoid. tyrosine kinase inhibitor, genistein increases daunorubicin 
accumulation in several MRP but not P-glycoprotein-overexpressing MDR cell 
lines (Versantvoort et al., 1993). The toxicity of genistein. however, limits its 
potential as a clinically useful resistance modifier. The second group of MRP 
modifiers are modulators of organic anion transport Probenecid, typically used in 
the clinic to compete with penicillin for transport in the renal proximal tubule 
thereby increasing circulating penicillin levels, has been shown to modulate MRP- 
mediated MDR (Gollapudi et a l,  1995). In addition the leukotriene LTD4 receptor 
antagonist. MK571 specifically modulates MRP-associated multidrug resistance 
(Gekeler et a l ,  1995b). This is especially relevant in light of the observations of 
Jedlitschky et a l  (1994) who demonstrated that MRP mediates the ATP-dependent 
transport of LTC4 and structurally related anionic amphiphilic conjugates. Finally, 
the PKC inhibitor. GF 109203X (Gekeler et a l ,  1995a) has been shown to affect 
MRP-mediated drug transport It is not been determined whether this effect is due 
to an interaction (either non-competitive or competitive) with drug binding sites or 
with the ATP binding sites of MRP or affects MRP activity indirectly by altering its 
phosphorylation state. Melvin Center's group have recently demonstrated that 
MRP is highly phosphorylated and that the phosphate groups are metabolically
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active and undergo cycles of phosphorylation and dephosphorylation in the cell. 
The protein kinase inhibitors H-7, staurosporine and chlereythrine can reduce 
phosphorylation and produce a concomitant inhibition of drug efflux in resistant 
cells (Ma et a l, 1995). These results may indicate that altering the phosphorylation 
state of MRP may affect its function.
5.1.2 Aims
The Xenova compounds are not exposed to a primary screen to evaluate their 
potential as modifiers of MRP-mediated resistance in the laboratories in Slough. In 
our laboratories all the compounds undergo assays involving the L23/P cell line 
and its resistant, MRP-overexpressing variant, L23/R (see Section 2.1). The aim of 
the experiments outlined in this chapter were to establish, (a) whether any of the 
XR compounds we received in Cambridge are modifiers of MRP-mediated 
resistance, (b) the extent of their modifying capacity, and (c) if XR compounds that 
act as MRP modifiers are also able to reverse P-glycoprotein-mediated MDR. We 
did not set out to compile a set of structure activity relationships for all of the new 
MRP test compounds but to elucidate the most active compounds and examine the 
activity of these compounds in more detail.
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5.2 Materials and Methods
5.2.1 Cell lines
For studies involving MRP we used the human large cell lung cancer cell line, 
L23/P and the adenocarcinoma line MOR/P together with their respective MRP- 
overexpressing variants L23/R and MOR/0.4R. For studies involving P- 
glycoprotein we used the human T-lymphoblastoid cell line CEM together with its 
P-glycoprotein overexpressing variant. CEM/VLB. Details of the derivation, 
maintenance and culture conditions of these cell lines are described in Section 2.1.
5.2.2 Drug sensitivity testing
The cytoxicity of the XR compounds and evaluation of their ability to sensitise the 
MRP-overexpressing resistant cell lines, L23/R, MOR/0.4R and the P-glycoprotein 
overexpressing cell line CEM/VLB were determined using the tétrazolium (MTT) 
reduction assay. This method is described in detail in Section 2.3.
5.2.3 Drug accumulation studies
The effect of the XR compounds on the ability of L23/R cells to accumulate
pHJdaunorubicin and pH]colchicine was determined as described in Section
2.5.1.i
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5.3 Results
5.3.1 XR9089 reverses resistance in COR-L23/R, an MRP-
overexpressing MDR cell line
All of the novel fungal products from Xenova were r o u t i n e l y  s c r e e n e d  n o t  O n l y  for 
their ability to modify P-glycoprotein-mediated MDR but also MRP-mediated 
MDR. Figure 5.1 demonstates the effect of all 10 compounds on the sensitivity of 
L23/P and L23/R to doxorubicin. Compounds, XR1824, XR1818 and XR9112 
were toxic at 5pM in this system. Only the results at IpiM are shown on these 
graphs.
Figure 5.1
(i) Effect of XR1500 on the sensitivity of L23/P and L23/R cells to doxorubicin
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Graphs represent typical data,sets. Similar results were obtained in 2 independent experiments. 
Fractional absorbance is defined by mean optical denisity of treated group divided by that of the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells.
Variation in fractional absorbance between replicate w ells wax generally less than 10%.
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Figure 5.1 (continued)
(ii) Effect of XR1779 on the sensitivity of L23/P and L23/R cells to doxorubicin
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(iii) Effect of XR9051 on the sensitivity of L23/P and L23/R cells to doxorubicin
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Graphs represent typical data sets. Similar results were obtained in 2 independent experiments. 
Fractional absorbance is defined by mean optical denisity of treated group divided by that o f the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells. 
Variation in Iractional absorbance between replicate wells was generally less than 10%.
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Figure 5.1 (continued)
(iv) Effect of XR1824 on the sensitivity of L23/P and L23/R cells to doxorubicin
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(v) Effect of XR1829 on the sensitivity of L23/P and L23/R cells to doxorubicin
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Graphs represent typical data sets. Similar results were obtained in 2 independent experiments. 
Fractional ateorbance is defined by mean qitical denisity of treated group divided by that of the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells. 
Variation in fraclional absorbance between replicate wells was generally less than 10%.
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Figure 5.1 (continued)
(vi) EHect of XR9006 on the sensitivity of L23/P and L23/R cells to doxorubicin
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(vii) Effect of XR9019 on the sensitivity of L23/P and L23/R cells to 
doxorubicin
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•  L23/P control O  L23/R control
■  L23/P+1nMXR □  L23/R+1hMXR
A  L23/P+5jiMXR A  L23/R +5plVI XR
Graphs represent typical data sets. Similar results were obtained in 2 independent experiments. 
Fractional absorbance is defined by mean optical denisity of treated group divided by that of the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells. 
Variation in fractional absorbance between replicate wells was generally less than 10%.
156
Figure 5.1 (continued)
(viii.) Effect of XR1818 on the sensitivity of L23/P and L23/R cells to 
doxorubicin
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(ix) Effect of XR9089 on the sensitivity of L23/P and L23/R cells to doxorubicin 
1.0 *
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doxorubicin (pM)
•  L23/P control 
■  L23/P+1nMXR 
A L23/P+5nMXR
O L23/R control 
□  L23/R+1nMXR 
A L23/R+5mMXR
Graphs represent typical data sets. Similar results were obtained in 2 independent experiments. 
Fractional al>sorbance is defined by mean optical denisity of treated group divided by that of the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells. 
Variation in fractional absorbance between replicate wells was generally less than 10%.
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Figure 5.1 (continued)
(x) Effect of XR9112 on the sensitivity of L23/P and L23/R cells to doxorubicin
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▲ L23/P+5nMXR
O L23/R control 
□  L23/R+1mMXR 
A L23/R+5^MXR
Graphs represent typical data sets. Similar results were obtained in 2 independent experiments. 
Fractional absorbance is defined by mean optical denisity of treated group divided by that of the 
control group. Each value represents the mean fractional absorbance in 4 replicate wells. 
Variation in fractional absorbance between replicate wells was genoally less than 10%.
Of the initial batch of 10 compounds selected for detailed study only one 
compound, XR 9089, showed any activity versus MRP-mediated MDR. XR9089 
at 1 and 5iiM was able to sensitise the resistant cell line, L23/R, to doxorubicin by 
factors of 2 and 4 respectively (Figure 5.1.ix). This initial observation then lead to a 
derivatisation programme at Xenova. Ten new compounds were synthesised from 
XR 9089 (Figure 5.2). These compounds were then tested in our laboratory and in 
the laboratories at Xenova for their ability to: (a) reverse the accumulation deficit in 
L23/R cells and (b) sensitise L23/R cells to doxorubicin. We also examined their 
ability to modify P-glycoprotein mediated MDR.
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Figure 5.2
Structure of test MRP compounds 
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Figure 5.2 (continued)
Structure of test MRP compounds
XR9173 I XR9123
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5.3.2. Effect of novel XR9089 derivatives on the. accumulation of
pHJdaunorubicin in L23/R cells 
On their arrival in Cambridge, all 10 of the test MRP XR compounds were 
examined for their ability to reverse the accumulation deficit in L23/R, MRP- 
overexpressing cells. Figure 5.3 demonstrates the difference in the ability of L23/P 
and L23/R cells to accumulate [^HJdaunorubicin. Table 5.1 shows the independent 
accumulation ratio values for 2  independent experiments.
Figure 5.3
Effect of test MRP XR compounds (5pM) on the accumulation of 
pHJdaunorubicin in L23/R cells.
i i i
* Accumulation ratio is (tefined by the ratio of daunwubicin accumulation in the presence/absence of 
modifier. In the case of L23/P accumulation ratio is represented by daunorubicin 
accumulationin L23/P divided by daunorubicin. accumulation in L23/R.
Values represents mean ot 2  independent experiments.
Accumulation ratios for the 2 independent experiments are given in table 5.1.
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Table 5.1
E ffect o f  test M R P com p ou n ds (5p.M) on the accu m u lation  o f
pHJdaunorubicin
in L23/R cells
GROUP Accumulation ratb
4.57
P/R ratio 3.54
(4.05)
1.00
Control 1.00
(1.00)
1.55
9032 1.93
(1.74)
1.82
9061 1.65
(1.73)
0.72
9062.1 1.30
(1.01)
0.94
9123 1.41
(1.17)
1.25
9124 1.40
(1.32)
1.13
9142 1.37
(1.25)
2.09
9143 2.27
(2.18)
3.12
9152 2.21
(2.66)
1.62
9167 1.31
(1.46)
4.69
9173 3.05
(3.87)
* Accumulation ratio is defined by the ratio o f daunorubicin accumulation in tlie presence/absence of 
modifier. Figures represent individual values, means o f 2 values are shown in parentheses. P/R ratio 
is defined by tlie ratio o f daunorubicin accumulation in the parent/resistant cell line.
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All the compounds modestly increased the accumulation of pHJdaunorubicin in 
L23/R cells. Compounds XR9173, XR9143 and XR9152 all had mean 
accumulation ratios of greater than 2 at a concentration of 5fiM. XR9173, however, 
was clearly the best compound in terms of reversing the accumulation deficit in 
L23/R cells. The compound caused accumulation to be increased by a factor of 4 
compared to the control value (accumulation in the absence of modifier) bringing 
accumulation levels in the resistant cell line almost to those observed in the parent 
line (in the absence o f the modifier).
At this stage, we decided to continue experimentation with only 3 of the MRP XR 
compounds. We chose the 3 compounds which produced the largest reversal of 
accumulation deficit in L23/R cells. It is clear from figure 5.3. that these candidate 
compounds were XR9173, XR9143 and XR9152 which had accumulation ratios of 
3.9, 2.2 and 2.7 respectively. We then went on to evaluate, in greater detail^ the 
ability of these 3 compounds to modify MRP-mediated MDR.
5.33 Effect of XR9173, 9143 and 9152 on the sensitiation of L23/R
ceiis to doxorubicin 
Firstly, we examined the effect of the 3 MRP XR compounds (MRP XRs) on the 
sensitivity of L23/R cells to doxorubicin. Figure 5. f  demonstrates that the 
sensitisation data supports the accumulation data shown in figure 5.5 XR9173 was 
clearly the most effective of the 3 MRP XRs in terms of reversing the accumulation 
deficit in L23/R cells and in sensitising the drug resistant L23/R cells to 
doxorubicin. We used the non toxic doses of 5 and lOpM. Toxicity studies 
performed in Cambridge and at Xenova confirmed that the IC5 OS of XR9173, 
XR9143 and XR9152 were greater than 20p,M (data not shown). For all three 
compounds there was little difference in the sensitisation observed on addition of 
either 5 or 10p.M of MRP XR. This may suggest that whatever mechanism is 
responsible for this reversal of drug resistance in this cell line is saturable. These
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data suggest that XR9173 is an efficient modifier of MRP mediated MDR. To 
confirm this observation, we decided to examine the potential of XR9173 to modify 
resistance in another MRP-overexpressing cell line, MOR/0.4R. In addition we 
examined its ability to sensitise both L23/R and MOR/0.4R to a number of different 
cytotoxic drugs.
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Figure 5.4
(a) Effect of XR9173 on the sensitisation of L23/R cells to doxorubicin
.01 .1 
doxorubicin (pM)
Figure 5.4
(b) Effect of XR9143 on the sensitisation of L23/R cells to doxorubicin
nraq0.0 
.0001 .01
doxorubicin (jlM)
Graphs r^resents typical data sets.
Similar results were obtained in a at least 3 independent experiments.
( • )  parentJ33/P cells, (o ) resistant, L23/R cells. (□) L23/R + 5pM 9173, (^ ) L23/R + lOpM 9173
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Figure 5.4
(c) Effect of XR9152 on the sensitisation of L23/R cells to doxorubicin
fc 0.8
« 0.6
G 0.4
.0001
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doxorubicin (jlM)
Graphs represents typical data sets.
Similar results were obtained in at least 3 independent experiments.
( • )  parent,L23/P cells, (o ) resistant, L23/R cells, (□) L23/R + 5pM 9173, (^) L23/R + 10|iM 9173
5.3.4 Effect of XR9173 on the sensitisation of L23/P and MOR/P and
their respective MRP-overexpressing MDR variants, L23/R and 
MOR/0.4R
The values in table 5.2 represent sensitisation ratios for XR9173 at two 
concentrations, IpM and 5pM. Sensitisation ratio is defined by the IC50 for the 
relevant drug in the presence of XR9173, divided by the IC50 for the relevant drug 
in the absence of XR9173 ( IC50 = concentration of cytotoxic drug required to 
reduce fractional absorbance to 50% of control values in the MTT assay).
When interpreting the data in table 5.2. it should be noted that the cell lines used are 
diffentially resistant to all three cytotoxic drugs. For example in the case of the L23 
cell lines; the resistant, MRP overexpressing, L23/R is 20- to 30- fold resistant to 
doxorubicin, 10- to 20-fold more resistant to colchicine and only 5- to 10-fold 
resistant to taxol compared to the sensitive L23/P cell line (Table 5.3). The 
resistance factors for MOR/0.4R also differ depending on the cytotoxic drug to
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which they are exposed. Resistance factor is defined by the IC50 o f the drug in the 
resistant line divided by the IC50 of tlie drug in the sensitive line.
Table 5.2
Effect of XR9173 on the sensitisation of L23/P and MOR/P and their respective 
MRP-overexpressing MDR variants, L23/R and MOR/0.4R
Sensitisation Ratio^ 
DOXORUBICIN
Sensitisation Ratio^ 
COLCHICINE
Sensitisation Ratio^ 
TAXOL
CELLS 9173
tp M
9173
S\iM
9173
l\lM  :
9173
5pM
9173
IfiM
9173 
5|iM • :
L23/P 1.6(0.2)
2.2*
(0.2)
1.2
(0.1)
1.7
(0.3)
1.1
(0.1)
1.1
(0.1)
L23/R 5.1*(0.7)
17.4*
(5.4)
4.5
(1.6)
8.5*
(2.3)
1.3
(0.1)
2.4
(0.4)
MOR/P 1.6(0.2)
3.3*
(0.9)
1.1
(0.1)
1.5
(0.1)
1.2
(0.2)
1.2
(0.2)
MOR/0.4R 3.7(1.2)
11.5*
(2.0)
3.0
(0.5)
8.1*
(0.9)
1.7*
(0.9)
3.2**
(0.2)
^Ratio o f IC50 in presence/absence o f modifier. *p<0.05(significantly different from 1), 
**p<0.01(highly significantly different from 1): Student's t test. Values are means o f  3 independent 
experiments. Parentheses show standard error.. IC50 = dose o f cytotoxic drug required to reduce 
fractional absorbance to 50% o f control values in the MTT assay
Table 5.3 shows the differing resistance factors for these two cell lines and the 
three cytotoxic drugs, doxorubicin, taxol and colchicine.
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T a b le  5.3
Resistance factors of doxorubicin, colchicine and taxol in the MRP- 
overexpressing cell lines L23/R and MOR/0.4R.
Resistance factor* Resistance factor* i Resistance factor*
DOXORUBICIN COLCIUCINE TAXOL
L23/R
L23/P 25.0 12.8 8.0
MOR/0.4R
MOR/P 32.2 14.8 5.8
Values are means o f at least 2 independent experiments. ^Resistance factor is defined by tlie IC50 of 
drug in resistant line divided by the IC50 o f drug in tlie sensitive line.
XR9173 at a concentration of 5|iM significantly increased the sensitivity of the drug 
sensitive, L23/P and MOR/P cell lines to doxorubicin.
In all other cases, XR9I73 had no significant effect on the sensitivity 
of the drug sensitive cell lines to doxorubicin, colchicine or taxol (Student's t test). 
In the drug resistant cell lines, XR9173 at a concentration of 5p.M significantly 
increased the sensitivity of the drug resistant cell lines, L23/R and MOR/0.4R to 
doxorubicin, colchicine and taxol. At lp.M, XR9173 was also signicantly increased 
the sensitivity of MOR/0.4R to colchicine and taxol. The ability of XR9173 to 
increase the sensitivity of MDR cell lines to cytotoxic drugs is clearly dependent on 
the cytotoxic drug used. From the values in table 5.2 we can see that L23/R cells 
are 25-fold resistant to doxorubicin, 12.8-fold more resistant to colchicine and 8- 
fold more resistant to taxol compared to the L23/P cells. XR9173 sensitises L23/R 
cells by 17.4-, 8.5- and 2.4-fold respectively to doxorubicin, colchicine and taxol. 
L23/R cells therefore have resistance factors in the presence of XR9173 (RF*) of 
7.6, 4.3 and 5.6 repectively for doxorubicin, colchicine and taxol compared to 
L23/P cells. XR9173, therefore, produces a decrease in resistance factor for L23/R 
cells of 70%, 66% and 30% for doxorubicin, colchicine and taxol respectively. In
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contrast, using the same evaluation method for MOR/0.4R cells, XR9173 produces 
a decrease in resistance factor of 36%, 30% and 56% for doxorubicin, colchicine 
and taxol respectively. It appears, therefore, that XR9I73 is a mote efficient 
modifier of taxol resistance than of doxorubicin and colchicine resistance in 
MOR/0.4 cells and a more efficient modifier of colchicine and doxorubicin 
resistance than of taxol resistance in L23/R cells. It appears, therefore, that the 
effect of XR9I73 may also be cell specific.
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5.3.5 Effect of XR9173 on the accumulation of pH]daunorubicin in
L23/P and L23/R cells
We examined the effect of XR9173 on the accumulation of pHjdaunorubicin and 
pH]colchicine in L23/R cells. Figure 5.5 a & b shows that XR9173 reversed the 
pH]daunorubicin and pH]colchicine accumulation deficit in L23/R, drug resistant 
cells in a dose dependent fashion. At a concentration of 5fiM, full reversal was not 
achieved, although drug accumulation in the resistant cell line reached 71% and 
8 6 % of the parental levels for pH]daunorubicin and pHJcolchicine respectively.
Figure 5.5
(a) Effect of XR9173 on the accumulation of pH jdaunorubicin in L23/R cells
1.0 2.0
9173
(llM)
•pcO.05 (significantly different from 1.0).
**p<0.01 (highly significantly different from 1.0, Student's t test) 
Accumulation ratio =ratio of pH]drug accumulation in the presence/absence of modifier. 
Values are means ± standard error of at least 3 independent experiments.
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Figure 5.5
(b) Effect of XR9173 on the accumulation of pH]colchicine in L23/R cells
o  4 .0 -
<  1.0 -
0.2 0.5 1.0 2.0
9173
(liM)
*p<0.05 (significantly different from 1.0).
**p<0.01 (highly significantly different from 1.0, Student's t test)
Accumulation ratio =ratio o f pH]drug accumulation in the presence/absence o f modifier. 
Values are means ± standard error of at least 3 independent cxpernnenL
5.3.6 Effect of XR9173 on P-glycoprotein mediated MDR
In order to establish whether or not XR9173 is also a modifier of P-glycoprotein- 
mediated MDR, we examined its activity in the drug sensitive cell line CEM 
together with the P-glycoprotein-overexpressing, MDR cell line, CEM/VLB.
(i) Effect o f  XR9173 on the sensitisation o f  the drug sensitive cell line, CEM  
and its P-glycoprotein~overexpressing subline, CEM/VLB to doxorubicin 
XR9173 was not able to increase the sensitivity of the drug sensitive cell line , CEM 
to doxorubicin (data not shown). In the drug resistant cell line, CEM/VLB, 
XR9173 (5|iM) restored sensitivity to doxorubicin to levels approaching that of the 
parent, drug sensitive cell line (Figure 5.6 & Table 5.4).
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Figure 5.6
Effect of XR9173 on the sensitisation of CEM/VLB drug resistant cells to
doxorubicin
1.2
1.0 -  
I  0.8 -
| o . :
i  0 .4 -
1 0.2 -
0.0
.01.001
doxorubicin (pM)
.0001
Graph represents typical data sets. Similar results were obtained in 2 independent experiments. 
Individual sensitisation ratios are shown in table 5.4 
( • )  parent,CEM cells, ( o ) resistant, CEM/VLB cells,
(□) CEM/VLB + IpM  9173, (^ ) CEM/VLB + 5pM 9173
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Table 5.4
Effect o f XR9173 (l& 5|lM ) on the sensitisation of L23/R cells to doxorubicin
SemsitisatiOjn SewsitisatîOïi Kesfsfaoce
CELL LINE Ratio Ratio Factor
(9173 % m ) (9173 s m )
L23/R 6.7 20.0 20.0
8.0 20.0 27.0
V a lu es from  2 ind ep en dent experim en ts are sh ow n .
^Ratio o f  IC 50  in p resen ce/a b sen ce  o f  m od ifier . IC 50  =  d o se  o f  c y to to x ic  drug required to reduce  
fractional absorb ance to  50% o f  control va lues in tlie M T T  assay . R esistan ce  factor is d efined  by  
tlie IC 5 0  o f  tlie drug in the resistan t lin e  d iv id ed  by the IC 50 o f  the drug in the sen sitive  line.
(ii) Effect o f XR9173 on the accumulation o f [^HJdaunorubicin in the drug 
sensitive cell line, CEM and its P-glycoprotein-overexpressing subline, 
CEM/VLB
XR9173 did not effect the levels of daunorubicin accumulation in the drug sensitive 
cell line, CEM (data not shown). However XR9173 was able to restore the 
accumulation deficit in the drug resistant, CEM/VLB, cell line. Figure 5.6 
demonstrates that IO}iM XR9173 caused a 4.5-fold increase in daunorubicin 
accumulation compared to control levels. In comparison 5|iM cyclosporin A (a 
known modifier of P-glycoprotein-mediated MDR in vitro) increased daunorubicin 
accumulation by 5-fold compared to control levels. It appears, therefore, that 
XR9173 is almost equivalent to cyclosporin A as a modifier of P-glycoprotein- 
mediated MDR. Therefore, over a period of 1 h, both cyclosporin A and XR9173 
restored the accumulation in the resistant cell line CEM/VLB cells to levels 
approaching that of the parental cell line, CEM.
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Figure 5.7
Effect of XR9173 on the accumulation of pH jdaunorubicin in the 
P-glycoprotein overexpressing subline, CEM/VLB (1 h exposure)
«
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I XR9173 
(3 (nM) g
* Accumulation ratio =ratio of pHjdrug accumulation in the presence/absence of modifier 
Values are means of at least 3 independent experiments. Error bars indicate standard error. 
P/R ratio=drug accumulation in drug sensitive cells divided by drug 
accumulation in drug resistant cells
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5.4 Discussion
5.4.1 Introduction
At present, only very few reports exist on compounds that are able to reverse MRP- 
mediated MDR. The effectiveness of those compounds that have been found to 
have modest activity in MRP-overexpressing cell lines is limited either by their 
toxicity or by their lack of potency. An effective modifier of MRP-mediated MDR 
would prove to be a useful tool in the evaluation of mechanisms underlying the 
activity of MRP.
5.4.2 XR9173, Structure activity relationships
The data presented in here indicates that XR9173 is an efficient modifier of both P- 
glycoprotein- and MRP-mediated MDR. Figure 5.2 shows that XR9173 has a 
tetrahydroisoquinoliné group within its structure. We demonstrated in Chapter 4 
that the presence of this group within a molecule tends to increase its activity as a 
modifier of P-glycoprotein mediated MDR, possibly by increasing the positive 
charge of the molecule at physiological pH. Common properties of modulators of 
P-glycoprotein-mediated MDR are lipophilicity and the ability to be protonated at 
physiological pH (i.e. be cationic). XR9173 is both lipophilic and cationic, it is, 
therefore, not surprising that the compound is an active modifier of P-glycoprotein- 
mediated MDR. It is much more difficult to provide a simple explanation for the 
activity o f XR9173 as a modifier of MRP-mediated MDR. As MRP is thought to 
be identical to the GSH conjugate transporter (Jedlitschky et al., 1994) and several 
groups have reported ATP-dependent transport of glutathione 5-conjugates it is 
possible that XR9173 interacts with this transport system. We know that MRP- 
overexpressing cells accumulate less daunorubicin and colchicine than their related 
parental cell lines and that XR9173 restores this accumulation deficit to levels 
approaching that of the parental, drug sensitive cells. It may, therefore, be possible 
that XR9173 interacts with the mechanism(s) involved in the transport of cationic 
drugs which may well be distinct from the GSH conjugate transporter.
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5.4.3 XR9173 as a modifier of MRP-mediated MDR
The results show that of the ten compounds used in the P-glycoprotein study, only 
one. XR9089, was able to sensitise L23/R, MRP overexpressing cells to 
doxorubicin. It is clear that an efficient modifier of P-glycoprotein-mediated MDR 
is not necessarily a good modifier of MRP-mediated MDR. This is in agreement 
with the work of Barrand et al. (1993) who concluded that the mechanisms 
responsible for resistance in L23/R are relatively insensitive to the effects of 
modifiers that alter drug accumulation in P-glycoprotein mediated MDR cells, for 
example, cyclosporin A, PSC-833 and verapamil. Of the ten derivatives of 
XR9089, XR9173 was clearly the most effective modifier of MRP both in terms of 
reversing accumulation deficit and sensitising resistant cells lines to cytotoxic 
doxorubicin. The ability of XR9173 to increase the sensitivity of MDR cell lines to 
cytotoxic drugs is clearly dependent on the cytotoxic drug used. XR9173 is more 
efficient at sensitising the MRP-overexpressing cell line, L23/R, to doxorubicin 
and colchicine than to taxol. Conversely, XR9173 is more efficient at sensitising 
the MRP-overexpressing cell line, MOR/0.4R to taxol than it is doxorubicin and 
colchicine. The effects of XR9173 appear, therefore, to be both dependent on the 
cytotoxic drug and the cell line.
The results presented here show a discrepancy between the ability of XR9I73 to 
increase drug accumulation in drug resistant cells and sensitise drug resistant cells 
to cytotoxic drugs. For example in L23/R cells, XR9173 is able to increase the 
accumulation of pHjcolchicine to 8 6 % of the parental level but only sensitises the 
resistant line to 6 6 % of the parental level. Interestingly, these discrepancies 
between the chemosensitising effects of verapamil and its modulatory influence on 
drug accumulation have also been noted for P-glycoprotein (Keizer et aL, 1989). 
These discrepancies may indicate that drug accumulation over the course of a few 
hours is not a good guide to the effects of the same drug over a longer term 
survival assay. Keizer èt al. also demonstrated similar levels of drug uptake in
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variants of a human squamous lung cancer cell line despite 4-fold differences in 
their sensitivity to doxorubicin. It is possible that redistribution of drug away from 
sensitive target sites as opposed to overall decreased cellular accumulation of drug 
may be a significant factor in determining drug resistance.
Our results indicate that XR9173 is also an efficient modifier of P-glycoprotein 
mediated MDR. A compound able to modify more than one type of MDR in vitro 
may be of potential use in the clinic as clinical drug resistance is thought to be 
caused by more than one mechanism.
5.4.4 O ther modifiers of MRP-mediated MDR
The first compound shown to enhance the decreased drug accumulation in an MRP- 
overexpressing cell line without affecting P-glycoprotein-mediated MDR cells was 
the isoflavonoid, tyrosine kinase inhibitor, genistein (Versantvoort et al., 1993). 
The group showed that genistein was able partially to reverse the daunorubicin 
accumulation deficit and completely reverse the VP-16 accumulation deficit in the 
MRP-overexpressing GLC4/ADR MDR cell line. They suggest that genistein may 
bind directly to the MRP transporter and be pumped out of the cell. Any potential 
clinical use of genistein is limited by its cytotoxic effects. Recently, Gekeler et aL 
(1995a) showed that MRP associated MDR of HL60/AR and GLC4/ADR cells is 
efficiently modulated by the selective bisindolylmaleimide PKC inhibitor, GF 
109203X. It remains unclear whether this compound acts via a direct interaction 
with MRP or via another mechanism involving the inhibition of PKC. Gekeler et 
al. (1995b) have also recently demonstrated that MK571, the leukotriene LTD4 
receptor antagonist, partially modulates MRP-mediated MDR. This result together 
with the demonstration that leukotriene LTC4, the GSH conjugate of LTA4 , is 
transported in an ATP-dependent manner into membrane vesicles prepared from 
mouse mastocytoma cells (Leier etal. 1994a), from MRP overexpressing multidrug 
resistant HL60/ADR cells (Jedlitschky et al. 1994), or from HeLa MRP
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transfectants (Leier et al 1994b) supports the evidence for a close relationship, if not 
identity, of the 190kDa MRP drug transporter with a GSH conjugate transporter. 
This is link between MRP and the glutathione conjugate transporter is discussed in 
greater detail in Chapter 6 .
Barrand et aL examined the effect of some modifiers of P-glycoprotein mediated 
MDR (Barrand et aL 1993) on L23/R, a cell line now known to overexpress MRP 
and used extensively in the experiments carried out in chapters 5 and 6  of this study. 
The group found that although cyclosporin A, PSC-833 and verapamil were all 
able to at least partialluy restore the daunorubicin and vincristine accumulation 
deficit in L23/R cells. Despite this all three modifiers produced only a modest 
degree of sensitisation to vincristine and daunorubicin. Verapamil at a 
concentration of 3 .3 |i.g/ml increased the accumulation of vincristine in L23/R cells 
to levels exceeding that of the drug sensitive cell line, L23/P. In contrast, however, 
the same dose of verapamil was not capable of restoring the sensitivity of the 
resistant cell line to that of the parent. This agrees with the results obtained with 
XR9173. Where the almost complete reversal of accumulation deficit did not 
correspond to the only partial sensitisation of the resistant cell line we observed.
In summary, of the original 10 derivatives of XR9089 tested for their ability to 
modifiy MRP-mediated MDR, XR9173 is the most active. The effects of XR9173 
appear to be both cell line and drug specific. The discovery of this novel modifier 
of MRP-mediated MDR provides us with a useful tool for the investigation of the 
mechanism(s) underlying this type of resistance.
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6.1 The proposed mechanisms of the multidrug resistance- 
associated protein (MRP)
6.1.1 MRP as a plasma membrane drug efflux pump
The multidrug resistance-associated protein (MRP) is a 190kDa membrane protein 
associated with resistance of human tumour cells to cytotoxic drugs. Transfection 
experiments , have demonstrated that the MRP gene is a drug resistance gene (Grant 
et aL, 1994). These types of study do not, however, provide any clues as to the 
mechanism of action of MRP. As MRP belongs to the ABC superfamily of 
transporter proteins (Cole et aL, 1992a and b; Higgins et aL, 1992), it is possible 
that it may function as a plasma membrane drug efflux pump, similar to P- 
glycoprotein. In support of this, decreased drug accumulation has been reported for 
several non-P-glycoprotein cell lines that were later discovered to overexpress MRP 
(Zijlstra et aL, 1987; Zaman et aL, 1993; Barrand et aL, 1994). In contrast , 
however, the MDR H69AR cell line in which the MRP gene was cloned does not 
possess a drug accumulation deficit (Cole et aL, 1992a & b). In addition the 
subcellular location of MRP did not seem to be similar to that of a plasma 
membrane transporter such as P-glycoprotein. A 190kDa protein, thought to be 
MRP was found to be located on the endoplasmic reticulum rather than the plasma 
membrane (Marquardt et al., 1990; Krishnamachary et al., 1993). From studies 
using the SW-1573, human lung carcinoma cell line stably transfected with an 
expression vector containing MRP  cDNA, Zaman et al. (1994) concluded that 
MRP acts as a drug efflux pump, similar to P-glycoprotein, extruding hydrophobic 
compounds from the cells against a concentration gradient These conclusions were 
based on the following pieces of evidence: (a) Like P-glycoprotein, MRP can cause 
resistance to a broad spectrum of mainly hydrophobic drugs; (b) MRP is 
predominantly located on the plasma membrane (this is in contrast to the findings of 
other groups); (c) MRP can decrease drug accumulation in the cell and this decrease 
is abolished by plasma membrane permeabilisation and finally; (d) MRP can 
increase the efflux of drugs from cells. Zaman's group have therefore proposed a
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model for MRP activity whereby the two ATP-binding motifs in MRP allow the 
protein, like P-glycoprotein, to use ATP hydrolysis to fuel an active transport efflux 
mechanism.
6.1.2 MRP as a transporter of glutathione-5 -conjugates
Several group have recently reported ATP-dependent transport of Glutathione S 
-conjugates by the multidrug resistance associated protein (Jedlitschky et aL, 1994; 
Muller et aL, 1994). Leier et al. (1994a) demonstrated that photoaffinity labelling 
of mastocytoma cell membranes with LTC4, the GSH conjugated leukotriene C4, 
specifically labels a 190-kDa plasma membrane protein. This is the molecular 
weight of MRP. This group have also demonstrated that MRP mediates the ATP- 
dependent transport of LTC4 and structurally related conjugates in membrane 
vesicles from HeLa cells transfected with an MRP expression vector (Leier et at., 
1994b). They speculated that the LTC4 transporter and MRP are infact the same 
protein. In agreement with this interpretation is the demonstration that MRP is 
present in many different types of tissue, including erythrocytes, like the GSH S 
-conjugate transporter (Zaman et al., 1993). One observation that decreases the 
plausibility of this model is that MRP confers resistance to drugs, such as 
doxorubicin and vincristine, that are not known to undergo major modifications in 
cells, or at least no modification that would turn the drug into a substrate for the GS- 
X pump (Muller et al., 1994). Several explanations have been suggested for the 
paradox that overexpression of MRP results in the transport of negatively charged 
molecules (LTC4, DNP-GS) as well as transport of neutral or positively charged 
drugs (VP-16 and doxorubicin): (a) negatively charged complexes may be formed in 
the cell, but due to instability they may not be detected. If the conjugated drug was 
unstable, it would be successively transported and then immediately split in the 
extra cellular medium into GSH and cytotoxic drug. It would be expected, 
therefore, that the export of drugs from inside MRP overexpressing MDR cells 
would lead to a rise in extra cellular GSH levels. Versantvoort et aL (1995a)
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however, were not able to demonstrate any increase in GSH release after exposure 
of GLC4/ADR, MRP overexpressing, MDR cells to daunorubicin; (b) Awasthi et 
aL (1994) suggested that the GS-X pump may be more versatile than was originally 
thought and might therefore be able to transport both conjugated and unconjugated 
drugs; (c) it is possible that MRP may exist in two states functioning as a 
bifunctional transport protein for anionic GSH 5-conjugates and cytotoxic drugs. 
An interesting interpretation of this model is one in which transport of GSH 5- 
conjugates might induce a conformational change in MRP which enables the efflux 
of cytotoxic drugs. Modulation of the transport of GSH 5-conjugates by GSH 
depletion would, therefore, affect the drug transport activity. This is supported by 
the fact that MRP-mediated drug transport can be regulated by GSH depletion with 
BSO (Versantvoort et al., 1995a). Additionally, this model allows for inhibition of 
drug transport by agents other than those which regulate GSH, for example, 
genistein (Versantvoort et at., 1994) (d) MRP might not be the GS-X pump but 
instead activate an endogenous GS-X pump. This explanation is rather unlikely due 
to the fact that LTC4 has been shown to specifically label a 190kDa protein (as 
discussed above). Alternatively, MRP may itself be the GSH 5-conjugate 
transporter which activates an endogenous latent drug transport protein.
For many years, there has been an association between drug resistance and raised 
cellular levels of GSH and glutathione -5-transferases (GSTs). To date the 
emphasis has been on detoxification of drugs and on the peroxidation products that 
some drugs generate. Efficient export of drug conjugates or cytotoxic peroxidation 
products from the cell may be essential to generate resistance to the continued 
presence of drug.
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6.2 Glutathione (GSH)
6.2.1 Chemical properties of GSH
It is clear that there is a link between cellular glutathione metabolism and the 
mechanism of action of MRP. It is important to understand the basics behind the 
metabolism of GSH and its cellular function with respect to the biology of cell 
membrane transport
Glutathione (GSH) is the most important non-protein thiol in living systems, and is 
of widespread occurrence in the intracellular milieu of animals, plants and micro­
organisms. GSH was isolated and named by the English biochemist Frederick 
Gowland Hopkins (1921). The chemical structure of GSH is given below in figure 
6. 1.
Figure 6.1 
Structure of GSH
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An understanding of the significance of GSH in the operation of cells has slowly 
evolved through studies on a variety of biological systems and biochemical 
reactions. It has recently become clear that GSH is involved in the regulation of 
transport of cytotoxic drug mediated by MRP. A better understanding of the 
biology and biochemistry of GSH function and metabolism may be the key to 
determining the mechanism(s) of action of MRP. The GSH status of cells is defined 
by the total cellular concentration of GSH and the nature of the distribution of the 
possible forms in which GSH can occur in cells. The most important forms of this 
compound include GSH itself, glutathione disulphides (GSSG) and mixed
184
disulphidcs, mostly GSS-protein. Other possibilities are thiol esters and GSH 
derivatives bound through linkages other than sulphur. In addition, hidden pools of 
GSH, in which GSH is available to some reactants, may exist (Palekar et al„ 1975). 
Other cellular components which behave chemically like GSH or GSSG, for 
example, cysteine or reactive disulphides, should be considered in any evaluation of 
the GSH status of a cell. GSH (MW 307.33) is a white crystalline solid which is 
freely soluble in water, dilute ethanol, liquid ammonia and dimethylformamide. 
The molecule possesses both acidic and basic groups.
6.2.2 Cellular function of GSH in cells and organelle membranes
The structural integrity of the cell membrane and the membranes of intracellular 
organelles depends upon a suitable level and normal distribution of the various 
forms of GSH within the cell. In this situation the GSH is involved in the 
regulation of thiol/disulphide ratio in proteins through interchange reactions, and 
protection of lipids against peroxide through the interception of free radicals and the 
decomposition of lipid hydroperoxides. Various membrane functions, including ion 
and sugar transport, mitochondrial functions, the release of neurotransmitters and 
the action of hormones, are apparently dependent upon a suitable thiol-disulphide 
balance within the cell which can be altered by a change in the GSH status of the 
cell or system. For example, in the lens, oxidation of a portion of the GSH is 
accompanied by a decrease in the sodium-potassium pump activity and by an 
increase in the permeability to cations, presumably due to alterations in the thiol- 
disulphide balance of the membrane proteins (Epstein, 1971). The GSH status may 
be involved in amino acid transport It has been shown that amino acid (and sugar) 
transport is irreversibly inhibited by the thiol oxidant diamide, probably via effect 
on protein kinase activity (Pillion et al., 1976). Orlowski and Meister proposed a 
different link between GSH metabolism and amino acid transport, via the y-glutamyl 
moiety, in the form of a series of six enzyme catalysed reactions (Meister et aL, 
1983). These six reactions constitute the y-glutamyl cycle, which accounts for the
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synthesis and degradation of GSH. In addition to the role of GSH in membranes, it 
also provides the reducing power for the conversion of ribonucleotides to 
deoxyribonucleotides and for a variety of thiol-disulphide interconversions. GSH is 
important, therefore, in the synthesis and repair of DNA and for the folding of 
newly synthesised proteins.
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6.2.3 The metabolism of GSH
Figure 6.2 shows some of the biochemical transformations of GSH, which is 
synthesised in two steps from glutamate, cysteine and glycine.
Figure 6.2
Pathways of GSH metabolism
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Pathways of glutathione (GSH) metabolism. 1, y-glutamylcysteine synthetase;
2. glutathione synthetase; 3. y-glutamyl transpeptidase; 4. cysteine glycine hydrolases;
5. Y-glyamyl cyclotransferase; 6 . %-oxoprolinase; 7. glutathione S -transferase;
8 , transport and reduction of Y-GIu-(CyS)2; 9. oxidation reduction pathways see figure 6.3.
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Metabolic utilisation of GSH follows several pathways including reactions catalysed 
by the glutathione S -transferases (mercapturate pathway). GSH is a substrate of the 
glutathione peroxidases which destroy hydrogen peroxide and organic peroxides. 
The glutathione disulphide (GSSG) formed is reduced to GSH in a NADPH 
mediated reaction. The utilisation of glutathione is initiated extracellularly by the 
actions of y-transpeptidase and dipeptidase. These enzymes are bound to the outside 
of the cell membrane and act on GSH, GSSG and glutathione S - conjugates. GSH 
is exported by the liver to the blood plasma and to the bile. Plasma GSH is used by 
many tissues, for example, the kidney, lung and brain. GSH itself is not 
significantly transported into the cells in these tissues but is broken down by 
membrane bound y-glutamyl transpeptidase and dipeptidase. The products of 
breakdown are transported and utilised for GSH synthesis. This is an important 
pathway of GSH metabolism.
Figure 6.3
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6.2.4 Sensitisation of tum ours to chemotherapy and radiation by BSO
As discussed in Section 1.3.3, many tumour cell lines resistant to alklating agents, 
for example melphalan, have increased levels of GSH. After the development of the 
amino acid sulfoximiiie inhibitors of y-glutamylcysteinc synthetase, it was suggested 
that treatment with these agents may make tumour cells more sensitive to 
chemotherapy (Meister et oZ., 1979). The potential usefulness of DL-buthionine 
S,R-sulphoximine (BSO) in the sensitisation of cells to radiation was first 
demonstrated in studies on several human lymphoid cell lines (Meister et nZ., 1983; 
Dethmers et aL, 1981). Cells that had 4 to 5% of the control levels of GSH were 
found to be more sensitive than the controls to the effects of gamma-irradiation 
treatment of mice bearing B-16 melanomas (Meister et aL, 1986). It was also found 
that treatment of resistant leukaemias with BSO led to sensitisation of the tumours 
to phenylalanine mustard (Suzuaka et aL, 1983). Studies on the relationship 
between glutathione levels and the expression of primary drug resistance and cross 
resistance in human ovarian cancer cell lines and in vivo studies in which an i.p. 
model of human ovarian cancer was developed in nude mice lead to a clinical trial 
of BSO which is currently still in progress (Hamilton et al., 1990).
6.2.5 The role of glutathione S  -transferases in anticancer drug 
resistance
Section 1.2.3, introduced the fact that some cell lines selected for resistance to 
alkylating agents have increased activity of one or more GST isoenzymes. The 
data in this field are ambiguous and sometimes conflicting. The following points 
concerning GST and drug resistance are well established: (a) tumours express high 
levels of GST, especially GSTa, although the isoenzyme components vary quite 
considerably between tissues and the isoenzymes are inducible; (b) nitrogen 
mustards are good substrates for the GSTa family of isoenzymes and are frequently 
overexpressed in cells with acquired resistance to these drugs; (c) most drugs of the 
MDR phenotype have not been shown to be GST substrates and although GSTti is
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frequently overexpressed in multidrug resistant cells, most indications are that this 
is an accompaniment to, rather than a cause of, the resistant phenotype; (d) 
transfection of GST complementary DNAs (cDNAs) has produced some lines with 
i n c r e a s e d  resistance to alkylating agents (Tew, 1994) In summary, GSTs are 
important determinants of drug response for some, but not all, anticancer drugs. 
Most studies have overlooked the potential importance of other enzymes involved in 
the maintenance of cellular GSH homeostasis, and this has complicated data 
interpretation.
6.3 XR9173
The data presented in Chapter 5 indicates that XR9173 is an efficient modifier of 
both P-glycoprotein- and MRP-mediated MDR. Figure 6.4 shows that XR9173 has 
a tetrahydroisoquinoliné group within its structure. We demonstrated in Chapter 4 
that the presence of this group within a molecule tends to increase its activity as a 
modifier of P-glycoprotein mediated MDR, possibly by increasing the positive 
charge of the molecule at physiological pH. We do riot have a simple explanation 
for the activity of XR9173 as a modifier of MRP-mediated MDR. As MRP is 
thought to be identical to the GSH conjugate transporter (Jedlitschky et al., 1994) 
and several groups have reported ATP-dependent transport of glutathione S- 
conjugates it is possible that XR9173 interacts with this transport system. In order 
to test this hypothesis we decided to examine; (a) the effect of XR9173 on the 
accumulation and efflux of the fluorescent, anionic dye calcein and (b) the effect of 
XR9173 on intracellular and released GSH levels. We know that MRP- 
overexpressing cells accumulate less daunorubicin and colchicine than there related 
parental cell lines and that XR9173 restores this accumulation deficit to levels 
approaching that of the parental, drug sensitive cells (Section 5.3.5). It may, 
therefore, be possible that XR9173 interacts with the mechanism(s) involved in the 
transport of cationic drugs which may well be distinct from the GSH conjugate 
transporter. Here we have used photoaffinity labelling studies and confocal imaging
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of intracellular fluorescent dye and drug distribution to try to establish the 
mechanism of action of XR9173.
Figure 6.4
The structure of XR9173
XR9173
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6.3 Materials and Methods
6.3.1 Cell lines
For studies involving MRP we used the human large cell lung cancer cell line, 
L23/P and the adenocarcinoma line MOR/P together with their respective MRP- 
overexpressing variants L23/R and MOR/0.4R. For studies involving P- 
glycoprotein we used the human T-lymphoblastoid cell line GEM together with its 
P-glycoprotein overexpressing variant, CEM/VLB. Details of the derivation, 
maintainance and culture conditions of these cell lines are described in Section 2.1.
6.3.2 Measuring drug accumulation and efflux using flow cytometry
(i) Drug accumulation
Resistance modifier (test compound) at varying concentrations and cyclosporin A 
2pM were added to cells inoculated at a concentration of 2xlOVml into Falcon 
tubes in a volume of 5ml. After 30 min fluorescent drug or dye was added to the 
cell suspension.. Samples were taken and drug accumulation determined by 
measuring intracellular fluorescence using a flow cytometer as described in Section
2.5.2.L
(ii) Drug efflux
Cells were loaded with calcein AM (calcein AM is transformed into the highly 
fluorescent calcein upon cleavage of ester bonds by intracellular esterases) in the 
presence of probenecid (5mM) for 30 min (probenecid, an organic anion transport 
inhibitor, has been shown to increase calcein accumulation in L23/R cells 
(Versantvoort et al., 1995b)). Calcein efflux was measured as described in Section
2.5.2.Ü.
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6.3.3 Confocal microscopy
The effect of XR9173 (5\xM) on the distribution of lOpM doxorubicin and 250nM 
calcein in L23/P and L23/R cells was determined as described in Section 2.8.2.Ü.
6.3.4 Glutathione (GSH) Assays
(i) Intracellular GSH levels
The effect of 5pM XR9173 on intracellular GSH levels in drug sensitive L23/P and 
MOR/P cells together with their respective MRP-overcxpressing variants L23/R and 
MOR/0.4R was determined as described in Section 2.9.1.
(ii) Cellular GSH release
The effect of 5pM XR9173 on GSH release from L23/P and L23/R cells was 
determined as described in Section 2.9.2.
6.3.5 Photoaffinity Labelling
The effect of XR9173 on the ability of pHjazidopine to photolabel P-glycoprotein 
in membrane protein prepared from drug sensitive CEM and P-glycoprotein 
overexpressing CEM/VLB cells was determined as described in Section 2.6.2.
6.3.6 Calcein-AM
Calcein acetoxy-methyl ester (calcein AM) is a lipophilic, non-fluorescent 
compound, which rapidly permeates the plasma membrane of cells and upon 
cleavage of the ester bonds by intracellular esterases is transformed into the highly 
fluorescent calcein. Calcein, an organic anion, is thought to be a substrate or MRP 
(Feller et at., 1995).
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6.4 Results
6.4.1 Effect of XR9173 on the accumulation of calcein in L23/P and
L23/R cells
The calcein accumulation deficit in L23/R is clearly demonstraied in figure 6.5. At 
t=0, the first sample taken immediately after the addition of calcein AM to the cell 
suspension, calcein fluorescence in L23/P was 6-fold greater than in L23/R. The 
addition of XR9173 to the cell suspension only modestly effected calcein 
fluorescence in both L23/P and L23/R.
Figure 6:5
Effect of XR9173,5pM on Calcein accumulation in L23/P and L23/R cells at 
time, t=0
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Values are means of at least 3 independent experiment. Error bars indicate standard error. 
Time,tp=0- the first sample taken immediately after the addition of calcein AM to the cell suspension.
Figure 6.6.a shows that XR9I73 at a concentration of 5pM had no effect on Calcein 
accumulation over a period of 90 minutes in the drug sensitive cell line, L23/P. In 
contrast figure 6.6.b demonstrates that the Calcein accumulation deficit observed in 
the drug resistant, MRP ovcrexpressing cell line, L23/R, was reversed on addition
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of 5pM XR9173. This increase in calcein accumulation however, began to drop 
after 30 minutes. It should be noted, however, that these figures represent the 
increase in calcein accumulation in relation to the t=0 value and that this value was 
much smaller for L23/R than for L23/P. Even though calcein accumulation was 
increased by XR9I73 in the resistant cell line, L23/R it was not restored to the 
levels observed in the drug sensitive, L23/P cell line.
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Figure 6.6
(
(a) Effect of XR9173 on the accumulation of calcein in L23/P cells
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Values are means of at least 3 independent experimenL Error bars indicate standaid error.
(b) Effect of XR9173 on tlie accumulation of calcein in L23/R cells
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Values are means of at least 3 independent experiment Error bars indicate standard error.
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5.4.2 Effect of XR9173 on the effliix of calcein from L23/P and L23/R
cells
Over a period of 30 minutes the drug sensitive cell line, L23/P retained calcein at 
the levels observed at t=0 (the first sample taken after the addition of calcein to the 
cell suspension). Calcein fluorescence then began to drop gradually over the next 60 
minutes. At 90 minutes calcein fluorescence was 90% of the t=0 value (Figure 
6.7.a). It appears, therefore, that there was a very small but significant (p=0.0099. 
Student's t test) efflux of calcein from L23/P cells over a 90 minute time period. In 
contrast no significant decrease in calcein fluorescence was observed in the 
presence of 5pM XR9173. This indicates that in L23/P the small amount of calcein 
efflux observed was prevented by the addition of 5pM XR9173.
In contrast to L23/P, after a period of 90 minutes calcein fluorescence decreased to 
30% of the t=0 value in the drug resistant, L23/R cells (Figure 6.7.b). In the 
presence of 5pM XR9173, the decrease in calcein fluorescence still occured but the 
decline was slower. After 30 minutes calcein fluorescence was at 50% and 70% of 
the t=0 value in the absence and presence of XR9173 respectively. After 90 
minutes, in the presence of XR9173, calcein fluorescence was at 40% of the t=0 
value (compared to 30% in the absence of XR9173). These data indicate that 
calcein is effluxed from L23/R cells and that XR9173 partially inhibits this efflux.
197
Figure 6.7
(a) Effect of XR9173 on the efflux of calcein from L23/P cells
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(b) Effect of XR9173 on the efflux of calcein from L23/R cells
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6.4.3 Effect of XR9173 on the intracellular distribution of calcein in
L23/P and L23/R
Figure 6.8 a and b shows L23/P, drug sensitive, cells after 30 minutes exposure to 
250nM calcein in the absence (Figure 6.8.a) or presence (Figure 6.8.b) of 5|aM 
XR9173. calcein fluorescence is so intense it is difficult to establish any pattern of 
distribution. The black spots on the cells are areas of pixel saturation due to intense 
calcein fluorescence.
Figure 6.8 c and d shows L23/R, drug resistant, cells after 30 minutes exposure to 
250nM calcein in the absence (Figure 6.8.c) or presence (Figure 6.8.d) of 5p.M 
XR9173. Without XR9173 no intracellular calcein fluorescence is observed. On 
addition of 5pM 9173, intracellular calcein fluorescence is partially restored.
Confocal settings:
For the experiment shown in figure 6.8: 60X objective; Confocal aperture 5/15; 
Gain 630; Zoom 1.0; Neutral density 3, Kalman 10.
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Figure 6.8
(a)lntracellular distribution of calcein in L23/P cells
(b) Intracellular distribution of calcein in L23/P cells in the presence of 
XR9173 (5pM)
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Figure 6.8
(c) Intracellular distribution of calcein in L23/R cells
(d) Intracellular distribution of calcein in L23/R cells in the presence of 
XR9173 (5pM)
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6.4.4 Effect of XR9173 on the intracellular distribution of doxorubicin
in L23/P and L23/R cells 
The subcellular distribution of doxorubicin inside the drug sensitive, L23/P cells 
and the drug resistant, L23/R cells following 2h exposures to an external drug 
concentration of lOpM doxorubicin was investigated under the confocal microscope 
exploiting the natural fluorescence of the anthracycline to visualise the drug. In the 
L23/P cells intense fluorescence was observed within the nucleus, at the nuclear- 
cytoplasmic boundary and extensively throughout the cytoplasm (Figure 6.9.a.). In 
the L23/R, resistant cell line, the extent of overall fluorescence was much less than 
in the L23/P cells. There was very little detectable iluorescence in the nucleus or 
the nuclear-cytoplasmic boundary. It appears that cytoplasmic fluorescence is 
localised into groups of vesicles lying in a distinct area around the nucleus (Figure 
6.9.C.). In order to examine the effect of XR9173 on the distribution of doxorubicin 
in L23/P and L23/R cells, the cells were exposed to 5pM XR9173 for 30 minutes 
before and during the exposure of the cells to doxorubicin. In the parental cell line, 
XR9173 (5pM) had very little visible effect on the distribution of doxorubicin 
within the cell. The main areas of fluorescence are still the nucleus and the 
nuclear-cytoplasmic boundary. Fluorescence within the nucleus, however, 
appeared to be diminished compared to the parental cell line in the absence of 
XR9173 (5|iM). The effect of XR9173 on the L23/R cell line was much more 
profound (Figure 6.9.d.). Fluorescence within the nucleus and the nuclear- 
cytoplasmic boundary were restored and even cytoplasmic fluorescence could be 
observed.
Confocal settings:
For the experiment shown in figure 6.9: 60X objective; Conlocal aperture 5/15; 
Gain 800; Zoom 1.0; Neutral density 1, Kalman 10
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Figure 6.9
(a) Intracellular distribution of doxorubicin in L23/P cells
(b) In trac e llu la r  d is trib u tio n  o f doxorub icin  in L23/P cells in the presence o f 
XR9173 (5 |iM )
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Figure 6.9
(c) Intracellular distribution of doxorubicin in L23/R cells
(d) Intracellular distribution of doxorubicin in L23/R cells in the presence of 
XR9173 (5pM)
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6.4.5 Effect of XR9173 on intracellular GSH levels
For studies involving GSH levels we used the large cell lung cancer cell line, L23/P 
and the adenocarcinoma cell line MOR/P together with their MRP overexpressing, 
resistant sublines L23/R and MOR/0.4R. In the parental MOR/P cell line, 
intracellular GSH levels were reduced to between 70% and 80% of the control 
values by XR9173 at a dose of between 1 and 20|iM (Figure 6.10.a and 6.11.a). 
This decrease was only significant at 20|iM (Student's t test). Interestingly, this 
decrease in GSH was not dependent on the dose of XR9173 used. In the parental 
L23/P cell line, 2 independent experiments showed that GSH levels were reduced to 
between 60% and 80% of the control values by XR9173 (1 to 20|iM). Again this 
decrease does not appear to be dose dependent. The results were also similar for 
both resistant, MRP overexpressing, cell lines (Figures 6.10.b and 6.1 l.b). Doses of 
XR9173 between 1 and 20|iM caused a decrease in intracellular GSH levels to 
between 30% and 50% of the control values (intracellular GSH in the absence of 
XR9173). Again this decrease in GSH levels was not dependent on the dose of 
XR9173 used.
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Figure 6.10
(a) Effect o f  XR9173 on intracellular GSH levels in MOR/P
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Values are means (standiird error) o f at least 3 independent experiment. *p<0.05 (significantly 
different from 100%). **p<0.01 (highly significantly different from 100%), Student's t test.
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Figure 6.11
(a) Effect of XR9173 on intracellular GSH levels in L23/P
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(b) Effect of XR9173 on intracellular GSH levels in L23/R
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V a lu es are m ean s (standard e n o r )  o f  at least 3 ind ep en d en t ex p erim en t. * p < 0 .0 5  (sig n ifica n tly  
d id cren t from  100% ). **p < 0 .01  (h ig h ly  s ig n ifica n tly  d ifferen t from  100% ), Student's t test.
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6.4.6 Effect of XR9173 on cellular GSH release
In order to account for the apparent decrease in intracellular GSH after exposure ol 
MOR/P, MOR/0.4R, L23/P and L23/R cells to XR9173 we decided to examine the 
effect of the compound on GSH release. To establish the effect of XR9173 on 
cellular GSH release we measured the difference in extra cellular GSH before and 
after one hours exposure of L23/P and L23/R cells to XR9173. Table 6.1. shows 
the results obtained. In both sensitive and drug resistant cells, XR9173 appears to 
decrease GSH release after 60 minutes. This decrease in GSH release is not,
how ever,statistically significant (p=0.09,Student'sttest) in L23/P cells. lnL23/R
cells, however, the decrease in release does not reach significance (p=0.03. Students 
t test).
Table 6.1
Effect of XR9173 on cellular GSH release
Cell line Hh modifier
GSH release (nmql/W® cells ) 
after 60 min
L23/P control 5.0 ±1.1
L23/P + 9173 (5|iM) 3.4 ± 0.3
L23/R control 4.9 ±1.4
L23/R+ 9173 (5pM) 2.9 ± 0.4*
Values are means ±  standard error o f at least 3 independent experiment. 
*p<0.05 (significantly different from L23/R control value), Students t test
2 ( ) 8
6.4.7 Effect of XR9173 on the ability of photo labelled [3H]azidopine
to bind to P-glycoprotein in membranes prepared from 
CEM/VLB cells
The gel photograph shown in Figure 6.12 shows the effect of XR9173 on the ability 
of pHjazidopine to photolabel P-glycoprotein in membranes prepared from 
CEM/VLB cells. Lane 1 shows no azidopine binding and represents the parental 
CEM cell line. Lane 2 is a control and represents CEM/VLB membranes after 
exposure to [^Hjazidopine but without exposure to UV light. As pHjazidopine 
requires photoactivation no binding occurs. Lane 3 shows the presence of a band at 
a molecular weight of IVOkDa representing [^Hjazidopine binding to P- 
glycoprotein. The pHjazidopine binding to P-glycoprotein is inhibited by 5|iM 
cyclosporin A (lane 4). Lanes 5 to 9 represent the effect of XR9173 at 
concentrations of 0.5 to 10 p.M on the ability of [^Hjazidopine to label P- 
glycoprotein. XR9173 inhibits this labelling in a dose-dependent manner.
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6.5 D iscussion
Calcein-AM has been recently described as an efficient functional probe for P- 
glycoprotein activity (Homolya et aL, 1993; Hollo et aL, 1994). The compound 
gives rise to fluorescent calcein following cleavage by cellular esterases. Calcein- 
AM has been shown to produce a large differential fluorescence between parental 
and P-glycoprotein overexpressing MDR cells. (Homolya et aL, 1993; Hollo et al,. 
1994). In addition, it has been suggested that P-glycoprotein transports calcein-AM 
directly from the cell plasma membrane compartment as calcein-AM and not 
calcein, stimulates the vanadate-sensitive ATPase activity in isolated cell 
membranes of P-glycoprotein overexpressing insect cells (Homolya et ai,  1993). 
The results presented here show that, like P-glycoprotein mediated MDR cells, the 
MRP overexpressing cell line, L23/R also has a calcein accumulation deficit 
compared to the parental L23/P cell line. Our test MRP modifier, XR9173 was able 
partially to restore this accumulation deficit. It should be noted that the differential 
in accumulation between L23/P and L23/R for calcein is much larger than for 
daunorubicin or colchicine (see Section 5.3.5). Also XR9173 (5pM) restores the 
accumulation of daunorubicin and colchicine to 71% and 86% respectively of the 
parental levels after one hour. In comparison XR9173 (5|iM) is only able to restore 
the calcein deficit in L23/R cells to >20% of the parental value. Versantvoort et al. 
(1995b) also demonstrated that L23/R cells have a much larger (and more rapid) 
accumulation deficit for calcein than for daunorubicin and rhodamine 123. The 
group also observed that unlike daunorubicin and rhodamine 123, calcein 
accumulation is not restored in L23/R cells following depletion of cellular GSH 
with BSO. It appears that the transport of the anionic dye, calcein and the cationic 
drugs, daunorubicin and colchicine is not equivalent and that differences in the 
mechanism(s) of transport exist. As discussed earlier in this chapter, several groups 
have reported ATP-dependent transport of glutathione 5-conjugates (Jedlitschky et 
al., 1994; Muller et a i,  1994). Loior et al. (1994a) demonstrated that photoaffinity 
labelling of mastocytoma cell membranes with LTC4, the GSH conjugated
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Icukotricne C4, specifically labels a 190-kDa plasma membrane protein. This is the 
molecular weight of MRP. The group have also demonstrated that MRP mediates 
the ATP-dependent transport of LTC4  and structurally related conjugates in 
membrane vesicles from HeLa cells transfected with an MRP expression vector 
(Leier et aL, 1994b). These findings have lead to the recent suggestion that MRP is 
identical to the glutathione conjugate transporter present in hepatocytes, 
macrophages and other normal cell types (Jedlitschky et at., 1994). It seems likely 
considering the data presented here that calcein may be a model substrate for MRP 
partially inactivating the MRP pump by competing for the same efflux mechanism 
as GSH. Versantvoort et at. (1995b) postulate that efflux of daunorubicin and 
rhodamine 123 occurs via a mechanism for which MRP action is necessary but not 
sufficient. They found that several agents were capable of modulating the transport 
of daunorubicin and rhodamine 123 such as, genistein, verapamil, BSO, probenecid, 
orthovanadate and oubain in L23/R cells. Only probenecid, however, restored 
calcein accumulation. The data presented here indicate that, like probenecid, 
XR9173 is also able efficiently to inhibit the transport of daunorubicin and partially 
restore the calcein accumulation deficit in L23/R cells. It may, therefore, have a 
dual function being able to inhibit (partially) the organic anion transporter and also 
inhibit the, as yet undefined, mechanism responsible for causing a decreased 
intracellular accumulation of cationic cytotoxic drugs. Interestingly, XR9173 is 
able to modulate drug transport in both MRP overexpressing and P-glycoprotein 
overexpressing MDR cell lines. The compound is also able to inhibit the labelling 
of P-glycoprotein by pHjazidopine indicating that the compound may be a substrate 
for P-glycoprotein. Like other known P-glycoprotein-mediated MDR modulators 
such as cyclosporin A and verapamil, it may modulate the transport of cytotoxic 
drugs by competitive inhibition of the P-glycoprotein drug efflux pump. Attempts 
to label MRP with pHjazidopine were unsuccessRil and it is not known whether 
XR9173 is also a substrate for MRP. It may be possible that the MRP transporter 
may regulate a related mechanism which is resposible for daunorubicin transport
2 1 2
anion transporter thought to be identical to MRP. It does, however, modulate the 
accumulation and efflux of calcein, an anionic fluorescent dye. The results 
presented here provide evidence to support the theory that MRP may co-exist with 
another transporter which is able to transport cationic drugs across the membrane 
and that these transport are able in some way to regulate each others activity.
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Modification of phosphorylation of P-glycoprotein and 
of drug transport by activators and inhibitors of protein
kinase C
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7.1 Introduction
7.1.1 Protein kinase C (PKC)
Protein kinases are regulatory enzymes which catalyse the covalent attachment of 
phosphate groups to proteins. This phosphorylation of target proteins induces 
conformational changes, which result in modified cellular activities. Protein kinases 
are now recognised as biological levers of immense importance which regulate, in a 
complex fashion, steps essential for cellular differentiation and proliferation (Gescher 
et aL, 1994). In eukaryotic cells, protein kinases fall, generally, in to two general
classes : those which transfer phosphate to serine or threonine residues and those
which phosphorylate tyrosine. One of the best studied kinases is the serine/threonine 
specific protein kinase C (PKC). PKC was first discovered by Nishizuka and co­
workers in 1977, who described it as a histone protein kinase activated by Ca^+, 
phospholipids and diacylglycerol or phorbol esters. PKC is now known to consist of 
a single polypeptide chain of 77-83kDa, made up of a regulatory domain that interacts 
with enzyme cofactors and a catalytic domain which transfers ATP-derived phosphate 
to acceptor substrates. The regulatory domain also contains the 'pseudosubstrate', an 
amino acid sequence closely resembling the PKC substrate recognition sites, which 
blocks access of substrates to the catalytic site in a reversible manner. In its inactive 
state it is thought that PKC is located predominantly in the cytosol. On activation it 
associates tightly with cellular membranes, a process referred to as PKC 
'translocation' or 'redistribution'. Sustained activation of PKC results in its own 
down regulation, mediated by proteolytic enzymes, a mechanism presumably 
designed to ameliorate the potentially disastrous consequences of unabated activation. 
Clarification of the role of PKC is complicated by the fact that PKC is an enzyme 
family with at least 11 different isoenzymes (a, p i, P2, y, 6, e, 0, rj, X, Ç and p.). 
These enzymes are differentially expressed in cells, have different requirements for 
activation and are regulated independently by activators such as the tumour- 
promoting phorbol esters (Nishizuka, 1992).
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Little is known about differences in cellular function between the individual PKC 
isotypes, although the expression of more than one isoform in à particular cell type 
suggests that distinct PKCs may activate different cellular pathways and 
phcsphorylate different substrates (Pongracz e ta l,  1995).
7 .1 .2  Cellular function of PKC
As activated PKC is predominantly localised in cellular membranes, the majority of 
PKC target proteins are also associated with membranes. It is also possible, 
however, that a proteolytically generated fragment of PKC, comprising the catalytic 
domain but not the regulatory domain, is able to phosphorylate cytosolic proteins 
crucial for cell function (Gescher et al., 1994). Focal adhesion contacts, discrete 
regions of the plasma membrane, appear to be important PKC substrates. These sites 
which are large bundles of actin filaments located at the cytoplasmic face of the 
plasma membrane, function as anchors for cytoskeletal stress fibres. They ensure a 
physical transmembrane connection between the cytoskeleton of neighbouring cells or 
between cytoskeleton and extracellular matrix (Jaken et al., 1992). Phosphorylation 
of proteins which are associated with focal contacts is thought to be responsible for 
the transient morphological changes of cells which occur prior to cell division. The 
myristoylated alanine rich C kinase (MARCK) protein family is one of the most 
extensively studied PKC substrates (Aderem et al., 1992). MARCKs, which binds 
to both actin and calmodulin with Ca^+, is capable of cycling between the plasma 
membrane and the cytosol in a phosphorylation-dependent manner. On 
phosphorylation of MARCKs by PKC there is a rapid translocation of the protein 
from the plasma membrane to the cytosol, where it associates with F-actin. On 
dephosphorylation MARCKs reassociates with the membrane. The protein is able, 
therefore, to provide a regulated cross bridge between F-actin and the plasma 
membrane. Other important PKC substrates include members of the src oncogene 
family, the epidermal growth factor receptor and the amiloride-sensitive Na+/H+ 
exchanger, a plasma membrane glycoprotein which regulates intracellular pH.
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In 1990, Chambers and co-workers were the first to demonstrated that P- 
glycoprotein, the ATP-dependent drug efflux pump associated with multidrug 
resistance in cancer cells, is a substrate for PKC in vitro. The group also 
demonstrated that stimulation of P-glycoprotein phosphorylation by phorbol esters in 
vivo leads to reduced drug accumulation in vincristine-resistant KB cells (Chambers 
et al., 1990a & b). A recent study by Ma et al. (1995) demonstrates that the 190kDa, 
multidrug resistance associated protein (MRP) is highly phosphorylated and that the 
phosphorylation levels can be reduced by inhibitors of PKC. This suggests that 
MRP may also be a substrate for PKC (Ma et al., 1995). The role of PKC in MDR is 
very controversial and has been the subject of intense research of late. This issue is 
discussed in detail later in this chapter.
The role of PKC is indeed very complex. The discovery that a whole range of 
isoenzymes that are differentially expressed in various cells and tissues and that vary 
both in activation conditions and substrate specificity partially explains how a protein 
that at first appeared to be a single ubiquitous enzyme is able to control so many 
diverse functions.
7 .1 .3  Inhibitors of PKC
PKC inhibitors can be divided into two broad classes: Those which inhibit the activity 
of the catalytic domain, competing with the phosphate group, donor ATP or the 
substiate; and those which target the regulatory domain of the enzyme, competing 
with cofactors. The indole carbazole, microbial product staurosporine is the 
prototypical protein kinase inhibitor. It interacts with the catalytic, kinase domain of 
PKC with high potency. Due to the ATP-competitive nature of its inhibitory action it 
also impedes a number of other kinases with similar potency. Staurosporine 
analogues have been developed which appear to be more selective for PKC, whilst 
retaining high potency for enzyme inhibition. Examples are the hydroxylated
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staurosporine derivative UCN-01 developed by Kyowa Hakko in Japan (Takahashi et 
al., 1987) and the N-benzoyl derivative CGP 41251 (Meyer et al., 1989) from Ciba 
Geigy in Switzerland. The PKC inhibitor l-(5-isoquinolinylsulfonyl)-2- 
nietliylpiperazine (H7), also inhibits PKC at the catalytic domain and is less specific 
for PKC than staurosporine. The fungal product, calphostin C, is a relatively 
selective PKC inhibitor (Kobayashi et al., 1989) which irreversibly targets the 
phorbol ester/diacylglycerol, regulator, binding site of PKC by light-dependent 
oxidation (Brans era/., 1991).
Lysophingolipids such as sphingosine are metabolites of membrane sphingolipids 
and arc therefore natural constituents of cells. They have been shown to inhibit the 
regulatory domain of PKC.
A number of drugs that are currently in clinical use, such as chlorpromazine, 
doxorubicin and suramin, arc moderately effective PKC inhibitors. One of the most 
effective is the anti-oestrogen, tamoxifen. Tamoxifen and certain of its metabolites 
inhibit PKC at the regulatory domain at clinically effective drug concentrations 
(O'Brian et al., 1985). It has been suggested that PKC inhibition may contribute to 
the anti-bieast cancer activity of tamoxifen.
7 .1 .4  Activators of PKC
Activators of PKC, such as the tumour-promoting phorbol ester TP A, cause a 
plethora of morphological and biochemical effects in cells (Blumberg, 1980). In 
some cell lines, exposure to PKA activators causes mitogenesis, yet in others it leads 
to inhibition of proliferation. The biochemical events which trigger the biological 
effects of PKC activators arc only poorly understood. It is unlikely that the activation 
of PKC on its own would be sufficient for some of these events to occur. It seems 
that a cellular response to exposure to phorbol esters may result from the interplay of 
a variety of factors in concert with PKC activation. Studies have reported that
220
enhancement of PKC activity of the phorbol ester TPA can increase vinblastine 
transport in MDR cells (Fine et al., 1988; Chambers et a i,  1992; Bates et a l,  1993). 
Since P-glycoprotein phosphorylation is increased by TPA treatment, these results 
suggest that alterations in phosphorylation can modulate drug transport. 
Interestingly, prolonged exposure of cells to TPA results in a down regulation of 
PKC levels (Nishizuka et al., 1988).
7.1 .5  The role of PKC and protein phosphorylation in multidrug
resistance
A potential regulatory mechanisms for P-glycoprotein function is covalent 
modification by phosphorylation. It is now evident that phosphorylation is a 
universal characteristic of the P-glycoproteins expressed in MDR cells (Roy et al., 
1985; Chambers et al., 1990b) and is a dynamic process, with rapid 
phosphorylation/dephosphorylation cycles (Ma et al., 1991). The protein kinases 
involved in P-glycoprotein phosphorylation have not been completely characterised. 
Protein kinase C has been implicated because phorbol ester (an activator of PKC) 
stimulation of P-glycoprotein phosphorylation has been documented in several MDR 
cell lines ( Hamada et al., 1987; Yü et al., 1991; Chambers et al., 1992; Bates et al., 
1992), PKC phosphorylates P-glycoprotein m vitro (Chambers et a i, 1990b; Posada 
et al., 1989), and the in situ and in vitro phosphorylation sites are very similar if not 
identical (Chambers et al., 1990a & b and 1992). In addition to regulation by PKC, 
P-glycoprotein is also phosphorylated in vitro by cyclic AMP-dependent protein 
kinase (PKA) (Mellado et al., 1987; Miyamoto et al., 1990) and by a calcium 
independent phospholipid-dependent protein kinase (Staats et al., 1990). It appears 
that P-glycoprotein may therefore be phosphorylated through the activation of 
different signal transduction pathways: The functional role of phosphorylation of P- 
glycoprotein has been evaluated by measurements of drug accumulation in MDR cells 
treated with phorbol ester and protein kinase inhibitors. Chambers et al. (1990a & b 
and 1992) demonstrated that phorbol ester-induced PKC activation and increased P-
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7 .1 .6  Aims
We observed that, at doses where some of the Xenova compounds were effective 
modifiers of P-glycoprotein-mediated MDR. they did not inhibit the photolabelling of 
P-glycoprotein with pHJazidopine (Chapter 4). This suggested that the mechanism 
of action of these compounds may be one other than competitive binding to P- 
glycoprotein. As discussed already in this chapter, many groups have shown that P- 
glycoprotein is phosphorylated and that it is a substrate for PKC. We therefore 
decided to examine the effect of the XR compounds on the phosphorylation of P- 
glycoprotein. Meanwhile scientists at Xenova tested the ability of the compounds to 
inhibit PKC and found that none of the compounds tested were able to inhibit this 
enzyme. A US company called Novascreen also tested the compounds in a series of 
receptor binding assays. In a test for the ability of the compounds to inhibit the 
binding of the phorbol ester PDBu to PKC all the compounds were inactive. It is, 
therefore, unlikely that the Xenova compounds effect drug resistance via modifying 
the phosphorylation status of P-glycoprotein. At this stage we had already set up the 
phosphorylation assay and begun to look at the effect of known PKC inhibitors and 
the PKC activiator TPA on the phosphorylation of P-glycoprotein. The results of 
these initial studies proved interesting and so we decided to continue with this study. 
The aims of the work presented in this chapter have, therefore, changed. The initial 
idea was to determine whether the effect of the Xenova compounds on P-glycoprotein 
function was due to their effect on P-glycoprotein phosphorylation status. After 
considering the results obtained by scientists at Xenova we decided to continue to 
pursue the investigations into the effect of altering P-glycoprotein phosphorylation on 
drug transport. Our new aims were as follows:
(i) To examine the effect of inhibitors of protein kinase C on drug transport in the 
MDR cell line CEM/VLB and the ability of this cell line to transport cytotoxic drugs;
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(ii) To establish whether any effect on drug transport in CEM/VLB caused by PKC 
inhibitors is due to the inhibitor binding directly to P-glycoprotein or to the inhibition 
of phosphorylation of P-glycoprotein by the inhibition of PKC.
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7 .2  Materials and Methods
7 .2 .1  Cell lines
We used the human T-lymphoblastoid cell line CEM and the small cell lung cancer 
cell line H69/P together with their P-glycoprotein overexpressing variants, CEM/VLB 
and H69/LX4 respectively. Details of the derivation, maintenance and culture 
conditions of these cell lines are described in Section 2.1.
7 .2 .2  Drug sensitivity testing
The cytoxicity of the PKC inhibitors was determined using the tétrazolium (MTT) 
reduction assay. This method is described in detail in Section 2.3.
7.2.3 Drug accumulation studies
The effect of the PKC inhibitors and TPA on the ability of CEM and CEM/VLB cells 
to accumulate pH]daunonibicin and pHjcolchicine was determined as described in 
Section 2,5.1.ii
7 . 2 .4  Phosphorylation of P-glycoprotein in membranes
In order to determine the effect of inhibitors and activators of protein kinase on the 
phosphorylation status of P-glycoprotein we adapted the method of Staats et al. 1990. 
Membranes, prepared from H69/P and H69/LX4 cells using the method outlined in 
Section 2.6.1 were incubated in a 25pi reaction as described in Section 2.7.1 
Briefly, incubations were carried out for 5 min on ice. The reaction was stopped by 
the addition of lOmM EDTA. After the addition of 5p.l sample buffer the samples 
were electrophoresed on a 7.5% polyacrylamide gel as described in Section 2.7.2.
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7 .2 .5  Phosphorylation and immunoprécipitation of P-
glycoprotein in intact cells
In order to correlate the effect of various protein kinase inhibitors on the transport of 
cytotoxic drugs in MDR cells and P-glycoprotein phosphorylation, we decided to 
examine P-glycoprotein phosphorylation in intact cells.
Cell lysates were prepared from p^P]orthophosphate labelled drug sensitive, CEM 
and drug resistant, CEM/VLB cells as described in Section 2 . 7 . 3  .ii P-glycoprotein 
was then immunoprecipitated using the monoclonal antibody, C219 as described in 
Section 2.73-iü
7 . 2 . 6  Photoaffinity Labelling
The effect of PKC inhibitors and TPA on the ability of pHjazidopine to photolabel P- 
glycoprotein in membrane protein prepared from drug sensitive CEM and P- 
glycoprotein overexpressing CEM/VLB cells was determined as described in Section 
2.6.2 .
7 . 2 .7  Light activation of calphostin C
The more selective PKC inhibitor, calphostin C irreversibly targets the regulatory 
domain of PKC in a reaction involving light-dependent oxidation. Experiments to 
access the ability of calphostin C to modulate drug transport and to inhibit the 
phosphorylation of P-glycoprotein have, therefore, been carried out under light and 
dark conditions.
Light activation:
For accumulation assays; cell suspensions were placed in Falcon tubes and gased by 
blowing CO2 over the surface of the cell suspension before sealing the tube with the 
cap. The appropriate dilutions of calphostin C were then added to each tube. The 
tubes were then exposed to a fluorescent light for 10 minutes. The cells were then
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placed in 2ml Eppendorf tubes and incubated at 37"C for a further 20 mins before 
the addition of the radiolabelled drug.
For MTT assays; cell suspensions were placed in falcon tubes and gased by blowing 
CO2 over the surface of the cell suspension before sealing the tube with the cap. The 
appropriate dilutions of calphostin C were then added to each tube. The tubes were 
then exposed to a fluorescent light for 10 minutes. The tubes were then incubated for 
2 hours at 37 "C in an incubator. After this time the cells were pelletted and rinsed 
twice with 2ml ice PBS. Finally the cells were resuspended in medium and seeded 
into 96 well plates. The plates were incubated for 4 days in an incubator at 37“C in an 
atmostpherè of 8% CÔ2. The assay was read as described in Section 2.3.
For photoaffinity labelling studies; various dilutions of calphostin C were added to 
membrane dilutions in 96 well plates. The plates were exposed to fluorescent light 
for 10 minutes before the addition of pH]azidopine. The experiment was then 
continued as described in Section 2.6.4.
For phosphorylation assays; cells were incubated in phosphate free medium for 2h in
r
Falcon tubes. After this time the appropriate dilutions of calphostin C were added to 
each tube. The tubes were then exposed to a fluorescent light for 10 minutes. The 
cells were then placed in 2ml eppendorf tubes and incubated at 37’C for a further 
20 mins before the addition of p^Pjorthophosphate. The assay was continued as 
described in Section 7.2.5.
For experiments involving non-light activated calphostin C, the above procedures 
were followed with the exception of light exposure. Any cells exposed to calphostin 
C were kept in the dark.
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7.3 Results
7.3 .1  Effect of protein kinase C inhibitors on the accumulation
of pHJdaunorubicin and pHjcolchicine in CEM and 
CEM/VLB cells
In order to examine the effect of the protein kinase C (PKC) inhibitors calphostin C, 
H7 and staurosporine on the transport of cytotoxic drugs in MDR cells we decided to 
measure the ability of these PKC inhibitors to modulate the transport of the tritiated 
drugs, pHjdaunorubicin and pHjcolchicine in drug sensitive CEM and drug resistant 
CEM/VLB cells. The values in table 7.1. represent accumulation ratios. 
Accumulation ratio is defined by pHjdrug accumulation in the presence of modifier 
(PKC inhibitor) divided by pHjdrug accumulation in the absence of modifier (PKC 
inhibitor). Staurosporine at concentrations between 0.5 and 2.0pM had no significant 
effect on the accumulation of either drug in either the parental cell line, CEM (2.0|iM 
result shown in figure 7.7.) or the drug resistant, P-glycoprotein overexpressing cell 
line, CEM/VLB (Table 7.1.). Like staurosporine, H7 at concentrations of 10 and 
20jiM also had no effect on drug transport in either the parent or resistant cell line 
(Table 7.1. and Figure 7.7.). The more selective PKC inhibitor, calphostin C 
irreversibly targets the regulatory domain of PKC in a reaction involving light- 
dependent oxidation. Experiments to access the ability of calphostin C to modulate 
drug transport have therefore been carried out under light and dark conditions. The 
data in table 7.1. demonstrates that light activated calphostin C increased the 
accumulation of both pHjdaunorubicin and [^Hjcolchicine in drug resistant, 
CEM/VLB cells to a much greater extent than non-light activated calphostin C. Non­
light activated calphostin C, however, produced a modest but statistically significant 
increase in the accumulation of pHjdaunorubicin but not pHjcolchicine. Figures 7.1 
and 7.2. show graphical representations of the difference in the effect of calphostin C 
on the accumulation of pHjdaunorubicin and pHjcolchicine in drug sensitive CEM 
cells and drug resistant CEM/VLB cells under light and dark conditions. There was 
no significant (Student's l test) effect of calphostin C (dark and light) on the
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accumulation of [PHjcolchicine in the parental cell line, CEM. Light activated 
calphostin C (400nM) did significantly increase the accumulation of pHjdaunorubicin 
in the drug sensitive CEM cell line (p=0.017. Student's t test) but had no significant 
effect on the accumulation of pHjcolchicine.
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Table 7.1 The effect of calphostin C and staurosporine on the
accumulation of pHjdaunorubicin and pHjcolchicine in 
CEM and CEM/VLB cells
PKC INHIBITOR D O S E Accumulation ratio* pHIDAÏlNORÏJBÏCliSI
Accumulation ratio^ 
' i^ r n ic o t c m c i m
1.02
Calphostin C(nM) 50 1 .40 N/D
1.19
(dark) 100 1 .90 N/D
1.48** 1 .1 6
200 (0 .0 8 ) 1 .4 5
n = 6
2.04* 1 .4 4
400 (0 .2 3 ) (0 .1 9 )
n = 5 n = 4
4.43** 3.20*
Calphostin C(nM) 200 (0 .2 5 ) (0 .0 3 )
n=3 n=3
8.82* 5.29*
(light activated) 400 (1 .8 7 ) (1 .3 0 )
n=3 n=3
1 .25 1 .4 9
0 .5 ( 0 . 22 ) 1 .7 3
n=3
1 .08 1 .1 4
Staurosporine(fiM ) 1.0 (0 .0 7 ) (0 .0 5 )
n=3 n=3
1 .48 1.02
2.0 (0 .3 6 ) 1 .8 2
n=3
1.22 0 .9 1
H7 (pM) 10.0 1 .03 1 .3 2
1 .5 2 0 .9 2
20.0 1 .16 1 .7 2
*p<0.05 (significantly different from 1.0). **p<0.01 (highly significantly different from 1.0) 
Student's t test.Values are means o f n independent experiments. Where n<3, individual values are 
shown. Parentheses show standard error. N/D- not determined
Accumulation ratio—
p H ] D N R  accumulation + modifier
p l l j D N R  accum ulation - m odifier
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Figure 7.1
(a) The effect of calphostin C (light and dark activated) on the
accumulation of pHjdaunorubicin in CEM cells
□  light activated
200nM 400nM
Calphostin C
(b) The effect of calphostin C (light and dark activated) on the 
accumulation of pHjdaunorubicin in CEM/VLB cells
H  dark
□  light activated
200nM 400nM
Calphostin C
*p<0.05 (significantly different from 1.0). **pc0 01 (highly significantly different from 1.0), 
Student's t test Values are means (standard error) of 3 independent experiments.
Accnmulanon ratio— P l i j D N R  a c c u m u la t io n  +  m o d if ie r  
p l iJ D N R  a c c u m u la t io n  - m o d if ie r
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Figure 7.2
(a) The effect of calphostin C (light and d ark  activated) on the 
accum ulation of pH jcolchicine in  CEM  cells
M  dark  
n  light activated
200nM 400nM
Calphostin C
(b) The effect of calphostin C (light and d ark  activated) on the 
accum ulation of pH jcolchicine in CEM/VLB cells
Ü  dark
□  light activated
200nM 400nM
Calphostin C
*p<0.05 (significantly different from 1.0).
**p<0.01 (highly significantly different from 1.0. Student's t test) 
Values are means (standard error) of 3 independent experiments.
Accumulation ralio=- pH]DNR accumulation + modifier
p l l lD N R  accumulation - modifier
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Figure 7.3 demonstrates that higher doses of calphostin G were able to increase 
accumulation in the resistant cell line, CEMA^LB without light activation. This effect 
may however be due to the toxicity of calphostin C, for example permeabilisation of 
the plasma membrane, at the doses used here and not to a direct effect on P- 
glycoprotein or other mechanisms causing the drug accumulation deficit seen in this 
cell line.
F igure 7.3
The effect of calphostin C (high dose, non light activated) on the 
accum ulation of pH jdaunorub ic in  in CEM /VLB cells
I
1
a
0.5 1.0
Calphostin C
fiM
Hgure represents a typical data sec 
Similar results were obtained iii 1 other independent experiment
Accumulation ratio=-
pH ID N R accumulation + modifier 
[^HJDNR accumulation - modifier
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7 .3 .2  Toxicity of calphostin C in CEM and CEM/VLB cells
Parent, CEM, and drug resistant, CEM/VLB, cells were exposed to calphostin C for a 
period of 2 hours in order to examine the acute toxic effects of the drug in these cell 
lines. Figure 7.4 indicates that the resistant cell line, CEM/VLB is slightly cross 
resistant to calphostin C. The mean IC5 0  ( dose of cytotoxic drug required to reduce 
fractional absorbance to 50% of control values in the MTT assay) of calphostin C in 
CEM and CEM/VLB cells is 0.17pM and 0.49pM respectively (Table 7.2).
F igure 7.4-
Toxicity of calphostin C (2h acute exposure, non-light activated) in 
CEM  and CEM/VLB cells
i  ^ct
"S 0.8 -
i  ■
C3
1  0 .4 -
2£  0 .2 -
0.0
.01 .1 1 10
Calphostin C (pM)
Values are means (±standaid enw ) of at least 3 independent experiments 
( • )  parent,CEM cells; (o )  resistant,CEM/VLB cells
To determine the effect of light activation on the toxicity of calphostin C we again 
exposed parent, CEM and drug resistant, CEM/VLB cells to calphostin C for a period 
of 2 hours in the presence of either light activated or non-light activated calphostin C. 
Figure 7.S shows that light activation clearly increases the toxicity of calphostin C to
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both CEM and CEM/VLB cells. IC50 values obtained in 2 independent experiments 
are given in table 7.2.
Figure 7.5
Toxicity of calphostin C (2h acute exposure) in CEM/VLB cells (light 
versus: dark)
1.2
o  1.0 -  
c
.Û 0.8 -
L . -
ca
g  0 .4 -
2 0 .2 -
0.0
.01 .1 1 10
Calphostin C (pM)
Figure represents a typical data set Similar results were obtained in 2 independent experiments. 
IC50  values for the 2 independent experiments are given in table 7.2. 
(•)parent.GEM cells(dark); (o)parent,CEM cells (light) 
(■)resistant,CEM/VLB ccUs(dark); (o)resisiant,CEM/VLB cells (light)
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Table 7.2
IC50S for calphostin C (light and non-light activated) in CEM and 
CEM/VLB cells
C ell lin e IC 50 (JJIM) 
±$taitdard error
CEM (dark) 0.17+ 0.05
CEM/VLB (dark) 0.49+0.11*
CEM (light) 0 .030.04
CEM/VLB (light) 0 .080.13
*p=0.032 (IC50 value in resistant, CEM/VLB cell line is significantly different from the IC50 value 
in sensitive, CEM cell line. Student’s t test). Values are means o f  n independent experiments. Where 
n<3, individual values are shown. IC50=concentration o f drug required to reduce fractional 
absorbance to 50% o f control values in tlie MTT assay
7 .3 .3  Effect of the protein kinase C activator, TPA on the
accumulation of pHjdaunorubicin and pHjcolchicine in 
CEM and CEM/VLB cells
Previous studies have reported that enhancement of PKC activity by the phorbol ester 
TPA can increase drug transport in multidrug resistant cells (Fine et al., 1988; 
Chambers e ta l ,  1990; Bates e ta l ,  1993). Since P-glycoprotein phosphorylation is 
enhanced by TPA treatment (Bates et at., 1993), these results suggest that increasing 
PKC activity and therefore increasing P-glycoprotein phosphorylation may increase 
the drug transport capability of P-glycoprotein and therefore make the cell more 
resistant to cytotoxic drugs. In order to establish whether increasing PKC activity 
causes an increase in drug resistance we decided to look at the effect of TPA in the 
ding resistant cell line CEM/VLB. Cells were exposed to TPA for 30 minutes before 
the addition of the radiolabelled drug. The cells were exposed to the 
radiolabelled drug for Ih in the continued presence of TPA. We observed that TPA 
caused a decrease in the accumulation of both pH]daunoruhicin and (-^Hjcolchicine in
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the drug resistant CEM/VLB cells. pHjDaunorubicin accumulation in CEM/VLB 
cells decreased with increasing doses of TPA (Figure 7.$.a ). The highest dose of 
TPA (500nM) caused a 50% decrease in pHjdaunorubicin accumulation compared to 
the control (pHjdaunorubicin accumulation in the absence of TPA). pHjColchicine 
accumulation in CEM/VLB cells decreased with increasing doses of TPA until a dose 
o f lOOnM (Figure 7.&b ). This dose of TPA caused a 57% decrease in 
pHjcolchicine accumulation compared to the control (pHjcolchicine accumulation in 
the absence of TPA). Higher doses of 200 and 500nM TPA did not cause 
pHjcolchicine accumulation to decrease any further.
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Figure 7.6
(a) Effect of TPA on the accumulation of pHjdaunorubicin in
CEM/VLB cells
0 10 20 50 100 200 500
TPA (nM)
(b) Effect of TPA on the accum ulation of pH jco lch ic ine  in  CEM /VLB 
cells
10 20 50 100 200 500
TPA (nM)
* p x 0 .0 5  (s ig n if ic a n tly  d ifferen t from  1 .0 ). * * p < 0 .0 1  (h ig h ly  s ig n if ic a n tly  d ifferen t from  1 ,0).
S tudent's t t e s t  V a lu e s  are m ea n s (standard error) o f  3 in d ep en d en t exp erim en ts.
Acciimuialion ratio—
p H lD N R  accumulation + modifier
p l l lD N R  accumulation - modifier
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Figure 7.7 shows that TPA was also able to reduce pHjcolchicine accumulation 
induced by the treatment of the cells with cyclosporin A (a modifier of MDR). 
Cyclosporin A (IpM ) was able to increase the accumulation of [^Hjcolchicine in 
CEM/VLB cells to 2.5 times the level of tlie control (pHjcolchicine accumulation in 
CEM/VLB cells in the absence of modifier). TPA (200nM) reduced this increase to
1.5 times the level of the control (Figure 7.6). Accumulation ratios for 2 independent 
experiments are shown in table 7.4.
Figure 7.7 Effect of TPA in combination with cyclosporin A on the 
accumulation of pHjcolchicine in CEM and VLB cells
3 -1
Figure represents mean of 2 independent experiments, independent values are shown in Table 7.3
PHID N R accumulation + modifier 
Accumulaüon m ü o - accumulation - modifier
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Table 7.3
Effect of TPA in combination with cyclosporin A on the accumulation 
of pHjcolchicine in CEM and VLB cells
GROUP Accttmnlation Ratio
1.0
Control 1.0
(1 .0 )
2 .7 9
CsA (IflM) alone 2 .3 7
(2 .5 8 )
2.01
CsA (l|iM )+TPA (20nM) 1 .57
(1 .7 9 )
1 .77
CsA (l|iM )+TPA (50nM) 1 .5 7
(1 .6 7 )
1 .62
CsA (1 l^M)+TPA  (lOOnM) 1 .40
(1 .5 1 )
1 .50
CsA (l[iM)+TPA (200nM) 1 .4 6
(1 .4 8 )
Values shown are accumulation ratios from 2 independent experiments, 
parentlieses show means o f 2 values.
Each individual value is the mean o f triplicate determinations within each independent experiment.
Accumulation ratio—
pH JD N R  accumulation + modifier 
pH JD N R  accumulation - m odifier
7 . 3 . 4  Effect of calphostin C, TPA and staurosporine on the
accumulation of [PHjdaunorubicin in CEM, drug sensitive 
cells
Figure 7.7. dem onstrates that the PKC inhibitors, staurosporine, H7 and calphostin C 
have no effect on the accum ulation o f pH jdaunorubicin  in the drug sensitive CEM  
cell line. The PKC activator, TPA also has no effect on drug accumulation in this cell 
line. Results were sim ilar in experim ents to examine the effects of these agents on the 
accumulation of [PHjcolchicine in the CEM  cell line (rcsiills not shown).
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Figure 7.9
Effect of calphostin C, TPA and staurosporine on the accumulation of 
[^Hldaunorubicin in CEM, drug sensitive cells
0
U
1
1
<
50 500
C A LC(nM )
50 200 2 20
TPA(nM ) STAOiM) H7 (pM)Control
Abbreviations: calphostin C (GAL C). staurosporine (STA)
Figure represents mean of 2 independent experiments. Individual values are shown in Table 7.4
PH ID N R accumulation + modifier 
Accumulation ra tio- pH ]D N R  accumulation - modifier
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Table 7.4
Effect of calphostin C, TPA and staurosporine on the accumulation of 
[PHjdaunorubicin in CEM, drug sensitive cells
GROUP Aecnmtilatlon R ada
0 .9 8
Calphostin C (dark, 50nM) 0 .9 8
(0 .9 8 )
1.17
Calphotin C (dark, 500nM) 1 .05
(1 .1 1 )
1.07
TPA (50nM) 1.03
(1 .0 5 )
1.21
TPA (200nM) 1.11
(1 .1 6 )
1.09
Staurosporine (2|iM) 1.03
(1 .0 6 )
0 .9 9
H7 (20[lM) 0 .9 7
(0 .9 8 )
V a lu es sh ow n  are accu m ulation  ratios from  2  ind ep en dent experim ents, 
p arentheses sh o w  m ea n s o f  2  v a lu es.
E ach ind iv idu al v a lu e  is  tlie  m ean  o f  trip licate determ inations w ith in  ea ch  ind ep en dent experim ent.
A ccu m u la tio n  ra tio —
[P H ]D N R  a c c u m u la tio n  +  m o d if ie r  
[p R jD N R  a c c u m u la t io n  - m o d if ie r
242
7.3 .5  Effect of the protein kinase C inhibitors, H7 and
staurosporine on the phosphorylation of P-glycoprotein in 
cell membranes prepared from H69/P and H69/LX4 cells
In the search for the mechanism(s) underlying the effects of the PKC inhibitors on the 
transport of drugs in MDR cells, we decided to look at their effect on the 
phosphorylation of P-glycoprotein in vitro . These studies were undertaken in 
membranes prepared from the small cell lung cancer cell line H69/P and its MDR 
variant H69/LX4. These were the preliminary studies in this section of my research. 
After looking firstly at the effect of staurosporine and H7 on the phosphorylation of 
P-glycoprotein in these membranes we decided that it would be more appropriate to 
look at the effect of PKC inhibitors in an intact cell system as we were, after all, 
performing all drug accumulation studies in whole cells and not membrane vesicles. 
We decided, therefore, to carry on our studies using a intact cell phosphorylation 
assay. We elected to use the CEM and CEM/VLB cell lines: (a) because this is the 
cell line that we used in the accumulation studies and we wanted to be able to make 
direct comparisons and (b) because these cell lines grow as single cell suspensions in 
comparison to the H69/P and H69/LX4 cells lines which grow as floating aggregates. 
Figure 7.9 shows the effects of the protein kinase C inhibitors, H7 and staurosporine 
on the phosphorylation of P-glycoprotein in cell membranes prepared from MDR, 
H69/LX4 cells. In lane 2, there is a clear band which represents the phosphorylation 
of P-glycoprotein in membranes prepared from the P-glycoprotein overexpressing cell 
line, H69/LX4. In contrast there is no band in lane 1, the parental cell line which does 
not express P-glycoprotein. Lanes 3 and 4 show the inhibition of phosphorylation of 
P-glycoprotein by H7 lOjiM and staurosporine 2p.M respectively.
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Figure 7.9
Effects of the protein kinase C inhibitors, H7 and staurosporine on the 
phosphorylation of P-glycoprotein in cell m em branes prepared from 
MDR, H69/LX4 cells.
170kDa
Lane 1, H69/P; Lane 2, H69/LX4; Lane 3 H69/LX4 + H7 lOpM; 
Lane 4 H69/LX4 + staurosporine 2|iM
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7 . 3 . 6  Effect o f  protein kinase C inhibitors and the protein
kinase C activator, TPA on the on the phosphorylation of 
P-glycoprotein in intact MDR, CEM/VLB cells
The effects of the non specific, PKC inhibitors staurosporine and H7 on the 
phosphorylation of P-glycoprotein in intact CEM/VLB cells are shown in figure 7.10 
Lanes 1 and 2 represent the parent, GEM, and resistant, CEM/VLB cell lines 
respectively. In Lane 2 the presence of a band at a molecular weight of 170kDa can 
be observed (molecular weight markers were run along side the proteins). This band 
represents the phosphorylation of P-glycoprotein. This band of P-glycoprotein is 
absent in the parental cell line, CEM. Lanes 3 and 4 represent the effects of 
staurosporine (2|iM) and H7 (10p.M) respectively on the phosphorylation of P- 
glycoprotein in CEM/VLB cells. Staurosporine and H7 do not appear to inhibit 
phosphorylation in this MDR cell line.
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Figure 7.^0
Effect of s tau ro sp o rin e  and H7 on the phosphory la tion  of P-
glycoprotein in intact MDR, CEM/VLB cells
170kDa
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Figure 7. H demonstrates the difference in effect o f  light- and non-light-activated 
calphostin C on the phosphorylation o f  P-glycoprotein in intact C EM  and CEMA^LB 
cells. A gain no band o f  phosphorylation is observed in Lane 1, the parental CEM  
cells line. In contrast in the P-glycoprotein overexpressing cell line, CEMA^LB (lane 
2) a band o f  phosphorylation is observed at a m olecu lar  w eight o f  170kDa (the 
m o lecu la r  w eight o f  P-g lycopro te in . Lanes 3, 4 and 5 represent the effect of 
calphostin C (2(X)nM:light), calphostin C (2(X)nM:dark) and 2(X)nM TPA  respectively 
on the phosphorylation o f  P-glycoprotein in C EM /V LB cells. This gel photograph 
clearly shows tliat light activated calphostin C was able to inhibit the phosphorylation 
o f  P-glycoprotein. In contrast, the sam e concentration o f  calphostin C without light 
activation had no effect. In lane 5 TPA, however, the density of  the phosphorylated 
band at 170kDa appears to be increased. Thus TPA  increased the phosphorylation of 
P-glycoprotein in CEM/VLB cells.
2 4 7
Figure 7.1)
Effect of calphostin C (light and dark activated) and TPA on the 
phosphorylation of P-glycoprotein in intact MDR, CEM/VLB cells
■ 170kDa
Figure 7. IX again demonstrates the effec t  o f  light activated calphostin  C on the 
phosphorylation o f  P-glycoprotein. In lanes 3 and 4 (CEM /VLB, resistant cells) light 
activated calphostin C at 200 and 400nM  respectively caused a complete loss o f  the 
band  o f  phosphoryla tion  observed at a m o lecu lar  w eight o f  170kDa in lane 1 
(C E M /V L B , resis tant cells). In com parison  there is no band in lane 2 which 
represents tlie drug sensitive parental cell line, CEM.
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Figure 7.1^
Effect of calphostin C (light activated) on the phosphorylation of P-
glycoprotein in intact MDR, CEM/VLB cells
nO kD a
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7 .3 .7 .  Effect of protein kinase C inhibitors on the ability of
photo-labelled [^H]azidopine to bind to P-glycoprotein in 
membranes prepared from CEM/VLB cells
T he  gel photograph  show n in F igure 7.13 show s the e ffec t  o f  cyc losporin  A, 
calphostin  C (dark), s taurosporine and H7 on the ability of [^HJazidopine to photo 
label P-glycoprotein in membranes prepared from C EM /V LB cells. Lane 1 shows no 
azidopine binding and represents the parental C E M  cell line. Lane 2 is a control and 
represen ts  C E M /V L B  m em branes after exposure  to p H ja z id o p in e  but w ithout 
exposure  to UV light. As pFllazidopine requires photoactivation no binding occurs. 
Lane 3 shows the presence o f  a band at a m olecular w eight o f  170kDa representing 
[3R ]az idop ine  b inding  to P-g lycopro te in . T he  [^H ]az idop ine  b ind ing  to P- 
glycoprotein was inhibited by 5 |iM  cyclosporin A (lane 4). Lanes 5, 6 , 7, 8 and 9 
show  the  e ffec t  o f  ca lphostin  C (dark) 200nM , ca lphost in  C (dark) 400nM , 
staurosporine  2}iM, H7 lOjiM and H7 20 |iM  on the ability o f  [^H ]azidopine  to 
photolabel P-glycoprotein in CEM /VLB cells. Only s taurosporine 2 |iM  in lane 7 
shows any inhibition of pH]azidopine photolabelling.
250
Figure 7.13
Effect of H7, staurosporine and calphostin C (dark) on the ability of 
photo-labelled [-^ll]azidopine to bind to P-glycoprotein in membranes 
prepared from CEM/VLB cells
Lane number 1 2 3 4 5 6 7
Legend:
Lane 1; CLM (parent),
Ltme 2; CEM/VLB (resistant) no UV light,
LcUie 3; CEM/VLB no modifier,
Lane 4; CEM/VLB + cyclosporin A 5|aM.
Lane 5 & 6; CEM/VLB + Calphostin C 200 & 400nM respectively, 
Lane 7; CEM/VLB + staurosporine 2|iM ,
Lane 8 & 9; CEM/VLB + H7 lOpM & 117 20pM
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In figure 7.14 lanes Ito 4 are ihe same as for figure 7.13. Lanes 5, 6 , 7, 8 and 9 
represent the effect o f  calphostin C (dark) 200nM, 500nM , Ip M , 2 |iM  and 5pM  
respectively. At the higher doses of 2 and 5pM  the pH Jazidop ine  photolabelling of 
P-glycoprotein was partially inhibited.
Figure 7.14
Effect of increasing doses of calphostin C (dark) on the ability of 
photo-labelled [^Hjazidopine to bind to P-glycoprotein in membranes 
prepared from CEM/VLB cells
Lane number 1 2 3
Legend:
Lane 1; CEM (parent),
Lane 2; CEM/VLB (resistant) no UV light.
Lane 3; CEM/VLB no modi tier.
Lane 4; CEM/VLB + cyclosporin A 5pM,
Lane 5, 6, 7, 8 & 9; CEM/VLB + Calphostin C (dmk) 0.2, 0.5, 1.0, 2.0, 5.0 pM  respectively
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The düTerence in the elTect of light and non-ligh t activated  ca lphostin  C is 
demonstrated by the gel photograph shown in figure 7.15. Lanes Ito 3 are the same 
as for figure 7.13. Lanes 4, 5, 6 , 7, and 8 represent the effect of calphostin C (dark) 
200nM , 400nM , calphostin C (light-activated) 20(,)nM, 400nM  respectively. As 
shown previously (Figure 7.12) calphostin C (dark) at concentrations of 200 and 
400nM  had no effect on the ability of pH jaz idop ine  to photolabel P-glycoprotein. It 
appears that 200 and 4 0 0 nM calphostin  C(ligh t-activated) did, how ever, cause 
inhibition of the pHJazidopine to photolahelling.
Figure 7.15
Effect of calphostin C (light and dark activated) on the ability photo­
labelled [^HJazidopine to bind to P-glycoprotein in membranes 
prepared from CEM/VLB cells
Lane number 1 2 3 4  5 6 7 8
Legend:
Lane 1; CEM (parent),
Lane 2; CEM/VLB (resistant) no UV light,
Lane 3; CEM/VLB no modifier.
Lane 4; CEM/VLB + cyclospohn A 5pM,
Lanes 5 & 6; CEM/VLB + calphostin C (dark) 20()nM & 400nM respectively.
Lanes 7 & 8; CEM /VLB + Calphostin C (light-activated) 200nM  & 400nM  respectively.
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7 . 4  D is c u s s io n
The studies presented here extend earlier observations of alterations in P-glycoprotein 
function after treatment of multidrug resistant cells with agents that interfere with P- 
gl y CO protein phosphorylation. Inhibition of PKC with calphostin  C decreased the 
phosphorylation o f  P-glycoprotein and increased the accum ulation o f  daunorubicin 
and colchicine in the P-glycoprotein overexpressing M D R cells, CEM /VLB.
Several groups have shown that P-glycoprotein is phosphorylated  (Carlsen et a l ,  
1977, Center, 1983; H am ada et a l ,  1987). Tsuruo demonstrated that TPA, verapamil 
and trifluoperazine could modulate P-glycoprotein phosphorylation (H am ada et a l ,  
1987). Subsequently , Fine and Cham bers dem onstrated increased drug resistance 
after treatment with the phorbol ester, TPA  (Fine et a l ,  1988; Cham bers et a l ,  1990). 
C ham bers observed that this increase in drug resistance was m ediated by decreased 
v inblastine accum ulation  and was associated with an increase  in P-glycoprotein  
phosphorylation. Bates et a l  (1992) confirmed the relationship between increased P- 
g lycopro tein  phosphoryla tion  and enhanced P-glycoprotein  m edia ted  vinblastine 
efflux after TPA  treatment. Other studies associated inhibition o f  P-glycoprotein  
phosphorylation by staurosporine with decreased drug efflux (Ma et a l ,  1991; Sato et 
a l ,  1990; Sam pson et a l ,  1993). O ur results indicate  that s taurosporine  has no 
s ignif icant effect on drug transport in the sensitive, C E M  or the drug resistant, 
CE M /V L B  cell lines. Interestingly, although staurosporine did not appear to inhibit 
the phosphorylation o f  P-glycoprotein in the intact drug resistant, CEM /V LB cells, it 
did inh ib it  the phosphoryla tion  o f  P-glycoprotein  in m em branes  prepared from 
another M D R  P-glycoprotein overexpressing cell line, H69/LX4. This m ay indicate 
that either the actions of staurosporine are cell specific or that s taurosponne is able to 
inhibit particular PKC isoenzymes with a greater potency than others. In intact cells, 
endogenous  protein kinases that are not associated with the m em brane  are still 
available to phosphorylate P-glycoprotein. If staurosporine is not specific for these 
enzym es but is able to inhibit the m em brane  associated  protein k inases in the
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H 69/LX 4 cell m em branes this may explain ihe apparent difference in activity of 
staurosporine in these two systems. Bates et al. (1993) observed that calphostin C 
affects PKC z and not a and that high levels of PKC z were located in the m em brane 
fraction. Similar specific isoenzyme studies need to be carried out with staurosporine 
in order to explain the differences observed in this study. Staurosporine is an indole 
carbazole produced by a Streptoniyces species which inhibits PKC and a variety of 
o ther  k inases  with high potency. The IC 5 0  (concen tra tion  required for 50% 
inhibition) for inhibition of PKC is 6 nM (O'Brian et al., 1990). If staurosporine is 
able to modulate the function of  P-glycoprotein by inhibiting its phosphorylation, it 
should  be capab le  o f  do ing  so at doses  in the nan o m o la r  range. L ooking  
retrospectively  at previous studies. M a et al. (1991) found that a dose of l | iM  
staurosporine partially restored the daunom ycin  accum ulation  in the vincristine 
resistant, P-glycoprotein overexpressing cell line, H L60/V inc. W e also used this 
concentration, as we found it to be non toxic in the CE M  and CEM /VLB cell lines. 
Sato et al., however, used a concentration of 20pM . There  is no doubt that these 
relatively high concentrations of  staurosporine should inhibit PKC and thus the 
phosphorylation o f  P-glycoprotein. Staurosporine itself exhibits a w ide range of 
toxic effects against various cultured cells. At high doses such as those used in the 
study by Sato et al., the possibility of toxic effects can not be imled out. It is possible 
that staurosporine may reduce the phosphorylation o f  P-glycoprotein by slowing 
down the incorporation o f  orthophosphate to ATP rather than (or in addition to) acting 
via the inhibition o f  PKC. Sato et al. also noted that staurosporine inhibited the 
pho toaff in ity  labelling  o f  P -g lycopro te in  with [^H Jazidopine  ind ica ting  that 
s taurosporine may com petitive ly  inhibit drug binding to P-glycoprotein by itself 
binding to the protein. Our results confirm  this. As show n in Figure 7.11 and 
discussed in Section 7.3.7, l | iM  staurosporine  partially inhibits  the b inding of 
p H Jaz id o p in e  to P-glycoprotein  in m em branes  prepared from C E M /V L B  cells. 
Further studies using low, non toxic doses o f  staurosporine in MDR cell lines known 
to be affected by the drug will determine whether the effect o f  staurosporine on drug
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iransnorl is via the inhibition o f  PKC or via a direct interaction with P-glycoprotein. 
L ike  s tau ro spo rine ,  the non specif ic  PK C inh ib i to r  H7 also  inh ib ited  the 
phosphory la tion  o f  P -g lycopro te in  in m em branes  prepared from drug resistant 
C E M /V L B  cells but not in intact drug resistant C E M /V L B  cells. H7 also had no 
effect on drug accumulation in either the parental CE M  or drug resistant CEM /VLB 
cells.
In addition to the controversy surrounding the action of staurosporine in M DR cell 
lines, calphostin  C has also been the subject of intense research for many groups 
Gupta et al. (1994) proposed that calphostin C, at a concentration that increased drug 
accum ulation and partially reversed drug resistance (250nM ) did not inhibit PKC 
activity either in the cytosol or m em brane fractions. These results contrast with tliose 
of  Bates et al. who found that calphostin C a t  a concentration o f  200nM inhibited 
PKC z in the m em brane fraction o f  M D R , SW 620A d300 cells. Our results confirm 
that light activated calphostin C inhibits the phosphorylation o f  P-glycoprotein and in 
turn m odu la tes  drug transport in the drug resistant cell line, C E M /V L B . The 
inhibition of PK C  in intact cells by calphostin  C has been show n to require light 
(Bruns et al., 1991). Our results demonstrate that P-glycoprotein phosphorylation is 
only inhibited by light activated calphostin C. In experiments carried out under dark 
conditions, calphostin C had no effect on the phosphorylation of P-glycoprotein. It 
appears that calphostin  C m ay inhibit P-g lycopro tein  phosphorylation  by light- 
dependent inhibition of PKC. Several groups have examined the effect o f  calphostin 
C on the transport of cytotoxic drugs in M D R cells (Bates et al., 1993; Gupta et al., 
1994). These  groups have not, however, published data on the difference between 
the effects of light and dark activated calphostin C on drug transport in M DR cells. 
Our data suggests that non-light activated calphostin C significantly increases drug 
accum ula t ion  in the M D R  cell line, C E M /V L B  w ithou t  any  e ffec t  on the 
phosphorylation status of  P-glycoprotein. This may suggest that calphostin C is able 
to reverse  M D R  by a m echan ism  other than via inhibition o f  P-glycopro tein
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phosphorylation due to its ability to irreversibly inhibit PKC. Interestingly, light 
activated calphostin C has a much greater elTect on drug accumulation. The increases 
in daunorubicin  and colchicine accum ulation observed  in the presence o f  light 
activated calphostin C were 3- to 4-fold greater than those observed in the presence of 
non-light activated calphostin C. There are several possible explanations that may 
account for the difference in the effects o f  light activated and non-light activated 
calphostin C. Firstly, the increased ability of light activated calphostin C to modulate 
drug transport in M D R  cells may be due to the inhibition of PKC by light activated 
calphostin C which in turn causes P-glycoprotein to becom e dephosphorylated with 
the result o f  a possible alteration in its function. Secondly, our data indicates that 
light activation enhances the toxicity of calphostin C in the drug resistant CEM /VLB 
cell line. Like staurosporine, calphostin C may reduce the phosphorylation o f  P- 
glycoprotein by slowing down the incorporation o f  orthophosphate  to ATP rather 
than (or in addition to) acting via the inhibition o f  PKC. The increased toxicity may 
cause  an increase in drug accumulation in C E M /V L B  cells by perm eabilising the 
membranes. In the presence of light calphostin C is know n to react with m olecular 
oxygen, generating singlet oxygen and forming endoperoxides (Bruns et al., 1991). 
M em brane destruction resulting from lipid peroxidation by singlet oxygen is thought 
to be the major cause o f  toxicity of calphostin C in mammalian cells. This may explain 
the increased drug accumulation observed in cells exposed to light activated calphostin 
C. This, however, does not explain why seem ingly toxic doses o f  calphostin C do 
not increase drug accumulation in the drug sensitive, CEM  cell line to the same degree 
as in the drug resistant, CEM /VLB cell line.
The results of our photoaffinity labelling experiments demonstrate that high doses of 
calphostin C inhibit the [^Hjazidopine photolabelling of P-glycoprotein. This is in 
agreement with the results o f  Bates et at. (1993) who also suggest that this inhibition 
at high dose may be the result of a change in the conformation of P-glycoprotein due 
to the effect o f  calphostin  C on the phosphorylation status o f  the protein. W e
2 5 7
obsei-ved no inhibition of [^HJazidopine labelling of P-glycoprotein in the presence of 
non-ligh t activated calphostin  C at doses used in our phosphory la tion  studies. 
H ow ever after light activation we did observe an inhibition of pHJazidopine labelling 
o f  P-glycoprotein. As the light activated form of  calphostin  C inhibits PK C  it is 
possible that it may prevent pH Jazidopine from labelling P-glycoprotein by altering 
its conform ation by dephosphorylating the protein. This  is in agreem ent with the 
theory o f  Bates et al. as discussed above. The results we obtained here do not prove 
that calphostin C causes an alteration in the drug binding capability of P-glycoprotein 
by dephosphorylating the protein but merely provide evidence to support the theory. 
The  results presented here using the PKC activator T PA  appear  to agree with the 
findings of previous studies (Fine et al., 1988; Cham bers et al., 1990; Bates et al., 
1993). The results o f  our phosphorylation experiments appear to indicate that T PA  
does increase the phosphorylation of P-glycoprotein, although further experiments are 
required to demonstrate a clear stepwise increase in P-glycoprotein phosphorylation 
with increasing doses of TPA. The accumulation studies presented here show that 
T P A  reduces  the in trace llu la r  accum ula t ion  o f  both [^ H d a u n o ru b ic in  and 
[^HJcolcicine in the M DR cell line, CEM /VLB after an incubation time of one hour. 
T P A  a c t iv a te s  P K C  and  th e re fo re  c a u se s  P -g ly c o p r o te in  to b e c o m e  
hypeiphosphorylated. The decrease in dm g accumulation observed in the presence of 
TPA  m ay indicate that either hypeiphosphorylated P-glycoprotein is a more efficient 
drug efflux pum p or that TPA  interferes in som ew ay with the passive diffusion of 
drugs across the cell membrane.
If  the state  o f  phosphorylation does m odulate  the affinity  o f  P-glycoprotein  for 
various substrates, and in turn their transport, one could also predict differential 
effects on the ability of P-glycoprotein antagonists to block transport. Experiments 
dem onstrating a differential effect of calphostin C on P-glycoprotein antagonism by 
verapamil and cyclosporin carried out by Susan Bates’ group are consistent with this. 
T he  group  predic ts  that som e antagonis ts  would he m ore  effective against
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phosphorylated P-glycoprotein and others against dephosphorylated P-glycoprotein. 
T h is  theory  is also cons is ten t  with p rev ious  obse rva t ions  o f  synergy  with 
combinations o f  antagonists, including verapamil and cyclosporin A (Hu et al., 1990) 
and quinine and verapamil (Lehnert et al., 1991). Understanding the basis o f  this 
regula tory  pa thw ay  m ay provide  insight into approaches  for deve lop ing  new 
strategies for reversing drug resistance.
Some of  the published data on the effect of PKC inhibitors on drug transport in M D R 
cells are contradictory and confusing. The PKC activity and other actions of  PKC 
inh ib itors  with respec t  to P -g lycopro te in  (i.e. ability  to b ind d irec tly  to P- 
glycoprotein) must be considered when interpreting existing data.
In summary, this study demonstrates that the light activated fonu of the PKC inhibitor 
calphostin C has a greater effect on the transport o f  cytotoxic drugs in the M D R  cell 
line C E M /V L B  than the non-ligh t activated  form . This  m ay  indica te  that P- 
glycoprotein-m ediated drug efflux is m odulated by phosphorylation. In the case of 
azidopine it appears that this m odulation is a consequence  o f  decreased binding, 
suggesting a m echanism  which involves altered function o f  P-glycoprotein possibly 
due to dephosphorylation of the protein.
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8.1 Introduction
Inevitably during the course of my 3 years of work at the Clinical Oncology and 
Radiotherapeutics Unit in Cambridge the goals of my work have changed. Initially 
the intention was for my studies to centre around the Xenova compounds, 
investigating their activity and mechanism(s) of action in cells which overexpress 
P-glycoprotein. However, as the screen for novel fungal product drug resistance 
modifiers at Xenova proved difficult to set up due to technical problems, I began 
initially to look at the activity of deoxyspergualin, a synthetic derivative of the 
antitumour antibiotic spergualin, in MDR cells. This enabled me to present work at 
meetings and to write my first scientific paper without the constraints of 
confidentiality that are associated with the Xenova compounds. The results of these 
studies are presented in Chapter 3.
While setting up the screen at Xenova, scientists identified derivatives of a natural 
product diketopiperazine which displayed promising activity as resistance 
modifiers. I selected 10 of these compounds as the basis of the structure-activity 
and mechanistic studies presented in Chapter 4.
In parallel with studies on P-glycoprotein-overexpressing cells, I routinely 
examined the activity of the Xenova compounds in the drug sensitive cell line 
L23/P and its MRP-overexpressing sub line L23/R. One of the initial 10 
compounds showed activity as a resistance modifier in the L23/R cell line. 
Scientists at Xenova then produced 10 derivatives of this compound. We then 
examined the resistance modifying activity of these 10 new compounds in MRP- 
overexpressing MDR cells with the aim of finding a potent modifier of MRP- 
mediated MDR. One compound, XR9173, was clearly the most effective amongst 
the 10 compounds. The results of these studies are discussed in Chapter 5. In 
Chapter 6 we went on to examine the possible mechanisms of action of XR9173 by
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examining its effect on calcein (an anionic fluorescent dye) accumulation and 
efflux, intracellular dmg distribution, and GSH levels.
We observed that, at doses where some of the Xenova compounds were effective 
modifiers of P-glycoprotein-mediated MDR, they did not inhibit the photolabelling 
of P-glycoprotein with [^H]azidopine. This may suggest that the mechanism of 
action of these compounds is one other than competitive binding to P-glycoprotein. 
Many groups have shown that P-glycoprotein is phosphorylated and that it is a 
substrate for PKC. We therefore decided to examine the effect of the XR 
compounds on the phosphorylation of P-glycoprotein. Meanwhile scientists at 
Xenova tested the ability of the compounds to inhiibit PKC and found that none of. 
the compounds tested inhibited PKC. A US company called Novascreen also 
tested the compounds in a series of receptor binding assays. In a test for the ability 
of the compounds to inhibit the binding of the phorbol ester PDBu to PKC all the 
compounds were inactive. It is, therefore, unlikely that the Xenova compounds 
effect drug resistance via modifying the phosphorylation status of P-glycoprotein. 
We had, at this stage, already set up the phosphorylation assay. This assay proved 
difficult to set up due to a problem with identifying the most appropriate antibody to 
use for immunoproecipitation. In the initial phase of the assay we chose to test the 
assay by examining the effect of known PKC inhibitors on the phosphorylation of 
P-glycoprotein. We observed a diffence in the effect of light- and dark-exposed 
calphostin C (a specific inhibitor of PKC) and so, despite the fact that it no longer 
seemed appropriate to use the assay to exam ine llie mechanism of action of the 
Xenova compounds, we were able to use it to investigate the role of 
phosphorylation in the function of P-glycoprotein. These studies are described in 
Chapter 7.
This final chapter summaries and highlights the main themes of the results obtained 
in each chapter.
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8.2 The effect of the immunosuppressive, antibiotic,
deoxyspergualin in drug sensitive and resistant cells
8.2.1 The toxicity of polyamines and deoxyspergualin in the presence 
and absence of copper amine oxidase in serum
The study presented in Chapter 3 supports the theory that aminoaldehydes and 
hydrogen peroxide produced by the oxidative deamination of polyamines by copper 
amine oxidases are responsible for the cytotoxicity of polyamines and 
deoxyspergualin in vitro in the presence of bovine serum. Our results using horse 
serum, however, which is low in copper amine oxidase content indicate that this 
may not be the only mechanism of toxicity. In agreement with other groups 
(Kuramochi et al. 1987; Shiro et al., 1992) we found that deoxyspergualin was still 
toxic even in the absence of serum containing copper amine oxidase. Also in 
agreement with the work of Kuramochi et al. (1987) our survival curves indicate 
that in the absence of copper amine oxidase the mechanism of action of 
deoxyspergualin may be cytostatic, and in the presence of copper amine oxidase the 
mechanism of action may be cytotoxic. Nishikawa et al., (1991) showed that 
deoxyspergualin arrested cells in Gq/Gi phase and reduced the cycling cell 
population. The conversion of Go to G i phase and progression to S phase are two 
critical steps for cell proliferation. The cytostatic effect of deoxyspergualin in the 
absence of copper amine oxidase is, therefore, reflected by the drugs' effect on the 
cell cycle.
8.2.2 Deoxyspergualin is not an effective modifier of multidrug 
resistance
Cyclosporin A and FK506 are natural products possessing potent 
immunosuppressive properties and also the ability selectively to restore sensitivity 
to cells with acquired multidrug resistance, We were able to demonstrate that 
deoxyspergualin does not inhibit the ability of pHJazidopine to photolabel P- 
glycoprotein suggesting that it is not a substrate for the protein. This is supported by
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the fact that deoxyspergualin does not reverse the accumulation deficit in 
EMT6/AR1.0 or H69/LX4 cells and that it is not capable of restoring the sensitivity 
of the drug resistant cell lines EMT6/AR1.0 or H69/LX4. These results indicate that 
deoxyspergualin does not modify classical multidrug resistance. The maintenance 
of activity in classical multidrug resistant cells and its potent in vivo anti-tumour 
activity, however, makes deoxyspergualin a promising agent for further 
investigations into its potential clinical use as an anti tumour agent
8.3 Xenova compounds as modifiers of P-glycoprotein-
mediated multidrug resistance
8.3.1 Introduction
In Chapter 4 our aim was to estabish the activity of a group of noval fungal product 
diketopiperazines as modifiers of P-glycoprotein-mediated multidrug resistance and 
to build up stucture activity relationships for the compounds. For those compounds 
that showed activity as resistance modifiers we have attempted to elucidate their 
mechanism of action.
8.3.2 The most effective modifiers of P-glycoprotein mediated
multidrug resistance contain a tetrahydroisoquinoline within 
their structure
All the molecules with the exception of XR9089 contain a diketopiperazine within 
their structures. Compounds containing this structure have previously been shown 
to be active resistance modifiers (Kamei et a i, 1990). Compounds XR9006, 
XR9051, XR9019 and XR9112 were the most active modifiers of P-glycoprotein- 
mediated MDR. These compounds contain a tetiahydroisoquinoline within their 
structures. This makes the molecules protonated at physiological pH and may 
explain why these compound are more efficient modifiers. Similarly other known 
modifiers of MDR, for example verapamil, contain the same functional group. 
Compounds that contain no positive charge at physiological pH , for example
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XR1500, were less effective modifiers of P-glycoprotein-mediated multidrug 
resistance. The two most active compounds, XR9051 and XR9006 have different 
acivities depending on the cytotoxic drug with which they are used in combination. 
The only difference in their structures is that the side chain containing the 
tetrahydroisoquinoline group is in the meta position on the benzylidene ring in 
XR9051 and in the para position in XR9006. This difference in positioning of the 
tetrahydroisoquinoline group will serve to alter the conformation of the molecule 
and may explain why two seemingly similar structures may have different activities.
There are several features of the 10 compounds studied in Chapter 4 which may 
explain their toxicity profile. Positioning of a reactive groups within a structure 
may alter the toxicity of a molecule. For example, XR9006 is more toxic than 
XR9051 and this may be due to the fact that the para positioning of the 
tetrahydroisoquinoline group means that it is more likely to be exposed and 
therefore may be more prone to amide hydrolysis by proteases than in the case of 
XR9051 where the tetrahydroisoquinoline group is in the meta position compared to 
the benzylidene ring. The addition of alkyl groups to the molecule increases the 
lipophilicity. causing the compound to accumulate to high degree in the cell 
membrane. This may affect the integrity (i.e. fluidity and rigidity) of the membrane 
and increase the toxicity of the compound. The most toxic molecule XR9112 has 
an ethyl group rather than a hydrogen of methyl group attached to the nitrogen in 
the 5 position of the diketopiperazine ring. This may explains why XR9112 is more 
potent at lower doses and also why it is toxic at higher doses. The addition of alkyl 
groups also increases the occurrence of steric interactions within the molecule and 
therefore causes changes in molecular conformation. These conformational 
changes may have important implications in terms of toxicity and activity.
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8.4 Xenova compounds as modifiers of MRP-mediated
MDR
8.4.1 Introduction
All the compounds originally tested as modifiers of P-glycoprotein-mediated MDR 
were also tested for their activity as modifiers of MRP-mediated MDR. One of the 
initial test compounds, XR9089, showed activity as a modifier in MRP 
overexpiessing cells. From this compound 10 more were synthesised and of these 
compounds XR9173 was the most efficient modifier of MRP-mediated MDR.
8.4.2 XR9173 is an effective modifier of P-glycoprotein- and MRP- 
mediated multidrug resistance
The data presented in Chapter 5 indicates that XR9173 is an efficient modifier of 
both P-glycoprotein- and MRP-mediated MDR. It is not surprising that the 
compound is an active modifier of P-glycoprotein-mediated MDR as the molecule 
has a tetrahydroisoquinoline group within its structure. The presence of this group 
within a molecule tends to increase its activity as a modifier of P-glycoprotein 
mediated MDR, possibly by increasing the positive charge of the molecule at 
physiological pH.
The possible reasons for the activity of XR9173 in MRP overexpressing cells are 
less straight forward. As MRP is thought to be identical to the GSH conjugate 
transporter (Jedlitschky et al., 1994) and several groups have reported ATP- 
dependent transport of glutathione 5-conjugates it is possible that XR9173 interacts 
with this transport system. Alternatively, it is possible that XR9173 interacts with 
the mechanism(s) involved in the transport of cationic drugs which may well be 
distinct from the GSH conjugate transporter.
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8,4.3 The mechanism of action of XR9173 is unlikely to be competitive
inhibition of the GSH conjugate transporter
As XR9173 is cationic it is unlikely that it exerts its activity in MRP overexpressing 
cells by itself being a substrate for the GSH conjugate/organic anion transporter 
thought to be identical to MRP. It does, however, modulate the accumulation and 
efflux of calcein, an anionic fluorescent dye. The data presented in Chapter 6 
indicate that, like probenecid, XR9173 is able to inhibit the transport of 
daunorubicin and restore partially the calcein accumulation deficit in L23/R cells. It 
may, therefore, have a dual function being able to inhibit (partially) the organic 
anion transporter and also inhibit the, as yet undefined, mechanism responsible for 
causing a decreased intracellular accumulation of cationic cytotoxic drugs. These 
results provide evidence to support the theory that MRP may co-exist with another 
transporter which is able to transport cationic drugs across the membrane and that 
these transport are able in some way to regulate each others' activity.
8.5 The relationship between phosphorylation status and
drug transport in multidrug resistant cells
The study presented in Chapter 7 demonstrates that inhibition of PKC with 
calphostin C decreased the phosphorylation of P-glycoprotein and increased the 
accumulation of daunorubicin and colchicine in the P-glycoprotein overexpressing 
MDR cells, CEM/VLB. The light-activated form of the PKC inhibitor calphostin C 
has a greater effect on the transport of cytotoxic drugs than the non-light-activated 
form. These results together with the observation tlian light-activated calphostin C 
is able to inhibit the ability of pHJazidopine to photolabel P-glycoprotein provide 
evidence that calphostin C causes an alteration in the drug binding capability of P- 
glycoprotein by dephosphorylating the protein. In addition TPA, a PKC activator, 
increases the phosphorylation of P-glycoprotein and reduces intracellular drug 
accumulation in the MDR cell line, CEM/VLB. The decrease in drug accumulation 
observed in the presence of TPA may indicate that either hypeiphosphorylated P-
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glycoprotein is a more efficient drug efflux pump or that TPA interferes in 
someway with the passive diffusion of drugs across the cell membrane. These 
results indicate that P-glycoprotein-mediated drug efflux may be modulated by 
phosphorylation and that this modulation may be a consequence, at least in the case 
of azidopine, of decreased binding. Non-light-activated calphostin C, however, 
significantly increases drug accumulation in the MDR cell line, CEM/VLB, without 
any effect on the phosphorylation status of P-glycoprotein. This may suggest that 
calphostin C is able to reverse MDR by a mechanism other than via inhibition of P- 
glycoprotein phosphorylation via irreve&ible inhibition of PKC. It is important, 
therefore, that the PKC activity and other actions of PKC inhibitors with respect to 
P-glycoprotein (i.e. ability to bind directly to P-glycoprotein) must be considered 
when hypothesising about their mechanism of action with respect to resistance 
modification.
8.6 Concluding remarks
When P-glycoprotein was first described it was thought to be a protein expressed 
only on drug resistant cells and hence potentially that elusive goal of chemotherapy 
the 'tumour-specific' target. When antibodies to P-glycoprotein became available, it 
became clear that the protein was widely expressed in normal tissues (Thiebaut et 
a l,  1978) and hence the ever-present dilemma of cancer chemotherapy- the narrow 
therapeutic ratio- was still present.
The clinical value of modulation of P-glycopiotein activity is still far from proven. 
Sikic (1993) argued that there is no proven case for the use of resistance modifiers 
in standard oncology practice. There is currently major clinical interest in 
lymphomas, leukaemias and myeloma. Modifiers are being combined with 
anthracyclines and vinca alkaloids. Large randomised trials are underway in both 
Europe and North America. Trials in drug resistant solid tumours are generally
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more difficult to design and the results are more difficult to interpret. The limited 
trials carried out so far have been fairly uniformly negative.
For the future there are three major questions that remain unanswered. Firstly, what 
is the constitutive role of P-glycoprotein in many of the normal tissues in which it is 
expressed? Secondly, how is MDRl gene expression controlled on a transcriptional 
level? Finally, How do we measure P-glycoprotein expression in a sufficiently 
precise way to determine its clinical significance? It appears, therefore, that despite 
the fact that research into P-glycoprotein activity has been ongoing for over two 
decades, its clinical values are far from proven.
The other MDR protein discussed in this thesis, the multidrug resistance-associated 
protein (MRP) is still in the early stages of research compared to P-glycoprotein. 
As yet, there is not enough detailed information concerning its expression in 
cancers and normal tissues to determine its significance in MDR. More in vitro 
studies are required to elucidate more potent modifiers of MRP and their potential 
clinical values.
269
amphipathic
R e f e r e n c e s
270
ADEREM, A. (1992) The MARCKS brothers: A family of protein kinase C substrates. 
Cell 71:713-716.
AlHARA, M., AlHARA, Y., SCHMIDT-WOLF, G. et al. (1991) A combined 
approach for purging multidrug resistant leukaemic cells in bone marrow using a 
monoclonal antibody and chemotherapy. Blood 77: 2079-2085.
ALLEY, M.C., SANDURO, D., MONKS, A. et a l  (1988). Feasibility of drug 
screening with panels of human tumour cell lines using a microculture tétrazolium 
assay. Cancer Res. 48: 589-601.
ALMQUIST, K.C., LOE, D.W., HIPFNER, D.R., e ta l  (1995) Characterisation of the 
Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected tumour 
cells. Cancer Res. 55: 102-110.
ALTENBERG, G.A., DIETMER, T.W., GLASS, D.C. et a l  (1994a) P-glycoprotein- 
associated chloride cunents are activated by cell swelling but do not contribute to cell 
volume regulation. Cancer Res. 54: 618-622.
ALTENBERG, G.A., VANOYE, C.G., HANS, E.S. et al. (1994b) Relationship 
between rhodamine 123 transport, cell volume and ion channel function of P- 
glycoprotein. J. Biol. Chem. 269: 7145-7149.
AMBUDKAR, S.V., LELONG, I.H., ZHANG, J. e ta l  (1992) Partial purification and 
reconstitution of the human multidug resistance pump: characteristaion of drug- 
stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89: 8272-8276.
ARCECl, R.J., CROOP, J.M., HORWITZ, S. et a l  (1987) The gene encoding 
multidrug resistance is induced and expressed at high levels during pregnancy in the 
secretory epithelium of the uterus. Proc. Natl. Acad. Sci. USA 85: 4350-4354.
ARCECl, R.J., STEIGLITZ, K., CROOP, J.M. e ta l  (1992) A monoclonal antibody to 
an external epitope of P-glycoprotein. Pro. Am. Assoc. Cancer Res. 33: 2815.
ARRICK, B.A. and NATHAN, C.F. (1984) Glutathione metabolism as a determinant 
of therapeutic efficacy. Cancer Res. 44: 4224-4232.
ASWATHl, S., SlNGHAl, S.S., SRIVASTAVA, S.K. et a l  (1994) Adenosine 
triphosphate-dependent transport of doxorubicin, daunomycin and vinblastine in human 
tissues by a mechanism distinct from P-glycoprotein. J. Clin. Invest 93: 958-965.
AZZARIA, M., SCHUR, E. and GROS, P. (1989) Discrete mutations induced in the 
predicted nucleotide-binding sites of the m drl gene abolish its ability to confer 
multidrug resistance. Mol. Cell Biol. 9: 5289-5297.
BAAS, F., JONGSMA, A.P.M., BROXTERMAN, H.J. et a l  (1990) Non P- 
glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein 
expression during in vitro selection for doxorubicin in a human lung cancer cell line. 
Cancer Res. 50: 5392-5398.
BALLIE-JOHNSON, H., TWENTYMAN, P.R., FOX, N.E. e ta l  (1985) Establishment 
and characterisation of cell lines from patients with lung cancer (predominantly small 
cell carcinoma). Br. J. Cancer 52: 495-504.
271
BARRAND, M.A., HEPPELL-PARTON, A C., WRIGHT K. etal. (1994) A 190kDa 
protein overexpressed in non-P-glycoprotein-containing multidrug resistant cells and its 
relationship to the MRP gene. J. Natl. Cancer Inst. 86: 110-117.
BARRAND, M.A., RHODES, T., CENTER, M.S. et al. (1992) Chemosensitisation 
and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human 
multidrug resistant large cell lung cancer cells expressing a 190k membrane protein 
distinct from P-glycoprotein. Eur. J. Cancer 29A: 408-415.
BARTLETT, N.L., LUM, B.L., FISHER, G.A., et al. (1994) Phase I trial of 
doxorubicin and cyclosporin A as a modulator of multidrug resistance. J. Clin. Oncol. 
12: 835-842.
BATES, S.E. CURRIER, S.J., ALVAREZ, M. et al. (1992) Modulation of P- 
glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistiy 31: 
6366-6372.
BATES, S.E., LEE, J.S.. DICKSTEIN, B. et a l (1993) Differential modulation of P- 
glycoprotein transport by protein kinase inhibition. Biochemistry 32: 9156-9164.
BECK, W.T. CIRTAIN, M.C. (1982) Continued expression of Vinca alkaloid 
resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer 
Res. 42: 184-189.
BECK, W.T. CIRTAIN, M.C., GLOVER, C.J., et a l  (1988) Effects of indole alkaloids 
on multidrug resistance and labelling of P-glycoprotein by a photoaffinity analogue of 
vinblastine. Biochem. Biophys. Res. Comm. 153: 959-966.
BECK, W.T., MUELLER, T.J. and TANZER, L.R. (1979) Altered surface membrane 
glycoproteins in Vinca alkaloid resistant human leukeamia lymphoblasts. Cancer Res. 
39: 2070-2076.
BECK.W.T.J. (1989) Unknotting the complexities of MDR: the involvement of DNA 
topoisomerases in drug action and resistance. Natl. Cancer Inst. 81: 1683-1685.
BELL, D.R., GERLACH, J.H., KARTNER, N. et a l  (1985) Detection of P- 
glycoprotein in ovarian cancer: a marker associated with drug resistance. J. Clin. 
Oncol. 3: 311-315.
BIEDLER, J.L. and RIEHM, H. (1970) Cellular resistance to actinomycin D in Chinese 
hamster cell in vitro: Cross resistance, radioautographic and cytogenetic studies. 
Cancer Res. 30: 1174-1184.
BINASHI, M., SUPINO, R., GAMBETTA, R.A. et a l  (1995) MRP gene 
overexpression in a human doxorubicin-resistant SCLC cell line. Alterations in cellular 
pharmacokinetics and in patterns of cross resistance. Int. J. Cancer 62: 84-89.
BJORNSTI, M.A., BENEDETTI, P., VIGILANTI, G.A. et a l  (1989) Expression of 
human topoisomerase I in yeast cells lacking yeast topoisomerase I: restoration of 
sensitivity of the cells to the antitumour drug camptothecin. Cancer Res. 49: 6318-23.
272
BLACK, S.M., BEGGS, J.D., HAYES, J.p . et al. (1990) Expression of human 
glutathione ,5-transferase in Saccharomyces cerevisiae confers resistance to the 
anticancer di*ugs Adriamycin and chlorambucil. Biochem. J. 268: 309-315
BLUMBERG, P.M. (1980) In viüo studies on the mode of action of the phorbol esters, 
potent tumour promotors. CriL Rev. Toxicol. 8 : 153-234.
BOOTE, D.J., DENNIS, I.E., TWENTYMAN, P.R. et al. (1994) A phase I study of 
intravenous SDZ-PSC 833 in patients with advanced cancer. Ann. Oncol. 5: 159.
BRADLEY, G., GEORGES, E., LING, V. et al. (1990) Sex dependent and 
independent expression of the P-glycoprotein isoforms in Chinese hamster. J. Cell 
Physiol. 145: 398-408.
BROXTERMAN, H.J., PINEDO, H.M., KUIPER, C.M. eta l. (1988) Induction by 
verapamil of a rapid increase in ATP consumption in multidrug resistant tumour cells. 
FASEB J. 2: 2278-2282.
BROXTERMAN. H J.. KUIPER, C.M., SCHUURUIS, G.J. eta l. (1994) Analysis of 
P-glycoprotein and non-P-glycoprotein multidrug resistance in acute myeloid 
leiScaemia. Proc. Am. Assoc. Cancer Res. 35: 2075.
BROXTERMAN, H.J., PINEDO, H.M., SCHUURUIS, G.J. etal. (1990) Cyclosporin 
A and verapamil have different effects on energy metabolism in multidrug resistant 
tumour cells. Br. J. Cancer 62: 85-88.
BRUCE, W.R., MEEKER, B.E., POWER, W.E. etal. (1969) Comparison of the dose 
and time-survival curves for normal and hematopoietic and lymphoma colony-forming 
cells exposed to vinblastine, vincristine, arabinosylcytosine and amethopterin. J. Natl. 
Cancer Inst 42:1015-1023.
BRUGGEMAN, E.P, CURRIER, S.J., GOTTESMAN, M.M. et a l  (1992) 
Characterisation of the azidopine and vinblastine binding site of P-glycoprotein. J. 
Biol. Chem. 267: 21020-21026.
BRUNS, R.F., MILLER, F.D., MERRIMAN, R.L. eta l. (1991) Inhibition of protein 
kinase C by calphostin C is light dependent Biochem. Biophys. Res. Commun. 176: 
288-293.
BUGG, B.Y., DANKS, M.K., BECK, W.T. et al. (1991) Expression of a mutant DNA 
topoisomerase II in CCRF-CEM human leukaemic cells selected for resistance to 
teniposide. Pro. Natl. Acad. Sci. USA 8 8 : 7654-7658.
BURGER, H., NOOTER, K., VAN WINGERDEN, R.G. et al. (1995) Expression of 
the multidrug resistance-associated protein (MRP) in hematological malignancies. 
Leukaemia 9: 546 (abstract).
BURGER, H., NOOTER, K., ZAMAN, G.J.R. et al. (1994) Expression of the 
multidrug resistance-associeted protein (MRP) in acute and chronic leukaemia. 
Leukaemia 6 : 990-997.
CALLAN, J.M., BARKER, E., SIMMERS, R.N. et al. (1987) Localisation of the 
human multiple drug resistance gene, MDRl to 7q 21.1. Hum. Genet. 77: 142-144.
273
CAMPOS, L., SABIDO, O., ROUAULT, J-P. etal. (1994) Effects of BCL-2 antisense 
oligodeoxynucleotides on in vitro proliferation and survival of normal marrow 
progenitor and leukaemic cells. Blood 84: 595-600.
CANDELL, J., VALLE, V. and SOLER, M. (1979) Acute intoxication with verapamil. 
Chest 75: 200-201.
CARLSEN, S.A., TILL, I.E. and LING, V. (1977) Modulation of drug permeability in 
Chinese hamster ovary cells: possible role for phosphorylation of the surface 
glycoproteins. Biochim. Biophys. Acta. 467: 236.
CENCIARELLI, C., CURNER, S.J., WILLINGHAM, M.C. et al. (1991) 
Characterisation by somatic cell genetics of a monoclonal antibody to the MDR 1 g&nt 
product (P-glycoprotein): determination of P-glycoprotein expression in multidrug 
resistant KB and CEM cell variants. Int. J. Cancer 47: 533-43.
CENTER, M.S. (1983) Evidence that Adriamycin resistant Chinese hamster lung cells 
is regulated by phosphorylation of a plasma membrane glycoprotein. Biochem. 
Biophys. Res. Commun, 115:159.
CENTER, M.S. (1985) Mechanisms regulating cell resistance to Adriamycin: evidence 
that drug accumulation in resistant cells is modulated by phosphorylation of a plasma 
membrane glycoprotein. Biochem. Pharmacol. 34: 1471-1476.
CHABNER, B.A. (1990) Clinical strategies for cancer treatment: the role of drugs. In: 
Cancer chemotherapy: principles and practice (Chabner, B.A. and Collins, J.M. Eds) 
Lippincott company, Philadelphia ppl-15.
CHAMBERS, T.C., CHALIKONDA, I. and EILON, G. (1990a) Correlation of protein 
kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation 
in multidrug resistant human KB cells. Biochem. Biophys. Res. Commun. 169: 253- 
259.
CHAMBERS, T.C., MCAVOY, E.M., JACOBS, J.W. et al. (1990b) Protein Kinase C 
phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J. 
Biol. Chem. 265: 7679-7686.
CHAMBERS, T.C., ZHENG, B. and KUO, J.P. (1992) Regulation by phorbol ester 
and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), 
of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug 
resistant human KB cells. Mol. Pharmacol. 41: 1008-1015.
CHAN, H.S.I., HADDAD, G., THORNER, P.S. (1990) Immunohistochemical detection 
of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. 
Oncol. 8 : 689-704.
CHAUDHARY, P.M. and RONINSON, LB (1991) Expression and activity of P- 
glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 6 6 : 85- 
94.
CHAUDHARY, P.M., MERCHETNER, E.B. and RONINSON, I.B. (1992) Expression 
and activity of the multidrug resistance P glycoprotein in human peripheral blood. 
Blood 80: 1-5.
274
CHAUFFERT, B., MARTIN, M., HAMMANN, A. etal. (1986) Amiodarone-induced 
enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer 
cells in vitro and in vivo. Cancer Res. 46: 825-830.
CHEN, C.J., CHIN, J.E., UEDA, K. et al. (1986) Internal duplication and homology 
with bacterial transport proteins in the MDRl (P-glycoprotein) gene from MDR human 
cells. Cell 47: 381-389.
CHIN, K-V., UEDA, K., PASTAN, I. et al. (1992) Modulation of activity of the 
promoter of the human MDRl gene by ras and p53. Science 255: 459-462.
CHOI, K., FROMMEL, T.O., STERN, R.K. et al. (1991) Multidrug resistance after 
retroviral transfer of the human MDRl gene correlates with P-glycoprotein density in 
the plasma membrane and is not affected by cytotoxic selection. Proc. Natl. Acad. Sci. 
USA 8 8 : 7386-7390.
COLE, S.P.C. (1992b) The MERCK Frosst award: Multidmg resistance in small cell 
lung cancer. Can. J. Physiol. Pharmacol. 70: 313-329.
COLE, S.P.C., BHARDWAJ, G., GERLACH, J.Hi etal. (1992a) Overexpression of a 
transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 
1650-1654.
COLE, S.P.C., SPARKS, K.E., FRASER, K. et al. (1994) Pharmacological 
characterisation of multidrug resistance MRP-tiansfected human tumour cells. Cancer 
Res. 54: 5902-5910. .
CORDON-CARDO, C., O’BRIEN, J.P., CASALS, D. et al. (1989) Multidrug 
resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier 
sites. Pro. Natl. Acad. Sci. USA. 8 6 : 695-698.
CORNWELL, M.M., PASTAN, I. and GOTTESMAN, M.M. (1987) Certain calcium 
channel blockers bind specifically to multidrug resistant human KB carcinoma 
membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262: 
2166-2170.
COWAN, K.H., BATIST, G. and TUPULA, A. (1986) Similar biochemical changes 
associated with multidrug resistance in human breast cancer cells and carcinogen- 
induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. USA 83: 9328-9332.
DALTON, W.S., GROGAN, T.M., MELTZER, P.S. et al. (1989) Drug resistance in 
multiple myeloma and non-Hodkin's lymphoma: Detection of P-glycoprotein and 
potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7: 
415-424.
DAMIANI, D., MICHIELI, M., MICHELUTTI, A. et al. (1993) D-Verapamil 
downregulates pl70-associated resistance to doxorubicin, daunorubicin and idarubicin. 
Anticancer Drugs 4: 173-180.
DANKS, M.K., YALOWICH, J.C. and BECK, W.T. (1987) Atypical multidrug 
resistance in a human leukaemic cell line selected for resistance to teniposide. Cancer 
Res. 47: 1297.
275
DANO, K. (1973) Active outward transport of daunomycin in Erlich ascites tumour 
cells. Biochim. Biophys. Acta. 323: 466-483.
DE JONG, S., ZIJLSTRA, J.G., DE VRIES, E.G. et al. (1990) Reduced DNA 
topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin- 
resistant human small cell lung carcinoma cell line. Cancer Res. 50: 304-309.
DEFFIE, A.M., BATRA, J.K., GOLDENBERG, G.J. et al. (1989) Direct correlation 
between DNA topoisomerase activity and cytotoxicity in Adriamycin-sensitive and 
resistant P388 leukaemia cell lines. Cancer Res. 49: 58-62.
DEGREGORIO, M.W., FORD, J.M., BENZ, C.C. et al. (1989) Toremifene: 
Pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J. Clin. 
Oncol. 7: 1359-1364.
DETHMERS, J.K. and MEISTER, A. (1981) Glutathione export by human lymphoid 
cells; depletion of glutathione by inhibition of its synthesis decreases export and 
increases sensitivity to iiTadiation. Proc. Natl. Acad. Sci. USA 78: 7492-96.
DEVAULT, A., GROS, P. (1990) Two members of the mouse mdr gene family confer 
multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 
10: 1652-1663.
DEVINE, S.E., LING, V., MELERA, P.W. et al. (1992) Amino acid substitutions in 
the sixth transmembrane domain of P-glycoprotein. Proc. Natl. Acad. Sci. USA 89: 
4564-4568.
DONG, Y-J., CHEN, G., DURAN, G.E.e/ al. (1994) Volume-associated chloride 
current is not related to P-glycoprotein overexpression. Cancer Res. 54: 5029-5032.
DUSRE, L., RAJAGOPALAN, S., ELIOT, H.M. et al. (1990) DNA interstrand cross­
link and free radical formation in the human multidrug resistant cell line from mitoycin 
C and its analogues. Cancer Res. 50: 648-652.
ENDICOTT, J.A., LING, V. (1989) The biochemistry of P-glycoprotein-mediated 
multidrug resistance. Ann. Rev. Biochem. 58: 137-171.
ENG, W.K., MCCABE, F.L., TAN, K.B. et al. (1990) Development of a stable 
camptothecin-resistant subline of P388 leukeamia with reduced topoisomerase content. 
Mol. Pharmacol. 38: 471-480.
EPSTEIN, D.L. (1971) Introduction to discussion of lens and red cell sulfhydryl 
membrane groups. Exp. Eye. R es.ll: 351-355.
FELLER, N., KUIPER, C.M., LANKELMA, J. etal. (1995) Functional detection of 
MDR/P170 and MRP/P 190 mediated multidrug resistance in tumour cells by flow 
cytometry. Br. J. Cancer 72: in press
FERNANDES, D.J., DANKS, M.K. and BECK, W.T. (1990) Decreased nuclear matrix 
DNA topoisomerase II in human leukaemia cells resistant to VM-26 and m-AMSA. 
Biochemistry 29: 4235-4241.
276
FERNANDES, D.J., SMITH-NANNI, C., FAFF, M.T. et al. (1988) Effects of 
antileukaemic agents on the nuclear matrix-bound DNA replication in CCRF-CEM 
leukaemia cells. Cancer Res. 48: 1850-1855.
FINE, R.L., PATEL, J. and CHABNER, B.A. (1988) Phorbol esters induce multidrug 
resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA 85: 582-586.
FISHER, G.A., BARTLETT, N.L., LUM, B.L., etal. (1994a) Phase I trial with taxol 
(T) with high dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR). 
Proc. Am. Soc. Clin. Oncol. 13: 144.
FISHER, G.A. HAUSDORFF, J., LUM, B.L., et al (1994b) Phase I trial of etoposide 
with the cyclosporine, PSC 833, a modulator of multidrug resistance (MDR). Proc. 
Am. Soc. Clin. Oncol. 13: 143.
FISHER, T.C., MILNER, A.E., GREGORY, C.D. etal. (1993) bcl-2 modulation of 
apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent 
of classical resistance pathways. Cancer Res. 53: 3321-3326.
FITZGERALD, D.J., WILLINGHAM, M.C., CARDARELLI, C O. et al. (1987) A 
monoclonal antibody- Pseudomonas toxin conjugate that specifically kills multidrug 
resistant cells. Proc. Natl. Acad. Sci. USA 84:4288-4292
FLEMMING, G.F., AMATO, J.M., AGREST, M. eta l. (1992) Megestrol acetate 
reverses multidmg resistance and interacts with P-glycoprotein. Cancer Chemother. 
Pharmacol. 29: 445-449.
FLENS, M.J., IZQUIRDO, M.A. and SCHEFFER, G.L.(1994) Immunochemical 
detection of multidrug resistance-associated protein MRP in human and multidmg 
resistant tumour cells by monoclonal antibodies. Cancer Res. 54: 4557-4563.
FOJO, A.T., AKIYAMA, S., GOTTESMAN, M.M. et a l  (1985) Reduced drug 
accumulation in multiple drug resistant human KB carcinoma cell lines. Cancer Res. 
45: 3002-3007.
FOJO, A.T., UEDA, K. SLAMON, D.J. et al. (1987) Expression of a multidmg 
resistance gene in human tumours and tissues. Proc. Natl. Acad. Sci. USA 84: 265-269.
FOLEY, G., LAZARUS, H., FARBER, S. etal. (1965) Continuous culture of human 
lymphoblasts from peripheral blood of a child with acute leukaemia. Cancer 18: 522- 
529.
FORD, J.M. and HAIT, W.N. (1990) Pharmacology of dmgs that alter multidmg 
resistance in cancer. Pharmacol. Rev. 42:156-199.
FORD, J.M., BRUGGEMAN, E., PASTAN, I. etal. (1990) Cellular and biochemical 
characterisation of thioxanthenes for reversal of mulitdrug resistance in human and 
murine cell lines. Cancer Res. 50: 1748-1757.
FORD, J.M., PROZIALECK, W.C., HAIT, W.N. (1989) Structural features 
determining activity of phenothiazines and related drugs for inhibition of cell growth 
and  reversa l of m u ltid ru g  resis tan ce . M ol. PhaiTnacol. 35: 105-115.
277
FOSTER, B.J., GROTZINGER, K.R., MCKOY, W.M. etal. (1988) Modulation of 
induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen 
or perhexiline malleate. Cancer Chemother. Pharmacol. 22: 147-152.
GAVERIAUX, C , BOESCH, B., JACHEZ, B. et al. (1991) PSC-833, a non- 
immunosuppressive cyclosporin analogue, is a potent multidrug resistance modifier. J. 
Cell Pharmacol. 2: 225-234.
GEKELER, V., BOERE, R., ISE, W. et al. (1995a) The specific bisindolymalemide 
PKC-inhibitor GF 109203X efficiently modulates MRP associated MDR. Biochem. 
Biophys. Res. Comm. 206: 119-126.
GEKELER, V., ISE, W., SANDERS, K.H. et al. (1995b) The leukotriene receptor 
antagonist MK571 specifically modulates MRP associated multidrug resistance. 
Biochem. Biophys. Res. Comm. 208: 345-352.
GEORGES, E., BRADLEY, G., eta l. (1990) Detection of P-glycoprotein-specific 
isoforms by gene-spccific monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87: 152- 
156.
GERLACH, J.H., ENDICOTT, J.A., JURANKA, P.F. et al. (1986) Homology between 
P-glycoprotein and a bacterial haemolysin transport protein suggests a model for 
multidrug resistance. Nature 324:485-489.
GERMANN, U.A., WILLINGHAM, M.C., PASTAN, I. et al. (1994) Expression of the 
human multidrug resistance transporter in insect cells by a recombinant baculovirus. 
Biochemistry 29: 2295-2303.
GESCHER, A. (1994) Exploiting tumour biology: novel approches to cancer therapy 
ESBP Otzenbausen Conference, 6 -8 th September. Ann. Oncol. 5: 205-207.
GESCHER, A. (1992) Towards selective pharmacological modulation of protein 
kinase C - opportunities for the development of novel antineoplastic agents. Br. J. 
Cancer 6 6 : 10-19.
GESCHER, A. and DALE, I, L. (1989) Protein kinase C- a novel target for rational 
anticancer drug design. Anticancer Drug Design 4:93-105.
GESSNER, T., VAUGHAN, L.A., BEEHLER, B.C. et al. (1990) Elevated pentose 
cycle and glucoronyltiansferase in daunorubicin-resisitant-388 cells. Cancer Res. 50: 
3921-3927.
GIACCIA, AT., LEWIS, A.D., DENKO, N.C. e ta l  (1991) The hypersensitivity of the 
Chinese hamster ovary variant BL-10 to bleomycin killing is due to a lack of 
glutathione S-tiansferase alpha activity. Cancer Res. 51: 4463-4469.
GILL, D. G., HYDE, S.C., HIGGINS, C. F. et a l  (1992) Separation of drug transport 
and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 
72: 23-32.
GILMAN, A. (1963) The initial clinical trial of nitrogen mustard. Am. J. Surg. 105: 
574-578.
278
GOLDBERG, H., LING, V., WONG, P.Y. et al. (1988) Reduced cyclosporin 
accumulation in multidrug resistant cells. Biochem. Biophys. Res. Commun. 152: 552- 
558.
GOLDIE, J.H., KRYSTAL, G., HARTLEY, D. et al. (1980) A methotrexate 
insensitive variant of folate reductase present in two lines of methotrexate-resistant 
L5178Y cells. Eur. J. Cancer. 16: 1539-1546.
GOLLAPUDI, S., TRAN, B., SANGHA, S. et al. (1995) Probenecid reverses 
daunorubicin resistance in multidrug resistant tumour HL60/AR and H69/AR cell lines 
that overexpress multidrug resistance-associated protein. Proc. Am. Assoc. Cancer. 
Res. 36: 345.
GOSLAND, M.P., LUM, B.L., SIKIC, B.I. et al. (1989) Reversal by Cefopefazone of 
resistance to etoposide, doxorubicin, and vinblastiine in multidrug resistant human 
sarcoma cells. Cancer Res. 49: 6901-6905.
GOTTESMAN, M.M. and PASTAN, 1.(1993) Biochemistry of multidrug resistance 
mediated by the multidrug transporter. Annu. Rev. Biochem, 62: 385-427.
GRANT, C.E., VALDIMARSSON, G., HIPFNER, D.R., et al (1994) Overexpression 
of multidrug resistance associated protein (MRP) increases resistance to natural product 
drugs. Cancer Res. 54: 357-361.
GREENBERGER, L.M. (1993) Major photoaffinity diaig labelling sites for iodaryl 
azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, 
transmembrane domains 6 and 12. J.Biol. Chem. 268: 11417-11425
GROS, P., BEN NERAIH, Y., CROOP, J. (1986a) Isolation and expression of a cDNA 
(mdr) tiiat confers multidmg resistance. Nature 323: 728-731.
GROS, P., CROOP, J. and HOUSMAN, D. (1986c) Mammalian multidrug resistance 
gene: complete cDNA sequence indicates strong homology to bacterial transport 
proteins. Cell 47: 371-380.
GROS, P., DHIR, R., CROOP, J. et al. (1991) A single amino acid substitution 
strongly modulates the activity and substrate specificity of the mouse mdrl and mdr3 
drug efflux pumps. Proc. Natl. Acad. Sci. USA 8 8 : 7289-7293.
GROS, P., FALLOWS, D.A., CROOP, J. etal. (1986b) Chromosome-mediated gene 
transfer of multidrug resistance. Mol. Cell Biol. 6 : 3785-3790.
GROS, P., RAYMOND, M., BELL, J. et al. (1988) Cloning and characteristaion of a 
second member of the mouse mdr gene family. Mol. Cell Biol. 8 : 2770-2778.
GUILD, B.C., MULLIGAN, R.C., GROS, P. et al. (1988) Retioviral transfer of a 
murine cDNA for multidmg resistance confers pleotropic drug reistance to cells without 
prior drug selection. Proc. Natl. Acad. Sci. USA 85: 1595-1599.
GUPTA, R.S., GUPTA, R., ENG, B. et al. (1988) Camptothecin-resistant mutants of 
Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer 
Res. 48: 7404-7410.
279
GUPTA, S., PATEL, K., SINGH, H. et al (1994) Effect of calphostin C (PKC 
inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug 
resistance possibly via P-glycoprotein. Cancer Letters 76: 139-145.
HAIT, W.N., GESMONDE, J.F., MURREN, J.R. et al. (1993) Terfenadine (Seldane): 
A new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. 
Pharmacol. 45: 401-406.
HAIT, W.N., STEIN, J.M., KOLETSKY, A.J. etal. (1989) Activity of cyclosporin A 
and a non-immunosuppressive cyclosporin on multidrug resistant leukeamic cell lines. 
Cancer Commun. 1: 35-43.
HAMADA, H. and TSURUO, T. (1986) Functional role for the 170-180 kDa 
glycoprotein specific to drug resistant tumour cells as revealed by monoclonal 
antibodies. Proc. Natl. Acad: Sci. USA 83: 7785-7789.
HAMADA, H. and TSURUO, T. (1988) Purification of the 170- to 180- kDa 
membrane glycoprotein associated with multidrug resistance: 170- to 180- kDa 
membrane glycoprotein is an ATPase. J, Biol. Chem. 263: 1454-1458.
HAMADA, H., HAGIWARA, K-L, NAKAJIMA, T et al. (1987) Phosphorylation of 
the Mr 170,000 to 180,000 glycoprotein specific to multidrug resistant tumour cells: 
Effects of verapamil. Trifluoperazine and phorbol esters. Cancer Res. 47: 2860-2865.
HAMILTON, T., O'DWYER, P., YOUNG, R. et al. (1990) Phase I üial of buthionine 
sulphoximine (BSO) plus melphalan (l-P A M ) in patients with advanced cancer. Proc. 
Meet. Am. Soc. Clin. Oncol. 9: A281.
HARKER, W.G., SLADE, D.L., DALTON, W.S. etal. (1989) Multidrug resistance in 
mitoxantrone-selected HL-60 leukaemia cells in the absence of P-glycoprotein 
overexpression. Cancer Res. 49: 4542-4549.
HART, S.M., GANESHAGURU, K. HOFFBRAD, A.V. et al. (1994) Expression of 
multidrug resistance-associated protein (MRP) in acute leukaemia. Leukaemia 8 : 2163- 
68.
HART, S.M., GANESHAGURU, K. ROBINSON, A.V. etal. (1995) Expression of the 
multidrug resistance (MDRl) and multidrug resistance-associated protein (MRP) genes 
in chronic lymphocytic leukaemia (CLL). Leukaemia 9: 535 (abstract).
HERZOG, C.G., TREPEL, J.B., MICKLEY, L.A. et al. (1992) Various methods of 
analysis of mTr-i/P-glycoprotein in human colon cancer cell lines. J. Natl. Cancer Inst. 
84:711-716.
HIGGINS, C.F. (1992a) ABC transporters from microorganism to man. Annu. Rev. 
Cell Biol. 8 : 67-113.
HIGGINS, C.F. and GOTTESMAN, M.M. (1992b) Is the multidrug transporter a 
flippase? Trends in Biol. Sci.17: 18-21.
HINDS, M., DEISSEROTH, K., MAYES, J. et al. (1991) Identification of a point 
mutation in the topoisomerase II gone from a human leukaemia cell line containing an 
amsacrine-resistant form of topoisomerase II. Cancer Res. 51: 4729-4731.
280
HIPFNER, D.R., GAULDIE, S.D., DEELEY, R.G. et al. (1994) Detection of the 
M rl90 000 multidrug resistance protein, MRP, with antibodies. Cancer Res. 54: 5788- 
5792.
HOFSI, E. and NISSEN-MEYER, J. (1989) Effect of erythromycin and tumour 
necrosis factor on the drug resistance of multidrug resistant cells: Reversal of drug 
resistance by erythromycin. Int. J. Cancer 43: 520-525.
HOLLO, Z., HOMOLYA, L., DA VIA, C.W. et al. (1994) Calcein accumulation as a 
fluorometric functional assay of the multidrug transporter. Biochim. et Biophys. Acta. 
1191: 384-388.
HOMOLYA, L., HOLLO, Z., GERMANN, U.A. eta l. (1993) Fluorescent cellular 
indicators are extmded by the multidrug resistance protein. J. Biol. Chem. 268: 21493- 
21496.
HORIO, M., GOTTESMAN, M.M. and PASTAN, I. (1988) ATP-denendent transport 
of vinblastine in vesicles from human multidrug resistant cells. Proc. Natl. Acad. Sci. 
USA 85: 3580-3584.
HSU, S.I., LOTHSTEIN, L., HORWITZ, S.B. etal. (1989) Differential overexpression 
of three mdr gene family members in multidrug resistant J774.2 mouse cells. Evidence 
that distinct P-glycoprotein precursors are encoded by unique mdr genes. J. Biol. 
Chem. 264: 12053-12062.
HU, X.F., MARTIN, T.J., BELL, D.R. et al. (1990) Combined use of cyclosporin A 
and verapamil in modulating multidrug resistance in human leukaemia cells. Cancer 
Res. 50: 2953-2957.
HUGHES, A.L. (1994) Evolution of the ATP-binding-cassette transmembrane 
transporters in vertebrates. Mol. Biol. Evol. 11: 899-915.
HYAFIL, R , VERGELY, C., DU VIGNAUD, P. et al. (1993) In vitro and in vivo 
reversal of multidrug resistance by GF120918, an acridonecaboxamide derivative. 
Cancer Res. 53: 4595-4602.
IN ABU, M. and JOHNSON, R.K. (1978) Uptake and retention of adriamycin and 
daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. 
Biochem. Pharmacol. 27: 2123-2130.
ISHIZUKA, M., MASUDA, T., MIZUTANI, S. etal. (1986) Induction of antitumour 
resistance to mouse leukemia L I210 by spergualins. J Antibiotics (Tokyo) 39: 1736- 
1743.
IZQUIERDO, M.A. (1994) Prognostic significance of the drug i'esistance-associated 
protein LRP in ovarian carcinoma. Ann. Oncol. 5: 98.
JACHEZ, B., BOESCH D, GRASSBERGER, M.A. et al. (1993) Reversion of P- 
glycoprotein-mediated multidrug resistance of cancer cells by FK506 derivatives. 
Anticancer Drugs 4: 223-29.
JACHEZ, B., NORDMANN, R., LOOR, F. et al. (1993) Restoration of taxol 
sensitivity of multidrug resistant cells by the cyclosporine SDZ PSC 833 and the 
cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst. 85: 478
281
JAFFREZOU, J.P., HERBERT, J.M., LEVADE, T. et al. (1991) Reversal of multidrug 
resistance by calcium channel blockers SR33557 without photoaffinity labelling of P- 
glycoprotein. J. Biol. Chem. 266: 19858-19864.
JAKENS, S. (1992) In: Lester DS and Epand RM (Eds) Protein Kinase C: Current 
consepts and future perspectives. Ellis Hoi'wood, Chichester p237 254.
JEDLITSCHKY, G., LEIER, I., BUCHOLZ, U. etal. (1994) ATP-dependent transport 
of glutathione-S-conjugates by the multidrug resistance-associated protein. Cancer Res. 
54: 4833-4836.
JOHNSTONE, E C., CROW, T.J., FRITH, C.D. et al. (1978) Mechanism of 
antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1: 848-851.
JONES, R.D., KERR, D.J., HARNETT, A.N. et al. (1990) A pilot study of quinidine 
and epirubicin in the treatment of adanced breast cancer. Br. J. Cancer 62: 133-135.
JULIANO, R.L. and LING, V. (1976) A surface glycoprotein modulating drug 
permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta. 455: 
152-162.
KAJIJI, S., TALBOT, T., GRIZZUTI, K. et al. (1993) Functional analysis of P- 
glycoprotein mutants identities predicted transmembrane domain 11 as a putative drug 
binding site. Biochemistry 32: 4185-4194.
KAMEI, H., OKA, M., HAMAGISHI, Y. et al. (1990) Piperafizines A and B, 
potentiators of cytotoxicity of vincristine. J. Anibiotics (Japan) Vol.XLIII, 8 : 1018- 
1020.
KANE, D.J., SARAFIN, T.A., AUTON, S. etal. (1993) Bcl-2 inhibition of neural cell 
death: Decreased generation of reactive oxygen species. Science 262: 1274-1276.
KARTNER, N. EVERNDEN-PORELLE, D., BRADLEY, G. etal. (1985) Detection of 
P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature. 316: 
820-823.
KAVALLARIS, M. MADAFIGLIO, J., NORRIS, M.D. et al. (1993) Resistance to 
tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug 
resistant cells. Biochem. Biophys. Res. Commun. 190: 79-85.
KEIZER, H.G.', SCHUUHRUIS, G.J., BROXTERMAN, H.J. etal. (1989) Correlation 
of multidrug resistance with decreased drug accumulation, altered subcellular drug 
distribution and increased P-glycoprotein expression in cultured SW-1573 human lung 
tumour cells. Cancer Res. 59: 2988-2993.
KELLEY, S.L., BASU, A., TEICHER, B.A. et al. (1988) Overexpression of 
metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815.
KESSEL, D. and WILBERDING, C. (1985) Anthracycline resistance in P388 murine 
leukaemia and its circumvention by calcium antagonists. Cancer Res. 45: 1687-1691.
282
KIOKA, N.J., TSUBOTA, Y., KAKEHI, T. et al. (1990) P-glycoprotein gene (MDRl) 
cDNA from human adrenal: normal P-glycoprotein carries Gly 18T5 with an altered 
pattern of cross resistance. Biochem. Biophys. Res. Commun. 162: 224-231.
KJELDSEN, E., BONVEN, B.J., ANDOH, T. (1988) Characterisation of a 
camptothecin-resistant human DNA topoisomerase I. J. Biol. Chem. 263: 3912-3916.
KLOKE, O. and OSIEKA, R. (1985) Interaction of cyclosporin A with antineoplastic 
agents. Klinische Wochenschrift 63: 1081-1082.
KOBAYASHI, E., NAKANO, H., MORIMOTO, M. et al (1989) Calphostin C (UCN 
1028C) a novel microbial compound is a highly potent and specific inhibitor of protein 
kinase C. Biochem. Biophys. Res. Commun. 159: 548-553.
KRAMER, R.A., ZAHKER, J., KIM, G. et al. (1988) Role of the glutathione redox 
cycle in acquired and de novo multidrug resistance. Science 241: 694-697.
KRISHNAMACHARY, N. and CENTER, M. (1993) The MRP gene associated with a 
non-P-glycoprotein multidrug resistance encodes a 190kDa membrane bound 
glycoprotein. Cancer Res. 53: 3658-3661.
KUNIMOTO, S., MIURA, K., IINUMA, H. etal. (1985) Cytotoxicity of spergualin 
and copper amine oxidase activity in medium. J Antibiotics (Tokyo) 38: 899-903.
KURAMOCHI, H., HIRATSUKA, M., NAGAMINE, S.gr al. (1987) The 
antiproliferative action of deoxyspergualin is different from tliat induced by copper 
amine oxidase. J Antibiotics 4: 234-238.
LATHAM, B., EDWARDS, D.P., DRESSLER, L.G. et al. (1985) Immunological 
detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype. 
Cancer Res 45: 5064-5069.
LEHNERT, M., DALTON, W.S., ROE, D. et al. (1991) Synergistic inhibition by 
verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human 
myeloma cell line model. Blood 77: 348-354.
LEIER, I., JEDLITSCHKY, G., BUCHOLZ, U. et al. (1994a) Characterisation of the 
ATP-dependent leukotriene C4 export canier in mastocytoma cells. Eur. J. Biochem. 
220: 599-606.
LEIER, I., JEDLITSCHKY, G., BUCHOLZ, U. et al. (1994b) The MRP gene encodes 
an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. 
J. Biol. Chem. 269: 27807-27810.
LING, V. and THOMPSON, L.H. (1974) Reduced permeability in CHO cells as a 
mechanism of resistance to colchicine. J. Cell. Physiol. 83: 103-16.
LINN, S., VAN KALKEN, C., VAN TELLINGTON, O. et al. (1994) Clinical and 
pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J. 
Clin. Oncol. 4: 812-19
LIST, A.F. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resisfance 
modifier in acute leukaemia. J. Clin. Oncology. 11: 1652-1660.
283
LUTZKY. J., ASTOR, M.B., TAUB, R.N. et al. (1989) Role of glutathione and 
dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 49: 4120- 
4125.
LUZ, J.G., WEI, L-Y., BASU, S. eta l. (1994) Transfection of M D Rl inhibits Na+- 
independent ClV'HCOg exchange in Chinese hamster ovary cells. Biochemistry 33: 
7239-7249.
MA, L., KRISHNAMACHARY, N. and CENTER, M. (1995) Phosphorylation of the 
multidrug resistance associated gene encoded protein P190. Biochemistry 43: 3338- 
3343
MA, L., MARQUARDT, D., TAKEMOTO, L. etal. (1991) Analysis of P-glycoprotein 
phosphoiylation in HL60 cells isolated for resistance to vincristine. J. Biol. Chem. 266: 
5593-5599.
MARQUARDT, D. and CENTER, M.S. (1990) Mechanisms of multidrug resistance in 
HL60 cells: detection of resistanee-ossociated proteins with antibodies against synthetic 
peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res. 50: 
1426-1430.
MARX, J. (1993) How p53 suppresses growth. Science 262: 1644-1645.
MASAAKI, I., TORU, M., SHIGETOSHI, M. et al. (1986) Induction of Antitumour 
Resistance to Mouse Leukemia LI 210 by Spergualins. J. Antibiotics 39: 1736-1743
MASUDA, H., TANAKA, T., MATSUDA, H. (1990) Increased removal of DNA- 
bound platinum in a human ovarian cancer cell line resistant to cis- 
diamminedichloroplatinum (n). Cancer Res. 50: 1863-1866.
MAURO, F. and MADOC-JONES, H. (1970) Age response of cultured mammalian 
cells to cytotoxic drugs. Cancer Res. 30: 1397-1408.
MCGRATH, J.P., VARSHAVSKY, A. (1989) The yeast STE6 gene encodes a 
homologue of the mammalian multidrug resistance P-glycoprotein. Nature 340: 400 
404.
MCGRATH, T. and CENTER, M.S. (1988) Mechanisms of multidrug resistance in 
HL60 cells: evidence that a surface glycoprotein distinct from P-glycoprotein 
contributes to reduced cellular accumulation of drug. Cancer Res. 48: 3959-3963.
MECHETNER, E.B. and RONINSON, B. (1992) Efficient inhibition of P- 
glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. 
Acad. Sci. USA 89: 5824-5828.
MEIJER, C , MULDER, N.H., TIMMER-BOSSCHA, H. eta l. (1991) Combined in 
vitro modulation of Adriamycin resistance. Int. J. Cancer 49: 582-586.
MEISTER, A. (1983) Glutathione metabolism and transport In: Radioprotectors and 
Anticarcinogens (NYGAARD, O. and SIMIC, M.G. (eds)). p .121-151. New York 
Academic Press 1983
284
MEISTER, A. (1986) Modulation of intracellular levels of glutathione. In: Biochemical 
Modulation of Anticancer Agents: Experimental Clinical Approaches. (F VALERIOTE, 
F. and BAKER, I.(eds).) p.245-275. Boston, MS: Martinus Nijhoff.
MEISTER, A. and GRIFFITHS, O.W. (1979) Effects of methionine sulfoximine 
analogues on the synthesis of glutamine and glutathione: possible chemotherapeutic 
implications. Cancer Treat. Rep. 63; 1115-1121.
MELLADO, W. and HORWITZ, S.B. (1987) Phosphorylation of the multidrug 
resistance associated glycoprotein. Biochemistry 26: 6900-6904.
MEYER, T., REGENASS, U., FABBRO, D. etal. (1989) A derivative of staurosporine 
(CGP 41 251) shows selectivity for protein kinase C inhibition and shows in vitro anti­
proliferative as well as in vivo anti tumour activity. Int. J. Cancer 43: 851-856.
MEYERS, M.B., RITMANN-GRAUER, L. and BIEDLER, J.L. (1988) Characteristics 
of a multidrug resistance-related antigen HYB-612. Proc. Am. Assoc. Cancer Res. 29: 
295.
MILLER, R.L., BUKOWSKI, R.M., BUDD, G.T. etal. (1988) Clinical modulation of 
doxorubicin resistance by the calmodulin inhibitor trifluoprazine: A phase I/II tiial. J. 
Clin. Oncol. 5: 880-888.
MILLER, T.P., GROGAN, T.M., DALTON, W.S. et aL (1991) P-glycoprotein 
expression in malignant lymphoma and reversal of clinical drug resistance with 
chemotherapy plus high dose verapamil. J. Clin. Oncol. 9: 17-24.
MICKISCH, G.H., RAHMAN, A., PASTAN, I. et al. (1992) Increased effectiveness of 
liposome-encapsulated doxorubicin in multidrug resistant transgenic mice compared 
with free doxorubicin. J. Natl. Cancer Inst. 84: 804-805.
MIYAMOTO, K-I. and WAKUSAWA. S., NAKAMURA. S. et al, (1990) 
Circumvention of multidrug resistance in P388 murine leukaemia cells by a novel 
inhibitor of cyclic AMP-dependent protein kinase, H-87. Cancer letters 51: 37-42.
MIYAMOTO, K-L, INOKO, K., WAKUSAWA, S. et al. (1993) Inhibition of 
multidrug resistance by a new staurosporine derivative* NA-382* in vivo and in vitroi 
Cancer Res. 53: 1555-1559.
MIYASHITA, T., KRAJEWSKA, S., KRAJEWSKA, M. et al. (1994) Tumour 
suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. 
Oncogene 9: 1799-1805.
MIYAZAKI, M., KOHNO, K., SABURI, Y. et al. (1990) Drug resistance to cis- 
diamminedichloroplatinura (II) in Chinese hamster ovary cell lines transfected with 
glutathione S-tranferase n gene. Biochem. Biophys. Res. Commun. 166: 1358-1364
MORROW, C.S. and COWAN, K.H. (1990) Multidrug resistance associated with 
altered topoisomerase II activity-topoismomerase II as a target for rational drug design. 
J. Natl. Cancer Inst. 82: 638-639.
MORROW, C.S. and COWAN, K.H. (1993) Antineoplastic drug resistance and breast 
cancer. Ann. New York Acad. Sci. 268: 289-312.
285
MOSCOW, J.A. and COWAN, K.H. (1988) Multidrug insistance. J. Natl. Cancer Inst. 
80: 14-20.
MOSCOW, J.A., FAIRCHILD, C.R., MADDEN, M.J. et al. (1989a) Expression of 
anionic glutathione S-transferase and P-glycoprotein genes in human tissues and 
tumours. Cancer Res. 49: 1422-1428.
MOSCOW, J.A., TOWNSEND, A.J., COWEN, A.J. etal. (1989b) Elevation of tc class 
glutathione S-transferase activity in human breast cancer cells by transfection of the 
GSTtc gene and its effect on sensitivity to toxins. Mol. Pharmacol. 36: 22-28.
MOSMANN, T. (1983) Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J. Immun. Methods 65: 55-63.
MULLER, M., MEIJER, C., ZAMAN, G.J.R. etal. (1994) Overexpression of the gene 
encoding the multidrug resistance-associated protein results in increased ATP- 
dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA 91: 13033- 
13037.
NADLER, S., TEPPER, M., SCHACTER, B. et al. (1992) Interactions of the 
immunosuppressant deoxyspergualin with a member of the Hsp 70 family of heat shock 
proteins. Science 258:484-485.
NAITO, M., YUS A, K. and TSURUO, T. (1989) Steroid hormones inhibit binding of 
Vinca alkaloids to multidrug resistance related P-glycoprotein. Biochem. Biophys. Res. 
Commun. 158: 1066-1071.
NEGRI, C., CHIESA, R., CERINO, A. et al. (1992) Monoclonal antibodies to human 
DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180- 
kDA isozymes. Exp. Cell Res. 200: 452-459.
NEMOTO, K., HAYASHI, R, ABE, T et a l  (1987) Immunosuppressive activities of 
15-deoxyspergualin in animals. J. Antibiotics 40: 561-62.
NEYFAKII, A.A. (1988) Use of fluorescent dyes as molecular probes for the study of 
multidrug resistance. Exp. Cell Res. 174: 168-176.
NG, W.F., SARANGI, F., ZASTÀMY, R.L. et a l  (1989) Identification of members of 
the P-glycoprotein multigene family. Mol. Cell Biol. 9: 1224-1232.
NISHIKAWA, K., SHIBASAKI, C., UCHIDA, T. et a l  (1991) The nature of in vivo 
cell killing of deoxyspegualin and its implications in combination with other antitumour 
agents. J. Antibiotics 44: 1237-1246.
NISHIZUKA, Y. (1988) The molecular heterogeneity of protein kinase C and its 
implcations for cellular regulation. Nature 334: 661.
NISHIZUKA, Y. (1992) Intracellular signalling by hydrolysis of phospholipids and 
activation of protein kinase C. Science 258: 607-614.
NITISS, J. and WANG, J.C. (1988) DNA topoisomerase-targeting antitumour drugs 
can be studied in yeast. Proc. Natl. Acad. Sci. USA 85: 7501-7505.
286
NIWA, K., YAMADA, K,, FURUKAWA, T. et al. (1992) Effect of the 
dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl-1.4-dihydro-2.6-dimethyl-5- 
(5.5-dimethyl-2-oxo-1.3.2-dioxaphodphorinan-2-yl)-1 -(2-morpholino-ethyl)-4-(3- 
nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumour cells to 
Adriamycin. Cancer Res. 52: 3655-3636.
O'BRIAN, C.A. and WARD, N.E. (1990) Staurosporine: A prototype of a novel class 
of inhibitors of tumour cell invasion. J. Natl. Cancer Inst. 82: 1734-1735.
O'BRIAN, C.A. LISKAMP, R.R., SOLOMON, D.H.et al. (1985) Inhibition of protein 
kinase C by tamoxifen. Cancer Res. 45: 2462-2465
OLTVAI, Z., MILLIMAN, Ç., KORSMEYER, S.J. et al. (1993) Bcl-2 heterodimerises 
in vivo with a conserved homolog, Bax, that accelerate programmed cell death. Cell 74: 
609-619.
OZOLS, R.F., CUNNION, R.E., KLECKER, R.W. et al. (1987) Verapamil and 
Adriamycin in the treatment of drug resistant ovarian cancer patients. J. Clin. Oncol. 5: 
641-647.
PALEKAR, A.G., TATE, S.S., MEISTER, A. et al. (1975) Decreased glutathione 
levels of kidney and liver after injection of methionine sulfoximine into rats. Biochem. 
and Biophys. Res. Commun. 62; 651-657.
PARCHMENT, R.E., LEWELLYN, A., SWARTZENDRUBER, D. et al. (1990) 
Serum copper amine oxidase activity contributes to crisis in mouse embryo cell lines. 
Proc. Natl. Acad. Sci. USA 87: 4340-4344.
PEARCE, H.L., WINTER, M.A. and BECK, W.T. (1990) Structural characteristics of 
compounds that modulate P-glycoprotein-associated MDR. Adv. Enzyme Regul. 30: 
357-373.
PILLION, D.J., LEDBACH, F.H., VON TERSCH, F. et al. (1976) Inhibition of alpha- 
methyl-D-glucoside transport by diamide. Biochim. Biophys. Acta. 419: 104-111.
PONGRACZ, J., CLARK, P., NEOPTOLEMOS, J.P. et al. (1995) Expression of 
protein kinase C isoenzymes in colorectal cancer tissue and their differential activation 
by different bile acids. Int. J. Cancer: 61 35-39.
POSADA, J.A., MCKEEGAN, E.M., WORTHINGTON, K.F. et al. (1989) Human 
multidrug resistant KB cells overexpress protein kinase C: involvement in drug 
resistance. Cancer Commun. 1: 285-292.
PRINSEP, M.R., CAPLAN, F.R., MOORE, R.E. et al. (1992) Tolyporphin, a novel 
multidrug resistance reversing agents from the blue-green alga Tolypothrix nodosa. J. 
Am. Chem. Soc. 114: 385-38&
RADERER, M. and SCHEITHAUER, W. (1993) Clinical trials of agents that reverse 
multidmg resistance. Cancer 72: 3553-3563
RAMU, A., GLAUBIGER, D., FUKS, Z. (1984). Restoration of doxorubicin 
responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br. J. Cancer 50: 
501-507.
287
RAVIV, Y., POLLARD, H.B., BRUGGEMANN, E. et al. (1990) Photosensitised 
labelling of a functional multidrug transporter in living drug resistant tumour cells. J. 
Biol. Chem. 268: 3975-3980.
REEVE, J.G., RABBITTS, P.H. and TWENTYMAN, P.R. (1989) Amplification and 
expression of mdrl gene in a multidrug resistant variant of small cell lung cancer cell 
line NCI-H69. Br. J. Cancer 60: 339-342.
RIORDAN, J.R. and LING, V. (1985) Genetic and biochemical characterisation of 
multidrug resistance. PhaiTnacol. Ther. 28: 51-75.
RIORDAN, JR ., ROMMENS, J.M., KEREM, B-S. etal. (1990) Identification of the 
cystic fibrosis gene: cloning and characterisation of complementary DNA. Science. 
245: 1066-1073.
ROBERTS, J. (1994) Proposals for concomittant use of several modulators of 
multidmg resistance in clinics. Anticancer Res. 14: 2371-2374.
ROCKWELL. S.C., KALLMAN. R.F.. FAJARDO, L.F. etal. (1972) Characteristics of 
serially transplanted mouse mammary tumour and its tissue-culture-adapted derivative. 
J. Natl. Cancer Inst. 49: 735-749.
RODENBURG, C.J., NOOTER, K., HERWEIZER, H. et al. (1991) Phase II study of 
combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal 
cell cancer. Ann. Oncol. 2: 305-306.
ROEPE, P.D., WEI, L-Y., CRUZ, J. et al. (1993) Lower electrical membrane potential 
and altered pHi homeostasis in multidmg resistant cells: further characterisation of a 
series of multidrug resistance cell lines expressing different levels of P-glycoprotein. 
Biochemistry 32: 11042-11056
ROEPE. P.D. (1992) Analysis of steady state and initial rate of doxombicin efflux from 
a series of multidrug resistant cells expressing different levels of P-glycoprotein. 
Biochemistry 31: 12555-12564.
RONINSON, I.B. (1983) Detection and mapping of homologous, repeated and 
amplified DNA sequences by DNA renaturation in agarose gel. Nucleic Acid Res. 11: 
5413-5423.
RONINSON, I.B., CHIN, J.E., CHOI, K. et al. (1986) Isolation of human mdr DNA 
sequences amplified in multidmg resistant KB carcinoma cells. Proc. Natl. Acad. Sci. 
USA 83: 4538-4552.
ROTHENBERG, M.L., MICKLEY, L., COLE, D.E, et al. (1989) Expression of the 
W rJ/P-glycoprotein gene in patients with acute lymphoblastic leukaemia. Blood 74; 
1388-1393.
ROY, S.N. and HORWITZ, S.B. etal. (1985) A phosphoglycoprotein associated with 
taxol resistance in J774.2 cells. Cancer Res. 45: 3856-3863.
RUBEN, R. and NEUBAUER, R.H. (1987) Semi-automated colorimetric assay for in 
vitro screening of anti-cancer compounds. Cancer Treat. Rep. 71: 1141-1149.
288
RUETZ, S. and GROS, P. (1994a) A mechanism for P-glycoprotein in multidrug 
resistance: are we there yet? Trends in Pharm. Sci. 15: 260-263.
RUETZ, S. and GROS, P. (1994b) Functional expression of P-glycoprotein in 
secretory vesicles. J. Biol. Chem. 269: 12777-12784.
RUSSO, A ., DE GRAFF, W., FRIEDMAN, N. el al. (1986) Selective modulation of 
glutathione levels in human normal versus tumour cells and subsequent differential 
response to chemotherapy drugs. Cancer Res. 46: 2845-2848.
SAFA, A.R. (1988) Photoaffinity labelling of the multidrug resistance-related P- 
glycoprotein with photoaffinity analogues of verapamil. Proc. Natl. Acad. Sci. USA. 
85:7187-7191.
SAFA, A.R. (1992) Photoaffinity labelling of P-glycoprotein in multidrug resistant 
cells. Cancer Invest. 10: 295-305.
SALMON, S.A., DALTON, W.S., GROGAN, T.M. etal. (1991) Multidrug resistant 
myeloma: laboratory and clinical effect of verapamil as a chemosensitiser. Blood 78: 
44-50.
SAMPSON, K.E., WOLF, C.L., ABRAHAM, I. et al. (1993) Staurosporine reduces P- 
glycoprotein expression and modulates multidrug resistance. Cancer letters 68: 7-14.
SARKADI, B., PRICE, E.M. and BONOHER, R.C. (1992) Expression of the human 
multidrug resistance cDNA in insect cells generates a high activity drug stimulated 
membrane ATPase. J. Biol. Chem. 267: 4854-4858.
SATO, W., YUSA, K., NAITO, M. et al. (1990) Staurosporine, a potent inhibitor of C- 
kinase, enhances drug accumulation in multidrug resistant cells. Biochem. Biophys. 
Res. Commun. 173: 1252-1257.
SCHECTER, R.L., ATONI-JAMALI, M.A., WOO, A. (1993) Expression of rat 
glutathione S-transferase complementary DNA in rat mammary carcinoma cells: impact 
upon alkylator-induced toxicity. Cancer Res. 53: 4900-4906.
SCHEFFER, G.L., WUNGAARD, P.L.J., FLENS, M.J. et al. (1995) The drug 
resistance-related protein LRP is the human major vault protein. Nature Medicine 1: 
578-582. .
SCHEPER, R.J., BROXTERMAN, H.J., SCHEFFER, G.L. et al. (1993) 
Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein mediated 
multidrug resistance. Cancer Res. 53: 1475-1479.
SCHEPER, R.J., BULTE, J.W.M., BRAKKEE, J.G.M. et al. (1988) Monoclonal 
antibody JSB 1 detects a highly consci’vcd epitope on the P glycoprotein associated 
with multidrug resistance. Int. J. Cancer 42: 389-394.
SCHEULEN, M.E., NUBLER, V., KRIEGMAIR. M. et al. (1994) Phase I study of IV 
dexniguldipine plus vinblastine. Proc. Am. Soc. Clin. Oncol. 13: 156.
SCHILDER, R.J., HALL, L., MONKS, A et al. (1990) Metallothionein gene 
expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer 45: 416- 
422.
289
SCHIMKE, R.T. (1984) Gene amplification, drug resistance and cancer. Cancer Res. 
44: 1735-1742.
SCHINKEL. A.H., ROELOFS, E.M. and BOSRT, P. (1991) Characterisation of the 
human mdr3 P-glycoprotein and its recognition by P-glycoprotein specific monoclonal 
antibodies. Cancer Res. 51: 2628-2635.
SCHNEIDER, E., COWEN, K.H., BADER, H. et al. (1995) Increased expression of 
the multidrug resistance-associated protein gene in relapsed acute leukaemia. Blood 85: 
186-193.
SCHNEIDER, E., YAMAZAKI, H., SINHA, B.K. et al. (1995a) Buthionine 
sulfoximine mediated sensitisation of etoposide-resistant human breast cancer MCF7 
cello ovorexpreosing the multidrug resistance associated protein involves increased drug 
accumulation. Br. J. Cancer 71: 738-743.
SCHUURHUIS, G.J., BROXTERMAN, H.J., CEVANTES, A. et al. (1989) 
Quantitative determination of factors contibuting to doxorubicin-resistant cells. 
J.Natl.Cancer Inst. 81: 1887-1892.
SCOTTO, K. W., BIEDLER, J. L., MELERA, P.W. et al. (1986) Amplification and 
expression of genes associated with multidrug resistance in mammalian cells. Science 
232: 751-755.
SETLOW, R.B. (1978) Repair deficient human disorders and cancer. Nature 271: 713- 
717.
SHIRO, T., HONGSI, J., YUJI, T. et al. (1992) The in vitro immunosuppressive effect 
of deoxyspegualin in man as compared with FK506 and cyclosporine. Transplantation 
53: 914-18.
SINGH, S. A., IGBAL, J., KRISHAN, A. (1990) Cytochrome P450 reductase, 
antioxidant enzymes and cellular resistance to doxorubicin. Biochem. Pharmacol. 40: 
385-87.
SIROTNAK, F.M. (1985) Obligate genetic expression in tumour cells of a fetal 
membrane property mediating folate transport: biological significance and implications 
for improved therapy of human cancer. Cancer Res. 45: 3992-4000.
SLAPAK, C.A., MIZUNMA, N. and KUFE, D.W. (1994) Expression of the multidrug 
resistance associated protein and P-glycoprotein in doxorubicin-selected human 
myeloid leukaemia cells. Blood 84: 3113-3121.
SLATER, T.F., SAWYER, B. and STRALI, U. et al. (1963) Studies on succinaie- 
tetrazolium reductase systems.III. Points of coupling of four different tétrazolium salts. 
Biochim. Biophys. Acta. 77: 383.
SLATER, L.M., SWEET, P., STUPECKY, M. et al. (1986a) Cyclosporin A corrects 
daunorubicn resistance in Ehrlich ascites carcinoma. Br. J. Cancer 54: 235-238.
SLATER, L.M., SWEET, P., STUPECKY, M. etal. (1986b) Cyclosporin A reverses 
vincristine and daunorubicin resistance in acute lymphocytic leukaemia in vitro. J. 
Clin. Invest. 77: 1405-1408.
290
SMIT, J.J., SCHINKEL, A.H., MOL,C.A.A.M. etal. (1994) The tissue distribution of 
the human MDR3 P-glycoprotein. Lab. Invest 71: 638-649.
SONNE VELD, P. and NOOTER, K. (1990) Reversal of drug-resistance by cyclosporin 
A in a patient with acute myelocytic leulaemia. Br. J. Haematol. 75: 208-211.
SONNEVELD, P., DURIE, B.G.M., LOKHORST, H.M. et al. (1992) Modulation of 
multidrug resistant multiple myeloma by cyclosporine. Lancet 340: 255-259.
STAATS, J., MARQUARDT, D. and CENTER, M.S. etal. (1990) Characterisation of 
a membrane-associated protein kinase of multidrug resistant HL60 cells which 
phosphorylates P-glycoprotein. J. Biol. Chem. 265: 4084-4090.
SUGIMOTO, Y., TSUKAHARA, S., OH-HARA, T. et al. (1990) Decreased 
expression of DNA topoisomerase I in camptothecin-resistant tumour cell lines as 
determined by a monoclonal antibody. Cancer Res. 50: 6925-6930.
SUZUKAKA, D , PETRO, B J. and VISTICA, D.T. (1986) Reduction of glutathione 
content of L-Pam resistant L I210 cells confers drug sensitivity. Biochem. Pharmacol. 
31: 121-124.
SUZUKAKA, K., VISTICA, B.P. and VISTICA, D.T. (1983) Dechlorination of L- 
phenylalanine mustard by sensitive and resistant tumour cells and its relationship to 
intracellular glutathione content. Biochem. Phannacol. 32: 165-167.
TAKAHASHI, I., KOBAYASHI, E., AS AND, K. eta l. (1987). UCN-01, a selective 
inhibitor of PKC from streptomyces. J. Antibiotics 40: 1782-1784.
TAKANO, H., KOHNO, K., ONO, M. et al. (1991) Increased phosphorylation of DNA 
topoisomerase II in etoposide resistant mutants of human cancer KB cells. Cancer Res. 
51: 3951-3957.
TAKEUCHI, T., IINUMA, H., KUNIMOTO, S. et a l  (1981) A new anti-tumour 
antibiotic, spergualin: isolation and antitumour activity. J. Antibiotics 34: 1619-21.
TAMAI, I. and SAFA, A. (1991) Azidopine noncompetitively interacts with 
vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J. 
Biol. Chem. 266: 16796-16800.
TAMARA, H., KOLCHI, C., YAMADA, R. e ta l  (1990) Molecular cloning of a 
cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of 
mutation sites. Nucl. Acid Res. 19: 69-75.
TAN, K.B., MATTERN, M.R., ENG, W-K. et a l  (1989) Non productive 
rearrangement of DNA topoisomerase I and II genes: correlation with resistance to 
topoisomerase inhibitors. J. Natl. Cancer Inst. 81: 1732-1735.
TANNOCK,. I..F. and HILL, R.P. (1992) The basic science of oncology (2nd Edition). 
McGraw-Hill, Inc. pp301-347.
TEW, K.D. (1994) Glutathione-associated enzymes in anticancer resistance. Cancer 
Res. 54: 4313-4320.
291
THIEBAUT, F., CURNER, ST., WHITAKER, J. et al. (1990) Activity of the 
multidrug transporter results in alkalinisation of the cytosol: measurements of cytosolic 
pH by microinjection of a pH-sensitive dye. J. Histochem. Cytochem. 38: 685-690.
THIEBAUT, F., TSURUO, T., HAMADA, H. et al. (1987) Cellular localisation of the 
multidrug resistance gene product P-glycoprotein in normal tissues. Pro. Natl. Acad. 
Sci. USA. 84: 7735-7738.
THIEBAUT, F ,  TSURUO, T., HAMADA, H. et al. (1989) Immunohistochemical 
localisation in normal tissues of different epitopes in the multidrug transport protein 
P I70: evidence of localisation in the brain capillaries and cross reactivity of one 
antibody with a muscle protein. J. Histochem. Cytochem. 37: 159-164.
THIERRY, A., RAHMAN, A. and DRITSCHILO, A. (1993) Overcoming multidrug 
resistance in human tumour cells using free and liposomally encapsulated antisense 
oligonucleotides. Biochem. Biophys. Res. Commun. 190: 952-960.
THOMAS, G.A., BARRAND, M.A., STEWART, S. et al. (1994) Expression of 
multidrug resistant-associated protein (MRP) gene in human lung tumours and normal 
tissues as determined by in situ hybridisation. Eur J Cancer 30A: 1705-1709.
TOLCHER, A.W., COWAN, K.H., SOLOMON, D. et al. (1994) A phase I study of 
paclitaxel (T) with R-verapamil (RV) in metastatic breast cancer (MBC). Proc. Am. 
Soc. Clin. Oncol. 13: 139.
TRENT, J.M. and CALLEN, D.F. (1991) Molecular and cellular biology of mulitidrug 
resistance in tumour cells. New York; Plenum, p 169-188
TSUJIMOTO, Y. and CROCE, C.M. (1986) Analysis of the, transcripts, and protein 
products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. 
Sci. USA 83: 5214-5218.
TSURUO, T., IIDA, H., KITATANI, Y. et al. (1984) Effects of quinidine and related 
compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in 
drug resistant tumour cell. Cancer Res. 44: 4303-4307.
TSURUO, T., IIDA, H., TSUKAGOSHI, S. et a l  (1981) Overcoming of vincristine 
resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of 
vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972.
TSURUO, T., IIDA, H., TSUKAGOSHI, S. eta l. (1982) Increased accumulation of 
vincristine and Adriamycin in drug resistant P388 tumour cells following incubation 
with calcium antagonists and calmodulin inhibitors. Cancer Res. 42: 4730-4733.
TWENTYMAN, P.R. (1980) Response to chemotherapy of EMT6 spheroids as 
measured by growth delay and cell survival. Br. J. Cancer 42: 297-304.
TWENTYMAN, P.R. (1988) Modification of cytotoxic drug resistance by non­
immunosuppressive cyclosporins. Br. J. Cancer 57: 254-258.
TWENTYMAN, P.R. (1992) Cyclosporins as drug resistance modifiers. Biochem. 
Pharmacol. 43; 109-117.
292
TWENTYMAN, P.R. and BLEEHEN, N.M. (1975) Changes in sensitivity to cytotoxic 
agents occuring during the life history of monolayer cultures of a mouse tumour line. 
Br. J. Cancer 31:417-423.
TWENTYMAN, P.R. and LUSCOMBE, M. (1987b) A study of some variables in 
tétrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer 
56: 279-285.
TWENTYMAN, P.R., FOX, N.E. and BLEEHEN, N.M. (1986c) Drug resistance in 
human lung cancer cell lines. Cross resistance studies and effects of the calcium channel 
blocker verapamil. Int. J. Radiat. Oncol. Biol. Phys. 12: 1355-1358.
TWENTYMAN, P.R., FOX, N.E. and WHITE, D.J.G. (1987a) Cyclosporin A and its 
analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant 
human lung cancer cell line. Br. J. Cancer 56: 55-57.
TWENTYMAN, P R., FOX, N.E., WRIGHT, K.A. et al. (1986a) Derivation and 
preliminary characteristics of adriamycin resistant lines of human lung cancer cells. Br. 
J. Cancer 53: 529-537.
TWENTYMAN, P.R., FOX, N.E., WRIGHT, K.A. et at. (1986b) The in vitro effects 
and cross resistance patterns of some novel anthracyclines. Br. J. Cancer 53: 585-594.
TWENTYMAN, P.R., REEVE, J.G., KOCH, G. et al. (1990) Chemosensitisation by 
verapamil and cyclosporin A in mouse tumour cell lines expressing different levels of 
P-glycoprotein and CP22 (sorcin). Br. J. Cancer 62: 89-95.
TWENTYMAN, P.R., WRIGHT, K.A. and REEVE, J.G. (1989) Resistance 
modification by cyclosporins in mouse multidrug resistant cell lines. Br. J. Cancer 83: 
7785-7789.
UEDA, K., CARDARELLI, C., GOTTESMAN, M.M. et a i  (1987) Expression of a 
full length cDNA for the human M D Rl gene confers cross resistance to colchicine, 
doxorubicin and vinblastine. Proc. Natl. Acad. Sci. USA. 84: 3004-3008.
UEDA, K., OKAMURA, N., HIRAI, M. etal. (1992) Human P-glycoprotein transports 
cortisol, aldosterone, and dexamethasone but not progesterone. J. Biol. Chem. 267: 
24248-52.
UMEZAWA, H., KONDO, S., IINUMA, H. etal. (1981) Structure of an antitumour 
antibiotic, spergualin. J. Antibiotics 34: 1622-24.
URA, K. and HIROSE, S. (1991) Possible role of DNA topoisomerase II on the 
transcription of the homeobox gene Hox-2.1 in F9 embryonal carcinoma cells. Nucleic 
Acid Res. 19: 6087-6092.
UTZ, I., HOFER, S., REGENASS, U. et al. (1994) The protein kinase C inhibitor 
CGP41251, a staurosporine derivative with antitumour activity, reverses multidrug 
resistance. Int. J. Cancer 57: 104-110
VALVERDE, M., DIAZ, M., SEPULVEDA, F. et al. (1992) Volume-regulated 
chloride channels associated with the human multidrug resistance P-glycoprotein. 
Nature 355: 830-833.
293
VAN DER BLIEK, A.M., BAAS, F., TEN HOUTE DE LANGE, T. et al. (1987) The 
human mdr 3 gene encodes a novel P-glycoprotein homologue and gives rise to 
alternatively spliced mRNAs in the liver. The E.M.B.O. Journal 6: 3325-3331.
VAN DER BLIEK, A.M., BAAS, F., VAN DER VELD-KOERTS, T. et al. (1986) 
Overexpression and amplification of five genes in a multidrug resistant Chinese hamster 
ovary cell line. Mol. Cell Biol. 6: 1671-1678.
VAN PUTTEN, L.M., LELIEVELD, P., KRAM-IDSENGA, L.K.J. etal. (1972) Cell 
cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother. 
Rep. 56: 691-700.
VAYUVEGULA, B., SLATER, L., MEADOR, J. etal. (1988) Correction of altered 
plasma membrane potentials. Cancer Chemother. Pharmacol. 22: 163-168.
VERSANTVOORT, C.H.M., BAGRIJ, T., WRIGHT, K.A., e ta l. (1995b) On the 
relationship between probenecid-sensitive transport of daunombicin or calcein and the 
glutathione status of cells overexpressing the multidrug resistance-associated protein 
(MRP). Int. J. Cancer (in press).
VERSANTVOORT, C.H.M., BROXTERMAN, H.J., BAGRIJ, T. et al. (1995a) 
Regulation by glutathione of drug transport in multi-drug resistant human lung tumour 
cell lines overexpressing multidrug resistance-associated protein (MRP). Br. J. Cancer 
72: 82-89.
VERSANTVOORT, C.H.M., BROXTERMAN, H.J., FELLER, N. et al. (1992) 
Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug 
resistant cell lines using digitonin. InL J. Cancer 50: 906-911.
VERSANTVOORT, C.H.M., BROXTERMAN, H.J., LANKELMA, J. et al. (1994) 
Competitive inhibition by genistein and ATP dependence of daunomycin in intact MRP 
overcxpressing human small cell lung cancer cells. J. Biochem. Pharmacol. 48: 1129- 
1136.
VERSANTVOORT, C.H.M., SCHUURHUIS, G.J., PINEDO, H.M. et al. (1993) 
Genistein modulates the decreased drug accumulation in non-P-glycoprotein-mediated 
multidrug resistant tumour cells. Br. J. Cancer 68: 939-946.
VOGELSTEIN, B. and KINZLER, K.W. (1992) p53 function and dysfunction. Cell 
70: 523-526.
WANG, X.Y., WALL, D.M., PARKIN, T.D. et al. (1994) P-glycoprotein expression in 
classical multidrug resistant leukaemia cells does not correlate with enhanced chloride 
channel activity. Clin. Exp. Pharmacol. Physiol. 21: 101-8.
WEAVER, J.L., lUE, P.S., ASZALOS, A. et al. (1991) Laser scanning confocal 
microscopy of daunorubicin, doxorubicin and rhodamine 123 in multidrug resistant 
cells. Exp. Cell Res. 196: 323-329.
WEAVER, J.L., SZABO, G.J.R. and PINE, P.S. (1993) The effect of ion channel 
blockers, immunosuppressive agents and other drugs on the activity of the multidrug 
resistance transporter. Int. J. Cancer 54: 456-461.
294
WEI, L-Y. and ROEPE, P.D. (1994) Low external pH and osmotic shock increase the 
expression of human multidrug resistance protein. Biochemistiy 33: 7229-7238.
WEINSTEIN, R.S., JAKATE, S.M., DOMINGUEZ, M.D. et al. (1991) Relationship of 
the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to 
local aggressiveness and lymph node metastasis. Cancer Res. 51: 2720-2726.
WILLINGHAM, M.C., CORNWALL, M.M., CARDARELLI, C O. et a l  (1986) Drug 
cell analysis of daunorubicin uptake and efflux in multidrug resistant and sensitive KB 
cells: effects of verapamil and other drugs. Cancer Res 46: 5941-5946.
WILSON, C.M. (1989) Amplification of a gene related to mammalian mdr genes in 
diVug-vQSisidXiiPlusmodiiimfalciparuni. Science. 244: 1184-1186.
WOOD, E.R. and ERNSHAW, W.C. (1990) Mitotic chromatin condensation in vitro 
using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase 
n. J. Cell Biol. I l l :  2839-2850.
WRIGHT, K.A. and TWENTYMAN, P.R. (1993) Derivatisation of a mouse tumour 
cell line with acquired resistance to cyclosporin A. Eur. J. Cancer 29: 389-394.
YANG, C-P.H., COHEN, D., GREENBERGER, L.M. et a l  (1990) Differential 
transport properties of two mdr gene products are distinguished by progesterone. J. 
Biol. Chem. 265: 10282-10288.
YANG, C-P.H., DEPINNO, S.H., GREENBERGER, L.M. etal. (1989) Progesterone 
interacts with P-glycoprotein in multidrug resistant cells and in the endometrium of 
gravid uterus. J. Biol. Chem. 264: 782-788.
YU, G., ADMAD, S., AQUINO, A. et a l  (1991) Transfection w i± protein kinase C 
alpha confers increased multidmg resistance to MCF-7 cells expressing P-glycoprotein. 
Cancer Comm. 3: 181-189.
ZAMAN, G.J.R., FLENS, M.J., VAN LEUSDEN, M.R. et a l  (1994) The multidrug 
resistance-associated protein MRP is a plasma membrane efflux pump. Proc. Natl. 
Acad. Sci. USA 91: 8822-8826.
ZAMAN, G.J.R., VERSANTVOORT, C.H.M., SMIT, J.J.M. et a l  (1993) Analysis of 
the expression of MRP, the gene for a new putative transmembrane drug transporter in 
human multidrug resistant lung cancer cell lines. Cancer Res. 53: 1747-1750.
ZAMORA, J.M., PEARCE, H.L. and BECK, W.T. (1988) Physical-chemical 
properties shared by compounds that modulate MDR in human leukaemic cells. Mol. 
Pharmacol. 33: 454-462.
ZIJLSTRA, J.G., DE VRIES, E.G.E., and MULDER, N.H. (1987) Multifactorial drug 
resistance in an Adriamycin resistant human small cell lung carcinoma cell line. Cancer 
Res. 47: 1780-1784
ZINI, N., MARTELLI, A.M., SABATELLI, P. et al. (1992) The 180-kDa isoform 
topoisomerase II is localised in the nucleolus and belongs to the structural elements of 
the nucleolar remnant. Exp. Cell Res. 20: 460-466.
295
ZWELLING, L.A., HINDS, M., CHAN, D. e ta l.  (1989) _ Characterisation of an 
amsacrine-resistant line of leukaemia cells. J. Biol. Chem. 264: 16411-16420.
296
